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ABSTRACT 
Lymphatic filariasis (LF) and onchocerciasis are highly endemic in Sierra Leone. Using World 
Health Organization (WHO) guidelines for monitoring national programmes where both 
infections are co-endemic, this study aimed to determine the impact of preventive 
chemotherapy on transmission intensity by measuring changes in human infection status 
using standard epidemiological indicators.  
Separate longitudinal studies designed to deliver WHO outcomes for programmes targeting 
the elimination of both diseases were conducted. Onchocerciasis mapping surveys from 
1988-2005 revealed that twelve of fourteen health districts were endemic. The baseline 
average mf prevalence was 53.1%, and mf densities in positive-only or entire populations 
were 28.87 and 15.33 mf/snip, respectively. Mf prevalence and density increased with age 
and was higher in males than females.  
Baseline prevalence and intensity surveys showed that LF was endemic in all 14 districts 
(Wuchereria bancrofti antigenaemia prevalence > 1%). Mean LF prevalence by ICT cards was 
21% (males 28%; females 15%) with higher prevalence in the northeast (Bombali 52%; 
Koinadugu 46%; Tonkolili 37%; Kono 30%) and lower in the southwest (Bonthe 3%; Pujehun 
4%). Mf prevalence was also relatively higher in the northeast (Bombali 6.7%; Koinadugu 
5.7%; Port Loko 4.4%; Kono 2.4%). Mf prevalence was higher in males (males 2.9%; females 
1.8%) and infection rate was higher in the over 20 years age-group (2.5%) than younger 
(1.7%). Arithmetic mean mf density was 50.30 mf/ml among mf-positive individuals and 1.19 
mf/ml in the population examined. 
Nationwide mass drug administration (MDA) using ivermectin plus albendazole was applied 
to eliminate both diseases. In 2010, after five rounds of MDA (2005-2009) with effective 
treatment coverage for onchocerciasis during 4/5 years, overall onchocerciasis mf 
prevalence was reduced by 60.26% (from 53.10% to 21.10%), overall mf density among 
positive-only individuals was reduced by 71.29% (28.87 to 8.29 mf/snip) and overall mf 
density among the entire population studied was reduced by 88.58% (15.33 to 1.75 mf/snip). 
Mf prevalence and density were higher in males, lowest in the 1-9 and highest in the 40-49 
year age groups.  Mf prevalence was reduced by >50% in 10/12 districts, and reduction in 
skin mf density was ≥50% among positives-only in 11/12 districts.  
After MDAs with effective treatment coverage in 2008-2010, LF mf prevalence decreased to 
less than 1% in 11/12 districts. Mf prevalence fell by 88.5% to 0.3%, with decreases of 70-
95% in seven and 100% (0 prevalence) in four districts, respectively. Overall arithmetic mean 
mf density after three MDAs was 17.59 mf/ml among mf positive individuals and 0.05 mf/ml 
for the entire population examined. 
After five MDAs, the overall mf prevalence was 0.54% and was higher in males (0.7%) than 
females (0.36%).  Eight of twelve districts with <1% mf prevalence passed the pre-
transmission assessment survey (TAS) and therefore qualified for a TAS to determine 
whether MDA could be stopped. Four districts failed the pre-TAS: Koinadugu (0.98% i.e. close 
to 1%), Bombali (2.67%), Kailahun (1.56%) and Kenema (0%). Following WHO 
recommendations, Kenema and Kailahun districts were paired to form a unit of 
approximately one million. Kenema, the spot check site, was considered to have failed the 
pre-TAS even though the mf prevalence was 0% because Kailahun, the sentinel site, failed.  
A qualitative study examining the impact of the Ebola virus disease (EVD) outbreak on the 
NTD programme found that despite a one-year absence of interventions, two rounds of MDA 
had been completed, including one during the ongoing outbreak in May/June 2015. Although 
it compromised the likelihood of achieving the 2020 targets of LF elimination and 
onchocerciasis control, the EVD outbreak has enhanced awareness about the important role 
of community volunteers in ensuring its success. While it may be the ‘endgame’ for LF, the 
NTD community and collaborating research institutions must address additional challenges 
if onchocerciasis is to be eliminated from Sierra Leone.   
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CHAPTER 1: INTRODUCTION 
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NEGLECTED TROPICAL DISEASES 
The significantly improved and excellent strategic investment in neglected tropical diseases 
(NTD) control globally has paved the way for the potential elimination of some NTDs such as 
lymphatic filariasis (LF) and onchocerciasis as public health problems in Sierra Leone (Hodges et 
al. 2011). NTDs are poverty-promoting parasitic and bacterial diseases with often stigmatising 
conditions that occur mainly in rural areas of low-income countries. NTDs are ancient 
afflictions even described in the Bible and other ancient literature (Molyneux, Hotez, Fenwick 
2005) and have afflicted humanity for millennia (Molyneux, Hotez, Fenwick 2005). Apart from 
affecting mainly the poor and exacerbating their poverty, there is strong evidence that when 
infected with NTDs one becomes increasingly susceptible to, or there is worsening of, the 
progression of morbidity from Human Immunodeficiency Virus/Acquired Immunodeficiency 
Syndrome (HIV/AIDS), Tuberculosis (TB), and Malaria. Therefore, NTD control/elimination is an 
indirect effective, low-cost means of reducing morbidity and mortality associated with these 
three global health problems (Gloeckner et al. 2010). NTDs affect over a billion people 
including over half a million children. It is estimated that annually 46-57 million disability-
adjusted life years (DALYs) are lost through NTDs (World Health Organization (WHO) Regional 
Office for Africa (AFRO) 2016). 
 
The momentum of the fight to combat NTDs has reached a peak unprecedented for public 
health programmes with the formation of a coalition of partners including donors, 
international health-oriented Non-Governmental Development Organisation (NGDOs), and 
pharmaceutical companies that are prepared to support endemic countries globally with their 
efforts to eliminate NTDs. This big development started in 2012 with the London Declaration 
on NTDs during which key donors pledged their support for this development and committed 
to either continuing to donate drugs or to provide the funds needed for the interventions. The 
key aspects of this coalition is joint support to control NTDs, coordination and collaboration at 
national and international levels, and regular reviews of progress through publication of 
reports that show how the key milestones established for the WHO 2020 targets for NTDs are 
being achieved (Bockarie et al. 2013; Uniting to combat NTDs 2015). 
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Among the 15 most common NTDs, seven have similar strategies to address their control, 
namely, single doses of effective treatment termed preventive chemotherapy (PC) given once, 
twice or four times a year, to broad segments of the population within communities that are 
endemic for these NTDs. These seven NTDs affect mainly the poorest communities in countries 
that usually have weak health systems (Baker et al. 2010). They are LF, onchocerciasis, 
schistosomiasis, three soil transmitted helminthiasis1 (ascariasis, trichuriasis, hookworm), and 
trachoma (Linehan et al. 2011). It has been suggested that NTDs rank sometimes higher than 
malaria and TB when DALYs lost is considered (Liese et al. 2010). 
 
The African region contributes an estimated 40% of the NTD global burden. All 42 countries in 
Africa have at least two of the NTDs that are targeted through PC and 36 are endemic for up to 
seven PC NTDs (WHO AFRO NTDP 2016). An estimated 169 million people need treatment for 
onchocerciasis and 468 million need treatment for LF in the WHO African region (WHO AFRO 
NTDP 2016). Due to increasing political commitment and government leadership in delivering 
treatments, there has been significant progress in tackling NTDs in the African region (WHO 
AFRO NTDP 2016). 
 
Since NTDs affect mainly the poorest communities in countries that usually have weak health 
systems (Baker et al. 2010), the affected countries themselves have not been able to address 
the NTD problem without substantial financial and technical input and assistance from 
international donors. Strategic investments in the control of NTDs mainly by the US 
Government through the United States Agency for International Development (USAID), the 
British Government through the Department for International Development (DFID), the Bill & 
Melinda Gates Foundation (BMGF), and pharmaceutical companies such as Merck and Co. Inc., 
GlaxoSmithKline, Pfizer, Johnson & Johnson, Merck and MedPharm, has enabled treatment for 
these seven debilitating NTDs targeted through PC (PC NTDs) paving the way for elimination of 
some of these NTDs as public health problems (Hodges et al. 2011). Since 2007, USAID, DFID 
and BMGF have pledged new funding to support the implementation of PC programmes 
globally (Baker et al. 2010). Each year pharmaceutical companies donate drugs to address 
                                                          
1 In other sections I refer to these seven NTDs as five NTDs because these 3 belong to the same group 
(helminthiasis). 
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NTDs at an estimated cost of US$3.8 billion, and it is estimated that 600 million DALYs will be 
averted between 2011 and 2030 if NTD goals are attained (Uniting to Combat NTDs 2015). The 
pharmaceutical companies Merck and Co. Inc., GlaxoSmithKline, Pfizer, Johnson & Johnson, 
Merck and MedPharm have also committed to donating NTD drugs needed by endemic 
countries for as long as needed (Baker et al. 2010). 
 
Many NTDs show significant geographic overlap and in many cases, are syndemic. There is 
usually, therefore, need to integrate activities targeting the seven NTDs to save costs and also 
allow the limited health workforce to maximise their effectiveness in controlling/eliminating 
these diseases (Molyneux, Hotez, Fenwick 2005). Since most countries in Africa and other parts 
of the world are endemic for more than two PC NTDs and are challenged in terms of human 
resource capacity, it is good that NTDPs use an integrated approach in addressing the NTD 
problem to reduce cost and ensure that health systems, though challenged in terms of human 
resource, can maximize their effectiveness against the NTDs. In 2006, WHO developed 
guidelines for PC of human helminthiasis using integrated approaches (WHO 2006; Baker et al. 
2010). Among the PC NTDs, Onchocerciasis, LF, and trachoma are currently targeted for 
elimination (Baker et al. 2010). The current minimal cost of 0.40 US$ per person treated per 
annum for NTDs will bring multiple health benefits to many and will have a socioeconomic 
impact in the affected countries (Molyneux, Hotez, Fenwick 2005). Some NTD experts believe 
that NTD control is one efficient way to combat poverty as most of these NTDs can be 
effectively treated at minimal cost. NTDs rank sometimes higher than malaria and TB when 
DALYs lost is considered (Liese et al. 2010). NTD experts urge the international NTD community 
including those from the countries affected to be committed to eliminating NTDs so that future 
generations can be protected from the disability, stigma, and blindness linked with diseases 
like LF and onchocerciasis (Molyneux 2009).  
 
WHO AFRO recently (23rd May 2016) launched the 5-year (2016-2020) Expanded Special 
Project for Elimination of NTDs (ESPEN) that will coordinate and guide countries endemic for 
NTDs in Africa to use effective and efficient strategies for controlling/eliminating PC NTDs. 
ESPEN is expected to make a significant contribution in accelerating the reduction of the 
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burden of PC NTDs in Africa through technical support and guidance to endemic countries 
(WHO AFRO NTDP 2016; WHO 2016b). 
 
 
STUDY AREA 
Sierra Leone is a poor West African country that belongs to what MacKinnon and MacLaren 
(2012) describe as “fragile and conflict-affected states” with health indicators that paint a dire 
picture for residents and the way forward for the health service appears bleak. Between 1991 
and 2002 there was a civil war in the country that had a devastating socio-economic effect and 
almost brought the entire health care delivery system to a standstill. However, the socio-
economic situation started improving after the end of the civil war in 2002, and the economic 
prospects were seen by many experts to be more optimistic. The neglected tropical diseases 
programme (NTDP) that started with the national onchocerciasis control programme (NOCP) in 
1989 was integrated in 2007 to include, besides onchocerciasis, other NTDs such as LF, 
schistosomiasis, soil-transmitted helminthiasis, trachoma, Guinea worm disease 
(Dracunculiasis), and Buruli Ulcer. The NTDP made significant achievements between 2005 and 
2013 with financial and technical support from the WHO Headquarter, AFRO, the WHO African 
Programme for Onchocerciasis Control (APOC), USAID, Helen Keller International (HKI), 
Sightsavers and the Centre for Neglected Tropical Diseases (CNTD) of the Liverpool School of 
Tropical Medicine (LSTM) (Pose and Rabinowitz 2014). Unfortunately, this was marred 
temporarily by an outbreak of Ebola Virus Disease (EVD) in West Africa that started in 
neighbouring Guinea in December 2013 and spread to Liberia in March 2014 and Sierra Leone 
in May 2014 (Boisen et al. 2015; Hersey et al. 2015). The EVD outbreak is believed to have 
caused almost the same devastating socio-economic effect as the civil war of 1991-2002 and 
appeared to have derailed the NTDP (Bartsh et al. 2015; Boisen et al. 2015; Helleringer and 
Noymer 2015; Hersey et al. 2015).  
 
General information on Sierra Leone 
The general information on Sierra Leone is provided in terms of the geography and climate, 
population and demographic situation, political and administrative organisation, and economic 
and socio-economic profile. 
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Geography and climate 
Sierra Leone is situated on the West coast of Africa between latitudes 70 and 100 north of the 
equator, and longitude 10.50 and 13.50 west of Greenwich. The country is bounded on the 
west by the Atlantic Ocean, on the north and east by Guinea and the south-west by Liberia. 
Population movement across these borders is high, and the three countries (Sierra Leone, 
Guinea, and Liberia) have had a recent history of civil strife. The country has a surface area of 
about 72,000 square kilometres or 28,000 square miles (Government of Sierra Leone (GoSL), 
Ministry of Health and Sanitation (MOHS) 2009; GoSL, MOHS 2012a). 
 
Figure 1: Map of Sierra Leone showing rivers - risk factor for onchocerciasis (Online, available 
from: http://www.mapsofworld.com/sierra-leone/river-map.html) 
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There are ten major rivers (Figure 1 above) running from north-east to the south-west of Sierra 
Leone that are connected to large tributaries (Wikipedia, (online) available from: 
https://en.wikipedia.org/wiki/List_of_rivers_of_Sierra_Leone; Accessed 29/06/2016).  
 
The country is tropical, and the tropical climate consists of two distinct seasons: the dry season 
that starts in November and ends in April, and the rainy season that starts in May and ends in 
October. The vegetation ranges from mangrove along the coasts to forest covered hills and 
savannah as one moves further inland (GoSL, MOHS 2009; WHO Sierra Leone 2009; GoSL, 
MOHS 2010; GoSL, MOHS 2012a; WHO AFRO NTDP 2013; WHO Sierra Leone 2014).  
 
Population and demographic situation 
There are 20 distinct language groups in Sierra Leone that reflect the diverse culture and 
traditions among which the largest ethnic groups are the Temne-35%, Mende-31 and Limba-
8% (GoSL, MOHS 2009; GoSL, MOHS 2012a; Wikipedia, (Online) available from: 
https://en.wikipedia.org/wiki/Ethnic_groups_in_Sierra_Leone; accessed 19/10/2016). The 
estimated total population in 2015 is 6.45 million people (African Health Observatory, WHO 
AFRO 2016). The country has a young population with relatively high proportion below 15 
years (>40%). The proportion of the population living in urban areas in 2008 was 38% (GoSL, 
MOHS 2009; WHO AFRO 2009; GoSL, MOHS 2010).  
 
Political and administrative organisation 
Sierra Leone is administratively divided into four regions (Figure 2): The Western Area and 
three provinces – Eastern, Northern, and Southern provinces. The three provinces are further 
divided into twelve districts (Eastern- Kailahun, Kono and Kenema districts; Northern- 
Koinadugu, Bombali, Kambia, Port Loko and Tonkolili districts; and Southern- Bo, Bonthe, 
Moyamba and Pujehun districts). The Western Area has been operationally divided into 
Western Urban district (mainly the capital) and Western Rural District, which comprises of the 
towns and villages surrounding the capital Freetown (GoSL, MOHS 2009).  
 
The twelve districts are sub-divided into chiefdoms that are governed by traditional Paramount 
Chiefs. Chiefdoms are subdivided into sections (governed by Section Chiefs), and Sections are 
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divided into villages (governed by Village Chiefs). There are 149 chiefdoms in the 12 districts of 
the three provinces that are governed by traditional Paramount Chiefs while the entire 
Western Area is subdivided into 30 wards headed by Councillors. Recent devolution of services 
to local communities has led to the creation of 19 local councils (14 district councils headed by 
elected district council chairmen and five city councils headed by elected Mayors) (GoSL, 
MOHS 2009; GoSL, MOHS 2010; GoSL, MOHS 2012a). Excluding the Western Area, Sierra Leone 
has 14,413 villages with populations between 100 and 500 inhabitants (Koroma, Turay and 
Moihua 2006). 
 
Figure 2: Sierra Leone maps showing health regions and districts (Online, available from:  
https://commons.wikimedia.org/wiki/Atlas_of_Sierra_Leone#/media/File:Sierra_Leone_Pro
vinces.png)   
      
 
Politically Sierra Leone is a constitutional democracy with a unicameral parliament that has one 
chamber with 124 seats. After gaining independence from Great Britain on 27th April 1961, 
Sierra Leone became a Republic on 19 April 1971 (GoSL, MOHS 2009; GoSL, MOHS 2010; GoSL, 
MOHS 2012a). The 11 year (1991-2002) civil war in Sierra Leone resulted in tens of thousands 
of deaths, internal displacement of a third of the population including health personnel, 
brought health services to a standstill in large parts of the country and resulted in the 
destruction of health-related properties that needed a long time to be replaced. The negative 
socio-economic impact of the war was still noticed even 12 years after the end of the civil war. 
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The health workforce was severely affected either through the death of many health workers 
or migration of health workers to other countries during the war (MacKinnon and MacLaren 
2012; Pose and Rabinowitz 2014).   
 
The rebuilding of governance infrastructure after the civil war started in February 2002 with 
disarmament and demobilisation of ex-combatants through the support of the United Nations 
and other development partners, followed by a successful presidential and parliamentary 
elections on 14th May 2002. Another set of successful presidential and parliamentary elections 
were repeated five years later, 28th July 2007, that resulted in a smooth transition of power 
from the then ruling party to the opposition party. This event is viewed by many as a major 
milestone in the re-establishment of strong constitutional democracy in the country, which 
signaled the end of the recovery phase and the start of a peacebuilding and development 
phase of post-conflict Sierra Leone (GoSL, MOHS 2009; GoSL, MOHS 2010; GoSL, MOHS 2012a; 
WHO Sierra Leone 2009; WHO Sierra Leone 2014). 
 
Economic and socio-economic profile 
Sierra Leone is classified as one of the least developed countries in Africa and the world in 
general. The 2007 Human Development Report ranked the country 177 out of 177, the least 
developed country in the world (WHO Sierra Leone 2009); 178 out of 178 in 2008 (GoSL, MOHS 
2009); and 183 out of 187 countries in 2012 with a human development index of 0.374 (United 
Nations Development Programme (UNDP) 2014a,b). However, the human development report 
of 2015 ranks the country 181 out of 188 and notes that the human development index has 
improved from 0.268 in 1980 to 0.413 in 2014 (a 50% increase) (WHO AFRO 2009; UNDP 2015; 
Focus 1000 2016). Gross national income (GNI) per capita in 2011 was US$ 1,815.1 (GoSL, 
MOHS 2009; UNDP 2014a,b). In 2006 it was estimated based on the 2004 census that 71% of 
Sierra Leoneans are poor (earning below $1.00 a day) and 26% of the population live in 
extreme poverty (i.e. they are unable to afford 2,700 calories of food per day) (UNDP 2009). 
About 70% of Sierra Leoneans lived below the poverty level in 2007 (GoSL, MOHS 2009). The 
country’s main economic sector includes mining, agriculture, and fisheries. Diamond, bauxite 
and rutile mining is the main source of foreign exchange. Two-thirds of the country’s 
population are involved in agriculture, mostly subsistence farming and contribute an estimated 
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51% of the overall national gross domestic product (GDP). Most of what is produced is used for 
domestic consumption, and income is low. The manufacturing sector is still developing and 
involves mostly processing of raw materials and light manufacturing for the domestic market. 
Living standards are expected to rise if the current stabilising macro-economic policy of the 
government is maintained. Post-conflict growth performance has been relatively better 
averaging 7.5% per year between 2005 and 2009 (GoSL, MOHS 2009). Gross national income 
per capita in 1990 was 430$, in 2000- 350$, and in 2008-750$ (UNDP 2014a,b).  
 
Inter-country collaboration takes place through the Mano River Union (MRU), which involves 
Sierra Leone and her neighbours, Liberia, Guinea and Cote D’Ivoire, and the Economic 
Community of West African States (ECOWAS), which comprises of all 15 West African states. 
Although the economy has recently improved, it is still dependent on the maintenance of 
peace and continued receipt of substantial external financial aid, which is needed to offset the 
severe trade imbalances and supplement limited government revenues. The country receives 
significant budgetary support from the European Union (EU), DFID, USAID, the African 
Development Bank (ADB), the World Bank, the Governments of China, Libya, Iran, Malaysia, 
and Morocco (WHO Sierra Leone 2009; WHO Sierra Leone 2014).  
 
General information on health services 
The information on the health situation and health services in Sierra Leone is provided in terms 
of the health indicators, health system organisation, health sector priorities, human resources 
for health and health sector financing.  
 
Health indicators  
Sierra Leone is among the poorest in the world as the health situation in Sierra Leone is critical 
compared even to other sub-Saharan African countries (GoSL, MOHS 2009; GoSL, MOHS 2010; 
GoSL, MOHS 2012a; MacKinnon and MacLaren 2012; Pose and Rabinowitz 2014). 
Communicable diseases including NTDs contribute over 70% of the burden of disease (African 
Health Observatory, WHO AFRO 2016).  
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Rural populations bear the greatest burden of diseases especially females within the rural 
population. Therefore, women are also more likely to stop economic activities due to illness 
than men. Health care costs remain high resulting in poor utilisation of health services (0.5 
visits per person per year). Out of pocket expenses for the health of about 61.3% is among the 
highest in Africa (African Health Observatory, WHO AFRO 2016). The Government has tried to 
address the inequality in utilisation of health services by devolving responsibility and 
accountability to the local level for effectiveness and efficiency of service delivery (GoSL, MOHS 
2010; GoSL, MOHS 2012a). The government introduced a free health care initiative in 2010 
that targets pregnant women, lactating mothers and children under five years to address the 
high maternal, child and under-five morbidity and mortality (WHO Sierra Leone 2014).  
 
Health system organisation 
The MOHS at the central level is currently headed politically by the Minister of Health and 
Sanitation, and two Deputy Ministers of Health and Sanitation (Figure 3 below). As part of 
public sector reforms initiated in 2003, the MOHS was divided into two main divisions at the 
central level: medical services and management services. The medical services division is 
currently headed by a Chief Medical Officer (CMO), who is assisted by two Deputy CMOs. The 
management services division is headed by a Permanent Secretary, who is usually a Chief 
Administrative Officer within the Ministries. Between the two main divisions of the MOHS, 
there are 13 directorates and 12 programmes. The NTDP is supervised directly by the Director 
of Disease Prevention and Control (DPC) (GoSL, MOHS 2009; GoSL, MOHS 2015).  
 
At the district level, health service is coordinated by a district health management team 
(DHMT) headed by a District Medical Officer (DMO). The DHMT is responsible for overall 
planning within districts; implementation of the national health policies in the districts; 
coordination and management of district health services; health education; ensuring provision 
of safe water and environmental sanitation; M&E of district health services, including health 
data collection, management, interpretation, dissemination and utilization (GoSL, MOHS 2010; 
GoSL, MOHS 2012a; GoSL, MOHS 2012b).  
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Figure 3: 
Organogram of the MOHS at central level 
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The health care system within districts is organised in a three-tier system: the first tier includes 
the frontline health facilities called peripheral health units (PHUs); the second includes district 
hospitals; and the third, the referral hospitals. PHUs (Table 1) are the first line health services 
and are divided into three groups: community health centres (CHCs), community health posts 
(CHPs) and maternal and child health posts (MCHPs). Currently, health care service within 
communities is delivered through a network of about 1,195 PHUs (GoSL, MOHS 2009; GoSL, 
MOHS 2010; GoSL, MOHS 2012b).   
 
Table 1: Details on types of peripheral health Units and the service they provide (GoSL, 
MOHS 2009; GoSL, MOHS 2010; GoSL, MOHS 2012a,b).  
S. 
No 
Type 
of 
PHU 
Population 
covered 
Usual 
Location 
Area 
covered 
Staffing Services provided Supervision 
1 CHC 10,000 to 
30,000 
people  
Chiefdom 
headquarter 
Entire 
chiefdom 
or five-
community 
health officers 
(CHOs), State 
Management of 
communicable diseases 
-malaria, acute 
Supervise activities 
in lower level PHUs- 
CHPs and MCHPs. 
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ten-mile 
radius 
enrolled 
community 
health nurses 
(SECHN), 
midwives, 
laboratory and 
pharmacy 
technicians 
respiratory infection 
(ARI), and diarrheal 
diseases; normal 
deliveries; minor 
surgical emergencies 
such as abscesses and 
injuries; inpatient care 
and some laboratory 
services 
Severe cases are 
referred to them 
from CHPs and 
MCHPs when 
necessary. They 
also supervise 
traditional birth 
attendants (TBAs) 
within chiefdoms 
2 CHP 5,000 to 
10,000 
people 
Section 
headquarter 
Entire 
sections 
or 5-mile 
radius 
Endemic 
diseases control 
assistants and 
SECHN 
Maternal and child 
health care services, 
communicable diseases 
Supervise MCHPs 
and TBAs within the 
section  
3 MCHP 500 and 
5,000 
people 
Relatively 
large 
villages 
3-mile 
radius 
Maternal and 
Child health 
Aides (MCHAs) 
Maternal and child 
health care services, 
communicable diseases 
TBAs within area 
covered 
 
The district hospitals form the secondary level facilities providing support and referral points 
for PHUs. They provide outpatient care for patients referred from PHUs and the population 
living within the immediate environs; in-patient and diagnostic services; management of 
accidents and emergencies; and technical support to PHUs. There are about 37 hospitals 
(secondary health institutions) among which 23 are government owned, and the rest are 
owned by private, mostly faith-based organisations, and NGOs. There are nine tertiary health 
facilities among which seven are in the Western Urban District (the capital Freetown). These 
facilities are inadequately equipped and under-staffed, thus providing limited health care 
services (GoSL, MOHS 2009; GoSL, MOHS 2010; GoSL, MOHS 2012a,b). 
 
Health sector priorities 
One of the key priorities of the GoSL is to improve the health of the nation. However, Sierra 
Leone has one of the highest under-five mortality rates in the world with almost one out of 
three children dying before the age of five years from malaria, diarrhoea, and/or pneumonia. 
Sierra Leone also has one of the highest maternal mortality rates in the world because of 
obstructed labour, haemorrhage, anaemia, and toxaemia in pregnancy (WHO Sierra Leone 
2009; Pose and Rabinowitz 2014). The health situation in Sierra Leone is therefore still in a dire 
position although significant progress has been made in reducing infant and maternal mortality 
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rates, improving immunisation coverage and use of long-lasting insecticide-treated bed nets 
(Sierra Leone Government, MOHS 2006; Pose and Rabinowitz 2014). 
 
To ensure effective implementation of the national health priority areas, the National Health 
Sector Strategic Plan 2010-2015 was developed around strengthening the six pillars of the 
national health system: (1) leadership and governance; (2) service delivery; (3) HRH; (4) 
medical products and technologies; (5) health care financing; and (6) health information 
system (GoSL, MOHS 2009; WHO Sierra Leone 2009; GoSL, MOHS 2010; GoSL, MOHS 2012a).  
 
Human Resources for Health 
According to MacKinnon and MacLaren (2012), human resources for health is key for 
accessibility of health services and determines the overall health of the country’s population. 
Accessibility to health care services is poor especially in rural areas due to an acute shortage of 
trained health professionals; the significant dichotomy of staff between rural and urban health 
facilities and among health cadres; and poor access to good quality healthcare, medical 
technology, and equipment. WHO has set benchmarks to determine if a country is facing a 
health workforce crisis. WHO determines that a country should have 2.28 health care 
professionals per 1,000 population as a minimum threshold for public health access. Countries 
with less than 2.28 health workers per 1,000 population are said to have a critical shortage of 
health professionals as this indicator sheds light on a country’s capacity to meet basic health 
needs (MacKinnon and MacLaren 2012). Sierra Leone in 2008 had a health care worker 
(physicians, nurses and midwives) density of 0.39 trained health workers per 1,000 population, 
which represents about one sixth of the minimum recommended by WHO (MacKinnon and 
MacLaren 2012). The current total workforce is estimated at over 8000 health personnel with 
over 50% of staff in the Western Area alone (GoSL, MOHS 2012a).  
 
As poor post-conflict countries, such as Sierra Leone, strive to rebuild their public health 
systems, the role of bilateral and multilateral donors in strengthening health service delivery 
becomes crucial. The donors and developing partners that support the MOHS in Sierra Leone 
have also supported the building of public management capacity in general including for 
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human resources for health, and also technical assistance and training to improve health 
service delivery (MacKinnon and MacLaren 2012; WHO Sierra Leone 2009).  
  
Health Sector Financing 
Expenditure on health as a percentage of GDP increased over the years from 4.3% in 2000 to 
7% in 2006. However, a high proportion (about 61.3%) of total health expenditure is out-of-
pocket spending (WHO Sierra Leone 2009; GoSL, MOHS 2012b). The main source of financing 
the public health sector is therefore through budget allocations still being strengthened by 
financial support from development partners such as the USAID, EU, DFID and ADB (WHO 
Sierra Leone 2009). In 2013, external resources as a percentage of total expenditure on health 
were 31.3%. Per capita total expenditure on health in 2013 was US$228.00. Total expenditure 
on health as a percentage of GDP was 11.8% in 2013, and general government expenditure on 
health as a percentage of GDP was 1,7% (African Health Observatory, WHO AFRO 2016).  
 
Neglected Tropical Diseases Programme 
Before 2007, only the NOCP existed (which was established in 1989). The NOCP was charged 
with nationwide surveillance for Guinea Worm Disease from 2005 to 2007 when the disease 
was declared eradicated in Sierra Leone. Consequently, reliable data on the prevalence of 
NTDs, especially for LF, before the NTDP was formed in 2007 are scarce (unpublished NTDP 
Reports 2008-2015; WHO Sierra Leone 2009; WHO Sierra Leone 2014). 
 
Epidemiology studies conducted using skin snip method between 1988 and 2005 have shown 
that 12 out of the 14 health districts are endemic for onchocerciasis. The NOCP was set up in 
1989, and by 1990 both preventive chemotherapy and vector control had been established in 
all 12 endemic districts with support from the WHO Onchocerciasis Control Programme (OCP) 
for West Africa and Sightsavers. However, between 1991 and 2002 the civil war which 
disrupted all programme activities led to the complete halt of programme activities in 1997. 
Onchocerciasis control activities restarted in 2003 under the Special Intervention Zones (SIZ) 
programme established for ex-OCP countries following the closure of the OCP in 2002. The SIZ 
programme was managed by APOC (unpublished NTDP Reports 2008-2015).  
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In 2005, with support from APOC, Sightsavers and the World Bank, the onchocerciasis control 
activities were reviewed and reorganized both technically (more staff were appointed) and 
administratively (the leadership changed) due to poor performance as the treatment coverage 
was 35% in 2003 and 28% in 2004, and geographic coverage could not be determined. In 2005 
the NOCP continued onchocerciasis control mainly through mass drug administration (MDA) 
using the community directed treatment with Ivermectin (CDTI) strategy under the guidance of 
APOC (Bockarie et al. 2013). Treatment results improved gradually and by the end of 2006 
MDA results for onchocerciasis increased to over 70% epidemiological coverage2 and 100% 
geographic coverage (unpublished NTDP Reports 2008-2015; Pose and Rabinowitz 2014).  
 
After advocacy by AFRO in 2006, the MOHS decided, in 2007, to integrate onchocerciasis 
control with the elimination/control of other NTDs starting with LF and the NOCP was renamed 
the National NTDP. Baseline surveys to determine LF microfilaraemia prevalence and density 
were conducted using ‘night blood survey (NBS) and the thick blood film (TBF) method’ in 2007 
(in six districts) and in 2008 (in the eight remaining districts) before LF MDA was launched. A 
phased integrated MDA for the treatment of onchocerciasis and LF starting with six districts in 
2007 was conducted (the remaining six of the 12 onchocerciasis-endemic districts were treated 
only for onchocerciasis) and upscaled to another six districts in 2008. Thus, integrated 
LF/onchocerciasis MDA was conducted for the first time in all 12 previously onchocerciasis-
endemic districts since 2008. The two districts that are not co-endemic for onchocerciasis and 
LF started treatment for LF separately in 2010. Since 2007 the NTDP Sierra Leone has been 
responsible for control/elimination of onchocerciasis, LF, schistosomiasis, soil transmitted 
helminthiasis, Buruli Ulcer, and Human African Trypanosomiasis (unpublished NTDP Reports 
2008-2015). 
 
Indicators for NTDs in Sierra Leone 
This study focuses on PC NTDs that include onchocerciasis, LF, schistosomiasis, soil transmitted 
helminthiasis, and trachoma. Although details of the onchocerciasis and LF situation in Sierra 
Leone will be provided in subsequent chapters, it is worth noting here that mapping/baseline 
                                                          
2 Epidemiological coverage is the coverage of an intervention among the total population expressed in 
percentage and is calculated as the total number of people treated divided by the total population of the 
area treated multiplied by 100 (WHO 2013). 
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studies conducted for onchocerciasis, LF, schistosomiasis, soil transmitted helminthiasis, and 
trachoma have shown that onchocerciasis is endemic in 12 out of 14 districts; LF is endemic in 
all 14 districts; schistosomiasis is endemic in 12 out of 14 districts; soil transmitted 
helminthiasis is endemic in all 14 districts. None of the 14 districts are endemic for trachoma. 
No schistosomiasis control activities were conducted in Sierra Leone before the arrival of 
USAID funding in 2008. Earlier studies indicated that both intestinal and urinary forms of 
schistosomiasis were prevalent in the north-east and baseline studies in 2008 showed 
moderate to high prevalence of Schistosoma mansoni in seven districts (Kono, Koinadugu, 
Kenema, Kailahun, Bo, Bombali and Tonkolili districts that involves 1.8 million people at risk) 
and low prevalence in the five coastal districts (Port Loko, Kambia, Moyamba, Pujehun and 
RWA). Bonthe and Urban Western District had zero schistosomiasis prevalence. Baseline 
survey/mapping was conducted with USAID funds for trachoma in 2008 in the five northern 
districts that border with districts in Guinea that have been demonstrated to be endemic for 
trachoma in neighbouring Guinea.  Since 2008 the NTDP has received financial and technical 
support from the USAID NTDP initially through the NTDP Control Programme that was 
managed by Research Triangle Institute (RTI) International (2008-2010) and later through the 
End NTDs in Africa (END in Africa) project (2011 – to date) to implement programme activities 
for the control/elimination of NTDs. After several country and field visits to conduct a 
situational analysis by members of the International Certification Committee (ICC) for Guinea 
Worm Disease between 2005 and 2007, Sierra Leone was certified by WHO based on the ICC 
recommendation as GWD free in 2007.  No studies have been conducted for diseases such as 
Buruli Ulcer and Human African Trypanosomiasis and no activities have been started in respect 
of these diseases (unpublished NTDP Reports 2008-2015; Koroma et al. 2010; Koroma et al. 
2011). 
 
Implementation of the NTDP 
The NTDP is under the direct supervision of the DPC Directorate of the MOHS and has an NTD 
Task Force chaired by the Director of DPC that supports coordination of NTD activities in the 
country. The NTDP is headed by a Programme Manager who is responsible for implementation 
of NTDP activities in the country with support from the NTD Task Force. The NTDP has 
technical officers responsible for the various NTDs - onchocerciasis, LF, SCH, and soil 
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transmitted helminthiasis (GoSL, MOHS 2009; unpublished NTDP reports 2008-2015). The core 
function of the NTDP at the central level is policy formulation and ensuring adherence to WHO 
guidelines; setting of standards and quality assurance; resource mobilisation; capacity 
development and technical support; provision of nationally coordinated services such as MDAs 
and impact assessment surveys; M&E for NTDs and training conducted at national level 
(unpublished NTDP Reports 2008-2015).  
 
At the district level, NTDP activities are coordinated by a district NTD focal point/coordinator 
who operates within the DHMT that is headed by a DMO (GoSL, MOHS 2009; GoSL, MOHS 
2012a; WHO AFRO NTDP 2013).  
 
The health care system within districts is used by the NTDP to reach every village in districts 
endemic for the targeted NTDs. Activities within communities are coordinated by PHU staff 
and implemented by community-directed drug distributors (CDDs) who are trained, supervised 
and supported by PHU staff. Each PHU staff covers villages that are in their catchment areas 
(WHO AFRO NTDP 2013). The second tier (district hospitals) and third tier (referral hospitals) 
are involved in NTDP activities such as management of severe cases of adverse events 
following treatment for NTDs and passive treatment for people who go to these institutions 
after missing any of the MDAs. Depending on the number of PHUs in districts, all the 1,195 
PHUs are involved in the MDAs and PHU staff train, supervise and monitor treatments 
conducted by CDDs. CDDs are usually people within affected communities (men and women) 
that are literate (mostly primary school teachers) or semi-literate community members that 
are selected by their community members to implement MDAs within communities. It is worth 
noting that due to the high number of severe adverse events reported in the first MDA that 
was conducted for SCH using praziquantel tablets it was decided that only PHU staff will 
distribute praziquantel tablets for treatment of SCH with the support of teachers in school and 
CDDs in communities (GoSL, MOHS 2009).  
 
Human Resources for the NTDP 
Since accessibility to health care services is poor especially in rural areas due to an acute 
shortage of trained health professionals, the NTDP implements activities within communities 
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using community volunteers or CDDs who are supervised, trained and monitored by PHU staff. 
This way, all communities within the 12 endemic districts have been treated for onchocerciasis 
and LF since 2008. The PHU staff are, in turn, supervised by DHMT members. Activities within 
districts are also supported, supervised and monitored by NTDP staff at the central level, and 
also by representatives of locally based NTD partners such as Sightsavers and HKI (Sierra Leone 
Government MOHS 2006; unpublished NTDP Reports 2008-2015). There are currently 1,195 
PHUs throughout the country that are staffed by different cadres of health workers: CHOs, 
MCHAs and SECHNs who oversee approximately 25,000 volunteer CDDs. These CDDs are the 
backbone of all the NTDP activities in the rural setting. While in the rural areas CDDs serve as 
volunteers within the NTDP, in the Western Area there are no volunteer CDDs and NTD drugs 
are distributed by paid health workers for a fixed number of days (normally five days) 
(unpublished NTDP Sierra Leone Reports 2008-2015; Pose and Rabinowitz 2014).  
 
NTDP Financing 
The main source of financing NTDP activities in Sierra Leone is through support from NTD 
partners such as USAID, Sightsavers, AFRO, APOC, the World Bank, LSTM CNTD and HKI.  The 
method of financing NTDP activities is such that the most remote villages, some of which are 
hard to reach, are accessed by DHMT staff and PHU staff at no cost to the community 
members themselves. Budgets include provision for movement to all areas of land and sea and 
include involvement of community volunteers as CDDs who receive only per diems during 
training but work for free as a service to their communities. In general, NTD funds move 
directly from the funding agencies to the NTDP central level and then the DHMTs with different 
partners requiring different methods of accounting. The different NTD partners also supervise 
field activities to ensure proper use of the funds they provide. NTDP funding before 2003 was 
from the OCP and Sightsavers; between 2003 and 2007 from APOC (through the SIZ 
programme), Sightsavers and the World Bank; and from 2008 to date from USAID, Sightsavers, 
APOC (SIZ programme closed in December 2007 and APOC closed in December 2015) and HKI. 
USAID support provided through the END in Africa project is managed locally in Sierra Leone by 
HKI (unpublished NTDP report 2008-2015).  
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Currently, USAID provides over 80% of the financial support needed by the NTDP. Funds from 
the different sources are pooled for overall integrated implementation of interventions. The 
CNTD supported refurbishment of the NTD laboratory in Makeni and two key operational 
research projects for endemic NTDs in the past six years (‘Transmission of lymphatic filariasis in 
two post-conflict urban cities in West Africa’ and ‘Impact assessment surveys to define the 
factors determining the successful implementation of MDA to eliminate LF in a fragile health 
system in post-conflict Sierra Leone’). Johnson & Johnson has supported the training/retraining 
of 70 doctors, mostly from the Northern Province, on surgical procedures for hydrocele, one of 
the complications of LF. The NTDP has also received, in recent years, financial support through 
HKI for the second round of de-worming of school-aged children in some districts. Funds for 
extra deworming efforts in 2010 came from the World Food Programme and in 2011 and 2012 
from the World Bank’s Fast Track Initiative through the Ministry of Education, Science and 
Technology. Mebendazole/albendazole for soil transmitted helminthiasis treatment has been 
donated from the Saint Andrews Clinic for Children in Sierra Leone, De-worm the World, Feed 
the Children, and World Vision Sierra Leone. TOMS Shoes and HKI established a partnership in 
2013 that has led to the donation and distribution of shoes to all CDDs (unpublished NTDP 
Reports 2008-2015). 
 
 
JUSTIFICATION, RATIONALE, AIM AND OBJECTIVES OF THE STUDY  
Results of onchocerciasis baseline studies3 showed that 12 out of the 14 districts are 
onchocerciasis-endemic while LF mapping studies showed that all 14 districts are LF endemic. 
Integrated MDA for the treatment of onchocerciasis and LF has been ongoing in the 12 districts 
co-endemic for both diseases since 2008 (unpublished NTDP reports 2008-2015). This study 
will document the progress and achievements made, and the experiences gained in the 
management of the programmes for the elimination of onchocerciasis and LF from the 
establishment of the respective programmes to date. The study will also discuss the way 
forward for the two diseases up to verification of elimination by WHO.  
 
                                                          
3 For onchocerciasis, the mapping results obtained are used also as baseline data as opposed to LF for 
which there is WHO guidelines on how to do mapping and baseline studies separately. 
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The study and associated publications also serve as an archive for LF and onchocerciasis data 
needed for verification of elimination of both diseases and will guide the NTDP towards the 
elimination of both diseases with minor adjustments as the programme continues depending 
on new strategies and diagnostic tools that will be adopted in the future by WHO. 
 
Why do the planned research studies in Sierra Leone? 
Available literature suggests that both onchocerciasis and LF can be eliminated as a public 
health problem and transmission of both diseases can be stopped completely with the 
implementation of the right strategies recommended by WHO. Furthermore, drugs for treating 
some of these parasitic infections (especially onchocerciasis and LF) are donated to the NTDP 
by pharmaceutical companies. Also, most of the strategies used for the elimination of 
onchocerciasis and LF are similar or the same. For example, the strategies for 
controlling/eliminating onchocerciasis and LF rely on the use of the same drug regimen 
(Ivermectin/Mectizan and albendazole) administered on a massive scale via treatment of 
entire communities. When the decision to integrate LF and onchocerciasis treatment was 
taken in 2007, albendazole was added to be co-administered with ivermectin and CDTI became 
CDTI plus albendazole. The addition of albendazole to the already existing onchocerciasis 
treatment with ivermectin facilitated integrated MDAs for onchocerciasis and LF. Both these 
drugs are donated to NTDPs by the manufacturers for as long as required (unpublished NTDP 
Reports 2008-2015).  
 
Many poor rural communities in Africa live in areas endemic for two or more of these NTDs, 
and 12 out of 14 districts of Sierra Leone are endemic for both diseases. Fortunately, only the 
NOCP existed in Sierra Leone before the idea of having an integrated NTDP was recommended 
by WHO to the MOHS, and so it was a straightforward exercise for the NOCP to be responsible 
for all NTDs in the country. The NOCP activities were completely integrated into the health 
system since the formation of the NOCP in 1989 and activities were coordinated at central 
level by the NOCP but coordinated at the lower levels (districts, chiefdoms, and villages) by 
health service personnel within the MOHS that operate at these levels. Therefore, with the 
NOCP responsible for LF elimination since 2007, the same applied to LF activities, which were 
in almost all cases co-implemented with onchocerciasis activities at all levels. Since health 
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workers at district, chiefdom and village levels have to visit the same communities several 
times in a year to deliver different interventions for different diseases the co-implementation 
of onchocerciasis and LF activities has reduced the burden of health workers and, to some 
extent, it has fostered integrated implementation at lower levels, rational and efficient use of 
human and financial resources, savings on time of implementers and beneficiaries, synergistic 
impact on the targeted NTDs where these are co-endemic, and also strengthened health 
services delivery systems. Integrated programmes are also easier to sustain as financial, human 
and other resources are shared. Integration is particularly important at this time of dwindling 
resources from donor nations and agencies. Sierra Leone has emerged from a vicious 11-year 
civil war that destroyed the economy, infrastructure and interrupted virtually all health 
services, other social sectors and developmental activities. During this phase of rehabilitation, 
reconstruction and recovery, it is good that the country can integrate disease control 
programmes and avoid having to run many vertical programmes that are expensive to sustain 
especially so when the bulk of the health budget is externally funded (unpublished NTDP 
Reports 2008-2015).  
 
The aim of the study  
The aim of the study is to determine the impact of integrated treatment of onchocerciasis and 
filariasis using the community directed treatment with ivermectin plus albendazole strategy 
and make recommendations on the way forward to achieve elimination of transmission of 
both diseases in Sierra Leone. 
 
Objectives of the study  
 To evaluate the impact of vertical treatment of onchocerciasis between 2005 and 2006 
plus integrated onchocerciasis/LF treatment between 2007 and 2009 on the transmission 
of onchocerciasis in Sierra Leone.   
 To evaluate the impact of vertical treatment of onchocerciasis in Sierra Leone before 2007 
on the LF transmission and intensity. 
 To evaluate the impact of integrated onchocerciasis/LF treatment in Sierra Leone at mid-
term (i.e. after three effective MDA rounds) on the LF transmission intensity  
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 To evaluate the impact of integrated onchocerciasis/LF treatment in Sierra Leone after five 
effective rounds of MDA on the LF transmission intensity. 
 To determine the way forward to achieve elimination of both diseases as a public health 
problem using the latest available WHO guidelines and diagnostic tools. 
 
Expected Output/Outcome of the Study 
The author of this study is working with the National NTDP of the MOHS in Sierra Leone to 
conduct these research studies in strict adherence to WHO guidelines and the policies, rules, 
and regulations of the MOHS. The author of this study has supported and will support the 
national NTDP to conduct, analyse and document all research relating to onchocerciasis and LF 
control in Sierra Leone. The research studies conducted for this thesis are a requirement of 
WHO for successful completion of the onchocerciasis and LF programmes and are all 
conducted strictly in line with WHO recommendations for the two diseases. Data collection 
and archiving are relatively poor in Sierra Leone, and through this study, the studies conducted 
relating to onchocerciasis and LF elimination are documented, and the data and information 
available can be used by the NTDP for decision making as the programme is implemented. 
According to WHO recommendations and requirements, the NTDP will need to put together a 
dossier of survey and treatment data that will be used in the near future by the Elimination 
Committees that will be set up to verify elimination of onchocerciasis and LF in Sierra Leone. 
This study and its content will serve as a good collection of all data needed by the NTDP for 
verification of elimination of onchocerciasis and LF in the near future. The international 
scientific community will benefit from the documented onchocerciasis/LF elimination 
experiences obtained from co-implementation of activities for the two diseases and 
integration of programme coordination within the MOHS service delivery system in Sierra 
Leone, a post-conflict country that has also recently been through an EVD outbreak. It is also 
hoped that countries with similar challenges (post-conflict, and with co-endemicity of 
onchocerciasis and LF), especially in Africa, can learn from the experience in Sierra Leone. The 
NTDP in Sierra Leone and the MOHS, in general, can use the experiences gained in the 
integrated management of onchocerciasis and LF for the integration of other disease control 
programmes. 
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It is expected that the study will demonstrate the following:  
• How onchocerciasis control activities can be co-implemented with LF control activities in 
areas where both diseases exist and the effectiveness of co-implementation for control 
of both diseases. 
• How the onchocerciasis and LF control programmes can be integrated into a country’s 
health care delivery system. 
• How an integrated control programme can be conducted in a post-conflict country with a 
weak health system and weak human resources for health.  
• The outcome in terms of reduction in prevalence and distribution of onchocerciasis and LF. 
 
 
METHODOLOGY 
Study design 
This is a nationwide longitudinal observational study of filariasis infection dynamics conducted 
in 14 districts undergoing MDA for the elimination of LF and onchocerciasis.  The study will 
quantify and test the hypothesis that annual rounds of PC can significantly reduce transmission 
intensity and eliminate LF as a public health problem after five-six years and onchocerciasis 
after 15-17 years. The study design will be consistent across all study districts and represents 
an observational study of human infection status and demographic information related to the 
force of transmission. The primary study design in each district is a community-based 
longitudinal investigation of changes in the mean trends and variability in parasitological and 
serological variables. Changes in the community infection load are monitored following the 
WHO PC guidelines. 
 
The original maps of the previously studied sentinel sites are updated using Geographic 
Information Systems.  New maps are created of spot check sites that change over time.  A 
census of the population is performed by house-to-house visits.  All members of the 
households are registered and name, sex, birth date, declared familial relationship, occupation, 
and duration of residence recorded.  Informed consent to participate in this observational 
study is obtained from all individuals 18 years old.  Consent is obtained from a parent or 
guardian of younger individuals. Prior to obtaining demographic information and obtaining 
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informed consent, repeated community meetings are held in all villages to communicate the 
purposes of the study and answer questions at the individual and community level.  Local 
district health workers are used as spokesmen as an integral part of the research team. 
 
The primary analysis quantifies the presence and community levels of microfilariae (MF), and 
antigen (Ag), indicators stratified by age, sex, and village using univariate statistical methods. 
Multivariate analysis will be performed to examine the risk of LF and onchocerciasis infection 
with factors such as prior level of endemicity and MDA coverage.  
 
Review of longitudinal survey data 
All treatment results for the period 2005-2015 (for onchocerciasis and LF), and all research 
studies conducted at baseline (1988-2005) and during universal treatment (2008-2013) for 
monitoring the impact of treatment are reviewed. Apart from NTDP data and information, 
extensive literature search will be conducted using the appropriate search words. Information 
obtained will be used to review the data from treatment and research studies conducted by 
the NTDP. Some of the data obtained from the research studies have been published already in 
international peer-reviewed journals. This study and all the data it contains will also be made 
available to the MOHS for use in the future as part of the dossier to be prepared for 
verification of elimination of onchocerciasis and LF in Sierra Leone.  
 
Sources of information and data for the study 
The following are used as sources of information for the review: 
 Mapping/Baseline data for onchocerciasis obtained using the skin snip method for the 
period 1988 – 2005. 
 Mapping/Baseline data for LF including mapping results obtained using ICT cards in 2005 
and baseline survey results obtained using NBS/TBF method in 2007/2008. 
 Results of onchocerciasis evaluation conducted in 2010.  
 Results of mid-term evaluation conducted for LF in 2011 after three years (2008-2010)  
 Results of pre-transmission assessment survey (pre-TAS) conducted in 2013 for LF after five 
years of treatment (2008-2012). 
 Results of MDA for onchocerciasis (2005-2015) and LF (2007-2015). 
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 Annual Implementation Plans for the period 2005-2015. 
 Annual NTDP Reports for the period 2005-2015. 
 Publications on NTDs in general with a focus on onchocerciasis and LF. 
 
Ensuring good representation for each study 
Sampling for each study was done in accordance with WHO guidelines and recommendations 
for each disease-specific study. All mapping and baseline surveys were conducted in all 14 
districts, and subsequent impact assessment surveys were conducted in the districts that were 
determined to be endemic based on mapping and baseline surveys conducted. Selection of 
sentinel sites for all impact assessment studies is based on the mapping results. The mapping 
sites with the highest prevalence rates were selected for the baseline study (for LF) and the 
sites selected for baseline studies are kept as sentinel sites for impact assessment studies. For 
onchocerciasis, the mapping sites with highest results were selected for impact assessment 
studies. The NTDP selected areas of highest risk to demonstrate reduction in disease 
prevalence or interruption of transmission with the assumption that reduction of prevalence in 
areas with the highest risk of exposure increases the confidence that areas in the lower 
transmission zones, covered by the same intervention strategy, would have also reduced 
disease prevalence or interrupted interruption (unpublished NTDP Reports 2008-2015).  
 
Ethical considerations 
This study involves several research studies for onchocerciasis and LF and involves participants 
that are ≥5 years. The author has received ethical approval for the studies from the LSTM 
Ethics Committee (see appendix 1 of page 290). Since all studies conducted were coordinated 
by the NTDP Sierra Leone, and within the NTDP Sierra Leone by technicians belonging to the 
NTDP itself, the MOHS and the University of Sierra Leone, ethical approval was sought and 
received for each of the studies by the NTDP from the Ethics Committee of the MOHS. Details 
on ethics will be provided for each of the research studies in subsequent chapters where the 
studies are discussed in detail. The following ethical issues were addressed during all the 
studies discussed for this thesis: ensuring that all guidelines are followed for the  protection of 
participants and members of the research teams from infection; ensuring that investigators 
receive all the relevant materials for their protection and the protection of participants; 
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treatment and follow-up of all those who are found to be positive; provision of enough 
information to participants of the study such as the reality that not all those affected with the 
disease can be cured but those affected can work with the NTDP to prevent spread of the 
diseases; proper disposal of blood specimen and materials after the survey; and proper cleaning 
of instruments and equipment before and after surveys. The research studies were designed 
and implemented to avoid any litigation and to avoid any conflict with routine health services. 
Litigation was avoided by ensuring the safety of the research teams and research participants 
and by properly engaging with community leaders and participants of the studies first during 
meetings with community leaders and then subsequently with entire communities where the 
surveys were conducted. Measures were put in place to avoid any conflict with the 
implementation of routine health services. The NTDP has in place a team of investigators for the 
studies that involved central level staff of the NTDP, the MOHS and the University of Sierra 
Leone. District health workers were not involved in the actual implementation of the studies but 
supported the research teams in identifying villages to be investigated and also leading the 
discussions with community leaders and communities. By covering only sites located within their 
areas of supervision the district health workers were not kept away from their jobs for more than 
two days. 
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CHAPTER 2: LITERATURE REVIEW ON ONCHOCERCIASIS AND 
LYMPHATIC FILARIASIS
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GLOBAL OVERVIEW OF ONCHOCERCIASIS 
 
Introduction 
Onchocerciasis, known as River Blindness and Robles’ disease, is a parasitic disease that affects 
over 37 million people and can lead to permanent changes mostly in the skin, the eye and can 
end in total blindness. The disease is caused by infection with Onchocerca volvulus (O. 
volvulus), a microscopic nematode (Taylor 2003; Boatin and Richards 2006; Basanez et al. 
2006; WHO APOC 2010; Traore et al. 2012; Katabarwa et al. 2013; WHO 2016b). The disease is 
transmitted to humans by the blackfly (Simulium spp.), and disease pathology is linked with the 
death of the MF in the skin and eyes (Basanez et al. 2006; Gloeckner et al. 2010; Traore et al. 
2012). Humans are known as main reservoirs for O. volvulus (APOC 2010). Some animals such 
as elands and buffalos are possible reservoir hosts, which makes control of the disease in areas 
where these animals co-exist more difficult (Crump et al. 2012). Other forms of the 
onchocerciasis parasite (besides O. volvulus) affect various animals including wild game, 
livestock, draught animals and dogs (Crump et al. 2012). Figure 4 shows the global distribution 
of onchocerciasis in 2015. 
 
Currently, there are an estimated 187 million people at risk of onchocerciasis (living in endemic 
areas) among which 37 million are onchocerciasis-infected. Among those infected, 4 million 
people live with skin manifestations of the disease and an estimated two million are either 
visually impaired or blind. The vast majority of infection is in sub-Saharan Africa (about 99% of 
reported cases) (Taylor 2003; Basanez et al. 2006; Traore et al. 2012; Uniting to Combat NTDs 
2015; WHO 2016b). With South Sudan, the total number of endemic countries in sub-Saharan 
Africa is 31 (20 ex-APOC and 11 ex-OCP) and Nigeria alone accounts for an estimated 25% of 
the total global burden of infection. The other 1% of the global infection is in Yemen and six 
Latin American countries (Brazil, Colombia, Ecuador, Guatemala, Mexico, and Venezuela) 
(APOC, 2010; Crump et al. 2012; Uniting to Combat NTDs 2015). The disease in Yemen and 
Latin America appears to have been imported from Africa (Hopkins and Boatin 2011; Lipner et 
al. 2006; Weil et al. 2000; Taylor, Hoerauf and Bockarie 2010).  
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Figure 4: Distribution and status of preventive chemotherapy for onchocerciasis, worldwide, 
2015 (WHO, Online; available from: 
ttp://www.who.int/mediacentre/factsheets/images/Onchocerciasis_2015.png?ua=1)
 
 
Onchocerciasis is a disabling disease that causes significant morbidity, psychosocial problems 
and reduces the ability to work, especially agricultural productivity, within populations 
affected. Onchocerciasis is the world’s second leading cause of blindness after cataract, and 
onchocerciasis-related blindness brings its own consequences as it can perpetuate poverty of 
families and communities. Blindness from onchocerciasis in people occurs early in life (20-30 
years) and usually, children stay from school to lead their blind parents around, which 
devastates the life of affected families and creates socio-economic problems for affected 
communities and countries. The cost to individuals and families of treating ailments relating to 
blackfly bites can be catastrophic for people who depend on subsistence farming for a living. It 
is also suggested that the nuisance of black fly bites can also reduce tourism and 
onchocerciasis can cause deaths among wild animals and livestock (Basanez et al. 2006; APOC 
2010; Gloeckner et al. 2010; Crump et al. 2012; Traore et al. 2012). 
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Transmission 
Among the many Onchocercal species available only O. volvulus is hosted by man and man is 
known as the main animal reservoir for the onchocerciasis parasite O. volvulus (Taylor et al. 
2009). Transmission of O. volvulus occurs in several stages (Figure 5). The female Simulium 
ingests the MF (baby worms) of O. volvulus while taking a blood meal from the skin of an 
infected person. After ingestion, the MF enters the gut and thoracic flight muscles of the fly 
developing to the 1st larva stage (L1), then the 2nd larva stage (L2) that moves to the proboscis 
of the fly, and finally to the 3rd larva stage (L3) that moves to the saliva. The larvae take seven 
days after being ingested to reach the L3 stage in the black fly, which is the infective stage. The 
L3s pass on to the next human while the fly takes another blood meal through the wound 
created in the skin when the fly bites the skin, remains in tissues for a few days and then 
transforms into the L4 stage (Taylor et al. 2009; APOC 2010; Hopkins and Boatin 2011, Tekle et 
al. 2012; Katabarwa et al. 2013).  
 
Figure 5: Transmission cycle of O. volvulus including stages in humans and flies (APOC; 
Online, available from: http://www.who.int/apoc/onchocerciasis/lifecycle/en/) 
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After one week, they are transformed into juvenile worms (L5 stage). It takes a further 7-15 
months before the juvenile worm becomes mature and the adult worm moves towards the 
nodule where mating takes place. Adult worms mate in the subcutaneous layer of the human 
skin and females produce 700-1500 larvae or MF each day. Although a vast majority of MF are 
found in the skin of an infected person, some are located in the eyes and other tissues. The 
cycle is restarted when the black fly takes another blood meal ingesting newly reproduced MF. 
To develop to the adult stage, the MF must enter the black fly, develop to the L3 stage and re-
enter the body of a human when the fly takes a blood meal. The adult lives for 10-14 years. The 
MF not ingested by the fly during a blood meal after reproduction live 6-24 months in the 
human host and then die. It has been noted that the vector is a day biting fly (Taylor et al. 
2009; APOC 2010; Hopkins and Boatin 2011, Tekle et al. 2012; Katabarwa et al. 2013). 
 
Black flies breed in rapids and fast-flowing water (streams and rivers) because the black fly 
needs well-oxygenated water to lay its eggs that also serves as a place where the larvae can 
develop. Rapid flowing water provides the oxygenation needed for the development of the 
vector larvae. Most larvae and pupae develop on rocks or vegetation just below the water 
surface although those of S. neavei develop on amphibious Potamonautes crabs. Aquatic 
stages of the fly require ten days to complete development depending on temperature and 
nutrients available. Eggs hatch after 36-48 hours, and the larval stage lasts for five-ten days 
depending on water temperature. Pupation and emergence of adult flies occur after further 
two-three days, and the black flies live for up to four weeks. The female fly mates only once on 
the day after emergence; then seeks a blood meal, which is necessary for maturation of her 
eggs; and is ready for oviposition four or five days after the meal. The time between blood 
meals varies from six to 12 days. Consequently, the transmission is most intense and the 
disease most severe within communities that are close to fast flowing rivers or streams. The 
risk of blindness is, therefore, higher for such communities that live close to rivers hence the 
name ‘river blindness’.  Development of the black fly and transmission of the disease is 
therefore linked to the flow of rivers and streams. For areas where rivers run throughout the 
year, transmission continues throughout the year, while in areas where the rivers run only 
during the rainy season, transmission occurs only during the rainy season. Therefore, some 
authors have suggested the need to provide onchocerciasis treatment to communities just 
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before the period or during the period when transmission by black flies is most intense (Samba 
1994; Boatin et al. 1998; Taylor et al. 2009; Hopkins and Boatin 2011).  
 
The black fly feeds as close to the breeding site as possible and so populations within 5km of 
the breeding site are most exposed although communities 12-15km away may be affected. 
Transmission of onchocerciasis takes place when the fly moves from the breeding site to feed 
on human blood by biting the skin (Kutin et al. 2004). Because the risk of infection is greater 
the closer a community is to a river; it appears as if those close to the river protect those that 
are far away from the river (Kutin et al. 2004; Taylor et al. 2009; Hopkins and Boatin 2011). 
Simulium rarely enters the house to bite and biting is usually in the mornings and late 
afternoon hours when people need the rivers for water, washing, and food. There have been 
reports of villages being abandoned because of the nuisance created by the continuous biting 
of the black fly and fear of being blind (Taylor et al. 2009; Hopkins and Boatin 2011). 
 
Recent studies have also shown that S. damnosum can fly 400-500km by moving with the 
prevailing wind in West Africa: from Guinea and Sierra Leone in the south to Mali in the north 
during the rainy season; and back from Mali to the south during the harmattan season 
(Hopkins and Boatin 2011). The issue of migration should be considered when discussing 
disease transmission especially the possibility of migration between neighbouring transmission 
zones. Therefore, it is important to ensure that neighbouring transmission zones are treated 
adequately with ivermectin and that geographic and therapeutic coverage are adequate in all 
zones within an endemic country (APOC 2010). As some of the fly species can travel long 
distances in Africa care must be taken when constructing dams as the fast runoff of the water 
is ideal to establish new breeding sites for Simulium black flies. This must be considered during 
construction and maintenance of new dams (Hopkins and Boatin 2011).  
 
Male/female nuances of onchocerciasis transmission 
The male/female differences in prevalence, the density of infection and clinical disease due to 
onchocerciasis is reviewed and related to differential exposure of females to infective vectors. 
Sex differentials are most marked in savannah areas of high transmission, and in these areas, 
worm burden is lower from early childhood in females as are ocular lesions. In forest areas, sex 
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differences are less significant, and ocular lesions are similar in men and women. Sex 
differences are most evident under conditions of high transmission, and it has been suggested 
that females are more resistant to infection than males. Further research is needed to obtain 
substantive evidence that onchocerciasis is less frequent in females. Little is known about 
onchocerciasis in pregnancy but increased resistance could influence the risk of transmission of 
infection from mother to child in highly endemic areas. Onchocerciasis infection in pregnancy 
is also likely to affect the immune response to tetanus toxoid vaccination in mothers and birth 
weight of children. Onchocerciasis, therefore, represents an important public health problem 
for women and their offspring (Brabin 1990). 
 
Transmission from mother to child 
A study analysed the impact and extent by which parental O. volvulus infection, intensity, and 
transmission of O. volvulus infective stage L3 larvae can influence transmission of 
onchocerciasis from mothers to their children. The study results showed that children from O. 
volvulus infected mothers were more likely to be infected with onchocerciasis than children 
from non-infected mothers. They were also more likely to acquire the infection earlier in life 
and developed higher infection levels (Kirch et al. 2003). 
 
Pathogenesis 
Adult worms (males and females) are found in fibrous nodules or onchocercomata found in 
subcutaneous tissues especially over bony prominences (although others can be found in 
deeper tissues). The adult worms found in the nodules under the skin of infected individuals 
can live 10-14 years. Female worms are larger than males (30-80 cm versus 3-5 cm long) and 
are found entwined around each other in the nodules. Each nodule may contain one/two male 
worms and 2/3 female worms, although larger nodules may have up to 509 adult worms 
(Taylor et al. 2009; APOC 2010; Hopkins and Boatin 2011; Tekle et al. 2012; Katabarwa et al. 
2013). Adult O. volvulus female worms live for up to 14-15 years producing millions of 
microscopic baby worms or larvae known as MF. Adult worms, which take a year to mature 
from the microfilaria stage, lodge in nodules under the skin releasing millions of MF into 
surrounding tissues, which then migrate through the body living up to 9-18 months (Omura 
and Crump 2004; Geary 2005). Since the adult worm is usually located in the subcutaneous 
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layer of the human skin, this limits access to the immune system towards them. However, the 
principal symptoms of onchocerciasis are due to MF because they can be spread all over the 
body. Live MF are no problem to the human host until they start to die after six months if not 
ingested by the black fly. The dead MF release Wolbachia surface protein inducing an immune 
response that leads to inflammatory reaction and local systemic changes. Wolbachia 
endobacteriae (symbionts of anthrops and filarial nematodes) contribute to the inflammation 
pathology associated with the disease. Wolbachia species are endosymbionts for adult 
onchocercal worms as well as MF. Although the immune reaction relating to one MF is small, 
the overall effect is devastating because of the large numbers of MF reproduced and that 
subsequently die thus provoking widespread and chronic reactions. At first, reactions are 
reversible but later permanent changes occur in the tissues (mainly the skin and the eyes) 
(Boatin and Richards 2006; Hopkins and Boatin 2011). The MF can enter all areas of the eye 
and when they die the ocular conditions can involve any part of the eye - conjunctiva, cornea, 
uvea and the posterior segment, including the retina and the optic nerve. Blindness is the 
result of anterior segment lesions, posterior segment lesions and secondary glaucoma or 
cataract (Boatin and Richards 2006). MF are found in the tissue of the eye of an infected 
individual from the conjunctiva to the optic nerve posteriorly. MF in the conjunctiva provokes 
itching. In the posterior segment, MF can be seen in the vitreous humour (Hopkins and Boatin 
2011). The intensity of infection is an important indicator of the disease because the more the 
number of adult worms, the more MF they produce and the more severe are the 
manifestations of the disease (APOC 2010).  
 
The pathogenicity of O. volvulus varies with different strains of the parasite. Savannah strains 
provoke much more blindness than the forest strain. Both savannah and forest strains provoke 
skin changes. Both strains are adapted to specific vector species; forest strains are transmitted 
by species of the vectors that are adapted to the forest areas and likewise with Savannah 
strains (Hopkins and Boatin 2011). Prolonged stays of several years and exposure to the fly 
bites and parasite introduction are needed for the disease to develop (Wikipedia (Online), 
available from: http://en.wikipedia.org.wiki.onchocerciasis; accessed 28/10/2013). However, 
there is a report of onchocerciasis infection after a 10-day stay in Cameroon, which was 
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completely cured with a single dose of ivermectin and additional treatment with doxycycline 
(Ezzedine et al. 2006).  
 
Vectors 
At least 15 simuliids species can transmit onchocerciasis depending on location (Taylor et al. 
2009). In Africa, the main vectors are members of the Simulium damnosum sensu lato (S. 
damnosum s.l) complex, which can travel long distances (up to 400km from their origin flying 
with the prevailing winds) (Brown 1962; Burnham 1998; Hopkins and Boatin 2011; Crump et al. 
2012). The S. damnosum s.l species includes an estimated 60 cytoforms and is responsible for 
transmission of 95% of all onchocerciasis cases. S. damnosum is a complex of sibling species 
with minor variations between the species, but they show adaptation to local circumstances. S. 
damnosum sub-complex contains species that are mostly responsible for transmission in 
Savannah areas whereas the S. sanctipauli, and S. squamosum subspecies are found more in 
forest areas. The vectors in East Africa in areas of Uganda, Tanzania, Ethiopia, and the Congo 
are members of the S. neavei complex that breeds on the carapaces of crabs. The S. neavei 
complex is usually restricted to localised areas and does not fly long distances. S. 
albivirgulatum is a separate species, which is found in the “Cuvette Central” of the River 
Congo. The larvae of this species are found on the underside of leaves floating down the River 
Congo and its tributaries, thus finding enough oxygen and nutrition for larval development. In 
the Americas, the principal vectors are S. ochraceum, S. metallicum, S. guianenses and S. 
exiguum. While in Africa the disease exists only in areas where the vectors are found, there are 
areas in the Americas where vectors exist in the absence of infection. Among the vector 
complexes, some bite humans almost exclusively while others are to varying degrees zoophilic 
(Brown 1962; Burnham 1998; Basanez et al. 2006; Crump et al. 2012). 
 
In hyper-endemic areas, an individual can receive several thousand bites a day from the flies. 
This can lead to an overall lowering of productivity, ill-health, disfigurement, and often 
abandonment of infested areas that can also devastate socio-economic wellbeing in affected 
communities (Crump et al. 2102). The seriousness of the disease within affected communities 
is determined by the number of black flies. The greater the number of black flies relative to the 
human population, the greater the intensity of disease transmission and the higher is the 
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endemicity level in terms of prevalence and density of infection in the human population 
(APOC 2010). 
 
Manifestations 
The people infected with onchocerciasis have symptoms of onchodermatitis (severe skin 
lesions), musculoskeletal pain and various stages of blindness. The most severe complications 
of onchocerciasis are irreversible ocular lesions of both the anterior and posterior segment of 
the eye, resulting first in impaired vision and finally in total blindness. Blindness is caused by 
the endosymbiont of the nematode, Wolbachia pipientis, which causes a severe inflammatory 
process in the eye that leads to blindness (Taylor 2003; Hopkins and Boatin 2011). Also, those 
affected may have decreased body mass index, work productivity, and social stigmatisation 
(Gloeckner et al. 2010). MF are found in the tissue of the eye of an infected individual from the 
conjunctiva to the optic nerve posteriorly and when in the conjunctiva can provoke itching of 
the eye (Hopkins and Boatin 2011). O. volvulus  infection also causes some systemic changes 
such as low body weight, general debility, and diffuse musculoskeletal pain. Bleeding and 
ulceration of the skin, secondary infections, bone pain, headache, and fatigue have also been 
reported. Evidence suggest that onchocerciasis is a risk factor for epilepsy and may be 
responsible for a type of hypo-sexual dwarfism in some endemic areas (e.g. the Nkalanga 
syndrome in Uganda). With a heavy MF load, there may be generalised lymphadenopathy and 
some dilatation of lymph vessels, leading to tissue swelling and mild elephantiasis (Hopkins and 
Boatin 2011). People who suffer from onchocerciasis suffer from more problems than the 
primary dermatological and ocular clinical symptoms. They suffer social stigma, diminished 
income generating capacity associated with persistent itching that leads to discomfort for the 
affected and financial woes for them and their families (Amazigo et al. 2007; Amazigo et al. 
2012). In most parts of the world, onchocerciasis has been not only an important public health 
problem but also a major obstacle to socio-economic development. Outside of the West and 
Central African Savannah, except certain areas in DRC, onchocercal blindness is not a major 
public health problem, but other complications of the disease can be highly prevalent. Skin 
lesions can affect more than a third of the adult population in hyper-endemic communities, 
ranging from unsightly and itchy papular onchodermatitis to gross depigmentation of the shins 
(leopard skin). In these communities, more than half the adult population suffers from severe 
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itching due to onchocerciasis. For the affected population, this itching can be maddening and 
disturbing and is thus seen as the most severe complication of the disease as it affects their 
well-being and those affected perceive it as a important public health problem (WHO 1995). 
 
Ocular disease and blindness 
Blindness is defined as visual acuity of less than 3/60 or a restriction of the visual field to less 
than 10 degrees of fixation in the better eye. Low vision is defined as visual acuity of less than 
6/18 but equal to or better than 3/60 in the better eye. The assessment of visual impairment 
and blindness in epidemiological surveys of onchocerciasis is usually based on a simple visual 
acuity test, such as the illiterate E- or the Sjogren hand test, at defined distances. 
Onchocerciasis can also cause a severe reduction in peripheral fields and it has been shown 
that some 25% of those functionally blind would have been missed if the examination were 
limited to the visual acuity test without peripheral field assessment. Studies conducted during 
the OCP suggest that in the absence of control, the prevalence of ocular lesions is more than 
three times the prevalence of blindness as measured by visual acuity testing (WHO 1983). 
 
Skin diseases of onchocerciasis  
Distribution and severity of onchocercal skin disease have been poorly studied and hardly 
anything was known about the importance of onchocercal skin disease for the affected 
populations. This was partly due to the absence of a standard classification scheme for 
documenting skin changes in onchocerciasis and also the difficulty in interpreting available 
literature on onchocercal skin disease because of the variety of non-standard clinical 
classification and examination methods used in the past. A simple standard classification and 
grading system for cutaneous changes in onchocerciasis was developed that was adopted by 
the WHO Expert Committee on onchocerciasis and recommended as the standard method to 
be used in surveys of onchocercal skin disease (Murdoch et al. 1993). This method classified 
the main onchocercal skin lesions into Acute Papular Onchodermatitis (APOD), chronic Papular 
Onchodermatitis (CPOD), Lichenified Onchodermatitis (LOD), Atrophy and Depigmentation. 
The method defines grades of severity for all lesions as well as grades of activity of the reactive 
skin lesions APOD, CPOD, and LOD. The main limitation of the method is that it is based on the 
differentiation of clinical, morphological groups that are consistent with cutaneous 
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onchocerciasis but for which the cutaneous changes are not specific or diagnostic of the 
disease and differential diagnosis will often be required. Field testing has shown that this 
method produces reliable results that can be reproduced, especially if the clinicians involved 
undergo a few days training in the application of the method (Murdoch et al. 1993; WHO 
1995). 
 
Geographic variations of onchocerciasis epidemiology 
The epidemiological pattern of onchocerciasis, especially the severe ocular disease, varies 
considerably between geographical zones. The differences in ocular pathology between the 
West Africa Savannah and forest areas is well documented. While onchocercal blindness can 
be more frequent in hyper-endemic communities in the Savannah, virtually no blindness is 
found in forest communities with similar intensity of infection. Some experts believe the 
explanation lies in the existence of various O. volvulus strains of different pathogenicity. The 
vector-parasite complex in the West African Savannah is responsible for the most severe form 
of ocular onchocerciasis in the world, as blindness can affect more than 10% of the population 
in the most affected villages, which are located in the river valleys where breeding sites of the 
vector are found, thus earning the disease this infamous name of River Blindness. However, 
the level of infection varies significantly among communities that are located in river valleys. 
The severity of onchocerciasis is closely related to the intensity and duration of the infection. In 
the West African Savannah, onchocerciasis is not apparent when the prevalence of MF in the 
skin snip remains below 35%, and severe blindness rates are found only in hyper-endemic 
villages (where MF prevalence is 60% or above). In the West African Savannah, the prevalence 
of onchocercal eye lesions and blindness are directly related to this index. Onchocerciasis 
becomes a major public health problem when the community MF load reaches 15-20mf per 
skin snip (mf/s), and blindness will affect more than 5% of the population when the community 
MF load exceeds 40mf/s. With such high blindness rate, the disease becomes insupportable 
and threatens the survival of the affected village itself. Fear of this disease has therefore led to 
the depopulation of many relatively fertile river valleys in the Volta River Basin and several 
neighbouring river basins in the West African Savannah (Duke, Lewis and Moore 1966; Prost, 
Hervouet and Thylefors 1979; Prost 1980; Dadzie et al. 1989; Zimmerman et al. 1992). The 
severity of onchocerciasis is related to the prevalence and intensity of infection at the 
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community level, and so the community diagnosis of endemicity is important to identify 
communities most in need of treatment (Taylor, Duke and Munoz 1992; WHO 1991). 
 
Diagnosis 
Diagnosis of onchocerciasis can be done through studies that detect the adult worm 
(macrofilariae) and the baby worms (MF) in individuals that live within at-risk communities. 
The detection of nodules on bony prominences is taken as a proxy for detection of adult 
worms that can be confirmed through nodulectomy (surgical opening of nodules and detection 
of adult worms within the nodules). MF can be detected using the skin snip method, during 
which the top layer of the skin of both sides of the groin (right and left iliac crest) is cut off 
using specially designed punches (2mm Holth corneoscleral punch) and the subcutaneous layer 
is examined under a compound microscope to detect the MF. Slit lamp can also be used by 
trained ophthalmologists to detect MF in the eyes of infected individuals because the MF can 
be seen in the posterior segment of the eye. OCP that covered 11 West African countries 
including Sierra Leone for the control of onchocerciasis between 1974 and 2002 mainly used 
the skin snip method to determine communities that should be treated for onchocerciasis. The 
cut off prevalence of 40% was used as a threshold for treatment because the skin snip method 
is relatively more sensitive and specific for detection of MF of O. volvulus. Communities that 
had ≥40% of people studied positive for MF in the skin were treated. APOC had used rapid 
epidemiological mapping for onchocerciasis (REMO) to obtain baseline data and determine 
communities that should be treated. This method is based on detection of nodules in specific 
areas of the body of individuals that live in communities suspected to be at-risk. Since this 
method is less sensitive and specific for the diagnosis of onchocerciasis because other diseases 
can also cause similar nodules in the skin of individuals, the cut-off point for treatment is 20%. 
Communities that have ≥20% of individuals studied having nodules are treated for 
onchocerciasis (Taylor 2003; Traore et al. 2012; Taylor et al. 2009; Thylefors, Alleman 2006). 
Since the MF can invade many organs and tissues, it is possible to detect them sometimes in 
blood and urine (Taylor et al. 2009; Hopkins and Boatin 2011; Dowell et al. 2013). Diagnosis of 
onchocercal ocular disease demands an ophthalmological examination that is conducted using 
slit lamps and ophthalmoscopes. MF is identified in the cornea and also in the anterior 
chamber of the eye when the head of the patient is positioned down for several minutes 
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before the examination. Ocular lesions of onchocerciasis include anterior segment lesions- 
sclerosing keratitis, and iridocyclitis; and the posterior segment lesions- choroidoretinitis and 
optical atrophy. Sometimes, lesions of the posterior segment of the eye are not visible due to 
obstruction by the anterior segment lesion. An ophthalmologist highly experienced in 
ophthalmological surveys of onchocerciasis is needed to obtain reliable results (Dadzie et al. 
1986; Dadzie et al. 1989). Since onchocerciasis endemic areas are usually remote and difficult 
to access, the impact of using optometrists for diagnosis is limited. This is in addition to the 
limited number of such experts in the endemic countries in general (Berger and Nnadozie 
1993). 
 
Skin snip methodology 
The standard and most reliable method to diagnose onchocerciasis infection and to determine 
its intensity is through microscopic examination of the skin snips for the presence and number 
of O. volvulus MFs. This method is highly specific but is not so sensitive for light infections. 
Sensitivity can, however, be increased by taking as many as six skin snips from areas of the 
body that harbour the parasites. The practice, however, is to take two skin snips from the right 
and left iliac crests, which is the site that usually has the highest concentration of skin MFs. 
Skin snip is done in all selected villages 11-12 months after last treatment, and the survey is 
usually cross sectional. All subjects above one year4 who agree to participate (or whose parent 
agree on their behalf) and voluntarily present themselves for the study are selected. They are 
asked for identification data - name, age, sex, occupation, and number of years resident in the 
village. Two skin biopsies are obtained from the right and left iliac crests of those studied. A 
two mm Holth corneoscleral punch is used to obtain the two bloodless skin snip biopsies. The 
scleral punch is sterilised with sodium hypochlorite solution and distilled water and then 
autoclaved under pressure for 15 minutes after taking biopsies from each participant. This was 
to prevent the transfer of HIV and other blood-borne infections. The samples are then 
microscopically examined for the presence and number (quantity) of O. volvulus MFs after 
incubation for 30 minutes in distilled water. Negative skin snip samples are further kept in 
saline solution for 24 hours and microscopically re-examined (currently, all snips are examined 
                                                          
4 This was recently changed from one year to five years for ethical reasons considering the pain 
experienced by participants when skin snipping is done. Currently participants are those ≥five years. 
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24 hours after collection). The number of MFs are counted, and the results are recorded for 
each person examined. Migration history is taken for each person during the last ten years 
before the survey. Pre- and post-treatment skin snip data are then analysed to determine and 
compare onchocerciasis infection levels using indicators of prevalence of microfilaria and 
community MF load. The results are expressed as a proportion of positive/negative people in 
the sample (Wanji et al. 2005; Afework et al. 2012; Katabarwa et al. 2013). 
 
Rapid Epidemiological Mapping for Onchocerciasis 
Since ivermectin treatment was introduced, researchers have focused on developing and 
testing simple and rapid methods for community diagnosis. The prevalence of palpable 
subcutaneous nodules is closely related to the prevalence of infection as determined by skin 
snip, with the prevalence of MF being about twice the prevalence of nodules. Furthermore, in 
the West African Savannah the prevalence of onchocerciasis has been shown to be directly 
related to the prevalence of nodules. The rapid assessment of endemicity of a community is 
now usually done through palpation for nodules in a sample of 30-50 adult males per 
community. The rapid assessment method though more rapid and acceptable than skin 
snipping still requires a visit and a rapid survey in all potentially endemic communities. A 
method for REMO was developed and successfully tested in Cameroon. These surveys are 
conducted only in a special sample of two to four percent of all communities, and the results 
are extrapolated to estimate the approximate endemicity level of the remaining communities. 
For REMO, researchers initially identify and select “high risk” communities every 30km along 
the river and additional primary communities located 10km away from those at “high risk”.  
Thereafter, if necessary, secondary communities are selected 10km away from the primary 
communities and tertiary communities and 10km away from secondary communities until 
members of the research team reach onchocercal nodule-free communities. Assessment of 
nodule rates is undertaken among 30-50 adults who are at least 20 years old and have lived in 
the community for 20 years or more. The results are expressed as a proportion of the number 
of positive people in the samples (Katabarwa et al. 2008; Katabarwa et al. 2012). 
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Rapid Assessment Procedure for Loiasis 
Since people or individuals with high microfilarial loads of Loa loa are at increased risk of 
neurological serious adverse events following ivermectin treatment against onchocerciasis, it is 
usually necessary to identify areas of onchocerciasis/Loa loa co-endemicity (Gardon et al. 
1997). This is done using the Rapid Assessment Procedure for Loiasis (RAPLOA), a newly 
developed rapid assessment procedure for loiasis that relates the prevalence of a key clinical 
manifestation of loiasis (history of eye worm) to the level of endemicity of the infection. This 
method is proven to be a useful tool for identifying areas of potential risk of Loa loa post-
Ivermectin treatment encephalopathy (Wanji et al. 2005). 
 
Treatment 
Control/elimination programmes for onchocerciasis focus mainly on prevention as the 
blindness resulting from the disease is irreversible. Before the concept of onchocerciasis 
elimination in Africa, onchocerciasis was considered a serious public health problem when 
microfilaridermia prevalence was greater than 40%, and treatment was based on this. Areas 
with less than 40% prevalence were not treated (APOC 2010). The two main treatment 
strategies for onchocerciasis control are vector control through larviciding and chemotherapy 
using ivermectin. Other possible interventions such as personal protection from exposure to 
vector biting with adequate clothing that is usually impractical, use of deodorants/insect 
repellants that are not so effective and can be expensive, or large-scale nodulectomy campaign 
have little practical value for onchocerciasis control (Taylor 2003; Thylefors, Alleman 2006). 
The OCP (1974-2002) began mainly with the vector control strategy to interrupt transmission 
of the parasite long enough for the human reservoir to die out (Hopkins and Boatin 2011; 
Molyneux et al. 2014). For APOC countries onchocerciasis control has almost exclusively been 
based on large-scale ivermectin treatment of at-risk populations conducted annually or six-
monthly with a recommended therapeutic coverage of ≥65% and geographic coverage of 100% 
to control the disease as a public health problem (APOC 2010).  
 
A single dose of ivermectin per annum can kill first stage larvae (MF) in those infected and 
prevent transmission within communities (Diawara et al. 2009). Ivermectin is effective as 
microfilaricide and kills 99% of MF with a single treatment. Since MF are responsible for most 
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manifestations of the diseases, treating with Ivermectin provides an immediate health benefit. 
However, ivermectin does not kill the macrofilariae (adult worm) and most macrofilariae start 
reproducing MF a few weeks after treatment with ivermectin resulting in a renewed increase 
in MF load. There is evidence that ivermectin affects the viability and reproductivity (fertility) 
of the adult worm and even though ivermectin does not kill the adult worm, the rate of 
increase of the MF load is less after each treatment. Computer simulation shows that the 
prevalence bounces up after each treatment but the MF load increases at a slower rate than 
before to a maximum level that is lower than the level reached after the previous treatment 
(APOC 2010).  
 
Vector control  
Vector control through routine aerial and ground application of larvicides and application by 
boat was the main strategy of OCP throughout its mandate. Vector control experience in West 
and East Africa has shown that vector control can be an effective strategy to achieve 
transmission interruption and parasite reservoir elimination as demonstrated in Kenya in the 
1950s (Roberts et al. 1967) and at a much larger scale in the OCP countries. In the OCP 
countries, vector control was highly effective especially in the Savannah areas where vector 
breeding sites are relatively easy to identify, limited in number and fairly accessible by 
helicopter (Philippon 1990). The cost of implementing vector control is high and should be 
maintained over a large area in at least the many foci where S. damnosum s.l is the vector to 
reduce the risk of reinvasion of transmission zones under control by infective vectors from 
other transmission zones that are still being treated. This suggests therefore that vector 
control is more feasible when managed by a multi-national project such as OCP and may be 
beyond the means of individual endemic countries themselves (Remme 2004). The use of DDT 
applied to the water at a concentration as low as 0.1 p.p.m. for 30 minutes leads to the 
elimination of the larvae of Simulium. Such larvicidal methods have eradicated S. neavei from 
Western Kenya and virtually eradicated S. damnosum from the Victoria Nile in Uganda (Brown 
1962). This was expensive but considered necessary. Vector control is no longer considered 
feasible or cost-effective after the closure of OCP in 2002 although it was implemented briefly 
in some of the Special Intervention Zones (SIZ) such as the north of Togo (Taylor et al. 2009). 
Vector control led to the interruption of transmission of the parasite causing human 
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onchocerciasis (O. volvulus) in many areas and introduction of ivermectin treatment in addition 
to vector control interventions led to a decline in anterior-segment lesions of the eye and the 
reduction of posterior-segment lesions (Boatin, 2008). The impact of vector control for 
controlling onchocerciasis was demonstrated in Uganda (Lakwo et al. 2006). 
 
Vector control versus vector control plus ivermectin MDAs 
It was demonstrated that the combined use of vector control and ivermectin treatment is 
more effective in reducing infectivity among black flies and reducing MF prevalence and 
density in humans than vector control alone. It is currently recommended by experts that only 
selective vector control should be conducted while the focus should be on ivermectin 
treatment (Guillet et al. 1995). 
 
Nodulectomy  
Nodulectomy has been used as a third form of onchocerciasis control, especially in Mexico, 
Ecuador, and Guatemala, where health workers went from village to village removing nodules 
mainly around the head. This approach can lessen the number of MF entering the eye though 
there is no strong evidence that this can prevent blindness (Burnham 1998). Although Mexico 
and other countries have used nodulectomy with significant impact on the reservoir, these 
campaigns may be impractical especially in Africa where 99% of those infected live (Remme, 
2004). 
 
Effect of ivermectin on transmission of onchocerciasis 
Ivermectin (otherwise known as Stromectol or Mectizan) is a semi-synthetic macrocyclic 
lactone and is considered an excellent tool for the treatment of onchocerciasis and reduction 
of blindness rates (Eezzuduemhoi and Wilson 2010). Initially, it was proposed that ivermectin 
was an agonist for neurotransmitter function because of its rapid and specific antiparasitic and 
anthelmintic action. Experiments confirmed this later when it was demonstrated that 
inhibition occurred via glutamate-gated chloride ion channels in nerve and muscle cells of the 
parasite. Ivermectin interacts with these channels and prevents their closure. As a result, 
synapse membranes become increasingly permeable to chloride ions which leads to 
hyperpolarization of the neuronal membrane and decreases or prevents neuronal 
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transmission. This, in turn, leads to paralysis of the somatic muscles, particularly the 
pharyngeal pump causing the death of the parasite. ϒ-aminobutyric acid (GABA)-related 
chloride ion channels that are present only in nematodes, insects and ticks are only inhibited 
with greater drug concentrations. In mammals, GABA receptors and neurones are found in the 
central nervous system while in arthropods and nematodes they are found in the peripheral 
nervous system. This plus the relatively low dose concentrations needed to kill arthropods and 
nematodes ensures that mammals can ingest ivermectin with a high degree of safety (Omura 
and Crump 2004; Geary 2005).  
 
Ivermectin kills the MF of the parasite by attacking its nervous and muscular system causing 
paralysis so that they can be killed by eosinophils and macrophages produced by the human 
body. With ivermectin treatment, the intense itching of the skin stops and the progression to 
blindness also stops. High treatment coverage within at-risk communities is needed to reduce 
infection rates and parasite loads of fly populations (Kutin et al. 2004). Although some studies 
have suggested that ivermectin inhibits production of additional offspring by reducing the 
fertility of the adult onchocercal worm thus preventing morbidity and transmission, the drug 
has mainly microfilaricidal effect and does not kill the adult worm. The adult onchocercal 
worms continue to produce MF a few months after treatment with ivermectin necessitating 
many years of treatment to control microfilarial loads (Diawara et al. 2009; Taylor et al. 2009). 
Mass treatment with ivermectin significantly reduces but does not stop transmission during 
first years of treatment and cannot kill the adult O. volvulus parasites. Long-term annual 
treatments are needed or at least 14 years of annual treatment is needed after the first dose 
because it is expected that the adult onchocercal worms will die naturally during the 14 years 
of treatment (Eezzuduemhoi and Wilson 2010). Computer simulations with the ONCHOSIM 
model predicted that treatment should continue for over 25 years before local transmission of 
the infection can be stopped in Africa. The model indicated the possibility of elimination in 
most endemic foci in Africa, but treatment is needed for as many as 25 years (Winnen et al. 
2002).  
 
The CDTI strategy adopted by APOC since 1997, after the multi-country study, promotes 
community participation as the key aspect of ivermectin distribution to improve access to 
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ivermectin and ensure community ownership of the process. The strategy is first introduced to 
communities by local health workers and NGDO representatives in a participatory manner. 
Through subsequent community meetings, they explain the roles and responsibilities of 
communities in the CDTI process. The communities are then encouraged to direct the planning 
and implementation of the interventions by first collectively selecting CDDs and then later 
planning the distribution process by deciding the method used (house to house or central 
location), the place where the distribution is conducted if a fixed location is accepted, when 
the distribution is conducted, by whom activities will be implemented, how all activities will be 
monitored, and the support, if any, that CDDs will receive (financial or otherwise) from the 
community. With CDTI communities collect their supply of ivermectin from a central point 
agreed upon with the health services and store it within the community until the distribution 
period. The health workers, with support from NGDO representatives, train, supervise and 
monitor the CDDs while the community directs the process. It has been suggested that when 
the community takes charge of onchocerciasis control, mass treatment can be sustained for up 
to 20 years. Overall programme implementation costs also reduce significantly because the 
community plays the leading role in all aspects of programme implementation. In addition to 
training communities to assume leadership of the CDTI process, NGDOs have also made a 
significant contribution to the CDTI process through operational research, provision of 
resources to complement national programmes by supporting health staff in remote 
communities, and through technical and financial support to NOCPs. An NGDO coalition was 
created in 1991 for onchocerciasis control that meets regularly to coordinate collaboration at 
international and national levels (Dadzie, De Sole and Remme 1992; Amazigo 1999; Boatin and 
Richards 2006; Taylor et al. 2009). The Community-Directed Intervention (CDI) Study Group 
2010; WHO APOC 2010; Meredith, Cross and Amazigo 2012).   
 
Ivermectin needs to be taken only once or twice a year, needs no refrigeration during handling 
and storage and is relatively safe so that it can be administered by minimally trained 
community health workers (Wikipedia, available from:  
https://en.wikipedia.org/wiki/Ivermectin; accessed: 19/10/2016). It has been demonstrated 
that ivermectin has less side effects than diethylcarbamazine (Greene et al. 1985; Albiez et al. 
1988). Other studies were also able to demonstrate that ivermectin has less ocular side effects 
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than diethylcarbamazine and significantly improves ocular status when used as opposed to 
diethylcarbamazine for the treatment of patients with ocular manifestations of onchocerciasis 
(Lariviere et al. 1985; Taylor et al. 1989; Taylor 1990a,b). When given as a single dose of 150 
mcg/kg it reduces MF in the skin by more than 90% after a few months and the reduction rate 
is maintained up to 1 year after a single dose (Basanez et al. 2008).  Ivermectin does not kill 
adult worms (macrofilariae) but can cause them to cease releasing MF, possibly by paralysing 
their reproductive tract thereby preventing morbidity and transmission (Duke et al. 2002; Duke 
2005; Basanez et al. 2008).  
 
Transmission is significantly reduced also, though not interrupted completely, because of the 
reduction of the microfilarial load after each successive treatment which translates into a 
significant drop in the annual transmission rate. The mean MF load is further reduced with 
each subsequent treatment round, and the annual level of transmission continues to reduce or 
decline. The population of the adult worm also reduces although at a slower rate through 
natural or treatment-induced death or sterilisation of old worms without replenishment. As 
this continues, the adult worm population can reach a low level at which the parasite can move 
irreversibly to its extinction even without any further ivermectin treatment. Thus, the parasite 
density is considered to have fallen below its “breakpoint” and ivermectin treatment can be 
stopped, bringing an end to the treatment phase (stage one) of the elimination process.  The 
concept of breakpoint means that treatment can be safely stopped even when infection and 
transmission are not completely zero. In the Senegal and Mali study conducted by APOC, it was 
demonstrated that no renewed transmission and infection was detected after treatment was 
stopped for three years even though there were some MF-positive individuals when treatment 
was stopped. Predictions were made in the 1990s even before empirical evidence that in the 
long-term interruption of transmission and elimination of the parasite reservoir is possible with 
just ivermectin treatment. First empirical evidence of the feasibility of onchocerciasis 
elimination with ivermectin treatment was made available through studies in three 
onchocerciasis foci in Senegal and Mali that showed that after 15-17 years of annual or six 
monthly treatments with ivermectin the prevalence and intensity of infection falls below 
thresholds for elimination of the disease (Diawara et al. 2009; APOC 2010; Traore et al. 2012; 
Bockarie et al. 2013). 
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Severe adverse events after treatment with ivermectin 
Ivermectin causes reactions that are known and do not last for long (less than a week to be 
resolved) and programme guidelines usually encourages staff to inform treated communities 
and individuals of the possible side effects so that when they occur they are reported and 
those affected receive the correct care. Reporting side effects is important and reporting forms 
do include areas for reporting side effects. According to the information on ivermectin from 
drugs.com (Online, available from: http://www.drugs.com/mmx/ivermectin.html; Accessed: 
25/05/2015) ivermectin reduces the number of MF in the eye slower than with 
diethylcarbamazine and thus reduces the possibilities of tissue changes relating to immune 
reaction of surrounding tissue to the dead O. volvulus and its endosymbionts Wolbachia 
pipientis. The drug does not cross the blood-brain barrier in humans, and most mammals and 
so no major reaction has been reported relating to the central nervous system (Drugs.com, 
Online, available from: http://www.drugs.com/mmx/ivermectin.html; Accessed: 25/05/2015). 
Ivermectin is proven to be teratogenic in experiments with mice and therefore not 
recommended for treatment of pregnant women (Drugs.com, Online, available from: 
http://www.drugs.com/mmx/ivermectin.html; Accessed: 25/05/2015). According to drugs.com 
(Drugs.com, Online, available from: http://www.drugs.com/mmx/ivermectin.html; Accessed: 
25/05/2015), ivermectin is secreted with breast milk and so not recommended for 
breastfeeding women in the first two weeks after delivery. Since safety and efficacy of 
ivermectin are not established for children weighing less than 15kg, it is not recommended for 
children below 15kg or five years to take the drug. The frequency of side effects is found to be 
related to the level of parasite infection and last for up to three days (Drugs.com, online 
http://www.drugs.com/mmx/ivermectin.html, 22/05/2015). Side effects of ivermectin can 
include Mazzotti type reactions (pruritus, edema, headache and rash), severe headache, 
orthostatic hypotension, confusion/disorientation, stupor, coma and death, especially in areas 
where loiasis is co-endemic (Pacque et al. 1990; Pacque et al. 1991; Chijioke and Okonkwo 
1992; Kamgno et al. 2004). APOC conducted an intensive study across Africa to determine the 
Loa loa areas where ivermectin treatment can cause a severe reaction that can lead to coma 
and death (Zouré et al. 2011). Some authors suggest the use of a six-week treatment with 
doxycycline, which kills the MF and sterilises and kills the female adult worm by killing the 
Wolbachia bacteriae that live in the worms, in areas where it is not safe to administer 
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ivermectin (Taylor et al. 2009). Pirmohamed et al. (2007) recommend good pharmacovigilance 
when treating communities with ivermectin so that side effects can be detected and managed 
early.  
 
Possible O. volvulus resistance to ivermectin 
Evidence has shown that ivermectin kills the MF of O. volvulus  and can have embryostatic 
effect on female adult worms (Bockarie et al. 2013), but there are suggestions that the 
onchocerciasis parasite O. volvulus  is developing resistance to ivermectin (Awadzi 2004; Eng 
and Prichard 2005; Ardelli, Prichard 2007; Hodgkin et al. 2007; Lustigman, McCarter 2007; 
Osei-Atweneboana et al. 2007a; Osei-Atweneboana et al. 2007b; Boatin 2008; Gloeckner et al. 
2010; Frempong et al. 2016). It has been recommended that more research be conducted on 
resistance of O. volvulus  to ivermectin including the use of genetic markers for monitoring 
sub-optimal or atypical responses of O. volvulus  to ivermectin (Awadzi 2004; Eng and Prichard 
2005; Ardelli and Prichard 2007; Burnham 2007; Cupp et al. 2007; Mackenzie 2007; Osei-
Atweneboana et al. 2007a; Osei-Atweneboana et al. 2007b; Bourguinat et al. 2008; Churcher 
et al. 2009; Taylor et al. 2009).  Many authors agree that resistance to ivermectin by O. 
volvulus will disrupt the global onchocerciasis control and elimination programme as 
ivermectin is currently the only available drug for onchocerciasis treatment. They also agree 
that although there is some sub-optimal response to ivermectin treatment and probably 
selection for development of resistance, more studies are needed to produce actual evidence 
of O. volvulus  resistance to ivermectin (Burnham 2007; Cupp et al. 2007; Hodgkin et al. 2007; 
Mackenzie 2007; Taylor et al. 2009). Currently, there are many ongoing onchocerciasis studies 
sponsored by big donors such as the BMGF to develop alternative drugs for treating 
onchocerciasis that can replace ivermectin (Turner et al. 2010). 
 
Other possible alternative treatments for onchocerciasis 
There is increasing concern that there are currently no alternatives to ivermectin and there is 
no vaccine for onchocerciasis, especially when some onchocerciasis experts have suggested 
the possibility that O. volvulus is developing resistance to ivermectin. There are other 
antibiotics being tried for treatment of onchocerciasis such as doxycycline, described below 
(Basanez et al. 2006). Trials of Rifampicin and Azithromycin to determine if they can deplete 
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Wolbachia from O. volvulus was unsuccessful, and the conclusion was that short courses of the 
two drugs cannot clear Wolbachia from O. volvulus (Richards et al. 2007). It should be noted 
that in areas where there is co-endemicity of onchocerciasis and LF, LF treatment (ivermectin 
plus albendazole) is a treatment for onchocerciasis and if onchocerciasis threshold for stopping 
MDA is reached, onchocerciasis evaluations can be conducted together with LF evaluations 
(APOC 2010).  
 
Moxidectin, an analogue of Ivermectin, is also a veterinary anthelmintic. Many clinical trials 
have shown Moxidectin to be a substitute for ivermectin but has no macrofilaricidal effect on 
O. volvulus (Cotreau et al. 2003; Tagboto and Townson 1996). In addition to efforts to discover 
new medicines, researchers are currently trying to discover other medicines for tropical 
diseases using strategies such as ‘piggy-back discoveries’ or testing of medicines already in use 
for treating other diseases caused by similar causative agents. These efforts need an extended 
period of time invested in testing and subsequent approval when a suitable drug is discovered. 
Drug repositioning or identification and development of new uses for existing drugs can 
potentially be less time consuming and more cost-effective. One such effort has targeted 
Moxidectin an analogue of ivermectin for replacement of ivermectin when necessary. Both 
Ivermectin and Moxidectin were initially only marketed as veterinary anthelmintics. The 
successful use of ivermectin has validated repositioning for the discovery of new drugs for 
NTDs (Hodgkin et al. 2007; Gloeckner et al. 2010).  
 
Effect of doxycycline on Wolbachia 
The importance of the endosymbiotic bacteria Wolbachia, found in O. volvulus, has become 
clear to researchers. Living MF cause little or no inflammation even in the anterior chamber of 
the eye. However, when they die the host response to degenerating worms can result in ocular 
inflammation causing progressive loss of vision and blindness that tend to occur in adulthood 
after many years of infection. Treatment with diethylcarbamazine can cause the Mazzotti 
reaction, the severity of which is dependent on the number of MF containing Wolbachia in the 
skin and eyes (Greene et al. 1985; Albiez et al. 1988). Acute and severe inflammatory 
responses in people infected with O. volvulus are associated with the release of Wolbachia into 
the blood following death or damage to worms, suggesting that Wolbachia may be the cause 
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of acute inflammatory disease. Post-treatment reactions might also be related to Wolbachia 
products that induce inflammatory responses. Anti-Wolbachia products could minimise 
inflammatory responses seen after treatment, a view supported by treatment of O. volvulus -
infected individuals with doxycycline, resulting in the elimination of skin MF, presumably 
through direct effects on the endosymbionts (Crump et al. 2012). The excellent impact of 
doxycycline on the onchocerciasis MF with little or no side effects has been demonstrated in 
several studies although treatment with doxycycline is needed daily for up to six weeks 
(Hoerauf et al. 2008; Wanji et al. 2009; Tamarozzi et al. 2012).  
 
The role of Merck & Co. Inc. in drug donation 
In 1987 Merck and Co. Inc. offered to donate ivermectin for treatment of onchocerciasis for as 
long as it was needed and this has been ongoing since 1988. Merck launched the Mectizan 
Donation Program (MDP) in 1987, a unique collaboration between public and private 
enterprises, a unique multi-sectoral coalition involving Merck, the Mectizan Expert Committee 
(MEC), the Task Force for Child Survival and Development (now the Task Force for Global 
Health), WHO, the World Bank, UNICEF, national Ministries of Health, more than 35 NGDOs, 
and thousands of local community health workers. The generous donation of ivermectin by 
Merck and Co. Inc. has increased general interest in health-related public-private partnerships 
and generated the momentum for other donations to tackle other NTDs. Mectizan has also 
been donated for the elimination of LF since 1998 in African countries and in Yemen where 
onchocerciasis and LF are co-endemic. Ivermectin is co-administered with albendazole donated 
by GlaxoSmithKline for LF elimination. The MDP works in collaboration with the Mectizan 
Expert Committee/Albendazole Coordination and its scientific advisory committee. The 
programme achieved important notable results including positive health impacts, economic 
benefits, strengthened health systems, and the empowerment of communities where the 
delivery and administration of ivermectin is managed. MDP also laid a foundation for efforts to 
integrate the management of NTDs. (Alleman, Twum-Danso and Thylefors, 2006; Boatin, 2008; 
Colatrella, 2008; Thylefors, Alleman, Twum-Danso, 2008; Thylefors, 2008; Hopkins and Boatin, 
2011; Meredith, Cross and Amazigo 2012; Pose and Rabinowitz 2014; WHO 2016b). Yameogo 
(2008) describes the donation of ivermectin in 1987 as a key factor for success with 
onchocerciasis control because vector control efforts were proving costly and ineffective in 
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certain areas and ivermectin distribution has become the primary strategy for onchocerciasis 
control.  
 
Paradigm shift towards onchocerciasis elimination 
Worldwide eradication of onchocerciasis could be challenging with ivermectin treatment 
alone, but analysis shows that the elimination of onchocerciasis using mass treatment 
programmes is feasible only in areas where high treatment coverage can be maintained 
throughout the treatment period which is long for onchocerciasis. Since relying on a single 
drug is high risk, priority should be given to research for alternative drugs, and safe, effective 
and affordable alternative elimination strategies such as the use of macrofilaricides (Alley et al. 
2001; Boatin and Richards 2006; Winnen et al. 2002). However, since 2009 there has been a 
paradigm shift from controlling onchocerciasis as a public health problem to eliminating the 
disease by stopping local transmission after studies in Senegal and Mali showed that it was 
possible to reduce the disease to a level where it reaches its demise and transmission is 
completely stopped. The recommended therapeutic coverage during treatment with 
ivermectin is ≥80% and geographic coverage of 100% if a country wishes to move towards 
elimination of onchocerciasis (Hodgkin et al. 2007; Diawara et al. 2009; APOC 2010; Tekle et al. 
2012; Traore et al. 2012; Bockarie et al. 2013). However, a few studies have indicated that 
elimination might not be so easy in some foci in Africa. In Cameroon and Uganda, 10-13 years 
of ivermectin treatment did not interrupt onchocerciasis transmission (Katabarwa et al. 2008), 
nor did 15 years of annual treatment in West Cameroon interrupt transmission (Katabarwa et 
al. 2013). The Joint Action Forum (JAF) of APOC has strongly recommended the use of 
alternative approaches including twice yearly treatments with ivermectin, where appropriate, 
to scale-up and speed up elimination in problematic areas, and also to address cross-border 
issues (APOC 2011). 
 
Community empowerment and ownership 
In sub-Saharan Africa and other undeveloped parts of the world many public health 
programmes and projects have to address the issue of delivering services in remote rural areas 
within poor countries with inadequate infrastructures (Amazigo et al. 2012). Despite large 
financial commitments at international level, challenges still exist with service delivery. 
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Community driven approaches used in the fight against onchocerciasis show that engaging 
communities in the delivery process maximise access and performance. This way communities 
can be empowered to extend access to health services themselves (Amazigo et al. 2012). The 
empowering of communities to be part of the solution of the onchocerciasis problem is 
important (Crump et al. 2012; Pose and Rabinowitz 2014). As part of community participation, 
CDDs who are usually literate or semi-literate members of their communities are selected to 
be able to complete basic reporting forms. The challenge in many African communities is that 
CDDs are mostly men because of local traditions and this can limit women’s access to 
treatment (Amazigo 1999). The involvement of communities in efforts to control 
onchocerciasis can also improve the sustainability of onchocerciasis treatment that should 
continue for at least 15 years (Amazigo et al. 2007). 
 
Although the concept of expecting communities to work without pay is still controversial and 
many programmes like the polio campaign pay volunteers, studies in four countries funded by 
APOC has highlighted possible problems with payment of volunteers such as fragmentation of 
remuneration (different rates by different programmes within the same country), lack of 
coordination at national level, and difficulty in sustaining cash incentives in the long term in 
such under-resourced countries where they are implemented (Amazigo et al. 2012). It is 
suggested that the following alternative forms of incentive be considered: transport money 
provided during training; and provision of working tools such as boots, raincoats, and rainproof 
bags to protect treatment registers (Amazigo et al. 2012). With CDTI, CDDs are not taken from 
their other responsibilities for too long and communities sometimes find ways of 
compensating CDDs such as by helping them with their farm work or building a house for them 
(Meredith, Cross and Amazigo 2012). Several other studies have been conducted in Nigeria and 
Ethiopia that show that community adherence to treatment through CDTI is generally good 
and identified key factors for improving adherence to treatment and the strategies needed to 
improve adherence (Brieger et al. 2002; Nuwaha et al. 2005; Yirga et al. 2010; Brieger et al. 
2011). 
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CDTI and other interventions 
A three-year study was conducted in Cameroon, Nigeria and Uganda between 2005 and 2007 
demonstrated the use of CDTI as a vehicle for delivering other public health interventions such 
as Vitamin A supplementation, distribution of insecticide-treated nets (distribution plus 
retreatment), home management of malaria and detection and referral of TB cases for short-
course directly observed treatment. It was shown that with the right training and support 
community implementers could deliver multiple interventions correctly and sustain them over 
time. It is suggested that CDTI coverage is better when the strategy is integrated with other 
interventions such as Vitamin A supplementation, home management of malaria and bed net 
distribution (CDI Study Group 2010).  
 
Effect of ivermectin on other diseases  
Several authors have conducted studies that show the effect of ivermectin on other diseases 
such as soil transmitted helminthiasis, pediculosis and scabies. A study conducted within 
communities receiving annual or biannual ivermectin treatment showed that among school-
age children living in endemic areas, ivermectin has significant effects on the prevalence and 
intensity of Trichuris trichiura infection, but appeared to have no impact on Ascaris 
lumbricoides or hookworm infection (Moncayo et al. 2008). Pediculosis and scabies are caused 
by ectoparasites and patients of both diseases present with itching. ivermectin is not officially 
approved for their treatment, but the effect can occur in areas treated for onchocerciasis 
(Meinking et al. 1995; David, Flinders and De Schweinitz 2004; Burkhart and Burkhart 2006). 
Every year malaria afflicts an estimated 500 million people worldwide and kills more than one 
million people, mostly in sub-Saharan Africa. Recent field studies in Senegal have suggested 
that ivermectin can kill the malaria vectors. ivermectin MDA reduced the proportion of 
Anopheles gambiae sensu stricto (s.s.) infected with Plasmodium falciparum in treated villages 
in southeastern Senegal (Kobylinski et al. 2011). 
 
History of onchocerciasis control  
It is suggested that the disease onchocerciasis has been around for centuries but was first 
scientifically observed almost 140 years ago. In 1874-1875, John O’Neil, a British naval surgeon 
who was based in Ghana (then Gold Coast) detected an irritating and intractable skin disease 
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among locals that was similar to scabies and known locally as ‘kra kra’ or ‘craw craw’. Through 
microscopic examination of specimens taken from papules of patients, he detected easily 
visible minute worms that contorted violently. He noted that there were two small dots at the 
head or blunted extremity of the worms, but their nature could not be determined (Crump et 
al. 2012).  
 
Between 1890 and 1945, Scientists described the worm, disease transmission and 
manifestation, and the vector. In 1915 Dr. Rodolfo Robles Valverde discovered that the disease 
is caused by filaria worms while caring for patients in Guatemala and also shed light on the life 
cycle and mode of transmission. His publication from Guatemala in 1917 on the “new disease” 
associated the disease with subcutaneous nodules, anterior ocular lesions, dermatitis and MF. 
In 1922 Blacklock started investigating the mode of transmission of onchocerciasis in Sierra 
Leone. As the MF were found in skin, not blood, he proposed that an anthropod transmitting 
the disease must damage the skin to be able to introduce the larvae in the skin in its efforts to 
reach the blood. He later noticed that a common small black fly named Simulium damnosum 
was biting people. He noticed that the flies do not actively seek a host but wait in short grass 
for an individual to pass biting low on the body, usually around the lower leg and ankle 
(Blacklock 1926). In 1945 Sir Harold Ridley inventor and surgical pioneer of the intra-ocular 
lens, was able to demonstrate the importance of onchocerciasis as a blinding disease after 
extensive research in Ghana (Crump et al. 2012).   
 
By 1946 vector control was suggested as the only feasible control intervention since no 
therapeutic drugs were available. It was suggested that the vector be killed in their breeding 
sites using the then successful insecticide dichlorodiphenyltrichloroethane (DDT). 
Subsequently, in 1946 vector control was initiated in Kenya that resulted in the eradication of 
Simulium neavei. In 1948 vector control was extended in Congo basin, and later to the Victoria 
Nile in 1954 (Crump et al. 2012). 
 
In 1954, skin snip diagnosis was developed that allowed detection of MF in the skin (Crump et 
al. 2012).  
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In 1972 the World Bank President visited West Africa and saw many people blind from 
onchocerciasis with the blindness rate in some villages as high as 50%. This led to the 
formation of the OCP in 1974 under the coordination of the World Bank (Crump et al. 2012; 
Bockarie et al. 2013; Molyneux et al. 2014). 
 
Between 1971 and 1988, ivermectin was developed and approved for use in humans through a 
collaboration between the Kitasato Institute in Japan and  Merck, Sharpe and Dome (MSD) 
laboratories in the US to discover new antibiotic agents from natural microorganisms. By 1981 
avermectin/ivermectin was marketed as an anthelmintic veterinary drug and became a best 
seller. MSD started manufacturing ivermectin for veterinary use, to deworm dogs, sheep, 
cattle, horses, pigs and other animals (Taylor 2003; Omura and Crump 2004; Crump et al. 
2012).  
 
By 1982 MSD reported activity against O. volvulus, thus revealing the possibility of using the 
drug in human public health and disease control. Clinical trials in many countries including 
Liberia and Sierra Leone confirmed the safety of the use of ivermectin for the treatment of 
human onchocerciasis. In 1987, the French government decided to approve the use of the drug 
for treatment of diseases in humans, following which MSD decided to donate the drug free of 
charge to help eliminate onchocerciasis. By 1987 ivermectin was registered for treatment of 
onchocerciasis in humans and MSD started its donation in 1988 for treatment in endemic 
communities (Taylor 2003; David, Flinders and De Schweinitz 2004; Omura and Crump 2004; 
Geary 2005; Burkhart and Burkhart 2006; Crump et al. 2012; WHO AFRO NTDP 2016).  
 
In 1988 MSD started the donation of the drug under the brand name Mectizan. Merck, Sharpe 
and Dome formed MDP, the first ever mass drug donation programme. Since its introduction 
more than 30 years ago ivermectin has proved to be one of the most successful therapeutic 
drugs in veterinary medicine, as well as the basis for one of the most successful public health 
programmes in the past century (Crump et al. 2012; Molyneux et al. 2014). 
 
Between 1975 and 2002, OCP was responsible for onchocerciasis control in 11 West African 
countries including Sierra Leone. Large scale onchocerciasis control started in the 1970s 
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through the OCP in West Africa (1974-2002). The OCP goal was to eliminate onchocerciasis as a 
public health problem and mitigate its negative impact on the social and economic 
development of affected areas. OCP started in 1975 as a vertical programme with its vector 
operations. The objective of vector control was to interrupt transmission of the parasite for 
sufficient periods to allow the adult parasites in the human reservoir to die out (Hopkins and 
Boatin, 2011; Molyneux et al. 2014). OCP is described as the first large successful public-private 
partnership established by WHO to address a public health problem and it was expected that 
the programme will improve accessibility to fertile land through vector control in OCP 
countries, lead to enhanced agricultural yields, elevated crop diversity, improved human 
nutritional status, and remove two important public health problems namely blindness and 
skin disease resulting from infection (Hodgkin et al. 2007). OCP’s history started in 1975 with 
support in 7 countries: Benin, Burkina Faso, Cote d’Ivoire, Ghana, Mali, Niger, and Togo. The 
programme later spread to a further four countries including Sierra Leone, and the name was 
changed from Onchocerciasis Control Programme to “the Onchocerciasis Control Programme 
in West Africa” maintaining the acronym OCP (Fobi et al. 2015). Initially, aerial larviciding was 
used in the absence of a safe drug for treatment, but chemotherapy started in 1989 with the 
donation of ivermectin by Merck and Co. Inc. in 1988, and the two strategies were continued 
up to the end of OCP in 2002 (Samba, 1994; Fobi et al. 2015).  
 
In 1992, the Onchocerciasis Elimination Program for the Americas (OEPA) was launched with 
the goal of eliminating morbidity and interrupting disease transmission in 13 foci in endemic 
Latin American countries, using intensive twice yearly ivermectin treatment and an aim of 
reaching 85% of the estimated 503,000 people deemed to be at risk. Marked gains in 
controlling onchocerciasis have been achieved more in the Americas than in Africa under the 
coordination of Onchocerciasis Elimination Programme for the Americas (OEPA). The effort to 
eliminate the disease from the region was launched in response to the Pan American Health 
Organization (PAHO) resolution in 1991 to eliminate the disease as a public health problem by 
2007. Onchocerciasis was found to be endemic in 13 foci in 1,845 endemic communities of 6 
countries (Brazil, Colombia, Ecuador, Guatemala, Mexico and Venezuela) (Vieira et al. 2007; 
Sauerbrey, 2008; Rodríguez-Pérez et al. 2008; Gustavsen et al. 2011).  
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In 1995, APOC was launched (Molyneux et al. 2014).  APOC was established in 1995 with the 
objective of establishing “effective and sustainable CDTI in all endemic areas”. The goal of 
APOC was to permanently protect an estimated 120 million at risk in 19 countries (now 20 with 
the independence of South Sudan) from the debilitating and disfiguring disease through CDTI 
that can be sustained by communities themselves after APOC may have closed. Duration of 
treatment was determined to be dependent on the initial or baseline endemicity level and 
treatment coverage (Hodgkin et al. 2007). APOC before its mandate ended in December 2015 
was another example of good public-private partnership coordinated by WHO since 1995 and 
was a partnership between affected communities, governments, bilateral and multilateral 
agencies, foundations, NGDOs, the scientific community, and the private sector including the 
pharmaceutical company Merck and Co. Inc.5 (Fobi et al. 2015). APOC evaluations between 
2008 and 2015 show that at least 25 million people live in previously endemic areas that now 
have few or no people MF positive due to years of onchocerciasis treatment. APOC had saved 
17.4 million DALYs during 20 years of existence using only US$27 per DALY (WHO 2016b). 
 
In 2003, SIZ was formed. The SIZ of the former OCP was launched in December 2002 under the 
coordination of APOC, following the closure of OCP in 2002 to sustain the momentum that had 
been gained for onchocerciasis control through ivermectin distribution and vector control 
(Hodgkin et al. 2007, Yameogo, 2008). Survey data obtained before the close of OCP in 2002 
was used to determine areas within the ex-OCP countries that still needed special attention, 
areas where the poor impact of treatment resulted in results in 2002 that were not in line with 
achievements of the OCP objectives and the situation suggested the possibility of 
recrudescence. SIZ was created in 2003 in five ex-OCP countries (Benin, Ghana, Guinea, Sierra 
Leone and Togo) to continue treatment for onchocerciasis under the coordination of APOC 
that lasted up until December, 2007 (Yameogo et al. 2008; Fobi et al. 2015).  
 
In 2009 - CDTI strategy was recommended to be used to deliver other integrated disease 
interventions including Vit A supplementation and antimalarial treatment (CDI Study Group 
2010). In December, 2015 the APOC mandate ended and in January, 2016 ESPEN was launched 
to last for an initial period of five years (WHO AFRO NTDP 2016; WHO 2016b). 
                                                          
5 This is the current name of what was once MSD. 
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History of onchocerciasis control in Sierra Leone 
Sierra Leone has a high burden of all five PC NTDs like many other African countries. 
Endemicity of NTDs was known in Sierra Leone as early as 1926 when Blacklock first described 
the transmission of onchocerciasis through the black fly, S. damnosum in the Kono district of 
Sierra Leone (Blacklock 1926). Onchocerciasis control efforts started as early as 1957 with 
insecticide treatments along the Tonkolili River that was found to be the most severely 
affected. It has also been documented that onchocerciasis is the second most common cause 
of blindness after cataract in Sierra Leone and so in the late 1980s the former OCP extended its 
activities to four other countries including Sierra Leone and vector control through larviciding 
with insecticides continued along rivers in hyper-endemic areas (Hodges et al. 2011). 
 
Vector control was conducted in the northern part of Sierra Leone in areas where blindness 
rate was as high as 6%. Sierra Leone was among the first countries where ivermectin treatment 
trials were conducted, and integrated vector control and ivermectin treatment was 
established. Considerable work was done in the 1950’s, 1960’s and then later in the 1990’s 
during OCP and demonstrated that onchocerciasis prevalence in Sierra Leone was between 
30% and 50% along the main rivers, and black flies were found to exist in the entire country 
except in areas around the capital Freetown and the southern coastal plain of the Bonthe 
district. Between 1988 and 2005 the distribution of onchocerciasis was mapped by the NOCP 
using the skin snip method for detecting O. volvulus MF and all districts were found to be 
endemic except the Western Area (Western Urban and Western Rural districts) (Hodges et al. 
2011).  
 
Although the OCP started activities in Sierra Leone in 1989, the civil conflict between 1991 and 
2002 impacted negatively on onchocerciasis control activities and in 1997 all onchocerciasis 
activities were stopped nationwide. So, for the last five years of the OCP, no activities were 
conducted in the country due to insecurity. With support from APOC, the NOCP of Sierra Leone 
restarted interventions in 2003 after the end of the civil war in 2002 through the SIZ. By then 
the CDTI strategy had already been developed and established as a principal strategy for 
onchocerciasis control by APOC since 1997, and so CDTI was implemented nationwide in meso-
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endemic and hyper-endemic areas under the SIZ (Yameogo, 2008; Hodges et al. 2011; APOC 
2012; Fobi et al. 2015).  
 
As the onchocerciasis situation in Sierra Leone was still unsatisfactory in December 2007 when 
SIZ closed, it was decided that APOC’s financial and technical support would continue and this 
was the situation until APOC finally closed in December 2015 (unpublished NTDP Reports 2005-
2015). 
 
Mapping for onchocerciasis was started in Sierra Leone in the 1980’s, early 1990’s and refined 
between 2003 and 2005 after the end of the civil conflict with technical and financial support 
from OCP, SIZ, and APOC (Linehan et al. 2011). Integration of onchocerciasis treatment with LF 
treatment started in 2007 with support from WHO/AFRO (Hodges et al. 2011). Social 
mobilisation was intensive in the beginning and continued on a smaller scale later in areas with 
poor coverage (Koroma et al. 2010; Hodges et al. 2011; Koroma et al. 2011). The successful 
implementation of the NTDP in Sierra Leone demonstrates the improvements that took place 
in the health system post-war. It is believed that the NTDP has had some socio-economic 
impact in the country. Furthermore, the NTDP has contributed significantly to health system 
strengthening in the country plus the reduction in NTD-related morbidity has also had a 
significant impact on poverty reduction in the country (Molyneux, Hotez, Fenwick 2005; Hotez 
et al. 2009; Hotez and Thompson 2009; Hodges et al. 2011). 
 
Other onchocerciasis studies conducted in Sierra Leone 
It was estimated through results of epidemiological mapping by OCP in 1990 that there was a 
total of 701,000 people infected with onchocerciasis out of an estimated total population of 
4.2 million, with an estimated 8,300 people blind due to onchocerciasis. In neighbouring 
Guinea and Liberia, the estimates were similar: estimated 510,000 infected within a population 
of 5.8 million and 9,000 blind for Guinea, and 600,000 infected with 2,600 blind within a total 
population of 2.6 million for Liberia (Remme 2004).  
 
Ophthalmological surveys were conducted in 13 highly infected villages located in various 
rivers basins of southern Sierra Leone to assess the pattern of onchocercal ocular disease and 
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blindness. The most significant finding was the high blinding potential of onchocerciasis in the 
degraded forest area where the prevalence of onchocercal blindness reached levels of up to 
6%. This finding is contrary to previous findings that indicated that onchocerciasis in the forest 
causes little blindness. Ocular onchocerciasis, without a doubt, is a problem of public health 
importance in south Sierra Leone. The rates of onchocercal ocular disease and blindness, on 
the other hand, were significantly lower than those found in Savannah villages with similar 
levels of endemicity. The problem this poses is that it is difficult to tell if the pattern of ocular 
onchocerciasis in south Sierra Leone is of the forest type or a pattern on its own (Dadzie et al. 
1992). 
 
O. volvulus infection in Sierra Leone was first reported by Blacklock in 1926, and he also 
suggested that the clinical manifestations varied within the regions of the country (Blacklock 
1926). The eastern region has the forest strain of the parasite, and so the disease is clinically 
characterised by low intensity of infection, mild skin disease, and relatively lower blindness 
rates.  In the south, there is a mixture of forest and Savannah strains of the parasite with high 
infection intensity, mild skin disease, and relatively higher blindness rates that are sometimes 
higher than blindness rates recorded for the Savannah area. The northern region has the 
Savannah strain of the parasite with high infection intensity, mild skin disease, and a relatively 
high blindness rate (Gbakima and Sahr, 1996). A microfilaraemia survey conducted and 
reported by Sierra Leonean researchers in the south (Moyamba district) showed an MF 
prevalence of 39.1% in men and 35.9% in women for O. volvulus. Prevalence was lower in 
children 5-9 years (13.3%) compared to older age groups (61.9% among those 40-49 years) 
(Gbakima and Sahr 1996). 
 
Entomology situation for onchocerciasis in Sierra Leone  
Regular entomology data collection on the vector of onchocerciasis was undertaken in five 
countries (Guinea, Guinea-Bissau, Mali, Senegal and Sierra Leone) of the Western Extension of 
OCP between 1986 and 1990 by national teams with personnel that were employees of the 
governments of the countries. The strategy was changed in the zone (i.e. the western 
extension of the OCP) in 1990 to include ivermectin treatment in addition to vector control. 
Before that, the strategy for onchocerciasis control was to interrupt transmission of the 
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disease through vector control. Some of the rivers in Sierra Leone and Guinea run throughout 
the year while others do not have water during the dry season (Sékétéli et al. 1993). 
 
 
Integrated MDA in Sierra Leone 
Treatment of onchocerciasis has always been annual as there has never been any need for 
biannual treatment in Sierra Leone. The NOCP continued MDA for onchocerciasis between 
2003 and 2006 before the NTDP was formed in 2007. Integrated MDA has been conducted 
since 2007 for onchocerciasis and LF elimination in Sierra Leone by unpaid community 
volunteers or CDDs. Other community-based health campaigns such as ‘Mother and Child 
Health Weeks’ pay community volunteers for their service and these same volunteers who 
work as CDDs are then called Community Health Workers. This, therefore, creates a major 
challenge for the NTD control programme (Hodges et al. 2012a). One unique intervention 
introduced to ensure good coverage is independent monitoring by students of the University 
of Sierra Leone. Independent monitoring helps ensure that MDAs are conducted with effective 
coverage even in hard to reach areas within rural and urban locations where vulnerable 
populations reside. Individuals eligible for MDA are interviewed by the independent monitors 
and those who recall having taken ivermectin and albendazole during the MDA are recorded. 
The programme coverage6 and results reported by the monitors by phone are compared daily 
with the expected targets. CDDs in areas where targets are not met are encouraged by the 
monitors in collaboration with the DHMTs to continue distribution, trace and treat absentees, 
and ensure the expected targets are met. Coverage in rapidly urbanised towns is also 
monitored this way during MDA. Monitoring of coverage is conducted in randomly selected 
sites in all 12 districts, in urban and rural areas after the MDA and the results are compared 
with coverage calculated from the pre-MDA census and reported as treatment figures. So far 
this method in addition to the supportive supervision provided at all levels by the NTDP, NTD 
partners, and the health service personnel at the different levels has ensured that coverage 
targets are met and maintained as high as possible. The effective epidemiological coverage of 
                                                          
6 Programme coverage is the coverage of an intervention among the eligible population expressed in 
percentage and is calculated as the total number of people treated divided by the total number of 
people eligible for the treatment within the population of the area treated multiplied by 100 (WHO 
2013). 
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65%, programme coverage of 80% and geographic coverage of 100% for both onchocerciasis 
and LF have been met since 2008 (Hodges et al. 2012b). 
 
The NTDP has had to address several challenges of MDA in Sierra Leone. There have been 
instances when donated drugs for onchocerciasis or onchocerciasis/LF MDA arrive later than 
anticipated, and this triggers a cascade of delays that end with delayed implementation of 
MDA. CDDs have been making stronger demands for incentives in place of salaries in the past 
five years. Extra incentives in the form of donated TOMS shoes to CDDs and their families, T-
shirts to CDDs, fliers on the houses of CDDs, rain boots, and bags have been provided to CDDs 
in the past five years as extra motivation to keep them committed. This has also however 
increased the overall cost of programme implementation. With the addition of treatment for 
LF and other PC NTDs, some CDDs now see their role as a full-time job and demand payment 
for their services. Since payment of salaries to CDDs cannot be accommodated by the NTDP 
currently, the policy of maintaining CDD participation in NTD control/elimination as 
volunteering leads to frequent attrition of CDDs that must be replaced. The new CDDs also 
should be trained to bring their performance to the same level as other CDDs. There are 
sometimes delays in programme implementation that lead to MDA being implemented at 
periods when other public health programmes such as the Expanded Programme on 
Immunization (EPI) and the Malaria Programme should conduct community-based activities. 
These programmes use the same community volunteers for their activities within communities 
and pay a certain fee for their services. This means that distribution relating to NTDs that is 
based on volunteering has to wait until after they complete activities for these other 
programmes. It is worth noting that the spirit of volunteering is still strong within rural 
communities albeit with some of these challenges (Hodges et al. 2011; Hodges et al. 2012b). 
The recent EVD outbreak has had its toll on programme implementation such that 2014 
treatment was delayed and conducted only in June 2015 (GoSL 2015). 
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GLOBAL OVERVIEW OF LF 
Introduction 
LF, described as a disease that affects poor people, is endemic in 73 countries in the tropics 
and subtropics (see Figure 6). NTDs are poverty-promoting diseases with often stigmatising 
conditions that are found mainly in rural areas of low-income countries. NTDs such as LF are 
ancient afflictions even described in the Bible and other ancient literature that have afflicted 
humanity for millennia (Molyneux, Hotez, Fenwick 2005). Marginalised people are usually 
affected, especially those living in areas with poor sanitation, and poor housing conditions 
(Ramaiah and Ottesen, 2014). LF is a major cause of physical and emotional suffering and also 
an economic loss (Huppatz et al. 2009). The 39 LF endemic countries in Africa are all low 
income (Grady et al. 2007; Bockarie and Molyneux 2009).  
 
An estimated 40 million people in the world have clinically significant LF manifestations 
(lymphoedema, elephantiasis, and urogenital disorders such as hydrocoele in men) (WHO 
1995; WHO 2015). LF is thus the second leading cause of permanent and long-term disability 
and has indirect losses associated with it due to diminished productivity or incapacitation of 
those affected. LF also creates a severe drain on local and national economies due to the acute 
and chronic manifestations, sub-clinical pathology of the renal and lymphatic system that 
affect all those infected with LF (Ottesen et al. 1997). LF thus leads to personal suffering as a 
result of the disabling and disfiguring lesions, and is also a significant impediment to socio-
economic advancement, both locally (at the community, district or regional levels) and 
nationally (Ottesen et al. 1997). LF experts suggest that eliminating LF in poor countries will 
reduce poverty, improve well-being, prevent disability, and improve health care services 
because LF is distributed globally, has socio-economic impact on those affected, is recognized 
by WHO as a key disabling disease, has 1.3 billion people at risk, 120 million infected, and an 
estimated 40 million persons have gross pathology relating to the disease (Molyneux 2003; 
Grady et al. 2007).  
 
LF is a parasitic infection that is transmitted by mosquitoes and is responsible for long-term 
chronic morbidity in the form of lymphoedema, genital pathology (especially hydrocele), 
recurrent disabling fevers (lymphangitis) and elephantiasis in over 40 million people around 
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the world” (Ottesen et al. 2008 cited in Bockarie, Kelly-Hope, Haskew 2010). LF affects an 
estimated 120 million people globally and is ranked by WHO as the second most common 
cause of long-term disability (WHO 1999). Since 70% of those infected with LF do not show 
symptoms of the disease but almost all those infected have subclinical damage to the 
lymphatic vessels (Sodahlon et al. 2013), a filariasis case can now be defined as all those 
persons who have evidence of active infection or all those who show positive LF antigen test 
irrespective of microfilaraemia status and presence or absence of chronic pathology (Melrose 
2004). 
Figure 6: Global distribution of LF in 2014 (WHO, online, available from: 
http://gamapserver.who.int/mapLibrary/Files/Maps/LF_2014.png) 
 
 
The microscopic MF of the parasite that causes LF was first observed by a British physician, 
Timothy Lewis, in 1870 in the urine of patients (Bockarie and Molyneux 2009). Currently, it is 
known that LF is transmitted in humans by three mosquito-borne microscopic worms: 
Wuchereria bancrofti (W. bancrofti), Brugia malayi and Brugia timori. LF is linked by many with 
elephantiasis (swelling of limbs and scrotum). However, in most endemic areas only a small 
minority of those infected with LF proceed to elephantiasis. Over 90% of LF cases are 
Bancroftian filariasis (i.e. caused by W. bancrofti), and this form is spread all over the tropics 
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and some sub-tropical areas. Brugia malayi is confined to Asia (Southeast and Eastern Asia); 
and Brugia timori is found only in Timor and its adjacent islands (WHO 2015). Brugian filariasis 
is highly endemic in India and China (before elimination), Indonesia, Thailand, Malaysia, 
Philippines, Viet Nam and Republic of Korea (Ottesen et al. 1997). W. bancrofti affects only 
humans and is the only LF parasite in Africa and the Americas that accounts for 90% of an 
estimated 120 million cases of LF worldwide. B. malayi and B. timori are exclusively found in 
Asia (Bockarie, Kelly-Hope, Haskew 2010). 
 
Table 2: Proposed classification of LF by Kumar 1996 
Infection rate Endemicity 
<10% Low 
10-20% High  
20-40% Hyper-endemic 
>40% Holoendemic 
 
Several attempts were made to classify LF using parasitology data and subjective clinical 
findings that are usually difficult to standardise. Kumar in 1996 proposed the use of 
microfilaraemia for classification of LF because it closely correlates with other LF-related 
indices and is, therefore, easier to use for setting cut-off points of different endemicity levels. 
The classification proposed by Kumar (1996) is as indicated in Table 2 above. 
 
The International Task Force for Disease Eradication completed a review of an estimated 100 
medical conditions including infectious diseases in 1993 and decided that six of them (including 
LF) were eradicable or potentially eradicable based on diagnostic tools and treatment 
strategies that were available. Since this review was conducted by independent experts, 
awareness and interest were raised over the plausibility of LF elimination among scientists and 
public health experts (Ottesen, 2000; Huppatz et al. 2009). In 1997 the World Health Assembly 
formulated resolution WHA50.29 that urged endemic communities to strengthen efforts for 
the elimination of LF as a public health problem (Ramaiah and Ottesen 2014; Bockarie and 
Molyneux 2009). LF is currently targeted for elimination as a public health problem while 
eradication is a more long-term objective (Ottesen et al. 1997). The motivation to move 
  
68 
 
towards elimination of LF as a public health problem was stimulated by the elimination of LF as 
a public health problem in countries such as Japan, Taiwan and mainland China. In China the 
drive to eliminate LF was based on the negative impact of the disease on agricultural 
productivity and the socio-economic impact was a 15:1 return after the disease was 
eliminated. It is estimated that a billion US$ is lost annually in India alone and this is in addition 
to the personal anguish, suffering, disability and stigmatisation experienced by about 50 
million clinically affected persons worldwide. The prevention of infection, suffering, and 
disability among children that are to be born should also be considered (Ottesen 2000).  
 
The optimism for the elimination of LF as a public health problem and possible eradication 
globally in the future is based on the availability of simple, rapid diagnostic tools, safe and 
effective donated drugs by Merck & Co Inc. and GlaxoSmithKline, and knowledge that W. 
bancrofti has no non-human host and B. malayi has only few animal hosts (Bockarie, Kelly-
Hope, Haskew 2010). Field diagnosis of infection is possible through simple finger-prick antigen 
detection tests that are conducted any time of day, and the clinical diagnosis is also now 
possible through ultrasound identification of living adult parasites (Ottesen 2000). The two 
principal goals of LF elimination are therefore interruption of transmission of infection, and 
alleviation and prevention of suffering and disability resulting from the disease (Ottesen 2000). 
NTD experts now believe that LF elimination is feasible through cheap affordable health 
interventions that provide benefits greater than just treating LF (Ottesen 2000).  
 
Between 2000 and 2012 over six billion treatments were given and over four billion treatments 
were taken within LF endemic communities (Molyneux 2003; Ramaiah and Ottesen 2014). The 
WHO publication on the LF situation in 2014 shows that there were 73 countries considered LF 
endemic among which 18 have progressed to the post-MDA surveillance stage, and 55 
countries still have to continue mass treatment of affected communities. Among this group of 
55 countries, 11 countries are yet to start MDA and have not shown evidence that they do not 
need MDA; MDA is yet to be upscaled to 100% geographic coverage in 23 countries (i.e. not all 
implementation units (IUs) or administration units at which the programme is implemented 
are being treated); and 21 countries have conducted at least one round of MDA in all endemic 
IUs (i.e. they have achieved 100% geographic coverage). In the 18, where surveillance is 
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ongoing to determine whether the targets for elimination have been achieved, MDA is 
continuing in some areas (WHO 2015). Significant progress is being made in the 35 LF endemic 
countries in Africa. MDA has been started partially in 25 countries but is yet to be scaled up to 
100% geographic coverage for elimination targets to be met. Two countries have stopped MDA 
nationwide (Togo and Malawi), and seven countries have achieved 100% geographic coverage 
and can stop MDA nationwide before 2020: Benin, Burkina Faso, Comoros, Ghana, Mali, Niger 
and Sierra Leone (WHO 2015). Among the 73 LF-endemic countries, 18 countries no longer 
needed MDA in 2015 and are conducting post-MDA surveillance, and the other 55 still need 
MDA. Among the 55 still needing MDA, 10 countries are yet to start MDA (WHO 2016a). 
Currently, Togo is the first country in sub-Saharan Africa to reach the stage of eliminating LF as 
a public health problem (Sodahlon et al. 2013). By 2014, the population requiring MDA was 
determined to have been reduced by 314.7 million, and based on mapping and TAS results the 
population requiring MDA has decreased from 1.410 billion in 2011 to 1.103 billion in 2014 
(WHO 2015). Over 6.2 billion treatments have been administered for LF to over 820 million 
people between 2000 and 2015. The estimate for people requiring treatment for LF has 
dropped from 1.410 billion in 2011 to 947 million in 2015 (WHO 2016a).  
 
Transmission 
A typical life cycle of the LF parasite starts when the vector mosquito takes a blood meal and 
ingests MF of the parasite in the process. The MF then shed their sheaths, penetrate the 
mosquito’s midgut and migrate to the thoracic muscles. The MF develop into L1 larvae, L2 and 
L3 larvae; then migrate to the head of the mosquito and the mosquito proboscis so that when 
the mosquito takes the next blood meal the L3 larvae enter the skin of the next host. Within 
the human host the L3 larvae develop into adult worms and are located in the lymphatic 
system; and the adult parasites produce sheathed MF that migrate into the lymphatic and 
blood system (McMahon and Simonsen 1996).  
 
It has been demonstrated that the mosquito infection rate (this is the number of mosquitoes 
that have MF after feeding on blood and the number of ingested MF per mosquito) increases 
with an increase in the number of MF in the blood of a human host. Bockarie (1997) was able 
to demonstrate that there is a positive correlation between the annual infective biting rate and 
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the annual transmission potential on the one hand and the MF rate, MF density, and 
prevalence of leg oedema. This suggests that transmission intensity is a key determinant of 
patent infection and morbidity. Kazura et al. (1997) also showed through a study in Papua New 
Guinea that the prevalence of leg oedema was highly and positively related to the annual 
transmission potential. The incidence of acute filarial attacks also has a direct relationship with 
transmission intensity.  
 
The concept of “facilitation” (that is the concept that the proportion of MF that develop 
generally increases as the number of ingested MF increases) should be considered by any 
programme moving towards elimination of LF. This is because theoretically, it is possible to 
reach a stage (called the ‘breakpoint” by some experts) when the circulating MF within a given 
population is insufficient to support transmission. However, it should be noted that MF density 
as low as 3 MF per ml can still cause infection in mosquitoes and that people with low MF 
densities after MDA can still potentially cause a rapid resurgence of LF. Mosquitoes that have 
blood meals from individuals with medium and low-level MF densities can still, therefore, 
maintain transmission especially if the main vector is Culex and not an Anopheles. The 
difference in transmission capacity of the two types of vector species is explained through the 
concept of limitation (i.e. that the Anopheles mosquito has a well-developed pharyngeal 
armature that destroys MF when they pass through during ingestion). Therefore, if the number 
of MF ingested is low during a blood meal, then the number that subsequently survives or is 
viable to infect the mosquito may be zero. MF can also be reduced/lost when ingested by the 
Anopheles mosquito through the fluid that is expelled from the anus of the mosquito species 
but not with Culex. It has therefore been suggested that there is a critical level of 
man/mosquito contact at which the disappearance of the LF infection from a population is 
possible (Pichon 2002).  
 
Gender difference in LF transmission 
Animal studies suggest that oestrogen hormones play a part in reducing filarial infection in 
females as several studies have shown that LF MF density is lower in women of reproductive 
age when compared to men of the same age. This difference could not be explained by 
differences in exposure (such as differences in clothing), is not associated with pregnancy but 
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could be related to the hormonal activity (Kaur 1997; Alexander and Grenfell 1999). A specific 
age distribution of microfilaraemia is consistent in all endemic areas, and this is that 
prevalence and density rise with age and peak between the ages of 15 and 25 years and a 
decline in adulthood (Sasa 1976). A study by Lammie et al. (1994) in Haiti showed 24.5% 
prevalence in children aged 1-5 years that increased to 70% in adults older than 50 years. More 
males are infected than females and incidence of the disease is higher in males. The prevalence 
of antigenaemia and microfilaraemia and the microfilaraemia density are closely related to 
transmission intensity (Day et al. 1991a,b). It was also demonstrated that higher MF 
prevalence in younger people is linked with the increased vector biting rates (Farid et al. 1997).  
 
Pathogenesis 
A British Physician Timothy Lewis was the first to observe the minute MF of the parasite that 
causes LF in 1870 in the urine of patients (Bockarie and Molyneux 2009). Patrick Manson on 
the 10th August 1887 fed some mosquitoes with the blood of his microfilaraemic gardener Hin-
Lo and succeeded in demonstrating the development of the larva within the insect. The 
mosquitoes used by Manson in the first experiment were confirmed to be Culex 
quinquefasciatus that is still regarded as one of the most important LF vectors. By 1976 other 
species of Culex and Anopheles, Aedes, and Mansonia were added as vectors of LF and the list 
currently has several hundreds of vectors (Manson 1878a, 1878b, 1884).  
 
LF parasites are long hair-like nematodes that dwell in tissues. Together with the 
onchocerciasis parasite they have arthropods as intermediate hosts and have a life cycle that 
involves a maturation stage in a blood-sucking insect and a reproductive stage in the tissues or 
blood of the human host (McMahon and Simonsen 1996). The adult male and female worms 
live in the lymphatic system or other tissues. MF produced by female worms, circulate in the 
blood and are ingested by the vector. Larval development takes place within the vector’s 
muscles. The infective L3 stage moves to the proboscis of the vector and is transmitted to the 
new host during subsequent blood meals. Unlike malaria, the infective stage is deposited onto 
the skin of the new host and finds its way through the skin generally through the puncture the 
mosquito makes during the bite, and are not injected directly into the skin of the new host. 
Filaria worms can be found in all classes of vertebrates except fish and are also common in 
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birds. Both filaria worms that cause LF and onchocerciasis in humans belong to the family 
Onchocercidae (Roberts and Janovy 1996).  
  
Intracellular bacteria were discovered in the 1970s in some species of female LF parasites that 
were later identified as belonging to the genus Wolbachia and have the same role as the 
symbiont bacteria found in arthropods that have a significant influence on the growth and 
reproduction of the host arthropod. It was then suggested that these symbionts could be 
implicated in the pathogenesis of LF and should be targeted through the antifilarial activity for 
elimination of the disease (Hoerauf et al. 1999; Hoerauf et al. 2000).  
 
Patrick Manson was able to demonstrate nocturnal periodicity of LF through his laboratory 
assistants. One worked during the day and the other during the night and the one that worked 
during the night found more filaria than the one that worked during the day.  He, therefore, set 
up an experiment in which serial blood samples were taken from the same patients during the 
day and night, and he found more MF in large numbers from the blood collected in the night, 
but MF were almost absent in the blood samples collected during the day. His findings were 
met with disbelief, but Myers and MacKenzie confirmed Manson’s findings. MacKenzie (1881) 
reversed the nocturnal periodicity by asking his patients to sleep during the day and remain 
awake in the night. Manson (1883) also did the same the following year. Changes in nocturnal 
periodicity have been obtained with as little as a three-day reversal in sleeping patterns. 
Manson later confirmed this finding in a human case in 1897. Thorpe in 1896 and Lynch in 
1905 reported that the MF (which was subsequently called W. bancrofti var pacific) had no 
periodicity. Turner and Edeson (1957) demonstrated that there are nocturnal and sub-periodic 
forms of Brugia malayi. Seventy percent (70%) of those infected with LF do not show 
symptoms of the disease, but almost all those infected have sub-clinical damage to the 
lymphatic vessels (Sodahlon et al. 2013). Damage to the lymphatic system places people at risk 
of secondary infection (WHO 1995).  
 
LF Vectors 
LF is a mosquito-transmitted parasitic infection (Grady et al. 2007). The detection of 
mosquitoes as vectors of W. bancrofti in China in 1877 by the British physician Patrick Manson 
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was the first time any association had been made between an insect and active transmission of 
an agent of an animal or human disease (Bockarie and Molyneux 2009). The parasite that 
causes LF can be transmitted by five genera of mosquitos: Anopheles, Aedes, Culex, Mansonia, 
Ochlerotatus (Bockarie and Molyneux 2009). Therefore, unlike malaria whose transmission 
cycle is dependent only on the Anopheles species, LF has a wide range of mosquitoes that 
serve as vectors, of which the most widespread and important species is Culex 
quinquefasciatus. Since this species breeds in collections of heavily polluted water in urban and 
semi-urban settings, this results in the high prevalence of LF in areas where rapid growth 
overtakes the available sanitation services. It is a night-biting mosquito, and LF in areas where 
it is the main vector show nocturnal periodicity. Other Culex species are capable of 
transmitting LF and are important vectors in some areas (Manson-Bahr 1959; WHO 1992). 
Aedes polynesiensis and Ae. Samoanus are the key vectors in the Pacific. They breed in crab 
holes and tree holes which make it difficult to control using conventional methods for other 
mosquitoes. They are also day-biting mosquitoes that account for the diurnal periodicity of LF 
in that region. Ae. poecilius, a night-biting mosquito, is the key vector in the Philippines 
(Manson-Bahr 1959; WHO 1992). Mansonia species are also important vectors of B. malayi, 
and sometimes W. bancrofti in areas where large parts of aquatic plants exist (Manson-Bahr 
1959; WHO 1992). Anopheles species are the key vectors for W. bancrofti in parts of Africa, 
Southern Asia, and Papua New Guinea. A. barbirostris, which breeds in open rice paddies, is 
the only vector known to transmit B. timori (Manson-Bahr 1959; WHO 1992). Bed bugs (Cimex 
species) can be naturally and experimentally infected with B. malayi and W. bancrofti with 
some limited larval development, but the extremely high mortality of the larvae within bed 
bugs means they cannot be seriously considered as a vector of filariasis (Burton 1963). In West 
Africa, the vector for LF and malaria are the same Anopheles species and vector control for one 
can impact the control of the other. The effect of vector control for malaria on LF endemicity 
status has been documented in several studies (Kelly-Hope et al. 2006; Reimer et al. 2013; de 
Souza et al. 2015).  
 
Manifestation 
LF causes acute and chronic morbidity of humans in tropical and sub-tropical parts of Asia, 
Africa, Western pacific and parts of the Americas (Bockarie and Molyneux 2009). An estimated 
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40 million individuals have the principal morbidities of LF (lymphoedema and hydrocoele). The 
Global Programme to Eliminate LF (GPELF) objectives are to interrupt transmission of causal 
parasite and alleviate suffering from the morbidities linked with the disease (Sodahlon et al. 
2013).  
 
Current literature suggests that there are usually five groups of people within LF endemic 
communities: 
1. People who are exposed with no evidence of disease. These are endemic normal people or 
people who are not microfilaraemic and have no clinical manifestation of the disease even 
though exposed to the disease. The possibility that they are immune to the disease is still 
debatable (Ottesen 1989; Kazura et al. 1993; Weil et al. 1996). They still have antigens to 
the worm and ultrasound has shown that they can have adult worms in their scrotum, 
which suggests that they are in the pre-patent stage of the disease (Simonsen et al. 1997b; 
Dreyer et al. 1996a). It has been shown in animals that some level of immunity occurs for 
LF that is probably T-cell mediated. People in this group could be immune to LF because 
there is conclusive evidence that herd immunity exists for LF in some communities. This 
may explain the reduction of MF intensity among older people; i.e. they develop immunity 
with long term exposure to the disease. The LF-related immunity noted is more directed 
against L3 larval stages of the worm (Weil et al. 1982; Michael and Bundy 1998).  
2. People who are microfilaraemic but asymptomatic. This is a more common manifestation 
of LF and can occur in children as young as 14 months. The individuals in this group usually 
have many MF in their blood but show no sign of the disease, and this may persist for 
decades. Most people in this group (about half) can be demonstrated using ultrasound to 
have motile adult worms in the lymphatics of their scrotum also known as the “filarial 
dance sign” (Lowman 1944; Ottesen 1992; Amaral et al. 1994).  
3. People who have an acute filarial disease with or without MF in the blood. LF is usually 
linked with elephantiasis when most people with LF do not have this condition. When 
people say, LF is not a problem they usually mean elephantiasis is not a problem. Acute LF 
can occur without MF in the blood and could be misdiagnosed in endemic communities as 
malaria or any other tropical infection. This results in wrong treatment and waste of 
resources for health. Acute attacks can be experienced by patients as young as three 
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months but the frequency increases in older children, teenagers and persists throughout 
life. The acute attacks can be experienced by people with or without MF in the blood and 
more among people with chronic LF. Sometimes filarial markers such as filarial antigen and 
antifilarial IgG4 antibody may be absent. This may be explained by the inflammatory 
response to L3 stages before adult worms are formed although some studies have shown 
that up to 30% of people with acute attacks have adult worms. Acute filariasis is usually 
manifested by acute adeno-lymphadenitis (ADL), characterised by intense lymphangitis 
and lymphadenitis that starts from the affected lymph node and shows reddening of the 
overlying skin. The attacks go with chills and fever. Males can have orchitis, epididymitis, 
and acute transient hydrocoele. An episode lasts for one week and can end or be resolved 
spontaneously (Wartman 1947; Dasgupta 1984; Nanduri and Kazura 1989; Addiss et al. 
1994; Roberts and Janovy 1996).  
4. People who have chronic disease with or without MF in the blood. The first sign of the 
chronic disease is either lymphoedema or hydrocoele after an acute attack. The onset of 
lymphoedema and hydrocoele is usually gradual. Efforts have been made to reduce chronic 
manifestation of LF using different techniques to increase lymph flow and prevent 
lymphoedema: hyaluronidase was used with some success; coumarin (a drug that 
increases macrophage-associated proteolysis and reduces stasis of protein in tissues) 
reduces lymphoedema and elephantiasis; surgical procedures such as establishment of a 
shunt between lymphatic and venous system or lymphatics and omentum can reduce 
lymphoedema in some patients; and lymphosuction was proposed as a new treatment for 
chronic lymphoedema. The risk of getting chronic disease increases as the MF density 
increases (Jordan 1959; Goldsmith 1974; Nanduri and Kazura 1989; Casley-Smith et al. 
1993; Dreyer et al. 1994; Clodius 1998). Lymphoedema can be graded as indicated in Table 
3 below (Gyapong et al. 1994; McMahon and Simonsen 1996). 
 
Table 3: Grading of lymphoedema cases (Gyapong et al. 1994; McMahon and Simonsen 1996) 
Manifestation Grade symptoms 
Elephantiasis of the limb 0. normal 
1. Loss of contour or lymphoedema 
2. Thick skin and loss of elasticity 
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3. Evident elephantiasis 
Hydrocoele 0. normal 
1. Swelling of spermatic chord 
2. Swelling up to 10 cm in diameter 
3. Swelling greater than 10 cm 
Scrotal elephantiasis 0. normal 
1. Lymphoedema 
2. Thick skin and loss of elasticity 
3. Evident elephantiasis 
 
5. People with tropical pulmonary eosinophilia. This is the least common manifestation of LF. 
There is usually severe hypersensitivity response with pronounced eosinophilia, extreme 
levels of serum IgE and high titres of antifilarial IgG and IgE. MF is not usually found in the 
blood, but adult worms can be detected by ultrasound. This type is clinically manifested as 
coughing in the night and asthma. Pulmonary infiltration is detected through a 
characteristic x-ray feature known as the “snowflake lung”. Fibrosis and permanent lung 
damage can occur due to the accumulation of eosinophils in the lung with subsequent 
release of cationic proteins and free radicals. This form is more common in Southern India 
and parts of Southeast Asia but less common in Papua New Guinea and Africa (Ottesen et 
al. 1982; Pinkston et al. 1987; Nanduri and Kazura 1989; Lobos et al. 1992; Ray et al. 1993; 
Magnussen et al. 1995; Dreyer et al. 1996b). 
 
Besides the five groups presented above, some LF patients have other manifestations of the 
disease such as chyluria. Chyluria is the presence of chyle in the urine following rupture of 
dilated lymphatic vessels in the bladder or kidneys into the urinary system. This is a rare 
complication of LF (Cahill 1965; McMahon and Simonsen 1996). It has been detected that 
parasites induce some level of immunosuppression to ensure their survival in the host 
(Nussenzweig 1982). Many studies have been documented to determine the prevalence of LF 
morbidity (Simonsen et al. 2002; Njenga et al. 2007; Jullien et al. 2009). Simonsen et al. (2002) 
showed that examination of scrotal tissue can be used to determine signs of adult worms 
through detection of the filarial dance sign (FDS) using ultrasound (Simonsen et al. 2002). It is 
worth noting that the goals of GPELF include the interruption of transmission and provision of 
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care for those with LF disease manifestation (i.e. morbidity control) such as acute inflammatory 
episodes, lymphoedema, and hydrocoele. Bacteria is the cause of acute episodes known as 
acute dermatolymphangioadenitis (ADLA).  
 
Community social attitudes to LF 
LF is seen as a terrible disease because it causes disfigurement (Rauyajin et al. 1995) and some 
of those affected are completely shunned by their families and communities. This is usually 
worse for women, and they refuse to leave the house, and marriage prospects for them are 
slim within their communities (Rauyajin et al. 1995). Those affected do not seek help or usually 
would turn to traditional medicine. It was reported that during the advanced stages of the 
disease traditional medicine is combined with western medicine to lower body heat (Rauyajin 
et al. 1995).  
 
Loss of income was reported in all families with someone affected by LF not only the poor. 
Poor families were pushed to near destitution. People with LF are reported as marginalised and 
forgotten (Perera et al. 2007). People refuse to sit, eat with them or marry them. In Tanzania 
having LF is considered an embarrassment, in Polynesia during the 1950’s men with 
elephantiasis of the scrotum were seen as social and procreative handicaps. In Ghana mild to 
moderate elephantiasis is accepted but those affected themselves are embarrassed about their 
disease and so prefer to stay at home. People with hydrocoele are teased, and those with 
chronic manifestations of LF cannot become chiefs in their villages (Kessel 1957; Evans et al. 
1993; Muhondwa 1983; Gyapong et al. 1996a,b).  
 
LF-related stigma is worse for women. Women with labial enlargement in the Philippines are 
seen to be promiscuous, and so there is poor reporting of this aspect of the disease by women. 
In Ghana, young women have problems getting married because young men think they 
(women with the disease) will not be able to work and he will also have to pay the cost of her 
treatment of the disease. In Nigeria, women with LF have problems getting married, or if they 
get married, there is no stability in the marriage and these women are deprived of happiness in 
the marriage. This unwillingness to marry women with LF is compounded by a belief that the 
offspring will also get the disease. In India, LF is considered to cause “grave social wounds”, 
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especially for women and most women with LF, have low self-esteem and fear of being 
rejected by their husbands (Gyapong et al. 1996a,b; Gyapong et al. 2000).  
 
Women had similar reactions about marrying men with manifestations of LF, but the decision 
was not usually theirs because relatives arrange the marriage. In Tanzania, it was documented 
that people from villages with low endemicity avoid marrying girls from villages with high 
endemicity, but within hyper-endemic communities, girls can be married even when they have 
some manifestation of the disease. However, although this happens the women cannot have 
‘good’ husbands and marital happiness is diminished. In Ghana, the divorce rate is higher than 
normal when women with LF are involved (Hunter 1992; Mujinja et al. 1997; Coreil et al. 1998; 
Ahorlu et al. 1999). 
 
Children unfortunately also suffer social effects of LF due to attacks of ADL that result in 
interruption of education. They also have medical and social effects of chronic pathology. They 
can also stop attending school because of the shame, embarrassment and ridicule suffered. It 
is reported that boys with hydrocoeles could not cycle, or walk to school, play or take part in 
sport because of the associated scrotal pain that results from exercise (Ramaiah et al. 2000).  
 
Beliefs on aetiology of LF 
Beliefs on the origin of LF varies widely. In developing countries, LF is attributed to sorcery and 
other supernatural causes. In Ghana, it is believed that one gets elephantiasis of the leg by 
stepping on spiritual things put on the ground by witch doctors at funeral festivities. It is 
believed that one gets elephantiasis of the arm by accidentally picking up the tail of an animal 
that a witch doctor drops on the ground. Some believe LF can be passed on in-utero to children 
when the father’s semen is infected. Few people know that mosquitoes transmit LF and 
minimising contact with mosquitoes can reduce the chances of getting the disease (Gyapong et 
al. 1996a,b; Gyapong et al. 2000). 
 
Socio-economic impact of LF 
Productivity is reduced especially during the late stages of the chronic disease when the 
complications such as hydrocoele and lymphoedema are more pronounced although people 
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with such late stages of the disease are beyond their most productive years (Kessel 1957; 
Muhondwa 1983). The impact of LF in similar communities can be severe. Gyapong et al. 
(1996b) estimate that 4.1% of the productive female labour force and 20% of the productive 
male labour force are disabled by between 10 and 60% because of chronic LF. An estimated 
20% of people with chronic advanced LF often give up their primary food producing role and 
do eventually settle for more sedentary occupations like weaving. This can overall reduce the 
food producing capacity of some communities. Elephantiasis, hydrocoele, and attacks of 
adeno-lymphangitis can physically incapacitate those affected and reduce their level of 
participation in socio-economic activities within communities they live in (Wynd et al. 2007). 
WHO member states are committed to eliminating the disease as a public health problem 
cognisant of its economic impact and the disability and social stigma it causes (WHO 2016a). 
 
Diagnosis 
Diagnostic tools help make decisions on where to treat, how to measure the impact of 
treatment, how to define targets, how to determine end points for stopping MDA and how to 
monitor for a possible resurgence of LF transmission after it is stopped (Weil and Ramzy 2007). 
Surveillance and other M&E results are important for establishing, determining and modifying 
strategies, reporting public health successes, and can be key for advocacy to obtain and 
maintain financial and technical support nationally and internationally (Baker et al. 2010).  
 
Currently, two methods are being recommended for diagnosis of LF: 
1. Demonstration of the existence of MF through direct techniques. Baseline survey (in 
sentinel sites only), and monitoring survey at midterm (after three years of post-mapping 
MDA) and after at least five years of post-mapping MDA (pre-TAS) are still recommended 
in sentinel and spot check sites. The baseline survey is required to obtain baseline data 
against which data obtained in impact monitoring surveys can be compared while the 
monitoring surveys at mid-term, and the pre-TAS are conducted to determine the decline 
in LF prevalence and intensity following MDAs and to determine eligibility for a 
transmission assessment survey (TAS) respectively. These studies are conducted using 
microscopy approach to examine night blood films. Samples of 60µl of blood taken 
between 10pm and 4am from 300-500 adults provide key information (WHO 2005; WHO 
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2010; WHO 2011a,b,c; WHO 2013). In areas where the LF parasite shows nocturnal 
periodicity blood can be collected two hours before or after midnight when the MF density 
is expected to be highest. In cases of diurnal periodicity, blood is taken two hours before or 
after midday (Sasa 1976). MF testing (through microscopy of thick blood films) is 
determined to be insensitive for active infections and misses people with low MF density 
and people with amicrofilaraemic LF infection that can lead to irreversible major lymphatic 
damage in these patients and they (the patients) can still contribute to LF transmission in 
the future within their communities. Thus, MF testing can lead to under-diagnosis and 
exclusion of areas with active LF transmission (Braga et al. 2003; Weil and Ramzy 2007). 
Other challenges of MF testing are the unsociable hours that the tests are conducted 
(before and after midnight) with high refusal and the extensive microscopy needed that 
requires extensive training. It has been therefore determined that other approaches are 
needed for endpoint assessments of LF infection in endemic communities and other 
methods such as exposure antibodies in children and polymerase chain reaction (PCR) 
methods for xenomonitoring filarial parasites in mosquitoes have been recommended 
(Farid et al. 2001).  
2. Detection of LF antigen. LF antigenaemia is linked with active LF infection, and several 
assays for LF antigen using polyclonal and monoclonal antibodies raised against various 
antigens have been developed. The ICT antigen test (ICT Diagnostics, Sydney, Australia) is a 
rapid immuno-chromatographic technique that uses specific monoclonal and polyclonal 
antibodies. The test is conducted using capillary and venous blood and is simple enough for 
use in the field by people who receive minimal training (Hamilton 1985; Weil et al. 1987; 
Zheng et al. 1987). While some authors (Phantana et al. 1999) consider the test highly 
sensitive (100%) and specific (96.3%) with predictive positive value of 70.7% and predictive 
negative value of 100%, others (Pani et al. 2000) think that the test is less sensitive for 
detecting low-level microfilaraemia. One significant development in the diagnosis of 
bancroftian LF is the introduction of the LF antigen test that does not depend on MF 
presence and so makes the NBS and the TBF method unnecessary. It has also been 
suggested that antigenaemia testing is far more superior for diagnosis of LF (prevalence 
and intensity) because microfilaraemia surveys alone can underestimate the prevalence of 
LF by up to 30%. The ICT test (and recently the filaria test strip (FTS)) test can be 
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undertaken using finger prick stick in the field and the results are obtained fast (WHO 
2016c). ICT cards were developed for the diagnosis of Bancroftian LF in human serum or 
plasma and had more advantages than MF tests. The survey is done in daytime and has 
high sensitivity and specificity when performed in serum. It is also done within short time 
and are simple to use with minimal training needed. Specificity of ICT cards ranges from 
between 72.4% and 100%. However, ICT is susceptible to classification errors as faint lines 
can be misread; and there could be cross reaction with soil-transmitted helminth infection 
since the antigens that the test can detect have not been clearly identified. It was also 
demonstrated that individuals remain positive up to two years after treatment with 
diethylcarbamazine (Braga et al. 2003). Currently, WHO recommends antigen detection 
with FTS, a similar test to ICT, that detects circulating LF antigen to decide where to treat 
(i.e. for mapping LF distribution), and to monitor progress towards elimination end points 
(for pre-Transmission Assessment Survey (TAS) and TAS) for LF (WHO 2016c). Alternative 
to ICT/FTS for measuring antigen is the ELISA-based approach that uses Og4C3 monoclonal 
antibody (Molyneux 2009). Some level of training is still needed in the use of ICT and FTS to 
avoid the misreading of slides leading to false positives. The ICT cards have been shown to 
have limited shelf life at ambient temperature (3 months at 30-degree centigrade) and 
have a longer shelf life when stored at four-degree centigrade. They should not be frozen. 
One hundred (100) microlitre of blood collected from finger prick into calibrated capillary 
tube or microtiter pipette coated with anticoagulant (ethylenediamine tetraacetic acid 
(EDTA) or heparin) or finger prick blood is collected in a microcentrifuge blood collection 
tube coated with EDTA or heparin. Blood should not be added directly from finger to the 
card. Two cards from each lot should be tested before the survey using a weak positive 
control. Test line with this control is faint, and so cards that are negative with the control 
should not be used. For transportation to the field, cards do not have to be put in a cool 
box but should also not be exposed to extreme heat for long. Lighting should be adequate 
when reading results to avoid missing the faint lines, especially at night. Results should be 
read ten minutes after closing card. The FTS has now replaced ICT and is being donated for 
TAS to some countries through WHO. FTS is developed by ALERE (Scarborough, ME, United 
States) through financial support from the pharmaceutical companies, MDP and the BMGF. 
A field study conducted to compare the ICT and FTS showed that the two tests had 
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similarly high rates of sensitivity and specificity and >99% agreement but the FTS detected 
26.5% more people with filarial antigenemia and had better test result stability than ICT 
(Weil and Ramzy 2007; Weil et al. 2013). TAS is a standardised tool recommended for 
deciding when to stop MDA (TAS1) and after stopping MDA to monitor and confirm that 
infection has been maintained below the pre-requisite elimination thresholds (TAS2 and 
TAS3) (WHO 2011a; WHO 2013; WHO 2015; WHO 2016b). TAS is conducted to determine if 
MDA can be stopped within an LF evaluation unit after at least 5 rounds of annual MDA.  
Lot quality assurance sampling forms the basis of the TAS survey design, but survey site is 
dependent on school enrolment rate in the evaluation unit. Eligible population for the 
survey is 1st and 2nd graders (6-7) year olds and their exposure to LF should be less because 
they have lived most of their lives during MDAs. The methodology provides critical cut-off 
values for positives based on sample size. This is a statistically powered threshold below 
which transmission is expected to be no longer sustainable. TAS survey design depends on 
net primary school enrolment in each EU (if ≥75% then the school-based survey is done, 
and if <75% then the community-based survey is done). The target population, vector type, 
and parasite species also help determine the required survey site, the target population for 
the survey, survey type, sample size, critical cut-off, and diagnosis tool. The survey sample 
builder (a Microsoft Excel computer tool) is used to assist principal investigators to 
navigate the TAS protocol and input required data. The survey sample builder, after the 
necessary input are made, provides random number lists and automated survey design 
calculations such as sample size, sampling intervals for a rigorous sampling. Survey 
methodologies for all TAS are the same (whether for stopping MDA (TAS1) or for post-MDA 
surveillance-TAS2 and TAS3 (Chu et al. 2013). 
 
Treatment 
MDA is the PC strategy recommended for delivering safe, anthelminthic drugs within 
populations known to be at risk of LF to prevent the morbidity resulting from the infection and 
also to interrupt transmission (WHO 2015). LF MDA involves annual administration of a 
combined dose of medicines to all within endemic areas that are eligible for treatment for at 
least five years (WHO 2015). MDA is stopped when after at least five years of annual treatment 
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it is demonstrated that the level of infection has been reduced to below already established 
target thresholds (WHO 2015).  
 
Interruption of infection transmission is achieved by treating the entire at-risk population long 
enough so that the levels of microfilaraemia are kept below the levels that allow transmission. 
The two-drug regimen involves 400 mg of albendazole plus diethylcarbamazine 6mg/kg or 
400mg albendazole plus ivermectin 200mcg/kg and is administered at least annually for 
between four-six years. This period corresponds with the lifespan of the parasite. For areas 
where fortified diethylcarbamazine salt is used treatment period is six-12 months of daily 
fortified salt intake (Ottesen 2000; Hotez 2011; WHO 2016a).  
 
Ivermectin and diethylcarbamazine rapidly decrease microfilaraemia, and the anti-MF effect is 
further increased when they are administered together with albendazole (a broad spectrum 
anthelminthic) that reduces adult worm viability and MF production (Ramaiah and Ottesen 
2014). The impact of MDA is noted right from the first round and increases with each 
treatment round. One round (assessment after 12 months) reduces MF by 26% to 41% and 
five-six rounds lead to 88%-90% reduction (Ramaiah and Ottesen 2014). Two rounds of 
treatment can clear LF infection in 0-5-year-old children, and 2-4 MDA rounds can free 1-10-
year-old children from LF infection. Single dose treatment can reverse LF pathology in children. 
Newly born children are protected from acquiring the infection as MDA has an impact on 
transmission from the first treatment round. Therefore, within communities treated for LF 
children 0-5 years are free from microfilaraemia and the disease (Ramaiah and Ottesen 2014). 
Using a model based on empirical observations of the impact of treatment on the clinical signs 
of LF it was estimated that 96.71 million LF cases, 79.20 million MF carriers, 18.73 million 
hydrocoele cases, and at least 5.49 million lymphoedema cases were prevented between 2000 
and 2014, but there are still up to 36 million cases of hydrocoele and lymphoedema globally 
(Ramaiah and Ottesen 2014; WHO 2015).  
 
Key factors responsible for the success of one programme and failure of others include the 
following: initial level of LF endemicity; efficiency/effectiveness of vector mosquitoes; MDA 
drug regimen; and population adherence (Kyelem et al. 2008). Other factors crucial for success 
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include high-level political commitment, development of appropriate social mobilisation 
strategies, involving communities in MDAs, and the introduction of morbidity management 
(Mohammed et al. 2006).  
 
LF programmes aim at 65% coverage of entire at-risk population and 80% coverage of the 
eligible population annually for a minimum of five years to interrupt transmission of the 
parasite (Bockarie and Molyneux 2009). Drug cost is not a barrier to elimination of LF because 
GlaxoSmithKline donates albendazole and Merck and Co. Inc. donates Ivermectin for LF and 
onchocerciasis treatment for as long as necessary (Bockarie and Molyneux 2009). The efficacy 
of MDA for stopping the spread of infection is demonstrated by countries continuing to show 
eligibility for MDA through mapping and implementation of TAS1 before stopping MDA. A 
programme must achieve a minimum of 65% coverage of the entire at-risk population in at 
least five annual rounds of MDA and show that less than 1% microfilaraemia or 2% 
antigenaemia has been achieved in each sentinel and spot check site that are evaluated (WHO 
2015). 
 
MDA for NTDs can be administered for as little as US$0.50 or less per person per year 
(Molyneux, Hotez, Fenwick 2005). The low cost of NTD interventions is driven by several 
factors: (1) commitment of pharmaceutical companies to provide NTD drugs free of costs; (2) 
the scale of the programmes (use of strategy that involves MDA, endemicity of many countries 
and high number of people and communities at risk); (3) many opportunities that exist for 
synergy in the delivery of interventions for NTDs (especially onchocerciasis and LF); and (4) 
volunteer contribution of communities and teachers in MDA (Conteh, Engels, Molyneux 2010). 
There has been an expansion of MDA due to increased commitment of endemic countries, 
bilateral donors and NGDOs (Molyneux and Malecela 2010). 
 
An estimated US$21.8 billion of direct economic benefits is gained over the lifetime of about 
31 million individuals that received treatment in the first eight years of the GPELF. Among this, 
more than US$ 2.3 is realised through protection of an estimated three million children from 
the disease when they are born in areas where LF transmission is interrupted. Moreover, 28 
million persons already infected benefit for prevention of disease progressing to the gruesome 
  
85 
 
manifestations. Moreover, this results in a lifetime economic benefit of approximately US$19.5 
billion. Another benefit is that health systems have fewer patient services to attend to relating 
to LF due to reduced LF morbidity and this saves US$ 2.2 billion that would otherwise be used 
for this service. MDA for LF offers great economic benefits and is an excellent investment in 
global health (Chu et al. 2010).  
 
Since albendazole, ivermectin and diethylcarbamazine show some but limited macrofilaricidal 
effect on LF, ivermectin is claimed to cause worm sterility and higher death rate of O. volvulus  
administered using more frequent doses), MDA for onchocerciasis and LF with albendazole, 
ivermectin or diethylcarbamazine may not fully address needs of individual patients that may 
be seeking treatment for symptoms. Chemotherapy against the endosymbiont Wolbachia with 
doxycycline has higher parasitic efficacy for onchocerciasis and LF and also more improvement 
of the disease is seen (Hoerauf 2008). Six-weeks of administering 200mg of doxycycline per day 
sterilises adult female OV worms. 200mg of doxycycline per day for 4-6 weeks show 50% and 
60% macrofilaricidal effects respectively (Hoerauf et al. 2008). With Bancroftian LF there is a 
reduction of 80-90% adult worms with 200mg of doxycycline per day for 4-6 weeks. Reduction 
of lymph vessel dilatation and hydrocoele was also observed with this regimen. Lymphoedema 
was halted and reversed in early stages. This treatment can be applied to individual cases 
(Hoerauf et al. 2008).  
 
Community participation improves programme interventions. In American Samoa churches 
and multiple media channels for health promotion led to sustained programme improvements. 
Other programmes may benefit from this use of MDA approach for disease control (King et al. 
2010). Training and motivation of drug distributors are important because they interact 
directly with populations treated and their behaviour can affect adherence by families and 
individuals (Krentel, Fischer, Weil 2013). Also important are the thorough preparation of 
personnel, supplies, and logistics for implementation and preparation of population towards 
the MDA (Krentel, Fischer, Weil 2013). Demographic factors such as age, sex, income level, and 
area of residence are often linked with adherence. Decisions to comply or not are affected by 
individual or community perception of potential benefits of participation against the risk of 
adverse reactions (Krentel, Fischer, Weil 2013).  
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Effect of ivermectin, albendazole and diethylcarbamazine on LF transmission 
Diethylcarbamazine: Diethylcarbamazine is a piperazine derivative that has proprietary names 
of Hetrazan, Banocide, and Notezine. Diethylcarbamazine is still the most widely used for LF in 
areas where there is no onchocerciasis as there is the severe reaction in these areas due to the 
mass death of O. volvulus that occurs with diethylcarbamazine (Campbell and Rew 1986; 
Molyneux et al. 2014). Diethylcarbamazine is given orally, rapidly absorbed, reaching peak 
blood levels after just 1-2 hours of taking. It reaches all parts of the body in about 25 minutes 
after taking; plasma half-life varies from 6.1-8.1 hours. Excretion is mainly renal, and plasma 
levels drop to zero in 48 hours. The exact mechanism by which diethylcarbamazine destroys, 
MF is still a subject of debate. Effect on MF is through the effect of the drug itself on the 
parasite and the facilitation of host-parasite interaction. It is suggested that 
diethylcarbamazine has macrofilarial and microfilarial effects but the macrofilarial effect is still 
questionable. A single annual dose of 300mg of diethylcarbamazine for adults and 150mg for 
children (combined with ivermectin and sometimes albendazole) is used. Low dose 
diethylcarbamazine significantly reduces prevalence and intensity of MF in treated 
communities and reduced prevalence of chronic pathology. Panicker et al. (1991) documented 
a 74.9% reduction of MF prevalence with annual treatment and 90% reduction with biannual 
treatment. Attacks of filarial fever and incidence of oedema cases also significantly reduce 
after diethylcarbamazine treatment. 
 
Ivermectin: Ivermectin has been used successfully for the treatment of onchocerciasis; this is 
discussed elsewhere. A single annual dose of 400mcg/kg, either alone or with 
diethylcarbamazine, has proved to be effective in producing long-term MF suppression in 
Bancroftian LF in some countries, or is also equally effective against Brugian LF. Nguyen et al. 
(1996) note that at 400mcg/kg dose of ivermectin, MF prevalence drops from 21% to 7%and 
the MF density dropped to 0.5% of the initial value. Zheng et al. (1991) also noted mild 
reactions to ivermectin and noted that acute cases of LF were less likely with ivermectin 
treatment than with diethylcarbamazine. Cao et al. (1997) noted that the severity of reaction 
or adverse events was directly related to the pre-treatment MF density but was noted to be 
independent of the dose. Weil et al. (1991) argue that adverse reactions such as nodule 
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formation, lymphangitis and epididymitis do not occur with ivermectin treatment because it 
does not kill the macrofilariae and it is the death of the macrofilariae that cause these 
reactions. A total of 15 men who were known to have living adult W. bancrofti detected 
through use of ultrasound were treated with 400mcg/kg of body weight every 2 weeks for 6 
months (total dose of 4.8mg/Kg). The MF were suppressed, but there were no changes in the 
motility or location of the adult worms. Dreyer in another study (Dreyer et al. 1995a,b) was 
able to remove live adult worms eight months after treatment with 400mcg/kg of ivermectin. 
Strong evidence exists that ivermectin ingested by a mosquito from a treated person during a 
blood meal reduces mosquito survival and fertility (Tesh and Guzman 1990; Nasr et al. 1996; 
Bockarie et al. 1999). 
 
Albendazole: Albendazole was used for the treatment of intestinal worms but recently is used 
as an anti-filarial. Addiss et al. (1997a,b) have demonstrated that at a standard dose of 400mg 
per person works well as a microfilaricide for LF treatment, and this effect is, even more, when 
albendazole is combined with diethylcarbamazine or ivermectin. Adverse reactions are not 
worse or less with albendazole than with diethylcarbamazine or ivermectin (Addis et al. 
1997a,b).  
 
Combination therapy: Combining diethylcarbamazine and ivermectin or albendazole and 
ivermectin is demonstrated to be effective in providing rapid and long-term LF MF clearance. 
Diethylcarbamazine and ivermectin were more effective than when used alone in clearing 
circulating filarial antigen in persons who are amicrofilaraemic and those who are 
microfilaraemic (Molyneux et al. 2014). Addiss et al. (1997) have demonstrated that 200-
400mcg/kg of ivermectin plus 400mg of albendazole are more effective in MF clearance than 
when used alone. 
 
Other effects of PC for LF 
Other non-LF benefits include treatment of children and women of childbearing age for soil 
transmitted helminthiasis (effect of albendazole), also for onchocerciasis, lice and scabies 
(effect of ivermectin) (Ottesen et al. 2008; Molyneux et al. 2014; WHO 2015). Beach et al. 
(1999) showed in a randomised placebo-controlled trial that six monthly dose of a combination 
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of ivermectin and albendazole was effective in controlling W. bancrofti, A. lumbricoides, T. 
trichuria and hookworm (Necator americanus and Ancylostoma duodenale) among Haitian 
primary school children. This combination also has the benefit of improving the height and 
weight of the children treated.  The effect of ivermectin on onchocerciasis, scabies and lice has 
been described above. 
 
Search for new antifilarial agents 
There is an active global search to develop safe and effective macrofilaricides, including search 
within the marine environment involving a synthetic marine alkaloid, aplysinopsin (Singh et al. 
1997). Another novel approach suggested is to deliver antifilarial drugs into the lymphatic 
system rather than the blood. Since adult worms live in the lymphatic system (the lymph 
nodes) and have good contact with lymph, this approach may lead to the discovery of a 
microfilaricide (Loiseau et al. 1997). It has also been demonstrated that administration of 
ivermectin, albendazole and diethylcarbamazine together as triple drug therapy is safer and 
more effective in reducing the MF of W. bancrofti in non-onchocerciasis areas than the usual 
combination of diethylcarbamazine and albendazole (Thomsen et al. 2016). Hoerauf et al. 
(1999, 2000) had suggested the targeting of the endosymbiont bacteria that live within the 
filaria worms and believes this can have a beneficial effect on the growth and survival of the 
filaria worms. Treatment of onchocerciasis patients with tetracycline also leads to sterilisation 
of female adult worms. 
 
Adverse reactions to anti-filarial drugs  
Reactions post-treatment are common in LF and onchocerciasis (it is called Mazzotti reaction 
with onchocerciasis), and most cases are relatively mild. They can, however, cause 
communities to be afraid of taking treatment and can result in failure of control/elimination 
programmes. Fever is the most common manifestation, but there could be lymphadenitis, 
arthralgia, chills, drowsiness, headaches and hypotension. The reaction is not caused by the 
drugs used for the treatment but occurs because of an inflammatory reaction induced by the 
dying MF. The severity of the reaction, therefore, tends to increase depending on the number 
of circulating MF. Laigret (WHO unpublished report 1983) discovered that reactions to 
diethylcarbamazine decrease and are less frequent as the treatment rounds increase. The 
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exact cause of the reaction is still unknown, but Turner et al. (1994) had shown that cytokines 
such as Interleukin 6 (IL-6) and tumour necrosis factor are implicated. Nodule formation, 
lymphadenitis, and epididymitis are sometimes seen near sites where dying adult worms are 
located. This reaction is more common with diethylcarbamazine because of its partial 
macrofilaricidal effect (Weil et al. 1991).  
 
Integration for NTD control/elimination  
Essential NTD drugs are currently being delivered as a package that targets multiple NTDs 
simultaneously. NTD control is now considered an important and vital global public health 
solution. ivermectin is effective in killing MF in persons with LF and is co-administered with 
albendazole as preventive chemotherapy to interrupt transmission of LF in sub-Saharan Africa 
(Hotez et al. 2009). Integration is needed when there is an overlap of geographic areas of high 
prevalence for multiple NTDs such as LF and onchocerciasis. Vertical MDA programmes can be 
integrated using a package of donated or low-cost generic drugs. In Africa, one such 
combination is ivermectin and albendazole. In Asia and the Caribbean ivermectin is replaced 
with diethylcarbamazine because onchocerciasis is not prevalent in these regions. The rapid 
packages can be administered for as little as $0.40-0.50 per person per year (Hotez et al. 2009).  
 
Opportunities for integration through the USAID NTDP currently exist, but several possible 
challenges have been identified for integration. Integration can lead to increased bureaucratic 
burden that can, in turn, lead to reduced effectiveness of health services. As the number of 
activities increases this becomes aligned to a full-time job for CDDs, and as CDDs, have limited 
time for other economic activities they demand payment. This can also affect the performance 
of a CDD. To address this concern, it is possible to increase the number of CDDs to address this. 
Another challenge/concern is that it is possible that a parallel health delivery system can be 
created when vertical programmes integrated with separate funding, drugs, delivery channel, 
and staff. Another challenge is harmonisation of information, education and communication 
(IEC) materials. Safety and efficacy of drug combinations also have to be considered. M&E 
activities should be carefully designed and implemented to answer operational questions 
(Kolaczinski et al. 2007).  
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Challenges of LF treatment through preventive chemotherapy  
There are always challenges in implementing health programmes in post-conflict settings 
(Molyneux and Malecela 2010). NTDPs must be implemented within a health system context 
and the health systems in most endemic countries are weak. This creates a challenge for NTD 
control programmes that usually means the capacity building is needed for successful 
implementation of the NTDPs (Molyneux and Malecela 2010). There has been a relatively weak 
contribution from governments of endemic countries to the direct implementation of NTDPs. 
Endemic countries themselves need to commit their own resources (financial or otherwise) for 
successful implementation of NTDPs (Molyneux and Malecela 2010). Different drug 
combinations involving diethylcarbamazine cannot be used in areas of Africa where 
onchocerciasis is prevalent because treatment with diethylcarbamazine induces severe and 
lethal reaction in areas that are also coendemic for Loiasis (Bockarie et al. 2013; Molyneux et 
al. 2014). Loiasis is caused by Loa loa (sometimes called ‘the African eye worm’) infection that 
is spread by Chrysops flies. The disease is present in Central and West Africa. Signs and 
symptoms include fugitive or ‘Calabar’ swellings, itching and joint pains. Sometimes there is an 
asymptomatic invasion of the eye by the worm that gives the name ‘eye worm’. Among 
filaroids, it infects travellers from non-endemic zones the most (McMahon and Simonsen 1996; 
Roberts and Janovy 1996). Most affected communities are remote and rural and therefore in 
most cases difficult to access. Health services can have difficulty accessing these communities 
and community members can have problems accessing health services. CDTI is a cornerstone 
for APOC’s success that involves communities themselves. In many areas where onchocerciasis 
and LF are co-endemic, drug delivery can be owned by communities. With CDTI trained health 
workers play a supervisory and technical role. They provide professional expertise and conduct 
household and community surveys to ensure programme requirements are met while 
community volunteers do the actual distribution (Bockarie, Kelly-Hope, Haskew 2010). The 
capacity of some LF endemic African countries to deliver PHC to rural poor is severely affected 
by civil conflicts. The experience gained from CDTI strategies in resource-poor settings has led 
WHO to develop a pro-poor strategy for health care delivery in countries with the challenges of 
conflict and poor infrastructure. This involves an integrated approach for PC. The CDTI 
approach has been successful in post-conflict and fragile states (Bockarie, Kelly-Hope, Haskew 
2010). Overall successful implementation of NTDPs depends on supervision and monitoring of 
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activities at all levels. Monitoring is not just an activity to gather data and report back to higher 
levels but can serve to inform managers of the current status of their elimination programmes 
(Bockarie, Kelly-Hope, Haskew 2010).  
 
Other challenges include the need to develop other antifilarial drugs. Although available drugs 
are effective, there is need to develop other anti-filarial drugs, especially macrofilaricides. 
There is currently no evidence of resistance but this can occur in the future, and the availability 
of other drug alternatives will be key when this occurs. Currently, it is necessary to develop 
techniques for monitoring drug resistance (Alley et al. 2001). 
 
Vector control 
Vector control has an impact on LF elimination since W. bancrofti requires a mosquito host to 
complete its life cycle and the disease can be eliminated through vector control (Bockarie and 
Molyneux 2009; Kelly-Hope et al. 2011). Integrated vector management, including distribution 
of bed nets, insecticide-treated or insecticide-impregnated bed nets (ITNs), and long-lasting 
insecticidal nets (LLINs), and indoor residual spraying (IRS), is recommended by WHO as the 
best approach that can improved efficacy, cost-effectiveness, ecological soundness and 
sustainability of vector control (van den Berg, Kelly-Hope and Lindsay 2013). Vector control 
reduces human-vector contact and can have a significant impact in reducing transmission of 
Malaria and LF both transmitted by Anopheles in West Africa (van den Berg, Kelly-Hope and 
Lindsay 2013). With Vector biting rates below 0.66 bites/man/hour, transmission of Malaria 
and LF is unlikely to be maintained. Therefore, vector control can have a significant impact on 
transmission of Malaria and LF in Africa (de Souza et al. 2015). One of the objectives of the Roll 
Back Malaria initiative is that at least 60% of children below 5 years and pregnant women 
should be sleeping under ITNs by 2010 and mass distribution of bed nets is needed to achieve 
this (Molyneux and Nantulya 2004; Blackburn et al. 2006). Vector control can reduce morbidity 
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and mortality due to Malaria among the poor and within hard-to-reach communities, and the 
same may be true for LF (Molyneux and Nantulya 2004).  
 
Vector control is an important tool for diseases transmitted by mosquitoes, in particular 
against Malaria and LF in West Africa where the vector is the same for both diseases 
(Blackburn et al. 2006; Kelly-Hope et al. 2006; de Souza et al. 2010). Anopheles transmits 
Malaria and LF in Africa (Blackburn et al. 2006). An. Gambiae and An. funestus are the 
predominant rural vectors for W. bancrofti (Bockarie et al. 2013), and control is enhanced 
using impregnated bed nets that can reduce the duration of required MDAs during the 
endgame (Bockarie et al. 2013). High ITN and LLINs use for Malaria control can, therefore, 
reduce the prevalence of W. bancrofti (Bockarie et al. 2013). There is currently increased 
suggestion to combine control efforts for Malaria (caused by the protozoa of the genus 
Plasmodium) and NTDs especially LF (van den Berg, Kelly-Hope and Lindsay 2013). In Sierra 
Leone like in other West Africa countries, LF is transmitted by Anopheles that transmit Malaria 
(de Souza et al. 2015).  
 
It has been suggested that the vector control effect of ITNs is limited because there are many 
vectors of LF among which some bite during the day and night when people are not under bed 
nets (Charlwood and Dagoro 1987). However, it is reported that Anopheles mosquitoes are 
susceptible to ITNs and LLINs (Stanton, Bockarie and Kelly-Hope 2013) and attempts to control 
one parasite in Malaria/LF co-endemic areas through vector control can lead to a change in 
prevalence of the other (Kelly-Hope et al. 2006). Vector control for Malaria control can, 
therefore, supplement MDAs for LF and reduce treatment years (Bockarie et al. 2013). Vector 
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control for LF is even more effective than for Malaria because unlike Malaria the parasite does 
not multiply in the vector and so a person must be exposed to many bites of infected 
mosquitoes to become infected (Bockarie and Molyneux 2009; Kelly-Hope et al. 2011). Overall, 
insecticide-treated bed nets (ITNs) are more effective in reducing transmission of Malaria than 
spraying, and this could be true also for LF (Bockarie and Molyneux 2009).  
 
Studies have indicated that vector control alone can interrupt LF transmission in areas where 
the vector is Anopheles mosquitoes and no transmission occurs afterwards (de Souza et al. 
2015). Increased distribution of bed nets can, therefore, accelerate LF elimination (Stanton, 
Bockarie and Kelly-Hope 2013). There is a suggestion that it is good to distribute ITNs and LLINs 
within entire population, especially in hard to reach areas (Stanton, Bockarie and Kelly-Hope 
2013). Schuurkamp et al. (1987) estimate a period of 11 years to bring LF prevalence to less 
than 2% in the Tabubil area of the Western Province of Papua New Guinea through vector 
control alone.  
 
Culex plays little, or no role in LF transmission in West Africa (de Souza et al. 2015) and usually 
resurgence of LF infection following vector control efforts occurs only in countries where the 
vector is Culex such as Zanzibar in the United Republic of Tanzania (de Souza et al. 2015).  
The impact of vector control through ITNs and LLINs is determined by the extent of distribution 
of ITNs and LLINs for Malaria control (Bockarie et al. 2013). There are currently suggestions of 
investigating the impact of ITNs/LLINs distribution on LF (Stanton, Bockarie and Kelly-Hope 
2013; Molyneux et al. 2014).  
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There is limited recognition of the number of bed nets distributed for Malaria control in the 
last decade and the impact this can have on LF prevalence in the absence of MDA for LF in 
Malaria/LF co-endemic areas (Molyneux et al. 2014). Recent scale-up of ITNs/LLINs distribution 
and use and IRS for Malaria can have a positive impact in reducing LF transmission in areas 
where the LF parasite is transmitted by Anopheles mosquitoes (Kelly-Hope, Molyneux and 
Bockarie 2013). Bed net use was low in Africa (Blackburn et al. 2006). In Central Nigeria in 
2004, 38,600 ITNs was distributed during MDA campaigns for LF (with ivermectin and 
albendazole) that increased ITN ownership to 80%, 9 times more than in 2003 (Blackburn et al. 
2006). Integration of ITN distribution and MDA improved ITN ownership and use significantly 
and did not adversely affect MDA coverage (Blackburn et al. 2006). Between 2008 and 2010, 
an estimated 294 million ITNs was distributed in sub-Saharan Africa for Malaria control (van 
den Berg, Kelly-Hope and Lindsay 2013). According to the Sierra Leone National Malaria 
Control Programme database of 2013, over 6 million ITNs was distributed nationwide in the 
past 5 years (Gerstl et al. 2010; Bennett et al. 2012; Statistics Sierra Leone and ICF International 
2013). IRS was also conducted in selected chiefdoms (sub-district) of 4 districts- Bo, Bombali, 
Kono and Rural Western District (Statistics Sierra Leone and ICF International 2013). 
 
In Sierra Leone, 40% of households owned mosquito nets in 2008 but this increased to 65% of 
households in 2013 (Statistics Sierra Leone and ICF International 2013). A reported 37% of 
households owned ITNs in 2008 but this improved to 64% in 2013 (Statistics Sierra Leone and 
ICF International 2013). In 2013, only 15% of households had universal coverage of LLINs (i.e. 
one LLIN per two persons who slept in a household the night before the survey) (Statistics 
Sierra Leone and ICF International 2013). 49% of children slept under ITNs the night before the 
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survey (Statistics Sierra Leone and ICF International 2013). Among households with ITNs, 73% 
of children slept under ITN the night before the survey (Statistics Sierra Leone and ICF 
International 2013).  60% of households are protected either through ownership of ITN or after 
receiving IRS in the past 12 months (Statistics Sierra Leone and ICF International 2013). 19% of 
households are protected through ownership of ITNs for every 2 persons or after receiving IRS 
in the past 12 months (Statistics Sierra Leone and ICF International 2013). 
 
There are many examples of successful use of ITNs, LLINs and IRS to control/eliminate LF in 
countries that support the suggestion that widespread use of vector control can have an added 
effect on reducing LF transmission. Gambia, Sao Tome and Principe, and Togo had the highest 
coverage rates for ITNs, and it is believed that MDA has either stopped or is considered 
unnecessary due to this. In Costa Rica, Suriname, and Trinidad and Tobago there is no evidence 
of ongoing LF transmission probably because of IRS done for a limited period during the 
Malaria eradication campaign of the 1970s (Bockarie, Kelly-Hope, Haskew 2010). In Solomon 
Islands and parts of Papua New Guinea, vector control through IRS has led to the interruption 
of LF transmission (Bockarie et al. 2013; de Souza et al. 2015). Vector control alone has led to 
the interruption of transmission of LF in the Solomon Islands (Bockarie and Molyneux 2009; 
Kelly-Hope et al. 2011). In East Africa and PNG, bed net distribution for Malaria prevention 
reduced LF prevalence even when the bed nets used then were not impregnated with 
insecticides (Molyneux and Nantulya 2004). Recent studies have shown that LF transmission 
has possibly been interrupted in The Gambia because of extensive ITN use for decades to 
control Malaria (Rebollo et al. 2015). Prevalence of LF (W. bancrofti) in The Gambia was among 
the highest in Africa. In the 1950s, the prevalence of W. bancrofti mf among those equal to or 
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older than 10 years was between 24.1% and 48.4% (Rebollo et al. 2015). The Malaria vectors in 
The Gambia are also responsible for transmission of LF and An. arabiensis, An. gambiae s.s., 
An. melas, and An. funestus are the key vectors of W. bancrofti in the country that are all 
susceptible to ITNs and IRS (Rebollo et al. 2015). ITNs were introduced in the country in the 
1990s (Rebollo et al. 2015). By 2008, 60% or more of ITN ownership coverage was reported 
(Rebollo et al. 2015). The absence of transmission in the whole country demonstrated through 
TAS (Rebollo et al. 2015). In 2013, the absence of transmission of W. bancrofti among children 
after 6-7 years of effective vector control in The Gambia strongly suggested the interruption of 
transmission of LF after 2 decades of ITN use (1950-1970s) and no MDA campaign has ever 
been conducted for LF in the country (Rebollo et al. 2015). 
 
The newly proposed strategy of combining coordinated vector control and MDA using 
albendazole monotherapy for LF elimination in areas where there is co-endemicity with Loiasis 
has not been applied by any national LF programme (WHO 2015). The breaking of vector-host 
contact by use of repellents and bed nets has been recommended as a strategy for NTD control 
in addition to chemotherapy (Reimer et al. 2013). 
 
Vector control for Anopheles is mainly through the use of synthetic pyrethroids currently 
recommended for bed net impregnation and IRS. However, resistance is already widespread to 
pyrethroids in some areas of West and Southern Africa. Dichlorodiphenyltrichloroethane (DDT) 
has been reintroduced to increase insecticide choice after its use was suspended for 3 decades. 
Unfortunately, the resistance of the vector is also already beginning to re-emerge to DDT. 
Resistance may, therefore, end up being a major challenge for Malaria and LF control or 
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elimination (de Souza et al. 2010; Bockarie et al. 2013; van den Berg, Kelly-Hope and Lindsay 
2013). It has therefore been suggested that the pattern of insecticide resistance among 
Malaria and LF vectors be assessed to find ways of avoiding the worsening of this problem 
(Molyneux et al. 2014).  
 
Morbidity management 
WHO (2016a) has indicated that LF patients and their caregivers experience co-infection with 
other diseases and mental illness, that LF is responsible for 2.8 million DALYs lost. Alleviation of 
suffering and prevention of disability from LF is based on reducing secondary bacterial and 
fungal infection of limbs and genitals that already have their lymphatic function compromised 
due to the infection as the secondary infection is already proven to be the main pathogenetic 
factors that enhance worsening of lymphoedema and elephantiasis. Strategies used include 
the introduction of the use of meticulous hygiene, and motivation of those affected through 
the creation of hope and understanding among patients, caregivers and the community in 
general (Ottesen 2000). Since opportunistic infections (bacterial and fungal infections) play a 
role in progression to chronic obstructive filarial disease, attention to basic hygiene, use of 
antibiotics and antifungals, local physiotherapy, can slow progression, prevent or sometimes 
even reverse elephantiasis (Melrose 2004). Morbidity management and disability prevention 
(MMDP) includes a basic package of health care services that should be provided to those with 
hydrocoele and lymphoedema that are required to alleviate suffering and prevent the disease 
from progressing further (WHO 2015). National programmes should include morbidity 
management and disability prevention (MMDP) in their strategies so that care can be provided 
to those affected by LF after transmission has been interrupted. Those affected have a right to 
health care and programmes need to realise this right (WHO 1995). Some experts also believe 
that MMDP can also improve adherence to MDA within communities (WHO 1995).  
 
The GPELF focusses MMDP on lymphoedema, elephantiasis and hydrocoele surgery. For other 
conditions, such as chyluria, lymphocele, scrotal lymphoedema, tropical pulmonary 
eosinophilia, adenopathy and haematuria standard practices for clinical management and 
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referral have to be used as there are no public health approaches available to address these 
conditions (WHO 1995).  
 
Disability encompasses limitations in specific body functions (also called impairment), whole 
body limitations or limitation in a social sense through inability to participate in social functions 
within their own communities.  Those affected therefore need psychological and social support 
for reintegration into their communities and economic life (WHO 1995). Patients need 
continued care and support throughout their life to manage and prevent progression to 
advanced stages of the disease (WHO 1995). WHO and partners have developed strategies and 
activities for managing lymphoedema (home based care) and increasing access to surgery for 
hydrocoele (Brantus 2009). There is now the integration of MMDP and PC for LF, and some 
progress has been made, but there are still many challenges to reach all those that need care 
as highlighted by Brantus (Brantus 2009). 
 
Lymphoedema  
Lymphoedema is debilitating and a chronic complication of LF that results from lymphatic 
insufficiency and can have serious physical, social and psychological consequences for the 
person affected (Barclay et al. 2006). The current management strategy for morbidity 
management and disability prevention involves a combination of strategies that aim to protect 
and decongest the oedematous limb/s and stimulate the development of supplementary 
lymphatic pathways thus controlling swelling in the long term. Aromatherapy has been 
proposed anecdotally as one such strategy because it is suggested that adding aromatherapy 
oils in massage cream can provide relief for people with cancer. Results of a trial conducted 
indicate that self-massage and skin care using aromatherapy oils provide improved relief to 
patients and, also slightly reduced the limb volume. This can be proposed to those who can 
afford it (Barclay et al. 2006). About 15 million people mostly women have lymphoedema or its 
advanced form elephantiasis mainly of the lower limb (WHO 1995). Lymphoedema and 
elephantiasis can be managed with simple measures such as improved hygiene and skin care 
aimed at preventing acute inflammatory episodes of adenolymphangitis. Proper wound care, 
exercise, elevation of affected limb and use of proper footwear can also provide relief. These 
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methods can reduce adenolymphangitis episodes and improve the quality of life of those 
affected and can be maintained as home-based care (WHO 1995).  
 
Hydrocoele 
Globally about 25 million men suffer from the urogenital disease of LF mainly hydrocoele that 
can be cured through surgery. The patient’s and his family’s economic situation and quality of 
life can improve significantly and also result in more participation within communities (WHO 
1995).  
 
Examples of successful LF programmes 
LF transmission has been interrupted in the following countries: Japan, South Korea, endemic 
areas of China, Sri Lanka, Thailand, Malaysia, Solomon Islands, Costa Rica, Suriname, Thailand 
and Trinidad and Tobago using different approaches: mass treatment with diethylcarbamazine 
tablets or use of diethylcarbamazine salt, selective treatments of infected persons, vector 
control or a combination of several approaches. Sri Lanka has eliminated Brugian filariasis and 
Brazil, Malaysia, Cost Rica, Suriname, Trinidad and Tobago have eliminated LF in smaller foci 
(Molyneux 2003). Japan has eliminated LF and other parasitic diseases through integrated 
nationwide community-driven campaigns of the 1960s and 1970s that also created a cadre of 
experienced clinicians, scientists and public health workers that had excellent operational and 
technical knowledge and, also the right positive attitude towards LF elimination (Ichimori, 
Graves, Crump 2006). Japanese experts have supported LF elimination efforts in neighbouring 
countries since the 1970’s and since 1999 have been working on this through the Pacific 
Programme to Eliminate LF (PacELF) that was created that year. PacELF has demonstrated that 
the successful model for LF elimination in Japan can be extended at the regional level (Ichimori, 
Graves, Crump 2006). Post-World War II conditions in Japan were the same as those in 
developing countries today, and the 15-year programme was successfully implemented 
through disease detection, drug distribution, prevention, and extensive health education. 
There were over 1 million people infected with LF in Japan in 1962 when a nationwide LF 
eliminate campaign was started with over 20% LF prevalence in some islands (Ichimori, Graves, 
Crump 2006).  
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China was one of the most heavily endemic countries of the world for LF with 864 endemic 
counties/cities in 16 provinces and a total population of 330 million at risk of getting LF. Among 
the 864, 542 were hypo-endemic (<5% microfilaraemia prevalence); 287 were meso-endemic 
(MF rate 5% - ≤20%); 33 were hyper-endemic (MF rate 20% - ≤30%); and 2 were super-endemic 
(MF rate >30%). LF elimination became a priority after the People’s Republic of China was 
founded in 1949. The ultimate goal of eliminating LF was achieved in 2006 (De-jian, Xu Li, Ji Hui 
2013).  
 
In Africa, two countries (Togo and Malawi) have succeeded in interrupting transmission of LF 
and are currently going through the necessary procedures for verification of elimination by 
WHO. Togo started MDA for LF after mapping and baseline studies for LF in 2000. By 2009 it 
was demonstrated that a break in transmission has been achieved after passing a TAS and 
MDA was stopped nationwide followed by post-MDA surveillance for six years that 
demonstrated interruption of transmission (Sodahlon et al. 2013; WHO 2016a). Malawi passed 
a TAS in 2014 and stopped MDA nationwide in 2015. Post-MDA surveillance is currently 
ongoing (American Society of Tropical Medicine 2015).  
 
Effect of other disease control interventions on LF 
Several authors have reported studies that have shown that distribution of ivermectin for 
onchocerciasis control has an impact on LF intensity and prevalence. It was noted that 
reduction of onchocerciasis MF prevalence can be as high as 100% (to zero MF prevalence) in 
some villages (Kyelem et al. 2003; Kyelem et al. 2005; Kelly-Hope et al. 2011). However, similar 
studies in Nigeria showed that 2-5 years of Ivermectin treated with good coverage had no 
significant effect on LF transmission (Richards et al. 2005a,b). 
 
History of LF control 
Not all elephantiasis is caused by LF and elephantiasis is not the most common sign of LF. 
Elephantiasis is, however, the most visible manifestation of LF and has been known since 
ancient times. Elephantiasis features in Greece, Roman and Indian mythology (talk of beings 
with enlarged or swollen legs); in Egyptian history statues of Pharaoh Mentuhotep 111 (200 
BC) and “Queen of Punt” Stella are depicted with deformities resembling elephantiasis of the 
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limbs); and in artwork from Nigeria and South America depicting scrotal swelling (Neisius 1927; 
Andrews 1959; Lawrence 1967; Lawrence 1990; Routh and Bhowmik 1993). Physicians and 
medical writers from early times knew the disease and even linked it to places where there is 
stagnant water (a relevant observation given the link between Culex mosquitoes that breed in 
stagnant water and LF transmission). Indians wrote of the disease as early as 600 BC, between 
600 and 250 BC people with elephantiasis were not allowed to be Buddhist priests; the Roman 
writer Lucretius Carus noted elephantiasis as characteristic disease of Egyptians that was 
facilitated by the climate around the Nile; Persian physicians of 10th–13th centuries AD and 
medieval European physicians gave accurate descriptions of elephantiasis and hydrocoele; and 
in the 19th century a firm link was made between elephantiasis, hydrocoele  and chyluria 
(Lawrence 1967; Hoeppli 1969; Lawrence 1970; Routh and Bhowmik 1993).  
 
Discovery of W. bancrofti: Jean-Nicholas Demarquay, a Cuban surgeon, discovered a worm-like 
creature in hydrocoele fluid in 1862 (Demarquay 1863); Otto Wucherer, a Brazilian, found the 
same organism in chylous urine in 1866 (Wucherer 1868); and MF was discovered in blood in 
1872 (Lewis 1872). Joseph Bancroft, a Brisbane physician and parasitologist, discovered a 
female adult worm in an abscess from the arm of a butcher in 1876 and other examples were 
found in South America and China. Sibthorpe and Bourne discovered the male adult worm in 
1888. In 1921, the name Wuchereria bancrofti was formally adopted (Seurat 1921). The 
detection of mosquitoes as vectors of W. bancrofti in China in 1877 by the British physician 
Patrick Manson was the first time any association had been made between an insect and active 
transmission of an agent of an animal or human disease (Bockarie and Molyneux 2009). The 
minute MF were also first observed by another British Physician Timothy Lewis in 1870 in the 
urine of patients (Bockarie and Molyneux 2009). The presence of W. bancrofti in Anopheles 
mosquitoes was first reported by Ronald Ross in 1900 (de Souza et al. 2014). 
 
Discovery of the Brugia species: Lichtenstein and Brug discovered a microfilaria in the Dutch 
East Indies (now Indonesia) in 1927 that was morphologically different from W. bancrofti and 
named it Filaria malayi (Brug 1927; Lichtenstein 1927; Brug 1928). Although accepted as such, 
this may not have been the first description of Brugia as Ashburn and Craig had described a 
case from the Philippines in 1905 that had MF that differed from W. bancrofti, and they called 
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it Filaria philippinesis (Ashburn and Craig 1905). Manson-Bahr reviewed the findings in 1941 
and reported that the MF were identical to the F. malayi discovered by Ashburn and Craig. In 
1940 Rao and Maplestone first described the adult worm (Rao and Maplestone 1940). Brug’s 
work was acknowledged in 1958 when Buckley proposed a new genus Brugia and F. malayi 
was renamed Brugia malayi (Buckley 1958; Buckley 1960). The zoonotic feature of Brugia was 
discovered in 1939 when MF that was later identified as those of B. malayi were discovered in 
a Kra monkey (Poynton and Hodgkin 1939). Another filarial species was discovered in the 
1960s in Portuguese Timor and given the name Microfilaria timori. Partono infected Mongolian 
gerbils with this new species and developed adult worms. He confirmed the new species 
belonged to the genus Brugia and named it B. timori (David and Edeson 1965; Partono et al. 
1977).  
 
In 1988 Merck and Co. Inc. launched the donation of ivermectin under the brand name 
Mectizan. Merck formed the MDP, the first ever mass drug donation programme. ivermectin is 
now donated for two global disease elimination programmes (onchocerciasis and LF) that are 
benefiting millions of the world’s poorest people after ivermectin/albendazole and 
diethylcarbamazine/albendazole combinations were approved by late 1990s for use to treat 
for elimination of LF (Thylefors, Alleman 2006; Thylefors 2008; Thylefors, Alleman, Twum-
Danso 2008). In 1997 the World Health Assembly formulated resolution WHA50.29 that urges 
endemic communities to strengthen efforts for control and elimination of LF (Ramaiah and 
Ottesen 2014; Bockarie and Molyneux 2009). In 2000 the GPELF in 2020 was established 
(Ramaiah and Ottesen 2014; Molyneux 2003; WHO 2015; Bockarie, Kelly-Hope, Haskew 2010).  
 
In 2009, the CDTI strategy was expanded to be used to deliver other integrated disease 
interventions including Vit A supplementation and antimalarial treatment (CDI Study Group 
2010). In January 2016, ESPEN was launched by WHO to last for five years (2016-2020) (WHO 
AFRO NTDP 2016; WHO 2016b). 
 
Mapping/baseline surveys for LF 
Mapping is needed to identify priority areas for MDA and to allow for planning for 
implementation of programme activities (Baker et al. 2010). Mapping/baseline studies on LF in 
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West Africa: Gyapong et al. (1996a) reported baseline studies on LF in Ghana that showed high 
MF prevalence (MF prevalence ranged between 1.8% and 20%) with considerable regional 
variation (northern Savannah and southern coastal areas had high prevalence while the middle 
forest belt had low prevalence). Dunyo et al. (1996a) also showed that LF microfilaraemia was 
common in four villages in the Western region of Ghana and overall prevalence ranged from 
9.2%-25.4%. They also showed that Anopheles gambiae s.l. and A. funestus were vectors of LF 
in the endemic villages. Gyapong et al. (2002) conducted a multi-country baseline study that 
showed that ICT positive prevalence among adult populations was as high as 70% in some 
communities studied, in large areas of Burkina Faso ICT prevalence ranged from 30%-50%, in 
most of Togo, Southern Benin and the greater part of Southern Ghana the LF prevalence was 
between 10%-30%. However LF prevalence was low in coastal Togo and Coastal Benin. Nigeria 
has been identified through mapping and baseline studies in 2009 to be the country in sub-
Saharan Africa with the highest number of cases of NTDs including LF and onchocerciasis 
(Hotez et al. 2012). Many other studies on mapping and baseline surveys for LF in other parts 
of the world have been reported (Simonsen et al. 1995; Onapa et al. 2001; Sunish et al. 2001; 
Nielsen et al. 2002; Murty et al. 2004; Chhotray et al. 2005; Das et al. 2006; Ngwira et a. 2007; 
Mishra, Bhadoriya 2009; Ruberanziza et al. 2009; Knight et al. 2010; Msyamboza et al. 2010; 
Foo et al. 2011).  
 
History of LF in Sierra Leone  
The presence of W. bancrofti in Anopheles mosquitoes was first reported in Sierra Leone by 
Ronald Ross in 1900 (de Souza et al. 2014). During the ten-year civil conflict that started in 
1991, an estimated 47% of the pre-war population were displaced and had to settle in camps 
or urban areas in Sierra Leone and in the neighbouring countries of Liberia and Guinea. With 
the population of Freetown increasing from an estimated 750,000 pre-war to 1.5 million post-
war in 1997, a rapid assessment for LF in seven camps showed an LF antigenaemia prevalence 
of 14.5% among internally displaced persons (De Souza et al. 2014). In West Africa LF is 
predominantly a rural disease and the principal vector for LF in West Africa are the Anopheles 
mosquitoes with Anopheles gambiae complex identified as the major vector. The role of Culex 
mosquitoes in the transmission of LF in West Africa is unknown although they are common in 
large cities and urban areas in West Africa (De Souza et al. 2014). LF was determined to be 
  
104 
 
common in rural and urban areas of Sierra Leone (Gbakima and Sahr 1996). Anopheles species 
was also determined to be the vector of W. bancrofti in Sierra Leone. The prevalence rate for 
W. bancrofti in Sierra Leone between 1913 and 1931 was 8.8% in 1930 and 20.6% in 
1931.Thomas (1958 cited in Gbakima and Sahr 1996) showed LF microfilaraemia rate of 44.2% 
in the north, 27.4% for the south-east and 27.7% for the south-west and 12.1% for Freetown. 
Vectors were identified as An. costalis and A. funestus (Gbakima and Sahr 1996). Other studies 
conducted in the 1990s in the south (Moyamba district) showed that LF microfilaraemia rate 
for W. bancrofti was 10.2% (Gbakima and Sahr 1996).  
 
A survey was conducted in 2011/2012 in Freetown and Monrovia (capitals of 2 neighbouring 
post-conflict countries that experienced significant rural-urban migration) to assess the impact 
of migration during the conflict period on LF transmission in urban areas. More Culex 
mosquitoes were collected than Anopheles in both countries (14,342 Culex against 1,731 
Anopheles gambiae). The results showed that An. gambiae are in low numbers with a level of 
LF MF infection too low to maintain transmission of LF (De Souza et al. 2014). TAS also 
conducted in Bo and Pujehun districts. Antigen prevalence in children was 0.19% and 0.67% 
respectively, levels lower than the 2% recommended for stopping MDA in Anopheles 
transmission areas (De Souza et al. 2014). 
 
There has been an excellent strategic investment in the control of NTDs led by the US and UK 
governments, the BMGF and key pharmaceutical partners that has enabled the treatment of 
millions of people for five targeted debilitating diseases (LF, onchocerciasis, schistosomiasis, 
soil-transmitted helminthiasis and trachoma). This has paved the way for the potential 
elimination of some of these diseases as public health problems (Hodges et al. 2011). Sierra 
Leone has a high burden of these five NTDs and has a fragile health system. After emerging 
from a devastating 10-year civil war, the country has successfully implemented the National 
NTD Control Programme, reaching 100% national coverage in 2010 (Hodges et al. 2011). The 
NTD Control Programme had used the existing Onchocerciasis Control Programme as a 
platform to cover other PC NTDs that involve primary health care workers. The programme has 
provided extensive training opportunities to health workers at national, district and community 
levels. The country currently has over 30,000 trained community volunteers who conduct MDA 
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in about 14,500 villages (Hodges et al. 2011). There is evidence that investments in NTD control 
can contribute to strengthening health systems, particularly at the primary level, through the 
extensive capacity building of frontline health workers and community-directed distributors 
(Hodges et al. 2011). USAID support through RTI International as a prime contractor started in 
2007. Technical and financial support from WHO and the USAID NTDP through RTI 
International enabled the completion of mapping of the five PC NTDs in Sierra Leone in 2005-
2008. Drug distribution is integrated for onchocerciasis and LF and all related activities for the 
two diseases after mapping are integrated including training, supervision and drug distribution 
within communities. MDA is however reported separately for the two diseases (Hodges et al. 
2011; Linehan et al. 2011).   
 
 
CHALLENGES OF NTD CONTROL 
Controlling NTDs has many challenges including the high cost of mass treatment programmes, 
poor patient adherence, emerging or existing drug resistance, and possible low therapeutic 
efficacy of ivermectin (Gloeckner et al. 2010). In areas of tropical rain forest in Africa, there is a 
common infection of patients with another filarial parasite, Loa Loa. Although the mobile Loa 
loa adult worm is found in the tissues often not far from the skin, the MF are located in the 
blood. When patients with high levels of MF in the blood are treated with ivermectin, the 
ivermectin treatment can provoke serious adverse events that can be as severe as an 
encephalopathy. The patient develops neurological symptoms such as drowsiness, slurring of 
speech, walking difficulties, and eventually coma may occur. If properly managed, the patient 
with coma will normally recover after a few days although some sequelae may remain. 
However, most of these cases live in remote areas with difficult access to suitable health 
services. In some cultures, patients in a coma are treated with local remedies which delays the 
transfer of the patient to a suitable health facility. Thus, patients already have major 
complications due to pressure sores and other infections by the time they reach health 
facilities putting the lives of these patients further at risk. Special measures are needed to 
manage these patients quickly and effectively where treatment is required for onchocerciasis 
(Hopkins and Boatin 2011). Civil conflicts have unfortunately been a reality for several African 
countries such as Sierra Leone. Conflict causes population movement, destroys infrastructure 
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and leads to significant brain drain when competent health workers look for jobs elsewhere 
where their skills can be better utilised. Annual treatment coverage in many parts of central 
Africa (especially in the Democratic Republic of Congo) remains far too low to have an impact 
on the transmission of the disease and efforts at scaling up are also difficult for the reasons 
mentioned above (Hopkins and Boatin 2011). Duration of treatment in onchocerciasis endemic 
areas is long because: (1) the adult form of the parasite lives so long that treatment with 
ivermectin has to continue until the adult parasites die after 14 years; (2) duration of 
treatment can depend on the pre-control endemicity level that reflects the initial worm load 
and the pre-control intensity of transmission; and (3) the treatment coverage during the 
control period has to be adequate. Since treatment takes long and should be maintained at 
high treatment coverage if the transmission is to be interrupted, it is to some extent difficult to 
maintain both donor and patient interest. It is therefore recommended that programmes be 
fully integrated into the PHC system and become part of the standard package of activities at 
this level to be sustainable (Hopkins and Boatin 2011). Several authors have indicated the 
possibility of cross-border transmission of NTDs including onchocerciasis and LF (Bhumiratana 
et al. 2005; Bhumiratana et al. 2010; Bhumiratana et al. 2013a; Bhumiratana et al. 2013b; 
Ramaiah 2013).  
 
Cross-border transmission as a problem 
Cross-border transmission of infectious diseases including NTDs is cited as a major problem for 
many infectious diseases and NTD control efforts (Kaferstein, Motarjemi, Bettcher 1997; 
Bhumiratana et al. 2005; Asian Development Bank 2010; Bhumiratana et al. 2010; HKI 2010; 
International Coalition for Trachoma Control 2011; NNN 2011; Centers for Disease Control and 
Prevention 2011; The Carter Center and MOH Uganda 2011; Bhumiratana et al. 2012; Hodges 
et al. 2012a; Hodges et al. 2012b; WHO 2012; Gustavsen, Sodahlon, Bush 2016). The HKI 
position paper on NTDs identifies cross-border population movement as a cause of cross-
border transmission of NTDs and notes that achievements in controlling NTDs can be 
undermined if control efforts in neighbouring countries are not the same (HKI 2010).  A recent 
publication by Gustavsen, Sodahlon, Bush (2016) has expressed similar cross-border concerns 
in relation to onchocerciasis among the MRU countries. The participants of the 2011 second 
session of the NTD NGDO Network (NNN) in Nairobi and several other authors recognise the 
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importance of cross-border issues for NTD control as control efforts are weaker in some 
countries. They have noted that surveillance challenges mean that we do not know the extent 
of the problem, especially in Africa although there are indications of continuing importation of 
infectious diseases by mobile populations due to increased trans-national trade, travel and 
migration. Cross-border movement was identified as a challenge for controlling NTDs 
(Kaferstein, Motarjemi, Bettcher 1997; Zhang et al. 2010; NNN, 2011; Pose and Rabinowitz 
2014).  
 
Migration is common in the world and may pose a problem for control of LF, onchocerciasis 
and other endemic diseases (Ramaiah 2013). There are four possible types of migration: 
movement from endemic to non-endemic areas; from rural to urban areas; from non-MDA 
areas to areas that have already reached LF control/elimination; and across borders (Ramaiah 
2013; Pose and Rabinowitz 2014). Usually, migrants are not able to create active transmission 
foci and cause infection among local people, but urban areas can be at risk due to a large influx 
of infected people which can end in urban areas needing longer treatment period (Ramaiah 
2013). The migration-facilitated resurgence in areas that have achieved LF elimination appears 
to be difficult, but the risk cannot be excluded especially in areas with a more efficient vector 
such as Culex (Ramaiah 2013). The problem of cross-border transmission through migration 
between Thailand and Myanmar has been highlighted in several publications (Bhumiratana et 
al. 2010; Bhumiratana et al. 2013a,b). Thailand had completed LF MDA and was waiting for 
verification that almost all previously endemic areas were free of LF in December 2012 (MDA 
2002-2006; post-MDA surveillance: 2007-2010). However, it was noted that there were 
pockets of infection along the border with Myanmar that were later shown to be due to 
migration from Myanmar. It was noted that the LF among Thai populations along the border 
with Myanmar was caused by nocturnal sub-periodic W. bancrofti, the same as that in 
Myanmar while the LF in Thailand is caused by nocturnal periodic W. bancrofti (Bhumiratana et 
al. 2010; Bhumiratana et al. 2013a). Ramaiah (2013) also dwells on the same Thai-Myanmar 
cross-border issue. Cross-border challenges were identified along Thailand-Myanmar border as 
up to 6% LF microfilaraemia rate, LF Antigenaemia rate of 22-36.8% and LF antibody 
prevalence rate of 54% was reported in border areas within Thailand. It was demonstrated that 
the control efforts in Thailand were confounded by migrants from Myanmar. Microfilaraemia 
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rates among migrants ranged from 4.4% to 8%; Antigenaemia rates 10% to 24%, and antibody 
prevalence rate of 42% were reported (Ramaiah 2013). They recommended that sentinel sites 
and periodic monitoring and evaluation mechanisms be set up to assess LF infection levels to 
pick up areas of possible resurgence along the border with Myanmar (Ramaiah 2013). 
 
Active trachoma prevalence in the Gambia is high only where cross-border movement from 
Senegal creates new pockets of infection (International Coalition for Trachoma Control 2011). 
Evidence indicated that Schistosoma mansoni was being spread in Sierra Leone in the 1980s 
due to cross-border population movement (Hodges et al. 2012a). While presently Uganda 
might have eliminated onchocerciasis, whose vector the black fly (Simulium damnosum) can 
move easily across borders and continue transmission in controlled zones, cross-border 
transmission along the border with the Democratic Republic of Congo and South Sudan 
remains a problem (The Carter Center and MOH Uganda 2011).  The ongoing migration 
between Mozambique, Swaziland and South Africa was noted as a concern especially so when 
the malaria situation in Mozambique was relatively worse than in the other two countries and 
action was taken to address malaria control through a regional initiative (Sharp et al. 2007).  
 
Human migration has been identified as a key determinant of the success of LF elimination 
programmes although information is scarce on the role of migration in creating new foci or on 
the reintroduction of infection in areas where local transmission has stopped (Ramaiah 2013).  
Presently, there is no indication of resistance in the West African sub-region, but it should be 
noted that it has been suggested in Ghana that there is resistance to ivermectin used for 
treating onchocerciasis in the country (Osei-Atweneboana et al. 2007a; Osei-Atweneboana et 
al. 2007b). This claim has so far not been confirmed by other authors but the possibility of 
atypical or sub-optimal response still exists that can create problems for onchocerciasis control 
in the sub-region. Some authors have indicated the possibility of transmission of certain strains 
of causative agents of infectious diseases that are resistant to available treatments (Awadzi 
2004; Eng and Prichard 2005; Burnham 2007; Cupp et al. 2007; Churcher et al. 2009; Taylor et 
al. 2009; Bhumiratana et al. 2013a).  
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Possible ways of addressing cross-border NTD transmission  
Cross-border transmission of infectious diseases including NTDs can be addressed by improving 
inter-country cross-border collaboration that will involve existing regional and sub-regional 
structures; by conducting surveillance for infectious diseases (in this case NTDs) along national 
borders; and learning from successful cross-border initiatives in Africa and Asia established for 
the control of Malaria and HIV. Countries can improve cross-border collaboration by providing 
technical support and services to each other and, also by holding cross-border meetings (Zhang 
et al. 2010; Gustavsen, Sodahlon, Bush 2016). Since many NTDs can spread across borders, 
endemic countries can work together to set clear plans for cross-border collaboration; share 
knowledge and experience in planning, programme implementation, training and advocacy; 
conduct active surveillance for infected individuals along border areas; and study vectors 
responsible for cross-border transmission of NTDs (Kaferstein, Motarjemi, Bettcher 1997; The 
Carter Center and the MOH Uganda 2011). In the Lubombo Spatial Development Initiative 
(LSDI) experts on malaria control from South Africa and Swaziland worked with the health 
authorities in Mozambique to improve control and surveillance activities for malaria control in 
Mozambique (Lubombo project 2008; Lubombo project 2009; Laas 2012). The MRU NTD 
meetings involving Sierra Leone, Guinea, Liberia and Cote d’Ivoire is one such forum that has 
been ongoing since 2006 (Gustavsen, Sodahlon, Bush 2016). The first objective of sharing 
experience and data on NTD control is clearly being achieved in the MRU, and so it was agreed 
that the annual meetings be continued at least for this purpose. However, it is noted that most 
of the recommendations made need to be addressed at higher levels in the MOHs or by 
international NTD partners and donors (MOHS Sierra Leone 2013; Gustavsen, Sodahlon, Bush 
2016).     
 
Cross-border collaboration can be improved by involving existing sub-regional structures. Many 
cross-border meetings are sometimes organised by major NTD partners but cross-border 
collaboration appears uncoordinated, and when meetings are held, and recommendations are 
made, follow-up is typically poor, and thus the recommendations are seldom implemented 
(The Carter Center and MOH Uganda 2011; Gustavsen, Sodahlon, Bush 2016). Such meetings 
can be coordinated at regional or sub-regional level thus making elimination/control of NTDs a 
sub-regional goal. Collaboration can be improved by taking advantage of existing sub-regional 
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structures such as the West African Health Organization (WAHO), the MRU and AFRO 
(Gustavsen, Sodahlon, Bush 2016).  
 
The USAID-supported END in Africa project that covers Sierra Leone, Ghana, Burkina Faso, Cote 
d’Ivoire, Niger and Togo for NTD control decided to implement some of the recommendations 
of the 2013 MRU meeting by organising a cross-border meeting in Accra in October 2016. This 
meeting had to take place at the beginning of the United States’ (US) fiscal year so the 
agreements can be finalised before activities are implemented. The purpose of this meeting 
was for countries within the project that share common borders (Ghana, Ivory Coast, Burkina 
and Togo) to sit and plan synchronised MDA and the project will use legal agreements for 
support to ‘push’ countries to synchronise MDA. As the project countries move towards the 
end game for elimination of both onchocerciasis and LF, the project will insert in the fiscal year 
2017 a clause in the agreements for Ghana, Ivory Coast, Burkina and Togo that requires that 
onchocerciasis and LF MDAs are synchronized in some selected districts along the borders that 
represent known transmission zones. Participants from the countries in this meeting will 
include NTDP managers, onchocerciasis coordinators and LF coordinators. The countries 
together identified districts along their borders that need to synchronise treatment and 
planned the ‘how’ and ‘when’ to synchronise treatment for the border districts. All this will be 
inserted into agreements that the project leadership and country partners will enforce. This 
initiative can enhance coverage and increase the impact of the project as countries move 
toward the elimination goal. In this case, funding will be from the same source and sub-
grantees of the project within the countries concerned are expected to resolve the challenges 
that have been linked with language and communication between countries (FHI360 2016). 
 
Some authors have recommended developing a common surveillance and reporting system 
and the use of similar indicators and forms for reporting NTDs (WHO AFRO 2009). Regular 
epidemiological and entomological surveys can be conducted in selected sites on both sides of 
the border to monitor the transmission of NTDs between countries (Bhumiratana 2005; HKI 
2010; International Coalition for Trachoma Control 2011; Ramaiah 2013). Others recommend 
routine surveillance in border areas (Khamsiriwatchara et al. 2011; Hodges et 2012b; WHO 
2012). However, given the limited human resource for health in Africa, it might be difficult to 
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set routine surveillance for NTDs in all the official border crossing points. Furthermore, there 
are so many unofficial border crossing points between African countries that setting a system 
in the official border crossing points will not have a significant impact. It is, however, possible 
to have an international team that can be set up by AFRO in collaboration with WAHO, to 
coordinate epidemiological and entomological surveys in selected sites along the borders of 
the 15 West African countries. The challenge would be to develop agreements between 
countries, as well as protocols and plans for realising this recommendation. This can also be 
addressed by encouraging discussion among countries (Lubombo 2008; Lubombo 2009; WHO 
2009; Laas 2012). Other small groups of countries such as the MRU countries can also establish 
similar surveillance mechanisms. 
 
Recently, the World Bank launched the Sahel project involving Niger, Burkina Faso and Mali 
that aims to address cross-border issues relating to NTDs and malaria in the three countries. 
This project also seeks to improve regional collaboration for the control of malaria and NTDs 
within these countries (World Bank 2015). The need to have regional collaboration in 
addressing cross-border issues is key especially after the recent outbreak of EVD that clearly 
demonstrated that regional collaboration is needed and had to be established to end the 
outbreak (Gustavsen, Sodahlon, Bush 2016). The initiatives mentioned above have shown that 
there could be a diverse group of stakeholders for cross-border collaboration to address cross-
border transmission of infectious diseases including NTDs in West Africa. There could be joint 
coordination by several international organisations. The author believes that in West Africa, 
WAHO, MRU and AFRO are the three best-positioned organisations to take on this challenge. 
WAHO, MRU and AFRO have a physical presence in the sub-region and in each country they 
cover that enables them to effectively foster international collaboration around cross-border 
initiatives. WAHO has a coordinator in each MOH within ECOWAS, WHO has a country office, 
and representation in all countries, and MRU has a secretariat in each of the four member 
states. 
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CHAPTER 3: IMPACT OF FIVE ANNUAL ROUNDS OF MASS DRUG 
ADMINISTRATION ON ONCHOCERCIASIS MICROFILARAEMIA 
PREVALENCE AND DENSITY IN SIERRA LEONE 
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ABSTRACT 
Background 
Studies to map onchocerciasis using skin snip method in 1988-2005 across Sierra Leone 
showed that 12 of the 14 health districts were onchocerciasis-endemic. Relatively better 
treatment coverage was achieved between 2005 and 2009 after the end of an 11-year civil 
conflict in the country in 2002. 
Methods 
To evaluate the impact of five years of effective treatment (2005-2009), 39 villages across the 
12 onchocerciasis-endemic districts with the highest MF prevalence at baseline were selected 
and surveyed using skin snips in 2010, and results were analysed and compared with the 
baseline data from the same 39 villages.  
Results 
The average MF prevalence across 39 sentinel villages was 53.1% at baseline. MF prevalence 
increases with age. The lowest MF prevalence of 11.00% was within the age group 1-9 years 
and the highest was within the age group 40-49 years (82.31%).  Overall MF density among 
positive-only was 28.87 mf/snip. MF load among positive-only also increases with age with the 
lowest within the age group 1-9 years and the highest in the age group 40-49 years. Males 
have higher MF prevalence and density than females. In 2010 after 5 rounds of MDA the 
overall MF prevalence reduced by 60.26%, from 53.10% to 21.10%; the overall MF density 
among positive-only reduced by 71.29% from 28.87 mf/snip to 8.29 mf/snip; and overall MF 
density among the entire population studied reduced by 88.58% from 15.33 mf/snip to 1.75 
mf/snip. MF prevalence was higher among males than females, and MF density among males 
was twice as high for males than females. The age group 1-9 years had the lowest MF 
prevalence and MF density while the age group 40-49 years had the highest MF prevalence 
and density. Ten of 12 endemic districts (83.33%) had >50% reduction in MF prevalence. Eleven 
of 12 districts (91.67%) had ≥50% reduction in skin MF density among positive-only.  
Conclusion 
In just five years of good MDA using the CDTI strategy, there is a significant reduction in MF 
prevalence and MF load among positive-only with the greatest reduction in skin MF prevalence 
observed in the age group 1-9 years, which indicates a significant reduction in transmission. 
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INTRODUCTION 
Sierra Leone is highly endemic for all seven PC NTDs like many other African countries. 
Endemicity of PC NTDs such as onchocerciasis was known in Sierra Leone since 1926 when 
Blacklock first described onchocerciasis transmission by the black flies S. damnosum in the 
Kono district of Sierra Leone (Blacklock 1926). Onchocerciasis control started in 1957 with 
vector control in Tonkolili district. Onchocerciasis was shown to be the second most common 
cause of blindness after cataract in Sierra Leone and so in the late 1980s the former OCP 
extended its activities to four other countries including Sierra Leone and vector control through 
larviciding with insecticides continued along rivers in hyper-endemic areas (Samba 1994; 
Yameogo 2008; Hodges et al. 2011; Fobi et al. 2015).  
 
As indicated previously, many studies were conducted on onchocerciasis in Sierra Leone by the 
NOCP and other researchers linked to the then OCP and APOC. NOCP has baseline data for 
more than 100 study sites (villages) in all 14 districts with a prevalence that varied from 0% to 
78.3%. Many sites had to be studied to determine areas that had to be treated, and it was 
determined that the Western Area (both Western Urban and Western Rural districts) and the 
southern coastal plain of the Bonthe district are non-endemic for onchocerciasis because the 
prevalence was 0% in these areas. Thus, it was determined that only the 12 provincial districts 
of Sierra Leone are endemic for onchocerciasis in Sierra Leone. Figure 7 shows point 
onchocerciasis MF prevalence for all sites studied at baseline and the areas where CDTI was 
being implemented in Sierra Leone in 2005.  
 
Treatment in the 12 districts with ivermectin was based on O. volvulus micro-filaridermia 
prevalence and the treatment policy then was to conduct treatment only in areas that had O. 
volvulus MF prevalence ≥40% (i.e. in areas considered to be meso-endemic with O. volvulus 
microfilaridermia prevalence between 40% and 59.9%; and hyper-endemic areas with O. 
volvulus microfilaridermia prevalence ≥60%). It should be noted that within each of the 12 
onchocerciasis-endemic districts there are hyper-endemic, meso-endemic and hypo-endemic 
areas (with O. volvulus microfilaridermia prevalence below 40%).  
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Although the OCP started activities in Sierra Leone in 1989, the civil conflict between 1991 and 
2002 impacted negatively on onchocerciasis control activities and in 1997 all onchocerciasis 
activities were stopped nationwide. Finally, for the last five years of the OCP (1997-2002), 
absolutely no onchocerciasis control activities were conducted in the country due to insecurity. 
With support from APOC, the NOCP of Sierra Leone restarted interventions in January 2003 as 
part of the SIZ after the end of the civil war in 2002. By then the CDTI strategy had already 
been developed and established as a principal strategy for onchocerciasis control by APOC 
since 1997, and so CDTI was implemented nationwide in meso-endemic and hyper-endemic 
areas under the SIZ (Hodges et al. 2011; Yameogo 2008; Fobi et al. 2015). It is reported that 
treatment reports for the period 1989-2002 are unreliable because relatively few areas that 
needed treatment were covered due to insecurity. Furthermore, 2003 and 2004 
epidemiological coverage was reported as 36% and 28% respectively, and geographic coverage 
(proportion of districts actually treated against the number targeted in each district) could not 
be determined for the two years. The year 2005 thus became the year of improvement in the 
efforts to control onchocerciasis, which coincided with management/administrative changes 
effected by the MOHS to improve onchocerciasis control efforts in the country, and treatment 
coverage has significantly improved since 2005 (unpublished NOCP/NTDP Reports 2005-2015). 
 
The purpose of this study is to analyse the results of an epidemiological evaluation using the 
skin snip method that was conducted to assess the impact of five annual rounds of MDA (2005-
2009) on onchocerciasis. A total of 39 villages spread across the 12 onchocerciasis-endemic 
districts, with baseline O. volvulus microfilaridermias prevalence ≥40%, were selected as 
sentinel sites for the 2010 evaluation. The current national policy is targeting onchocerciasis 
for elimination, and the use of the 39 sentinel sites for monitoring treatment impact is with the 
assumption that the reduction of onchocerciasis prevalence in these relatively high prevalence 
areas is an indication of an overall reduction of onchocerciasis prevalence.   
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METHODS 
Ethics approval 
The baseline and 2010 studies were conducted by the NOCP of the MOHS, Sierra Leone, with 
technical and financial support from the OCP and APOC/SIZ. Ethical approval for data collection 
was obtained from the Ethics Committee of the MOHS, and upon arrival at the randomly 
selected communities, the investigating teams met with community leaders and explained the 
nature of their work. All volunteers/participants aged one year or above (at baseline) or five 
years and above (2010 evaluation) in each site were eligible for inclusion without 
discrimination on gender, social status, religion or ethnicity. Volunteers participated in the 
studies after informed consent was verbally obtained and recorded by the team leader, as 
literacy rates are low in Sierra Leone.  Consent was obtained from participants themselves, or 
from the parents of all participants below the age of 18 years. Data collection was conducted 
such that participants will remain anonymous during data entry and analysis. No individual’s 
identity can be revealed upon publication.  
 
Mass drug administration 
In 2005 and 2006 MDA was conducted only for onchocerciasis with Ivermectin by the NOCP 
with support from APOC/SIZ. Integrated onchocerciasis/LF annual MDA with ivermectin and 
albendazole was piloted in 2007 in six rural onchocerciasis/LF co-endemic districts located in 
border areas with neighbouring Guinea and Liberia: Bombali, Kailahun, Kambia, Koinadugu, 
Kono, and Pujehun. The same year, onchocerciasis only MDA was conducted in the other six 
onchocerciases/LF districts. Integrated onchocerciasis/LF MDA was scaled up to cover all 12 
onchocerciases/LF coendemic districts in 2008 with the following additional districts added to 
the previous six districts: Bo, Bonthe, Kenema, Moyamba, Port Loko and Tonkolili. The 
onchocerciasis programme has been using CDTI since the restart of onchocerciasis control 
efforts in 2003 after the end of the civil war in 2002. Besides the district headquarter towns 
and a few other commercial centres, the other areas of the districts are rural in Sierra Leone 
and consist of villages with population ≤500 people. Within rural communities ivermectin and 
later Ivermectin plus albendazole were distributed by CDDs who are literate members of 
different communities that are selected by their communities and trained by health workers to 
conduct MDA and report all incidence of adverse events following treatment to district health 
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workers. The CDDs were trained to use dose poles to determine the number of tablets of 
ivermectin to be administered depending on the height of the person treated.  Between 1 and 
4 tablets of 3mg ivermectin was administered to all those treated. District health workers 
conducted training of CDDs to prepare them for the MDA within their communities and 
provided supervision during MDA. NTDP staff and members of the DHMTs also supported 
training and supervision of the MDA. MDA is conducted once a year between September and 
December, which is the post-harvest period when communities have accepted MDA 
(unpublished NOCP/NTDP Reports 2005-2015).  
 
Treatment for onchocerciasis (whether alone or integrated with LF treatment) is done using 
community registers. The NOCP (and later the NTDP) is supported to provide at least one 
register (depending on the population size) for each of the communities. The register is 
designed to capture all members of each community targeted for treatment, including those 
eligible for treatment and those not eligible for treatment, and is, therefore, a good source of 
demographic information for the communities that use them. Before each MDA, CDDs conduct 
a pre-MDA census and update the community register to reflect those that leave the 
community, those that join the community and the newly born. MDA details are also captured 
in the registers. After each MDA, the MDA details are summarised on village reporting forms 
by drug distributors and submitted to the supervising health workers. The supervising health 
workers prepare PHU summary reports for all villages areas targeted and submit the reporting 
forms to the DHMTs. Each DHMT then submits the district summary reports for the MDA to 
the NTDP, which collates MDA results from all districts (unpublished NOCP/NTDP Reports 
2005-2015).     
 
Baseline and 2010 onchocerciasis studies 1988-2005, and 2010 
Onchocerciasis infection and its density were determined using the method of microscopic 
examination of the skin snips for the presence and number of O. volvulus MF. Two skin snips 
were taken from the right and left iliac crests, which is the site that usually has the highest 
concentration of skin MF. Skin snip was done in all selected villages 11-12 months after last 
treatment, and the survey was cross-sectional. All subjects who were one year or above who 
agreed to participate (or whose parent/s agreed on their behalf) and voluntarily presented 
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themselves (or are brought by their parents) were included in the study. They are asked for 
identification data - name, age, sex, occupation, and a number of years they are resident in the 
village. Two skin biopsies are obtained from the right and left iliac crests of those studied. A 
2mm Holth corneo-scleral punch is used to obtain the two bloodless skin snip biopsies. The 
scleral punch is sterilised with sodium hypo-chlorite solution and distilled water and then 
autoclaved under pressure for 15 minutes after taking biopsies from each individual. This was 
to prevent the transfer of HIV/AIDS and other blood-borne infections. The samples are then 
microscopically examined for the presence and number (quantity) of O. volvulus MF after 
incubation for 30 minutes in distilled water. Negative skin snip samples are further kept in 
saline solution for 24 hours and microscopically re-examined. The number of MF are counted, 
and the results are recorded for each person examined. Migration history is taken for each 
person during the last ten years prior to the survey. Pre- and post-treatment skin snip data are 
then analysed to determine and compare onchocerciasis infection levels using indicators of MF 
prevalence and MF density. The results are expressed as a proportion of positive/negative 
people in the sample (Wanji et al. 2005; Katabarwa et al. 2008; Tekle et al. 2012; Katabarwa et 
al. 2012; Katabarwa et al. 2013). Since only those one year and above (for baseline) and five 
years and above (for 2010 evaluation) who volunteered for the study were snipped, the 
number of people studied per village varied significantly. Furthermore, the number of people 
studied in each district also varied significantly because the number of villages selected at 
baseline per district also depended on the size and population of the district. Training and 
refresher training of technicians in the survey teams were conducted to ensure standardisation 
of data collection and that all survey teams use the standard skin snip methodology 
recommended by the then OCP and APOC. At baseline, a total of 7,116 people were tested in 
all the 39 villages; males 3,461 (48.6%) and females 3,655 (51.4%). In 2010, For quality control, 
OCP and later APOC recruited scientists that worked in the field with the NOCP survey teams 
and examined all positive slides and 10% of the negative slides. 
 
Statistical analysis 
Results were entered into MS Excel and analysed in SPSS (IBM, Version 19). Prevalence and 
density of MF were calculated for all 12 districts, by sex and age groups and compared with the 
baseline data. For the villages, only MF prevalence was calculated and compared with baseline 
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MF prevalence data. The 95% confidence intervals (CIs) for prevalence were calculated using 
the Wilson score method without continuity correction (Newcombe 1998). The arithmetic 
mean MF density of infection with 95% CI was calculated using the total population examined 
and the positive samples only. The Chi-squared test was used to compare the differences in 
prevalence, and the Kruskal-Wallis test was used to compare the differences in MF density. 
Treatment coverage was calculated according to the WHO guidelines and reported using two 
indicators: epidemiological coverage and programme coverage (WHO 2011a). Epidemiological 
coverage is the proportion of people ingesting the drugs among the total targeted population 
in the endemic communities and districts. Programme coverage is the proportion of people 
ingesting the drugs among people in the endemic districts that are eligible for treatment. The 
total population used in rural areas was the total number of people registered during the pre-
MDA census (Koroma, Turay, Moihua 2006), with an annual growth rate of 2.5%. Spatially 
smoothed contour maps of the interpolated onchocerciasis MF prevalence in the 39 sentinel 
sites at baseline and after five MDAs were produced (see Figure 8) as described previously 
(Zoure et al. 2011).   
 
 
RESULTS 
MDA results 2005-2009 
A total of 8,451 villages were treated with ivermectin each year in 2005 and 2006 for 
onchocerciasis only, and 14,253 villages (including the 8,451 treated previously for 
onchocerciasis only) and urban areas were treated between 2007 and 2009 in the 12 districts 
for both onchocerciasis and LF using ivermectin and albendazole. Geographic coverage for 
onchocerciasis in these districts during this period was 100% although the treatment coverage 
was not always that required by WHO (≥65% epidemiological coverage and ≥80% programme 
coverage) (WHO, 2011a). As discussed previously, treatment coverage in 2003 and 2004 was so 
poor that it was considered ineffective and is not considered here. In 2005, coverage improved 
significantly but seven of the 12 districts achieved <65% epidemiological coverage and <80% 
programme coverage. Overall, epidemiological coverage was 61.6%, and programme coverage 
was 76.4%. With more concerted programme efforts and more technical/financial support 
from NTD partners, coverage significantly improved the next year and has been maintained 
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above 65% epidemiological coverage and above 80% programme coverage since 2007. Table 4 
below shows treatment coverage between 2005 and 2009. It should be noted that between 
2007 and 2009 treatment was conducted in all villages and urban areas of the 12 districts. 
Treatment, therefore, included villages and urban areas that were considered hypo-endemic 
(with <40% microfilaridermia prevalence) and were never treated before the introduction of LF 
treatment. 
 
Dynamics of onchocerciasis distribution in Sierra Leone at baseline 
Baseline studies conducted between 1988 and 2005 in an estimated 150 sites in all 14 health 
districts of Sierra Leone had shown that all the 12 provincial health districts of Sierra Leone 
were found to be endemic for onchocerciasis with the prevalence of skin snip MF positives 
≥1%. Data from the 39 sites of the 12 onchocerciasis-endemic districts selected as 
onchocerciasis sentinel sites are analysed to determine the baseline onchocerciasis MF 
prevalence, onchocerciasis MF density for the entire population studied and onchocerciasis MF 
intensity for positives only. Table 5 summarises the results of the baseline and 2010 
onchocerciasis MF prevalence, MF density for the entire population studied and MF density for 
positives-only for each of the 12 districts, by sex, and by age groups. The percentage reduction 
of MF prevalence, MF density for the entire population studied and MF density for positive-
only and their corresponding p-values are also summarised in Table 5. Since for each district 
the sites selected as sentinel sites were those with the highest baseline prevalence, the 
baseline prevalence for each of the 12 districts varied from 39.01% (95% CI: 36.17-41.91) to 
61.94% (95% CI: 54.09-69.20). The overall MF prevalence for all 7116 participants studied in 
the 39 sentinel sites was 53.09% (95% CI: 51.93-54.25). The MF prevalence for males was 
higher than the MF prevalence for females (55.19%, 95% CI: 53.52-56.84 for males and 51.11%, 
95% CI: 49.49-52.73 for females). Onchocerciasis MF prevalence in the northern districts 
(Kambia 61.94%, 95% CI: 54.09-69.20; Tonkolili 60.40, 95% CI: 57.17-63.54; Koinadugu 58.83, 
95% CI: 50.77-65.52; Bombali 57.88%, 95% CI: 52.78-62.82; and Port Loko 57.12, 95% CI: 53.29-
60.86) tended to be higher than prevalence in the southern districts (Moyamba 58.20%, 95% 
CI: 55.20-61.14; Bo 54.30%, 95% CI: 51.77-56.81; Pujehun 53.57%, 95% CI: 49.43-57.66; and 
Bonthe 40.56%, 95% CI: 33.65-47.85), while the prevalence of the eastern districts are 
relatively the lowest (Kailahun 49.73%, 95% CI: 42.56-56.90; Kenema 45.12%, 95% CI: 39.44-
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50.90; and Kono 39.01%, 95% CI: 36.17-41.91). The MF prevalence is lowest for the age group 
1-9 years (11.05%, 95% CI: 9.80-12.43); increases sharply to 50.57% (95% CI: 47.87-53.26) for 
the age group 10-19 years; continues to increase and peaks at 82.31% (95%: 79.39-84.90) for 
the age group 40-49 years; and then drops to 76.17% (95% CI: 72.84-79.20) for the age group 
≥60 years.  
 
Dynamics of microfilaraemia density at baseline 
The baseline data from the 39 sentinel sites were analysed to determine the microfilariae 
density for the entire population studied and also the density among those that were 
microfilariae positive. The overall arithmetic mean density for the entire population studied in 
the 39 sentinel sites is 15.33 mf/snip (95% CI: 14.43-16.24 mf/snip) and the mean arithmetic 
density among those MF positive is 28.87 mf/snip (95% CI: 27.29-30.46 mf/snip). The mean 
arithmetic density for the entire population studied is 21.11 mf/snip (95% CI: 19.49-22.72 
mf/snip) for males and 9.94 mf/snip (95% CI: 9.09-10.79 mf/snip) for females. The mean 
arithmetic density for positives-only is 38.16 mf/snip (95% CI: 35.47-40.84 mf/snip) for males 
and 19.38 mf/snip (95% CI: 17.85-20.92 mf/snip) for females. The mean arithmetic density for 
entire population studied and for positives-only is twice higher for men than for women. The 
mean arithmetic density among the entire population studied ranges from 6.51 mf/snip (95% 
CI: 3.47-9.54 mf/snip) for Kenema to 22.09 mf/snip (95% CI: 19.28-24.91 mf/snip) for Tonkolili 
district. The mean arithmetic density among positives-only ranges from 14.42 mf/snip (95% CI: 
7.91-20.94 mf/snip) for Kenema to 37.48 mf/snip (95% CI: 31.36-43.60 mf/snip) for Kono 
district. The trend between the regions observed for the MF prevalence is not clear cut for the 
mean arithmetic density. While the northern districts have relatively higher mean arithmetic 
density for entire populations studied (Tonkolili- 22.09 mf/snip, 95% CI: 19.28-24.91 mf/snip; 
Koinadugu- 18.38 mf/snip, 95% CI: 12.65-24.12 mf/snip; Kambia- 17.80 mf/snip, 95% CI: 11.02-
24.58 mf/snip; Bombali- 16.85 mf/snip, 95% CI: 12.73-20.97 mf/snip; and Port Loko- 13.83 
mf/snip, 95% CI: 11.12-16.53 mf/snip) than the southern and eastern districts, Bo district in the 
south has a mean arithmetic density for entire population studied of 18.91 mf/snip (95% CI: 
16.59-21.23 mf/snip), higher than most of the northern district and Kono district has a mean 
arithmetic density for entire population studied of 14 mf/snip (95% CI: 12.01-17.25 mf/snip) 
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higher that some southern districts. The trend observed for the prevalence is also not clear-cut 
for the mean arithmetic density for positives-only. 
 
The mean arithmetic density for entire population studied is lowest among the age group 1-9 
years (0.91 mf/snip, 95% CI: 0.51-1.30 mf/snip), increases sharply to 6.91 mf/snip (95% CI: 
5.92-7.91 mf/snip) in the age group 10-19 years, then increases further to peak at 35.94 
mf/snip (95% CI: 31.44-40.44 mf/snip) in the age group 40-49 years and drops to 21.58 mf/snip 
(95% CI: 18.44-24.72 mf/snip) in the age group ≥60 years. The mean arithmetic density for 
positives-only follows the same pattern: lowest for the age group 1-9 years (8.24 mf/snip, 95% 
CI: 4.77-11.72 mf/snip), increases to 13.67 mf/snip (95% CI: 11.85-15.49 mf/snip) in the age 
group 10-19 years, peaks at 43.66 mf/snip (95% CI: 38.39-48.93 mf/snip) in the age group 40-
49 years, and drops to 28.34 mf/snip (95% CI: 24.39-32.29 mf/snip) in the age group ≥60 years.  
 
Prevalence of onchocerciasis microfilaridermia in 2010 
The overall onchocerciasis microfilaridermia prevalence was 21.12% (95% CI:20.07-22.20%); or 
24.49% (95% CI: 22.94-26.12%) for males, and 17.76% (95% CI: 16.39-19.21%) for females. The 
microfilaridermia prevalence among districts ranged from 6.90% (95% CI: 2.71-16.43%) for 
Koinadugu districts to 29.96% (95% CI: 27.19-32.89%) for Moyamba district. For the age 
groups, the lowest microfilaridermia prevalence is within the age group 1-9 years (1.71% (95% 
CI: 1.22-2.39%); then increases to 16.09% (95% CI: 13.82-18.65%) within the age group 10-19 
years; peaks at 38.75% (95% CI: 34.74-42.91%) for the age group 40-49 years; and then drops 
slightly to 29.33% (95% CI: 25.73-33.21%) within the age group ≥60 years.   
 
Microfilaridermia density in 2010 
The overall arithmetic mean MF density was 1.75mf/snip (95% CI: 1.48-2.02mf/snip) in the 
total participants examined and 8.29 mf/snip (95% CI: 7.07-9.50mf/snip) among MF-positive 
individuals. For males, the arithmetic mean MF density was 2.55mf/snip (95% CI: 2.04-
3.06mf/snip) in the total participants examined and 10.40 mf/snip (95% CI: 8.43-12.36mf/snip) 
among MF-positive individuals. For females, the arithmetic mean MF density was 0.96mf/snip 
(95% CI: 0.77-1.15mf/snip) in the total participants examined and 5.40mf/snip (95% CI: 4.40-
6.40mf/snip) among MF-positive individuals. There was a significant difference in MF density in 
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males versus females (p<0.05) as density for the entire population among males was over 
twice as high as density among females and density for positives-only among males was almost 
twice as high as that for females. The mean MF density by the district was below 4mf/snip for 
all districts (and well below 1mf/snip in four districts- Koinadugu, Kono, Pujehun and Tonkolili) 
for the entire population examined; and below 12mf/snip among those who were mf positive. 
Among districts, the arithmetic mean MF density for entire population ranges from 
0.05mf/snip (95% CI: 0.00-0.11mf/snip) in Koinadugu district to 3.10mf/snip (95% CI: 1.80-
4.40mf/snip) in Port Loko district; and the arithmetic mean MF density for positives-only 
ranges from 0.75mf/snip (95% CI: 0.00-1.55mf/snip) in Koinadugu district to 11.91mf/snip (95% 
CI: 7.12-16.71mf/snip) in Port Loko district. Among the age groups, the arithmetic mean MF 
density for the entire population studied is lowest among the age group 1-9 years (0.04 
mf/snip, 95% CI: 0.02-0.06mf/snip); increases slightly to 0.08 995% CI: 0.51-1.08 mf/snip in the 
age group 10-19 years; continues to increase and peaks at 4.09mf/snip (95% CI: 2.65-
5.54mf/snip) in the age group 40-49 years; and then drops slightly to 2.10 mf/snip (95% CI: 
1.47-2.73mf/snip) in the age group ≥60 years. The arithmetic mean MF density for positives-
only is also lowest among the age group 1-9 years (2.47mf/snip, 95% CI: 1.49-3.45mf/snip); 
increases slightly to 4.49 (95% CI: 3.31-6.58mf/snip in the age group 10-19 years; continues to 
increase and peaks at 10.56mf/snip (95% CI: 6.99-14.13mf/snip) in the age group 40-49 years; 
and then drops slightly to 7.04mf/snip (95% CI: 3.18-10.89mf/snip) in the age group 50-59, and 
7.17mf/snip (95% CI: 5.22-9.12mf/snip) in the age group ≥60 years.  
 
Reduction in MF prevalence and density after five years of MDA 
Reduction of MF prevalence 
Overall, MF prevalence dropped by 60.22% (P=0.00); 54.24% among males (p=0.00), and 
64.12% among females (p=0.00). Reduction in MF prevalence among districts was in general 
greater than 50% (P<0.05) except for Bonthe district and Moyamba district that had 34.25% 
(p=0.009) and 48.52% (P=0.000) reduction respectively. Koinadugu and Pujehun districts had 
over 80% reductions in MF prevalence (p=0.000). Among the age groups, the highest reduction 
in MF prevalence (82.55%) was recorded in the age group 1-9 years followed by the reduction 
in the age group 10-19 years (66.40%). The reductions were all statistically significant P<0.05) 
except for Gawula (P=0.1279) and Yakaji (P=0.1092).  
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Reduction of MF density 
Overall, arithmetic mean MF density for the entire population studied dropped by 88.58% 
(P=0.00) while arithmetic mean MF density for positives-only dropped by 71.29% (P=0.000). 
For males, arithmetic mean MF density for the entire population studied dropped by 87.92% 
(P=0.000) while the arithmetic mean MF density among positives-only dropped by 72.75% 
(P=0.000). For females, the arithmetic mean MF density for the entire population studied 
dropped by 90.34% (P=0.000) while the arithmetic mean MF density among positives-only 
dropped by 72.14% (P=0.000). Among districts, reduction in arithmetic mean MF density for 
the entire population was in general >70% (PP<0.05) except for the Bonthe district that had 
56.43% (P=0.004); and arithmetic mean MF density for positives-only was, in general, >50% 
(P<0.05) except for Bonthe district where the reduction of MF density among positives-only 
(33.80%) was not statistically significant (P=0.2470). The reduction of mean arithmetic MF 
density among positives-only was also not statistically significant for Kenema district (55.06%, 
P=0.2170). Koinadugu district had close to 100% drop in both densities for the entire 
population and positives-only (P=0.000). Among the age groups, the reduction of the 
arithmetic mean MF density for the entire population studied was in general above 80% with 
the highest reduction among the age group 1-9 years (95.60%); and the reduction of the 
arithmetic mean MF density for positives-only was in general above 60% with the highest 
reduction among the age group 50-59 years (81.13%).  
 
 
DISCUSSION 
Overall at baseline MF prevalence among the 39 sentinel villages was 53.09% with 55.19% for 
males and 51.11% for females. The following distinct epidemiological patterns were 
determined from the data analysed: (1) The MF prevalence was higher in males than females; 
(2) the prevalence is lowest for the age group 1-9 years followed by the age group 10-19 years; 
and (3) onchocerciasis MF prevalence was higher in the northern districts than in the southern 
and eastern districts. Distinct epidemiological patterns were also noted for the density: the 
mean arithmetic MF density for the entire population studied and for positives-only was 
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almost twice higher for males than for females; was lowest among the age group 1-9 years 
followed by the age group 10-19 years; and the age group 40-49 had the highest arithmetic 
mean MF density for entire population studied and for positives-only. The average density for 
northern districts was higher than that of southern and eastern districts although some 
southern and eastern districts had a density higher than some northern districts.  
 
In general, males had higher infection levels than females. Although MF prevalence in males 
was only slightly higher than in females, the MF density for the entire population and positive-
only was about twice as high in males than in females. The male/female differences in 
prevalence, the density of infection and clinical disease due to onchocerciasis have been 
discussed and are related to differential exposure of females to infective vectors (Brabin1990). 
 
The prevalence is lowest for the age group 1-9 years followed by the age group 10-19 years. 
Lower age groups (1-9 years and 10-19 years) have the lowest MF prevalence and MF density 
even within highly endemic areas and peak MF prevalence, and MF density was observed in 
the age group 40-49 years. This also tends to indicate that onchocerciasis transmission to 
children may have reduced due to previous onchocerciasis control efforts although it may also 
be because children spend less time at the river banks and may be less open to bites of the 
black fly. A previous study analysed the impact and extent by which maternal O. volvulus 
infection can be transmitted to their children and showed that children from onchocerciasis-
infected mothers are more likely to be infected with onchocerciasis (Kirch et al. 2003). One 
can, therefore, conclude that transmission of onchocerciasis to children in Sierra Leone has 
been low because females are less infected than men and children may be less exposed to the 
disease vector. 
 
Onchocerciasis MF prevalence was higher in the northern districts than in the southern and 
eastern districts. The northern districts (Bombali, Kambia, Koinadugu, Port Loko and Tonkolili 
districts) have higher average MF prevalence and MF density than southern districts (Bo, 
Bonthe, Moyamba and Pujehun districts) that also have higher average MF prevalence and MF 
density than Eastern districts (Kailahun, Kenema, and Kono districts). A study was conducted in 
1987-1988 to compare the onchocerciasis situation in forest areas and Savannah areas of the 
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country. Prevalence of O. volvulus MF, nodules and moderate or severe skin lesions was higher 
in the forest than in Savannah villages. In forest villages, the MF prevalence was 71.8% at the 
iliac crest while the corresponding MF prevalence for the Savannah villages were 51.9%. The 
study also showed that males were more infected with the disease than females (McMahon et 
al. 1988c). This observation made in the past might be the explanation for the regional 
variation noted in this analysis.  
 
The MF prevalence reported for these villages was similar to the MF prevalence reported 
previously by other authors in Sierra Leone and elsewhere (McMahon et al. 1988a; Gbakima 
and Sahr 1996; Wanji et al. 2005). The overall MF prevalence of 55.09% is significantly higher 
than the 16.69% MF prevalence (701,000 infected among 4.2 million) reported by OCP for 
Sierra Leone in 1990 (Remme, 2004), but is similar to the >60% MF prevalence reported in 
1988 for the northern districts (McMahon et al. 1988a). The results were also similar to MF 
prevalence reported in villages of one district of Cameroon (Wanji et al. 2005). The MF 
prevalence reported here for Moyamba district is higher than the prevalence reported in 1996 
for Moyamba district in southern Sierra Leone. However, this study in 1996 also highlighted the 
relatively low MF prevalence (13.3%) observed among children 5-9 years compared to older 
age groups: 61.9% among those 40-49 years (Gbakima and Sahr 1996). 
 
The 2010 evaluation in the same 39 sentinel sites revealed a significant decrease in 
onchocerciasis MF prevalence and density after just five rounds of annual MDA with 
ivermectin.  
 
The same epidemiological dynamics at baseline was observed in the 2010 evaluations: mf 
prevalence was higher in males than in females and MF density was twice as high in males than 
females. The regional disease distribution observed at baseline (northern districts with 
relatively higher prevalence, followed by southern and then eastern having the lowest relative 
prevalence) appears to have changed slightly in the past five years. In 2010, the southern 
districts had relatively the highest average prevalence, followed by the average prevalence of 
eastern districts, and northern districts having relatively the lowest average mf prevalence.  
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Two studies discuss the regional dynamics for onchocerciasis in Sierra Leone. A study 
conducted to compare the onchocerciasis situation in forest areas (the northern region) and 
Savannah areas (the south-east) of the country shows that O. volvulus MF prevalence was 
higher in the forest (71.8%) than in Savannah villages (51.9%). This study also demonstrated 
that males are more commonly infected with onchocerciasis than females (McMahon et al. 
1988c). Blacklock who first reported onchocerciasis endemicity in Sierra Leone in 1926 also 
suggested that the clinical manifestations of onchocerciasis vary within the regions of the 
country. It was suggested that the eastern region has the forest strain of the O. volvulus 
parasite and that the disease is clinically characterised by low intensity of infection, mild skin 
disease and relatively lower blindness rates.  In the south, there is a mixture of forest and 
Savannah strains of the parasite with high infection intensity, mild skin disease and relatively 
higher blindness rate that are sometimes higher than blindness rates recorded for the 
Savannah area. The northern region has the Savannah strain of the parasite with high infection 
intensity, mild skin disease, and relatively high blindness rate ((Blacklock 1926; Gbakima and 
Sahr 1996). However, it appears that after five years of effective treatment this pattern has 
changed with northern districts now having relatively the lowest average MF prevalence 
compared to the eastern and southern districts. 
 
For the age groups, the lowest microfilaridermia prevalence and density were observed within 
the age group 1-9 years, followed by the age group 10-19 years and was highest for the age 
group 40-49 years.  This also tends to indicate that onchocerciasis transmission to children may 
have reduced even further with five years of treatment and probably also due to previous 
onchocerciasis control efforts before NOCP activities started, although it may also be because 
children spend less time at the river banks and may be less open to bites of the black fly. A 
previous study had shown that children from onchocerciasis-infected mothers are more likely 
to be infected (Kirch et al. 2003). Another study showed that after 4 years of MDA children 5-9 
years who had not received any treatment for O. volvulus infection in the Mbam valley of 
Cameroon had low infection rate compared to older children because of reduced exposure to 
onchocerciasis as a result of the overall reduction in MF prevalence and density within the 
community (Pion, Clement and Boussinesq 2004). One can, therefore, conclude that 
transmission of onchocerciasis to children in Sierra Leone has been low because females are 
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less infected than men and that overall reduction in MF prevalence and MF density has 
reduced exposure of children to the disease. 
 
Similar studies to determine onchocerciasis MF prevalence and MF density have been reported 
in Nigeria and Cameroon (Opara and Fagbemi 2008; Kamga et al. 2011; Sam-Wobo et al. 2012). 
Epidemiological studies conducted to determine onchocerciasis MF prevalence and MF density 
after repeated annual treatment with ivermectin in 11 selected communities along the Ogun 
River System, southwest Nigeria, showed that onchocerciasis prevalence ranged from 19.1% to 
45.6% while community MF density ranged from 0.11 to 1.03mf/snip (Sam-Wobo et al. 2012). 
With over 60% baseline onchocerciasis MF prevalence in Fundong health district of Cameroon, 
the MF prevalence reduced to 3.5% after six rounds of continuous MDA using the CDTI strategy 
(Kamga et al. 2011). After seven years (1995-2001) of ivermectin treatment for onchocerciasis 
in 3 onchocerciasis-endemic villages of the Etung Local Government Area of Lower Cross River 
Basin, Nigeria, microfilaridermia prevalence reduced from 63.3% at baseline to 39.3% and 
community MF density dropped from 7.11 to 2.31mf/snip. It was also noted in this study that 
males were significantly more infected with O. volvulus than females and MF prevalence and 
intensity increased with age. Adults between the age group of 21 and 50 years accounted for 
52.7% of MF-positive cases (Opara & Fagbemi 2008). 
 
There are certain limitations for this analysis. The baseline data used for the analysis were 
obtained over a long period. Some villages were studied in 1988, others in 1989, then there 
was a break of about 11 years before more villages were studied in 2002, 2003, 2004 and 2005. 
It is possible the epidemiological situation may have changed in villages studied in 1988 and 
1989. However, this was addressed during the selection of sentinel villages. The villages 
selected first were those with more recent data (2002-2005). Villages with older data (1988, 
1989) were only selected when more recent data (2002-2005) were not available for a district. 
This way it was ensured that selection of the villages was based on more recent data. 
Convenient sampling was used to get participants in the studies and only those within the 
targeted villages who voluntarily accepted to participate in the study were included. Therefore, 
the number of participants for the study varied significantly between districts and villages. 
However, this sampling method is in line with current WHO/APOC guidelines for surveys to 
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monitor the impact of onchocerciasis treatment on onchocerciasis MF prevalence and density. 
In the 2010 evaluations, only children ≥ five years of age were studied while children between 
1 and 5 years were studied at baseline. This has resulted in fewer children 1-9 years examined 
in the 2010 evaluation. The decision not to study children below 5 years of age was made 
based on the high refusal rate observed in communities during baseline studies among parents 
when children below 5 years were to be studied. This decision has proven to be more ethical 
and will be maintained until a better methodology is developed for onchocerciasis evaluation 
that does not create so much fear in children and parents for their children. Another possible 
limitation of this study is that the focus for onchocerciasis has shifted from control to 
elimination. This means that areas previously considered hypo-endemic for onchocerciasis with 
<40% MF prevalence should be evaluated to know the impact of treatment. With this paradigm 
shift, it will be worthwhile to add control sites in future evaluations selected from hypo-
endemic areas so the impact of treatment in all areas can be monitored.  
 
 
CONCLUSION 
There was a significant reduction of onchocerciasis MF prevalence and MF density across the 
12 rural onchocerciasis-endemic districts of Sierra Leone after five annual MDA. Treatment 
coverage over this period also demonstrated that there is good MDA adherence. The results 
show that the onchocerciasis elimination programme in Sierra Leone is on course to reach the 
objective of eliminating onchocerciasis in Sierra Leone by the year 2025. However, MDA must 
continue in all onchocerciasis-endemic districts with good treatment coverage to reach the 
recommended number of rounds using positive experiences and lessons learnt from other 
countries. 
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Figure 7: Baseline (1988-2005) point prevalence and CDTI zones for onchocerciasis in Sierra Leone (APOC 2005*) 
   
* Maps were prepared for the NOCP in 2005 by APOC. 
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Figure 8: Maps showing point onchocerciasis mf prevalence for the 39 sentinel sites at baseline and in 2010 after five MDA rounds 
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Table 4: Summary results of annual MDA carried out for onchocerciasis elimination in Sierra Leone 2005– 2009 
  2005 2006 2007 2008 2009 
  Population Treatment Population Treatment Population Treatment Population Treatment Population Treatment 
Districts 
Eligible Total 
No. 
treated 
Epid 
Cov 
Prog 
Cov Eligible Total 
No. 
treated 
Epid 
Cov 
Prog 
Cov Eligible Total 
No. 
treated 
Epid 
Cov 
Prog 
Cov Eligible Total 
No. 
treated 
Epid 
Cov 
Prog 
Cov Eligible Total 
No. 
treated 
Epid 
Cov 
Prog 
Cov 
Bo 
201218 251523 193861 77.1 96.3 205955 257444 181006 70.3 87.9 246697 308371 219651 71.2 89.0 267153 333941 235427 70.5 88.1 291059 363824 268222 73.7 92.2 
Bombali 
197106 246383 170035 69.0 86.3 201746 252183 178195 70.7 88.3 208794 260993 197105 75.5 94.4 226285 282856 209378 74.0 92.5 316656 395820 303593 76.7 95.9 
Bonthe 
39626 49533 32347 65.3 81.6 40559 50699 40367 79.6 99.5 44830 56038 43493 77.6 97.0 72086 90108 59373 65.9 82.4 76100 95125 70821 74.5 93.1 
Kailahun 
178800 223499 91874 41.1 51.4 183009 228761 167859 73.4 91.7 186791 233489 177950 76.2 95.3 228464 285580 210281 73.6 92.0 199581 249476 193931 77.7 97.2 
Kambia 
84967 99961 84914 84.9 99.9 86967 102314 85622 83.7 98.5 84788 105985 82802 78.1 97.7 102602 128253 95393 74.4 93.0 100700 125875 84244 66.9 83.7 
Kenema 
170033 212541 117021 55.1 68.8 174036 217545 171765 79.0 98.7 175058 218823 164789 75.3 94.1 230055 287569 210935 73.4 91.7 183729 229661 172236 75.0 93.7 
Koinadugu 
111040 138800 85785 61.8 77.3 113654 142068 101258 71.3 89.1 111862 139827 105067 75.1 93.9 153577 191971 141749 73.8 92.3 157016 196270 142405 72.6 90.7 
Kono 
139026 173782 108005 62.1 77.7 142298 177873 131556 74.0 92.5 138281 172851 135745 78.5 98.2 141170 176463 127063 72.0 90.0 99605 124506 93520 75.1 93.9 
Moyamba 
150661 188327 101658 54.0 67.5 154208 192760 140934 73.1 91.4 160683 200854 149242 74.3 92.9 169114 211392 162675 77.0 96.2 162347 202934 156181 77.0 96.2 
Port Loko 
143167 168432 139170 82.6 97.2 137918 172397 134917 78.3 97.8 163872 204840 157423 76.9 96.1 127351 159189 106236 66.7 83.4 175292 219115 156077 71.2 89.0 
Pujehun 
120406 150508 91277 60.6 75.8 123241 154051 109061 70.8 88.5 158146 197682 145323 73.5 91.9 171640 214550 155988 72.7 90.9 186227 232784 180047 77.3 96.7 
Tonkolili 
188831 236038 101379 43.0 53.7 193276 241595 184953 76.6 95.7 202266 252833 192167 76.0 95.0 207034 258792 177206 68.5 85.6 272062 340078 256268 75.4 94.2 
TOTAL 
1724882 2139327 1317326 61.6 76.4 1756868 2189690 1627493 74.3 92.6 1882069 2352586 1770757 75.3 94.1 2096531 2620664 1891704 72.2 90.2 2220374 2775468 2077545 74.9 93.6 
*Geographic coverage of villages for onchocerciasis was 100% in all 12 districts over the five years (2005-2009). 
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Table 5. Crude Onchocerciasis microfilaraemia prevalence and density by district, sex, and age groups in Sierra Leone after five annual rounds of MDA 
 Baseline survey  2010 Epidemiological Evaluation  Percentage reduction 
(%) 
Significance test (P-values) 
No of 
persons 
examined 
for MF 
MF 
prev 
(%) 
Pop mf 
density 
(mf/sn
ip 
Positive-
only MF 
density 
(mf/snip) 
 No of 
persons 
examine
d for MF 
Percentage 
MF 
prevalence 
(95% CI) 
Population 
MF density 
(mf/snip) 
(95% CI) 
Positive-only 
MF density 
(mf/snip) 
(95% CI) 
 
MF 
prev 
Pop MF 
density  
Positive-
only MF 
density 
MF prev 
Populati
on MF 
density 
Positive-
only MF 
density 
Overall 7116 53.09  15.33 28.87   5621 21.12 
(20.07-
22.20) 
1.75 (1.48 - 
2.02) 
8.29 (7.07 - 
9.50) 
 
60.22 88.58 71.29 0.0000 0.0000 0.0000 
By district                 
Bo 
1499 54.30  18.91  34.82  
 1079 25.77 
(23.24-
28.46) 
2.95 (2.11 - 
3.80) 
11.46 (8.40 - 
14.53) 
 52.55 84.40 67.09 0.0000 0.0000 0.0000 
Bombali 
368 57.88  16.85  29.10  
 494 16.19 
(13.21-
19.70) 
1.58 (0.86 - 
2.29) 
9.72 (5.71 - 
13.72) 
 72.02 90.62 66.60 0.0000 0.0000 0.0000 
Bonthe 
180 40.56  7.00 17.25 
 165 26.67 
(20.51-
33.16) 
3.05 (0.41 - 
5.68) 
11.42 (1.71 - 
21.13) 
 34.25 56.43 33.80 0.0090 0.0040 0.2470 
Kailahun 
183 49.73  12.06  24.25 
 118 23.73 
(16.96-
2.01 (0.47 - 
3.55) 
8.46 (2.31 - 
14.62) 
 52.28 83.33 65.11 0.0000 0.0000 0.0010 
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32.16) 
Kambia 
155 61.94  17.80  28.73 
 98 23.47 
(16.18-
32.76) 
1.04 (0.43 - 
1.65) 
4.41 (2.24 - 
6.58) 
 62.11 94.16 84.65 0.0000 0.0000 0.0000 
Kenema 
286 45.12  6.51  14.42 
 101 20.79 
(14.02-
29.70) 
1.35 (0.18 - 
2.51) 
6.48 (1.09 - 
11.86) 
 53.90 79.26 55.06 0.0000 0.0000 0.2170 
Koinadugu 
168 58.33 18.38 31.51 
 58 6.90 (2.71-
16.43) 
0.05 (0.00 - 
0.11) 
0.75 (0.00 
1.55) 
 88.18 99.73 97.62 0.0000 0.0000 0.0050 
Kono 
1105 39.01 14.63 37.48 
 521 9.02 (6.85-
11.79) 
0.32 (0.18 - 
0.46) 
3.53 (2.31 - 
4.75) 
 76.87 97.81 90.58 0.0000 0.0000 0.0000 
Moyamba 
1055 58.20 12.06 20.74 
 988 29.96 
(27.19-
32.89) 
1.64 (1.27 - 
2.01) 
5.46 (4.35 - 
6.58) 
 48.52 86.40 73.67 0.0000 0.0000 0.0000 
Port Loko 
653 57.12 13.83 24.21 
 738 26.02 
(22.98-
29.30) 
3.10 (1.80 - 
4.40) 
11.91 (7.12 - 
16.71) 
 54.45 77.58 50.81 0.0000 0.0000 0.0000 
Pujehun 
560 53.57 9.84 18.36 
 348 7.76 (5.39-
11.03) 
0.60 (0.06 - 
1.14) 
7.76 (1.03 - 
14.49) 
 85.52 93.90 57.73 0.0000 0.0000 0.0020 
Tonkolili 
904 60.40 22.09 36.50 
 913 16.10 
(13.86-
18.63) 
0.67 (0.43 - 
0.91) 
4.16 (2.81 - 
5.50) 
 73.34 96.97 88.60 0.0000 0.0000 0.0000 
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By sex                 
Male 3461 55.19 21.11 38.16   2805 24.49 
(22.94-
26.12) 
2.55 (2.04 - 
3.06) 
10.40 (8.43 - 
12.36) 
 54.24 87.92 72.75 0.0000 0.0000 0.0000 
Female 3655 51.11 9.94  19.38   2816 17.76 
(16.39-
19.21) 
0.96 (0.77 - 
1.15) 
5.40 (4.40 - 
6.40) 
 64.12 90.34 72.14 0.0000 0.0000 0.0000 
                 
Age 
groups 
                
1-9 
2182 
11.05 0.91  8.24   1930 1.71 (1.22-
2.39) 
0.04 (0.02 - 
0.06) 
2.47 (1.49 - 
3.45) 
 82.55 95.60 70.02 0.0000 0.1680 0.0200 
10-19 
1317 
50.57 6.91 13.67   889 16.09 
(13.82-
18.65) 
0.80 (0.51 - 
1.08) 
4.94 (3.31 - 
6.58) 
 66.40 88.42 63.86 0.0000 0.0000 0.0000 
20-29 
780 
78.21 19.94  25.50   648 38.27 
(34.61-
42.07) 
3.68 (2.48 - 
4.88) 
9.58 (6.58 - 
12.58) 
 49.09 81.54 62.43 0.0000 0.0000 0.0000 
30-39 
824 
80.95  28.88  35.64   624 37.18 
(33.48-
41.04) 
3.49 (2.34 - 
4.64) 
9.38 (6.43 - 
12.33) 
 52.41 87.92 73.68 0.0000 0.0000 0.0000 
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40-49 
735 
82.31  35.94  43.66   542 38.75 
(34.74-
42.91) 
4.09 (2.65 - 
5.54) 
10.56 (6.99 - 
14.13) 
 51.20 88.62 75.81 0.0000 0.0000 0.0000 
50-59 
575 
81.39  30.37  37.31   416 37.02 
(32.52-
41.76) 
2.61 (1.15 - 
4.06) 
7.04 (3.18 - 
10.89) 
 52.55 91.41 81.13 0.0000 0.0000 0.0000 
≥60 
684 
76.17 21.58  28.34   566 29.33 
(25.73-
33.21) 
2.10 (1.47 - 
2.73) 
7.17 (5.22 - 
9.12) 
 59.74 90.27 74.70 0.0000 0.0000 0.0000 
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CHAPTER 4: LYMPHATIC FILARIASIS MAPPING BY 
IMMUNOCHROMATOGRAPHIC TEST CARDS AND BASELINE 
MICROFILARIA SURVEY PRIOR TO MASS DRUG 
ADMINISTRATION IN SIERRA LEONE 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The results of this chapter have been published as the manuscript: 
Koroma JB, Bangura MM, Hodges MH, Bah MS, Zhang Y and Bockarie MJ (2012) Lymphatic 
filariasis mapping by immunochromatographic test cards and baseline microfilaria survey prior 
to mass drug administration in Sierra Leone. Parasites & Vectors; 5:10.  
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ABSTRACT 
Background  
National mapping of LF was conducted using ICT in 2005 to determine endemicity and 
geographic spread of the disease. A baseline microfilaria survey was then conducted to 
determine LF prevalence and microfilaria intensity. 
Methods 
In 2005 1,982 persons of 15 years and over from 14 health districts were selected and fingertip 
blood samples were tested with ICT cards. In 2007-8 blood samples were taken between 10pm 
and 2am and examined for MF from 9,288 persons from 16 sentinel sites representing each 
district and two additional sites for districts with populations over 500,000 (Bo and Kenema). 
Results 
The overall LF prevalence by ICT cards was 21% (males 28%, females 15%). All districts had a 
prevalence of W. bancrofti antigen > 1%. Distribution of LF prevalence showed a strong spatial 
correlation pattern with high prevalence in a large area in the northeast gradually decreasing 
to a relatively low prevalence in the south-west coast. High prevalence was found in the 
northeast, Bombali (52%), Koinadugu (46%), Tonkolili (37%) and Kono (30%). Low prevalence 
was found in the south-west, Bonthe (3%) and Pujehun (4%). The MF prevalence was higher in 
the northeast: Bombali, 6.7%, Koinadugu 5.7%, Port Loko 4.4% and Kono 2.4%. Overall there 
was a significant difference in MF prevalence by gender: males 2.9%, females 1.8% (p = 0.0002) 
and within districts in Kailahun, Kono, Port Loko, Moyamba and Koinadugu (all p < 0.05). The 
MF prevalence was higher in people >20 years (2.5%) than in people ≤20 years (1.7%) 
(p=0.043). The overall arithmetic mean MF density was 50.30mf/ml among MF-positive 
individuals and 1.19mf/ml in the population examined which varied significantly between 
districts. 
Conclusions 
The ICT results showed that LF was endemic nationwide and that preventive chemotherapy 
(PC) was justified across the country. Both the ICT and microfilaraemia surveys found that 
prevalence was greater in males than females. The increase in microfilaraemia prevalence by 
age was evident when grouped as ≤20 versus >20 years demonstrating early exposure. 
Baseline LF microfilaria load will be used to monitor PC programme progress.
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BACKGROUND 
LF is a chronic, debilitating disease that affects people in tropical and sub-tropical areas of Asia, 
Africa, the Western Pacific and some areas of the Americas. LF is caused by the parasites W. 
bancrofti or B. malayi and transmitted by Culex, Anopheles and other mosquitoes (Ottesen 
1997; Molyneux and Taylor 2001; Bockarie and Molyneux 2009). An estimated 90% of all LF 
cases worldwide and all cases in Africa are infections with the parasite W. bancrofti. The main 
LF vectors in West Africa are the Anopheles mosquitoes (Kelly-Hope et al. 2006). 
 
Over 120 million people in over 80 countries worldwide in the tropics and sub-tropics and over 
40 million people in Africa are infected with the parasite (Ottesen 2006; Ottesen et al. 2008). 
Bancroftian filariasis, which is prevalent in Africa, is endemic in rural as well as urban 
communities thriving within poor communities (Dunyo et al. 1996b; Kelly-Hope et al. 2006; 
Okon, Ibor and Opara 2010).  
 
LF has a wide range of clinical manifestations from acute attacks of filarial fever, chronic 
conditions such as hydroceles, lymphoedema, elephantiasis of limbs, and enlarged breasts, to 
kidney damage, thus causing great morbidity and disability for those affected (WHO 1992). 
Filariasis is one of the most common causes of permanent disability worldwide creating the 
highest disease burden in terms of DALYs among tropical diseases (Ottesen et al. 2008). Those 
affected also suffer psychosocial stigmatisation and economic suffering as it can lead to job 
loss or inability to work. The disease is therefore a major cause of poverty as it creates 
economic burden for those affected, their dependants, their communities and the country as a 
whole (Dunyo et al. 1996b; Huppatz et al. 2009; Mishra and Bhadoriya 2009; Ruberanziza et al. 
2009; Okon, Ibor and Opara 2010).  
 
In 1993 the International Task Force on Disease Eradication identified LF as one of six diseases 
that could be eradicated, which led the World Health Assembly in 1997 to pass resolution WHA 
50.29 calling for the elimination of LF as a public health problem in the world by 2020. By 2000, 
the GPELF was launched by WHO to support LF elimination programmes in endemic countries 
and a Global Alliance to Eliminate Lymphatic Filariasis (GAELF) was established as a partnership 
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of countries, NGDOs, academic and research institutions, pharmaceutical companies, 
international organizations, and advocacy and resource mobilization partners to support the 
GPELF (Ottesen et al. 1997; Mohammed et al. 2006; Bockarie and Molyneux 2009; Ruberanziza 
et al. 2009; Addiss 2010).  
 
Circulating MF are responsible for transmission, therefore transmission can be 
broken/interrupted by reducing the number of people with microfilaraemia within affected 
communities through annual MDA for 4-6 years to ≥80% of the entire at-risk population which 
can reduce microfilaraemia to zero or close to zero (Gyapong et al. 2005; WHO 2008). Before 
MDA is started in a country, implementation units to be targeted should be determined 
through a rapid assessment study and also baseline data on LF MF level should be obtained to 
monitor the effectiveness of MDA. There are already countries that have succeeded in 
eliminating the disease (Cape Verde, China, Costa Rica, Solomon Islands, South Korea, 
Suriname, and Trinidad and Tobago) using a combination of strategies that include vector 
control and single annual doses of 2-drug treatments (albendazole together with ivermectin or 
diethylcarbamazine) (Gyapong et al. 2005; WHO 2008). The currently preferred strategy for LF 
elimination recommended by WHO is the preventive chemotherapy using the available drugs 
(WHO 2000a,b; WHO 2006). The GPELF has been strengthened by the donation of albendazole 
by GlaxoSmithKline and continued donation of ivermectin by Merck & Co. Inc. (Linehan et al. 
2011). In Sierra Leone, reports from health facilities indicated endemicity of LF in all districts, 
and in 1996, a study in Moyamba district using the thick blood film method showed MF 
prevalence: 10.2% with 36.5% clinical manifestation (26.6% hydroceles and 9.4% 
lymphoedema/elephantiasis of the lower extremities) (Gbakima and Sahr 1996).  
 
In 2004, a country profile of communicable diseases in Sierra Leone developed by WHO, 
quoting an anonymous 1999 study in 55 sites including the capital Freetown, showed that 
14.5% of people tested for CFA of W. bancrofti were positive (WHO 2004). The Northern 
Province had the highest prevalence (19.6%), followed by Western Area (12.8%), Eastern 
Province (12.7%) and Southern Province (10.9%) (WHO 2004). Infection was noted in children, 
and this indicated ongoing transmission and infections acquired early in life. 
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In preparation for the national LF elimination programme, national mapping was conducted in 
2005 using ICT cards. The national LF elimination programme started when the MOHS, Sierra 
Leone in consultation with WHO decided to conduct the integrated management of 
onchocerciasis, LF, schistosomiasis, soil-transmitted helminths and trachoma, and the existing 
NOCP became National NTDP in 2006 (Hodges et al. 2011).  
 
Based on the mapping results, the implementation units (districts) for LF MDA were 
determined, and national baseline data on MF level were collected pre-MDA. The current 
paper presents the distribution and the level of infection of LF in Sierra Leone which formed 
the base for the national LF elimination programme. 
 
 
METHODS 
Ethics statement 
The studies were conducted by the National NTDP of the MOHS, Sierra Leone. Ethical approval 
for data collection was obtained from the Ethics Committee of the MOHS and upon arrival at 
the randomly selected communities the investigating team met with the community leaders 
and explained the nature of their work. All participants aged 15 years or above in each site 
were eligible for inclusion without discrimination on gender, social status, religion or ethnicity. 
People participated in the studies after informed consent was verbally obtained and recorded 
by the team leader, as literacy rates are low in Sierra Leone. Data collection was conducted 
such that participants remained anonymous during data entry and analysis. No individual 
identity can be revealed upon publication. 
 
National mapping of LF with ICT cards in 2005  
Although previous studies and clinical records indicated that LF was prevalent particularly in 
the north, detailed data on distribution and level of risk throughout the country was not 
available, and all districts including the Western urban district and Western rural district were 
included in the mapping. Thirty-four (34) communities were randomly selected from all 
districts in consultation with WHO/AFRO with each district having at least one community 
selected. Participants who were 15 years of age or above were selected for the antigenaemia 
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study using ICT cards (WHO, 2006). During the survey, ICT cards were kept overnight at 8°C in 
district cold rooms for the expanded programme on immunisation and during the day the 
cards were transported in cold boxes and vaccine carriers with ice packs. The left index finger 
was pricked with a sterile lancet after cleaning with cotton wool soaked with spirit and 100μl 
blood collected and applied straight to the ICT cards. The survey teams were trained to read 
the results of the ICT cards at exactly 10 minutes after application, according to the 
manufacturer’s instructions. No late reading of ICT cards was reported by the survey teams. 
Due to limited resources and the high sensitivity and specificity of the ICT (WHO, 2005), 50 
persons were sampled in each randomly selected community and if a positive case was 
identified the sampling was complete and the teams moved on to the next site. If in the first 50 
samples there was no positive case found, a further 50 persons were sampled bringing the 
total to 100 per site (WHO, 2005). Training of technicians in the use of the ICT cards to detect 
W. bancrofti antigen and data recording took place in Makeni and York Village, Western urban 
district. Three teams of three technicians (two for specimen collection and one for reading and 
recording of results) worked with a village volunteer (usually a school teacher) who served as 
registrar. Data included name, sex, village, chiefdom and district. A total of 1,982 people were 
tested; males 904 (45.6%) and females 1,078 (54.4%). 
 
Baseline microfilaraemia data collection before MDA 
Sampling was conducted in accordance with WHO guidelines (WHO 2005) of two sentinel sites 
per implementation unit (district for Sierra Leone) with a population of one million people. Ten 
of the fourteen health districts of Sierra Leone have a population below 500,000 and one 
sentinel site per district was selected representing a population ≤ 500,000. One sentinel site 
each was selected for Western rural district (232,294) and Western urban district (901,953). Bo 
district (Bo Town: Bo District, 222,561: 347,610) and Kenema district (Kenema Town: Kenema 
District, 188,869: 377,067) had a population above 500,000 and two sentinel sites were 
selected in these two districts, making a total of 16 sites. Communities/villages that showed 
the highest ICT prevalence in each district in 2005 were selected as MF sentinel sites (WHO 
2005). The survey was performed in two phases according to funding availability: Bombali, 
Koinadugu, Kambia, Kono, Kailahun and Pujehun in 2007 and Tonkolili, Port Loko, Kenema, 
Bonthe, Moyamba, Bo, Western urban district and Western Rural district in 2008. Pre-
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sensitization was carried out before the survey in each site. Five hundred participants of 15 
years of age or above were recruited per site. In sites with less than 500 people selected, extra 
participants were recruited in neighbouring villages. To ensure the standardisation of activities 
and data, two-day practical training was performed before the study started for all technicians. 
Fingertip blood was collected between 10pm and 2am from each volunteer. A 60μl blood 
sample was collected, smeared gently and uniformly in a circular shape and allowed to air dry 
at room temperature for 12-24 hours. The following day the dried smear was 
dehaemoglobinized by flooding with distilled water for three-five minutes, air dried again, fixed 
with methanol for 30-60 seconds, stained with Giemsa for ten minutes then examined for MF 
under a light microscope by experienced examiners. Positive findings of MF were recorded, 
and individual MF density of infection was calculated and expressed as the number of MF per 
ml of blood (mf/ml) (26-29). A total of 9,288 night blood samples were examined. The mean 
age (± standard deviation) of the subjects examined was 37.7 ± 17.04 years (males: 37.27 ± 
17.6, females: 38.12 ± 16.5). For quality control, all positive slides and 10% of the negative 
slides were preserved and examined by an experienced researcher.  
 
Statistical analysis  
Results were entered into Epi-Info version 3.5.2 and analysed in SPSS (IBM, Version 19). 
Prevalence of positive circulating LF antigen or microfilaraemia was calculated. The 95% CIs for 
prevalence were calculated using the Wilson score method without continuity correction 
(Newcombe 1998). The arithmetic mean MF density of infection with 95% CIs was calculated 
using the total population examined and the positive samples only (WHO 2005). Chi-square 
test was used to compare the differences in prevalence and Kruskal-Wallis test was used to 
compare the differences in MF density. Correlation analysis was conducted for the two sets of 
data (ICT and microfilaraemia prevalence) and the significance of the correlation tested 
(Trochim 2006). The coordinates of each sample site were recorded using hand-held units of 
global positioning system (site coordinates available upon request). Spatial analysis of the LF 
antigenaemia prevalence (ICT card data) was conducted using the kriging method in the 
Geostatistical Analyst Extension of ArcGIS version 10 (ESRI, Redlands, USA). Spatially smoothed 
contour maps of the interpolated prevalence of antigenaemia and the predictive probability 
for the ICT prevalence of greater than 1% were produced (Zoure et al. 2011). 
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RESULTS 
Distribution of LF in Sierra Leone  
Table 6 summarises the results of the survey using ICT cards for each district. All the districts of 
Sierra Leone were found to be endemic for LF with a prevalence of ICT positive tests ≥1%. Point 
prevalence for each survey site was shown in Figure 9. Among 34 sites surveyed, only one site 
in Bonthe district was shown to be negative. The median prevalence across the 34 sites was 
20% ranging from 0% to 68% (inter-quantile range: 11.7-31%). Overall ICT positive prevalence 
was 20.8%. High prevalence was found in the northeast part of the country (Bombali 52%, 
Koinadugu 46%, Tonkolili 37% and Kono 30%). Relatively low prevalence was found in the 
south-west coastal districts (Bonthe 3.1% and Pujehun 4.4%). There were significantly more 
positive ICT tests in males (27.54%, 95% CI: 24.7-30.6%) than in females (15.2%, 95% CI: 13.2-
17.5%) (p <0.00001). Detailed analysis of prevalence among different age groups was not 
carried out as detailed age information was not recorded for the ICT card survey.  
 
Microfilaraemia prevalence and density 
Overall 9,288 night blood samples, male 4,335 (46.7%) and female 4,953 (53.3%), were 
examined for MF as shown in Table 6. There were less than 5% false positives and no false 
negative slides. All positive slides were reexamined, and three were redefined as artefacts. No 
MF of Mansonella perstans was detected.  
 
In total, 220 persons (2.4%, 95% CI: 2.1-2.7%) had a positive blood smear and there was 
significantly higher MF prevalence in males 3.0% (95% CI: 2.6-3.6%) versus females 1.8% (95% 
CI: 1.4-2.2%) (p=0.0002). Age distribution of the MF prevalence is also shown in Table 6. 
There was a significant difference in MF prevalence among age groups with higher prevalence 
in persons of 41-50 years (p=0.041). The point prevalence of microfilaraemia for each site is 
shown in Figure 10. There was a significant correlation between the MF prevalence and the ICT 
card prevalence (r=0.86, p < 0.05). In line with the ICT results, the MF prevalence (95% CI) was 
higher in the northeast part of the country: Bombali, 6.9% (5.3-8.8%), Koinadugu 5.7% (4.1-
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7.7%), Port Loko 4.4% (2.9-6.6%), Kailahun 2.6% (1.6-4.1%) and Kono 2.4% (1.6-3.6%). No MF 
was found in persons examined in the Western urban district and Pujehun. 
 
The overall arithmetic mean MF density was 50.30 mf/ml (95% CI: 39.89-60.71 mf/ml) among 
MF-positive individuals, and 1.19mf/ml (95% CI: 0.90-1.48 mf/ml) in the population examined 
(Table 6). There was significantly higher MF density in the male population than in the female 
population (p<0.0001). There was also a significant difference in MF density among age groups 
in the total population examined (p=0.041). There was no significant difference in MF density 
by sex or age groups of infected persons (p>0.1). 
 
Spatial prediction of LF distribution 
The spatial analysis of the ICT card data showed a strong spatial correlation pattern as the 
semi-variance in prevalence data in relation to the distance between survey sites (Figure not 
shown). The predicted spatial distribution of LF by kriging is shown in Figure 11. This shows a 
widespread distribution of LF prevalence with a clear geographical distribution pattern in Sierra 
Leone: high (>40%) in a large area spanning the northeast of the country with two clusters of 
predicted prevalence of over 50%, gradually decreasing towards the southwest, and ending 
with a low prevalence (<5%) in the coastal part of Bonthe and Pujehun districts. Figure 12 
shows the predicted probability of the LF prevalence being over 1%, which shows high 
probability throughout the country with only two small clusters of relatively low probability 
(<50%) in Bonthe and Moyamba. 
 
 
DISCUSSION 
All districts in Sierra Leone were endemic with LF and qualified for MDA. Distribution of LF 
prevalence showed a strong spatial correlation pattern with high prevalence in a large area in 
the north-east gradually decreasing to relatively low prevalence in the south-west coast. ICT 
results showed two distinct patterns: males were more infected than females and districts in 
the north-east part of the country and had a higher prevalence than other districts. The ICT 
results obtained in this study were higher than in 2004, but the same pattern of a higher 
prevalence for CFA in the north than all other regions was repeated (WHO 2004). Three distinct 
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patterns were also noted in the microfilaraemia survey: microfilaraemia was higher in males 
(3.0%) versus females (1.8%), increased with age in the population peaking at 41-50 years, and 
showed a higher prevalence in the northeast than in other parts of the country. In two districts 
(Western urban district and Pujehun), microfilaraemia was not identified among the subjects 
examined, even though ICT prevalence was 11.7% and 4.4% respectively. 
 
The MF prevalence was lower than that reported in 1996, but that study was conducted in an 
area with clearly visible signs of the disease to highlight the seriousness of the problem 
(Gbakima and Sahr 1996). There were many such areas in the districts where LF signs were 
clearly visible among the population but in this study, the sites were randomly selected to 
avoid bias. Therefore, the results of this study were more representative of the MF prevalence 
in the district population. The results acquired in this study on MF prevalence and MF 
density/intensity will form the basis for monitoring and evaluation of the effectiveness of MDA 
in interrupting LF transmission in each district. 
 
Similar patterns are noted for both studies in geographical and sex distribution of the disease, 
which further strengthens the notion that these results are representative of the actual 
national picture. The ICT positive prevalence was nine times greater than the MF prevalence. 
Several authors have reported that ICT positive prevalence, which detects antigen released by 
adult W. bancrofti, can be 3-5 times higher than MF prevalence. People can be infected with 
the disease and still be amicrofilaraemic, which may explain the zero MF prevalence in 
Western urban district and Pujehun district in these studies (Braga et al. 2003; Weil and Ramzy 
2007; Foo et al. 2011). 
 
Previous studies demonstrated the impact of long-term treatment with ivermectin alone for 
onchocerciasis control on LF prevalence and transmission, which showed that in villages 
treated for many years with ivermectin, LF microfilaraemia prevalence and intensity were 
significantly lower than in untreated villages (Kyelem et al. 2003; Kyelem et al. 2005). 
Antigenaemia rates were significantly higher than microfilaraemia rates generally (Kyelem et 
al. 2003; Kyelem et al. 2005). Onchocerciasis was endemic in 12 of 14 health districts in Sierra 
Leone (Hodges et al. 2011). Community-based treatment with ivermectin for the control of 
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onchocerciasis in Sierra Leone started in the late 1980’s but did not reach full geographical 
coverage due to insecurity at the beginning of the civil war in 1991 and were subsequently 
suspended in 1994. In 2003, CDTI was introduced but therapeutic coverage was low in the 
post-conflict setting. In 2005 the NOCP was reorganised, and therapeutic coverage reached the 
prerequisite ≥ 65% and has been maintained in all endemic districts since (Hodges et al. 2011). 
The relatively low microfilaraemia rates in our study and the difference between antigenaemia 
rates and microfilaraemia rates may have been due to the ivermectin treatment for 
onchocerciasis control in Sierra Leone before the surveys were conducted. 
 
The current results are in line with other studies that males have a higher prevalence than 
females for CFA as well as for microfilaraemia (Murty et al. 2004; Mishra and Bhadoriya 2009; 
Upadhayula et al. 2010). The most probable reason for this is that males spend more time 
exposed to the bites of mosquitoes. 
 
The distribution of MF prevalence increasing with age shown in this study is in line with results 
of many other studies (Okon, Iboh, Opara 2010; Mishra and Bhadoriya 2009; Foo et al. 2011; 
Murty et al. 2004; Upadhayula et al. 2010). This emphasises the socio-economic impact of the 
disease as the age groups affected most are the major workforce in the villages. In Sierra 
Leone, an estimated 70% of adults are farmers (Koroma, Turay, Moihua 2006), and disability 
from LF incapacitates those affected and increases poverty, which is a cause for concern as the 
country is among the poorest in the world and demands appropriate attention for the 
elimination of the disease. It has been suggested that adults could be more exposed to 
mosquito bites because of higher relative heat, more carbon dioxide output or simply because 
they have a relatively greater surface area that can be bitten by mosquitoes (Upadhayula et 
2010). Similar studies on antigenaemia and microfilaraemia for W. bancrofti have been 
conducted in other countries that reflected similar gender and age pattern as our studies 
(Onapa et al. 2001; Gyapong et al. 2002; Ngwira et al. 2007). 
 
There are certain limitations for the current studies. Firstly, children below 15 years were not 
selected for circulating filarial antigen and for microfilaria according to the WHO guidelines 
(WHO 2004). The WHO profile for LF in Sierra Leone in 2004 indicated that children were 
148 
 
148 
 
infected and that the infection could be acquired early in life (WHO 2004). It has been 
suggested that excluding children below 15 years could bias the studies towards older people, 
and since it is common knowledge that filariasis infection increases with age, the prevalence 
might have been over-estimated for the general population compared to other studies that 
used population-based sampling methodology (Foo et al. 2011). While this may have been true 
in this study, considering the overall global objective is LF elimination, such slight over-
estimation of LF prevalence due to the age bias should not have made much difference in 
terms of MDA decision in Sierra Leone. Secondly, it is recommended that ICT cards be stored at 
or around 8°C (Ruberanziza et al. 2009). Although efforts were made to keep the cards in a 
cold box during the field work, the relatively poor field conditions in the remote villages may 
have made it difficult to keep the box cold at all times. In such field conditions, reading every 
card within the time limit may not have been guaranteed. This may in part explain the higher 
ICT positive prevalence (9 times greater than the MF prevalence) in the current studies than in 
other studies (Braga et al. 2003; Weil and Ramzy 2007; Foo et al. 2011). However, taking both 
ICT and MF positive prevalence together, there is a strong correlation between the results of 
the two surveys for the 14 health districts as shown through correlation analysis. Therefore, 
the results can be considered to be representative of the true LF endemic situation in Sierra 
Leone. 
 
Based on the information provided by these studies, the national NTDP started LF MDA in 2007 
(Hodges et al. 2011). Four rounds of MDA with albendazole and ivermectin were delivered in 6 
districts, three rounds in seven districts including the Western ruraL district, and two rounds in 
the Western urban district (Hodges et al. 2010). It is hoped that the assessment results will 
provide tools to evaluate the impact of the MDA and to adjust the course of MDA if necessary. 
 
 
CONCLUSION 
LF mapping using ICT cards was successfully conducted in 2005 in all districts of Sierra Leone 
which showed that all districts were endemic for LF and qualified for MDA. Baseline data 
collection with night blood smear was conducted in 2007-08 before MDA, which provided 
baseline values for MF prevalence and MF density and confirmed LF endemic status 
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determined by ICT card survey across the country. These surveys provided tools for the NTDP 
to design and implement MDA and provided the basis for future monitoring and evaluation of 
the national LF elimination programme. 
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Table 6:   Crude LF prevalence with antigen detection and microfilaraemia tests by district, sex and age group in Sierra Leone 
 Mapping Baseline studies 
 No of persons 
tested by ICT 
cards 
Percentage 
prevalence of antigen 
positives (95% CI) 
No of persons 
examined for 
MF 
Percentage 
prevalence of MF 
positives (95% CI) 
Population MF 
density (mf/ml) 
(95% CI) 
Positive-only MF 
density (mf/ml) (95% 
CI) 
Overall 1982 20.8 (19.1 - 22.7) 9288 2.4 (2.1 - 2.7) 1.19 (0.90 - 1.48) 50.3 (39.89 - 60.71) 
By district 
      Bo 173 15.0 (10.5 - 21.1) 1005 2.0 (1.3 - 3.1) 1.97 (0.84 -3.11) 99.17 (58.32 - 140.01) 
Bombali 150 52 (44.1 - 59.8) 830 6.9 (5.3 - 8.8) 1.93 (1.28 - 2.57) 28.07 (21.70 - 34.44) 
Bonthe 160 3.1 (1.3 - 7.1) 504 1.2 (0.6 - 2.6) 0.83 (0.02 - 1.63) 69.44 (13.68 - 125.21) 
Kailahun 110 19.1 (12.8 - 27.4) 624 2.6 (1.6 - 4.1) 2.08 (0.00 - 4.89) 81.25 (0.00 - 195.58) 
Kambia 110 15.5 (9.9 - 23.4) 619 2.1 (1.2 - 3.6) 0.97 (0.23 - 1.71) 46.15 (17.04 - 75.27) 
Kenema 180 13.3 (9.1 - 19.1) 1016 0.6 (0.3 - 1.3) 0.34 (0.00 - 0.70) 58.33 (4.42 - 112.24) 
Koinadugu 200 46 (39.2 - 52.9) 636 5.7 (4.1 - 7.7) 1.99 (0.95 - 3.04) 35.19 (19.83 - 50.54) 
Kono 100 30 (21.9 - 39.6) 875 2.4 (1.6 - 3.6) 1.11 (0.37 - 1.84) 46.03 (20.09 - 71.97) 
Moyamba 200 10.5 (7.0 - 15.5) 500 1 (0.4 - 2.3) 0.67 (0.00 - 1.36) 66.67 (6.33 - 127.00) 
Port Loko 210 20.5 (15.6 - 26.4) 500 4.4 (2.9 - 6.6) 3.53 (1.48 - 5.59) 80.30 (44.49 - 116.12) 
Pujehun 160 4.4 (2.1 - 8.8) 624 0 (0 - 0.6) - - 
Tonkolili 100 37 (28.2 - 46.8) 500 2.4 (1.4 - 4.2) 0.63 (0.24 - 1.03) 26.39 (17.99 - 34.79) 
WA Rural 69 7.3 (3.1 - 15.9) 500 1.2 (0.6 - 2.6) 0.33 (0.01 - 0.65) 27.78 (6.60 - 48.96) 
WA Urban 60 11.7 (5.8 - 22.2) 555 0 (0 - 0.7) - - 
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By sex 
      Male 904 27.5 (24.7 - 30.6) 4335 3.0 (2.6 - 3.6) 1.66 (1.11 - 2.20) 54.42 (38.81 - 70.02) 
Female 1078 15.2 (13.2 - 17.5) 4953 1.8 (1.4 - 2.2) 0.78 (0.52 - 1.04)) 44.13 (32.50 - 55.76) 
       By age 
group (yrs) 
      15-20 - - 1873 1.8 (1.3 - 2.5) 0.78 (0.38 - 1.19) 44.44 (26.37 -62.52) 
21-30 - - 2019 2.6 (2.0 - 3.4) 1.77 (0.73 - 2.80) 68.59 (31.79 -105.39) 
31-40 - - 1830 2.4 (1.8 - 3.2) 1.01 (0.55 - 1.47) 43.02 (27.55 -58.50) 
41-50 - - 1404 3.4 (2.5 - 4.4) 1.60 (0.94 - 2.27) 47.87 (32.75 - 62.99) 
>50 - - 2162 2.1 (1.6 - 2.8) 0.89 (0.49 - 1.30) 42.96 (27.40 - 58.53) 
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Figure 9: Geographical distribution of LF point prevalence by circulating antigen detection 
with ICT cards according to survey locations in Sierra 
Leone
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Figure 10: Geographical distribution of LF point prevalence by MF detection and point MF 
density according to survey locations in Sierra Leone 
 
154 
 
154 
 
 
Figure 11 Spatially smoothed contour map of predicted LF prevalence by ICT cards in Sierra 
Leone. 
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Figure 12 Spatially smoothed contour map of the predicted probability that the prevalence of 
LF antigenaemia exceeds 1%. 
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CHAPTER 5: IMPACT OF THREE ROUNDS OF MASS DRUG 
ADMINISTRATION ON LYMPHATIC FILARIASIS IN AREAS 
PREVIOUSLY TREATED FOR ONCHOCERCIASIS IN SIERRA LEONE 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The results of this chapter have been published as the manuscript: 
Koroma JB, Sesay S, Sonnie M, Hodges MH, Sahr F, Zhang Y and Bockarie MJ (2013) Impact of 
Three Rounds of Mass Drug Administration on Lymphatic Filariasis in Areas Previously Treated 
for Onchocerciasis in Sierra Leone. PLoS Negl Trop Dis 7(6): e2273. 
doi:10.1371/journal.pntd.0002273 
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ABSTRACT 
Background 
1974–2005 studies across Sierra Leone showed onchocerciasis endemicity in 12 of 14 health 
districts and baseline studies 2005–2008 showed LF endemicity in all 14 HDs. Three integrated 
annual MDA were conducted in the 12 co-endemic districts 2008–2010 with good geographic, 
programme and epidemiological coverage. The midterm assessment was conducted 2011 to 
determine the impact of these MDAs on LF in these districts. 
Methodology 
The MF prevalence and intensity in the 12 districts were determined using the TBF method and 
results compared with baseline data from 2007–2008.  
Principal Findings 
Overall MF prevalence fell from 2.6% (95% CI: 2.3%–3.0%) to 0.3% (95% CI: 0.19%–0.47%), a 
decrease of 88.5% (p = 0.000); prevalence was 0.0% (100.0% decrease) in four districts: Bo, 
Moyamba, Kenema and Kono (p = 0.001, 0.025, 0.085 and 0.000 respectively); and seven 
districts had reductions in MF prevalence of between 70.0% and 95.0% (p = 0.000, 0.060, 
0.001, 0.014, 0.000, 0.000 and 0.002 for Bombali, Bonthe, Kailahun, Kambia, Koinadugu, Port 
Loko and Tonkolili districts respectively). Pujehun had baseline MF prevalence of 0.0%, which 
was maintained. Only Bombali still had an MF prevalence >1.0% (1.58%, 95% CI: 0.80%–
3.09%)), and this is the district that had the highest baseline MF prevalence: 6.9% (95% CI: 
5.3%–8.8%). Overall arithmetic mean MF density after three MDAs was 17.59 mf/ml (95% CI: 
15.64 mf/ml–19.55 mf/ml) among MF positive individuals (65.4% decrease from baseline of 
50.9 mf/ml (95% CI: 40.25 mf/ml–61.62 mf/ml; p = 0.001) and 0.05 mf/ml (95% CI: 0.03 mf/ml–
0.08 mf/ml) for the entire population examined (96.2% decrease from baseline of 1.32 mf/ml 
(95% CI: 1.00 mf/ml–1.65 mf/ml; p = 0.000)). 
Conclusions 
The results show that MF prevalence decreased to,1.0% in all but one of the 12 districts after 
three MDAs. Overall MF density reduced by 65.0% among MF-positive individuals and 95.8% 
for the entire population. 
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BACKGROUND  
LF and onchocerciasis are among two of the major NTDs, presently targeted for elimination 
using the WHO recommended strategy of preventive chemotherapy and transmission control 
(PCT) (Molyneux et al. 2003; WHO 2006; Ottesen et al. 2008). LF is a disease caused by the 
nematodes Wuchereria bancrofti, Brugia malayi and Brugia timori, and transmitted by 
mosquitos. It is highly endemic in the tropics and subtropics (Africa, Asia, South Pacific and 
some parts of South America). The elimination strategy is through annual MDA with 
albendazole and ivermectin/diethylcarbamazine (Molyneux et al. 2003; WHO 2006). LF 
elimination is implemented through the GPELF which has expanded MDA coverage from three 
million people treated in 12 countries in 2000 to more than 450 million in 53 countries in 2010 
(WHO 2010; WHO 2011a). During that period, the disease was eliminated in China and Korea. 
Nine countries no longer require MDA because of a natural decline in transmission intensity in 
areas of low disease endemicity. Globally, a total of 73 countries (including the recently 
independent Republic of South Sudan) are presently endemic for LF. Onchocerciasis, caused by 
Onchocerca volvulus, is transmitted by blackflies belonging to the Simulium damnosum 
complex. It is mainly endemic in Africa, Yemen and the Americas (Boatin and Richards 2006). 
Control of the disease in Africa is through APOC using the annual community-directed 
treatment with ivermectin (CDTI) (WHO APOC 2010). In 2008 alone, 56.7 million people 
received treatment in 19 endemic African countries (WHO APOC 2010).  
 
In Sierra Leone, both diseases are widely distributed across the country and co-endemic in 12 
of the 14 administrative districts.  The early distribution and clinical manifestations of both 
diseases in Sierra Leone were described previously (McMahon et al. 1988a,b,c,d; Whitworth et 
al. 1991; Whitworth et al. 1992; Whitworth et al. 1993; Mabey et al. 1996; Post and Crosskey 
1985; Dadzie, De Sole, Remme 1992; Gbakima et al. 2000;). The NOCP was established in the 
1980s to control onchocerciasis, and with the support from APOC, CDTI started in 2002 in meso 
and hyper-endemic communities nationwide (Hodges et al. 2011). After further national 
mapping of LF in 2005 and baseline data collection on MF prevalence and density in 2007-2008 
(Koroma et al. 2012), CDTI was expanded to include albendazole distribution to control LF in six 
co-endemic districts (Hodges et al. 2011). With support from the USAID NTD Program, 
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managed at the time by RTI International, the NOCP was transformed into the National NTDP 
in 2008 to integrate other NTDs into the control effort (Hodges et al. 2013).   
 
Annual MDA with ivermectin and albendazole has been implemented since then.  By early 
2011, all 12 rural health districts (except Western Urban district and Western Rural district) 
had received at least three rounds of MDA. According to the WHO guidelines (WHO 2011a), a 
mid-term survey was conducted in July/August 2011 in sentinel and spot check sites in the 12 
rural health districts to assess progress towards LF elimination and identify any 
implementation units (districts) that may require additional effort to reach the target of LF 
elimination. In this paper, we describe the remarkable impact of three rounds of MDA on LF 
prevalence and MF density in areas of low LF endemicity which may be related to previous 
treatment with ivermectin for onchocerciasis control. 
 
 
METHODS 
Ethics statement 
This study was conducted by the National NTDP of the MOHS, Sierra Leone as part of the 
routine monitoring and evaluation activities of the national control programme. Ethical 
approval for the study was obtained from the MOHS Research and Ethics Committee. Informed 
oral consent was obtained from each participant before samples were collected and their 
acceptance was recorded on a form by the team leader, as literacy rates are low in the country. 
All participants aged five years and above in each site were eligible for inclusion without 
discrimination on gender, social status, religion or ethnicity. Participants’ identities were 
protected by collecting, recording and analysing data such that participants remained 
anonymous.  
 
Mass drug administration 
Annual MDA with ivermectin and albendazole was piloted in 2007 in six rural districts located 
in border areas with neighbouring Guinea and Liberia: Bombali, Kailahun, Kambia, Koinadugu, 
Kono, and Pujehun. This was scaled up to cover 12 rural districts in 2008 with the additional 
districts added to the previous six: Bo, Bonthe, Kenema, Moyamba, Port Loko and Tonkolili. 
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Geographic coverage for the endemic districts targeted reached 100% in 2010 when MDA was 
scaled up to cover the remaining two health districts: Western Urban district and Western 
Rural district (Hodges et al. 2010). Within rural communities, ivermectin and albendazole were 
distributed by CDDs who are literate members of the respective communities selected by their 
communities and trained by health workers. In urban areas students in medical and nursing 
institutions are trained to conduct MDAs. District health workers conduct training for MDA and 
provide supervision during MDAs. NTDP staff and members of the DHMTs also support training 
and supervision for MDAs. MDA is conducted once a year between September and December, 
which is the post-harvest period that communities have accepted for MDAs.  
 
Before each MDA, CDDs conduct a pre-MDA census. Details on all community members are 
recorded in the community registers and updated each year prior to subsequent MDA. MDA 
details are also captured in the registers. After each MDA, the MDA details are summarised in 
the reporting forms by drug distributors and submitted to the supervising health workers. The 
supervising health workers prepare summary reports for all villages/urban areas targeted and 
submit the reporting forms to the DHMTs. Each DHMT then submits the district MDA report to 
the NTDP, which collates MDA results from all districts.     
 
Survey site selection 
Sampling was conducted in accordance with WHO guidelines in one sentinel site and one spot 
check site per population of one million people. The 12 rural districts that had conducted at 
least three rounds of MDA were involved in this study. As the populations of the districts were 
small, the 12 districts were put in six groups of two districts depending on geographical 
proximity and epidemiological characteristics so that the total population for each group was 
about a million (WHO 2011a). For the baseline study in 2007 and 2008, sentinel sites were 
randomly selected for all 14 health districts according to WHO guidelines (Koroma et al. 2012; 
WHO 2011a). In each of the six groups, a sentinel site was selected in one district for this study, 
and a spot check site was selected in the other district, in consultation with the DHMTs. The 
groups included the following pairs of districts: Bonthe (sentinel site (SS)- Moboya) and 
Moyamba (spot check site (SCS)- Taninahun Kapuima); Koinadugu (SS-Kumala) and Bombali 
(SCS-Makoba Yelima); Bo (SS-Gelehun) and Pujehun (SCS- Kundorwahun); Port Loko (SS-
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Gbabai) and Kambia (SCS- Kamasasa); Kailahun (SS-Manowa) and Kenema (SCS- Joru); Kono 
(SS- Tombodu) and Tonkolili (SCS-Rosint). In the ¨sentinel site¨ districts data obtained in this 
study were compared with baseline data, while among the ¨spot check site” districts, the 
results of this survey were compared with baseline results obtained in the original sentinel 
sites in these districts. See Table 7 below for details of the survey sites used during the 
midterm evaluation. 
 
Table 7: Survey site selection for midterm LF evaluation carried out in 12 districts in 2011 
Groups of 
districts 
Districts  Sentinel sites  Spot check sites 
1 Bonthe  Moboya  
Moyamba -  Taninahun Kapuima 
2 Koinadugu  Kumala  - 
Bombali  -  Makoba Yelima 
3 Bo     Gelehun - 
Pujehun    - Kundorwahun 
4 Port Loko    Gbabai - 
Kambia -  - Kamasasa 
5 Kailahun    Manowa - 
Kenema    - Joru 
6 Kono     Tombodu - 
Tonkolili    - Rosint 
 
Sampling and diagnosis 
The survey teams met with community leaders upon arrival in communities and explained the 
nature of their work, after which, meetings were held with the general community to explain 
the study and its significance and respond to questions from community members before the 
study was conducted. Some 300-500 participants of five years of age or above were recruited 
per site according to WHO guidelines (WHO 2011a). In sites with less than 300 participants, 
more participants were recruited in neighbouring villages. To ensure standardisation of 
activities and data, two-day practical training was conducted for all technicians before the 
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study started. Fingertip blood was collected between ten pm and two am.  A 60 µl blood 
sample was collected from each participant, smeared gently and uniformly in a circular shape 
and allowed to air dry at room temperature for 12–24 hours.   
 
The next day, the dried smear was dehaemoglobinized through flooding with distilled water for 
three–five minutes, air dried again, fixed with methanol for 30–60 seconds, stained with 
GIEMSA for 10 minutes, and examined for MF under a light microscope by experienced 
examiners.  Positive findings of MF were recorded, and individual MF density of infection was 
calculated and expressed as the number of MF per ml of blood (mf/ml).  A total of 6,023 
“midnight” blood samples were collected and examined for MF as shown in Table 8, male 
3,170 (52.6%) and female 2,853 (47.4%). The mean age (± standard deviation) of the subjects 
examined was 28.91±18.92 years (males: 27.65±18.77, females: 30.32±18.92). For quality 
control, all positive slides and 10% of the negative slides were preserved and examined by an 
experienced researcher. There were no false positives and no false negatives. The coordinates 
of each sample site were recorded using hand-held units of global positioning system.  
 
Statistical analysis 
Results were entered into MS Excel and analysed in SPSS (IBM, Version 19). Prevalence and 
density of mf were calculated for all 12 districts and compared with the baseline data. The 95% 
CIs for prevalence were calculated using the Wilson score method without continuity 
correction (Newcommbe 1998). The arithmetic mean MF density of infection with 95% CI was 
calculated using the total population examined and the positive samples only (Koroma et al. 
2012; WHO 2005). The Chi-squared test was used to compare the differences in prevalence, 
and the Kruskal-Wallis test was used to compare the differences in MF density. Treatment 
coverage was calculated according to the WHO guidelines (WHO 2011a). Programme coverage 
was the percentage of people ingesting the drugs among the total targeted population in the 
endemic districts. Epidemiological coverage was the percentage of people ingesting the drugs 
among the total population in the endemic districts. The total population used in rural areas 
was the total number of people registered during the pre-MDA census, while the total 
population used in urban/non-rural areas was the projected figure according to the 2004 
national census (Koroma, Turay, Moihua 2006), with an annual growth rate of 2.5%. Spatial 
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analysis of the LF MF prevalence was conducted using the kriging method in the Geostatistical 
Analyst Extension of ArcGIS version 10 (ESRI, Redlands, USA). Spatially smoothed contour maps 
of the interpolated prevalence of MF at baseline and after three MDAs were produced as 
described previously (Zoure et al. 2011; Koroma et al. 2012).   
 
 
RESULTS 
MDA results 2008-2010 
A total of 14,253 villages and urban areas were treated each year during the three years in the 
12 districts. This represents 100% geographic coverage for endemic villages and urban areas in 
all 12 districts during each of these three rounds of MDA, as shown in Table 9. Over four 
million people were targeted for treatment each year during the three years. Overall 
epidemiological coverage7 was 70.1%, 74.1% and 75.2% in 2008, 2009 and 2010 respectively at 
the national level, and was ≥65.0% in each district in each round, except in Bonthe, where it 
was 59.5% in 2008. Epidemiological coverage also improved between 2008 and 2010. Five 
districts had <70.0% in 2008 (Bo: 66.3%, Bonthe: 59.5%, Kono: 69.0%, Port Loko: 66.6% and 
Tonkolili: 68.6%); while in 2009 and 2010, all districts had >70.0% epidemiological coverage, as 
shown in Table 9. The overall programme coverage was 82.5%, 87.1% and 88.5% in 2008, 2009 
and 2010, respectively. The programme coverage is a measure of how well MDA was 
conducted and is considered adequate when ≥80.0% (15). Programme coverage by the district 
in each round was ≥80.0%, except in Bo, Bonthe and Port Loko, which had 78.0%, 70.0% and 
78.3% respectively in 2008, as shown in Table 9. 
 
Microfilaraemia prevalence 
Five districts (Bo, Kenema, Kono, Moyamba and Pujehun) had 0.0% MF prevalence. One district 
(Pujehun) had baseline MF prevalence of 0.0%, which was maintained. Another six districts had 
MF prevalence between 0.0 and 1.0%: Bonthe (0.20%), Kailahun (0.20%), Kambia (0.40%), 
                                                          
7 The indicators used for coverage in this study is different from what is in the publication because WHO 
made some changes in the latest monitoring and evaluation guidelines for LF. What was referred to as 
epidemiological drug coverage (EDC) in the publication is now simply epidemiological coverage in the 
study, while drug coverage (DC) that is in the publication is now replaced by programme coverage in the 
study (WHO 2011; Koroma et al. 2013). 
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Koinadugu (0.80%), Port Loko (0.20%) and Tonkolili (0.19%). Only one district had MF 
prevalence of over 1%: Bombali (1.58%). Overall MF prevalence among males was 0.35% and 
among females 0.25%. Prevalence by age group, 5-14 years (N=1947), 15-20 years (N=858), 21-
30 years (N=858), 31-40 years (N=849) and 41-50 years (N=640), was 0.21%, 0.12%, 0.58%, 
0.59% and 0.47% respectively, while prevalence in the age group >50 years (N=871) was 0.0%. 
In total, 18 persons (0.30%, 95% CI: 0.19-0.47%) had a positive blood smear, and there was no 
significant difference in MF prevalence in males 0.35% (95% CI: 0.19-0.62%) as compared to 
females 0.25% (95% CI: 0.12-0.51%) (p=0.47). There were also no significant differences in 
prevalence among age groups.  
 
Compared with the baseline, overall MF prevalence decreased by 87.5%, from 2.40% to 0.30%, 
after three rounds of MDA. As shown in Table 8, among the 11 districts with baseline MF 
prevalence ≥1%, seven districts showed MF prevalence reduction of over 90% after three 
rounds of MDA, three districts by over 80%, and only one district by below 80%. Spatial 
prediction suggested a sweeping reduction in MF prevalence from the baseline level after 
three MDAs across the country. There was an 88.3% decrease in MF prevalence among males: 
3.00% to 0.35%; and an 86.1% decrease in MF prevalence among females: 1.80% to 0.25%. 
There was 0.21% prevalence among the age group 5-14 years, but this could not be compared, 
as the baseline study did not include participants <15 years. Decreases in MF prevalence 
among the age groups 15-20, 21-30, 31-40, 41-50 and >50 years ranged between 75.4% and 
100.0%. Figures 13, 14 and 15 show graphs of the reduction of LF MF prevalence, MF density 
for the entire population studied and MF density for positive-only. Figure 16 shows predicted 
MF prevalence at baseline (A) and predicted MF prevalence after three rounds of MDA (B).  
 
MF density 
The overall arithmetic mean MF density was 0.05 mf/ml (95% CI: 0.03-0.08 mf/ml) in the total 
participants examined and 17.59 mf/ml (95% CI: 15.64-19.55 mf/ml) among MF-positive 
individuals. The mean MF density by district was well below one mf/ml for the population 
examined and below 21 mf/ml among those who were MF positive. There was no significant 
difference in MF density in males versus females (p>0.05). There was also no significant 
difference in MF density among age groups in the total population examined (p>0.05). Overall 
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mean MF density among MF positive individuals decreased by 65.0%, from 50.3 mf/ml at 
baseline to 17.63 mf/ml; and in the total population examined, there was a 95.5% decrease, 
from 1.19 mf/ml at baseline to 0.05 mf/ml. In Bo, Kenema, Kono and Moyamba, there was 
100.0% decrease in MF density among both MF positive participants and the entire population. 
Six districts, Bonthe, Kailahun, Kambia, Koinadugu, Port Loko and Tonkolili, had a >90.0% 
decrease in MF density for the entire population, and a >36.0% decrease in MF density among 
positive participants. Bombali had the lowest decreases in MF density, 86.3% for the entire 
population and 40.6% among positive individuals. Table 8 shows the reduction of MF density in 
the 12 districts after 3 MDAs. There was a 96.2% decrease in MF density among all males and a 
66.6% decrease in MF density among males that are MF positive, and there was a 94.7% 
decrease in MF density among all females and a 62.2% decrease in MF density among females 
that are MF positive. The age groups 15-20, 21-30, 31-40 and 41-50 years had >90.0% decrease 
in MF density for the entire population and >60.0% decrease in MF density among MF positive 
individuals. The age group >50 years had a 100.0% decrease in MF density for the entire 
population and among MF positive individuals.   
 
 
DISCUSSION 
LF is widely endemic across Sierra Leone, transmitted by Anopheles mosquitoes. All districts 
qualified for MDA intervention in accordance with WHO guidelines because they had baseline 
LF prevalence by ICT cards ≥1.0% (Koroma et al. 2012; WHO 2005). Remarkable progress in LF 
elimination has been achieved since the start of co-administration of ivermectin and 
albendazole in 2007. The results from the 12 rural districts showed that over the three years, 
geographic coverage was 100% in all 12 districts, epidemiological coverage was ≥65.0% in all 
districts except for Bonthe in 2008 (59.5%), and programme coverage was ≥80.0% in all 
districts except for Bo (78.0%), Bonthe (70.0%) and Port Loko (78.3%) in 2008. The treatment 
coverage was verified through independent monitoring activities, as described previously 
(Hodges et al. 2011; Hodges et al. 2012b). The current assessment showed that the average MF 
prevalence in the country was only 0.30% and the average population MF density was only 
0.05 mf/ml after three rounds of MDA, with no microfilaria detected in six of the 12 districts, 
including all the districts in the Southern Province and only one district showing MF prevalence 
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of >1% (Bombali, 1.58%). This represents an overall reduction of 87.5% in MF prevalence and 
95.5% in population MF density. 
 
The number of MDA rounds needed to eliminate LF depends on baseline infection rates, 
vectoral capacity, the efficacy of the MDA regimen used, and community adherence with 
treatment. It is possible to eliminate LF in some IUs with low baseline infection rates using less 
than five rounds of MDA, while more than six MDA rounds may be needed for IUs with 
relatively high baseline LF prevalence (El-Setouhyet al. 2007; Grady et al. 2007; Huppatz et al. 
2009). The high level of reduction in MF prevalence and intensity after three rounds of MDA in 
Sierra Leone may have been partly due to the relatively low baseline MF level (Koroma et al. 
2012).  
 
Pre-baseline prevalence of LF was high in southeastern Sierra Leone. Blacklock in 1922 
examined 240 men in Mabang village and found 20% to be microfilaraemic, with the 
prevalence of elephantiasis and hydrocoele of 4.6% and 3.8%, respectively ((Blacklock 1926; 
Hawking 1957). Surveys in the early 1990s showed an average MF prevalence of 34.8% in three 
villages in the Moyamba district (Gbakima, Pessima, Sahr 1996). Similarly, high prevalence 
rates were recorded in neighbouring Liberia prior to the 1980s (Brinkmann 1977; Zielke and 
Chlebowsky 1979). In 2007-2008, the pre-treatment MF prevalence for the 12 districts outside 
the Western Area ranged from 0 – 6.9%, although prevalence was below 3% in the 
southeastern districts (Koroma et al. 2012). This significant reduction of MF prevalence from 
earlier high levels prior to the start of the LF MDA coincides with the commencement of CDTI 
for onchocerciasis control in the 1980s (Hodges et al. 2011). The significant impact of CDTI on 
LF infection has been reported in some countries (Kyelem et al. 2003; Kyelem et al. 2005). 
Therefore, it is likely that annual nationwide CDTI has impacted significantly on LF infections in 
Sierra Leone, resulting in a relatively low level of MF prevalence at baseline.  
 
Three rounds of MDA with adherence ≥65.0% in Papua New Guinea reduced MF prevalence 
from 18.6% to 1.3%, a 94.0% reduction (Weil et al. 2008). The authors believed that the large 
decrease in prevalence occurred in part because the vector transmitting LF in the study area 
was the Anopheles mosquito, which is less efficient than Culex on the transmission of filariasis 
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(Weil et al. 2008). This may have also been the case in Sierra Leone. Similar successes in 
reducing MF prevalence after annual MDA rounds have been reported by many authors. In 
Kenya, there were similar reductions in MF prevalence (from 20.9% to 0.9%, a 95.7% reduction 
of MF prevalence) even when there were missed rounds of MDA (Njenga et al. 2011). 
Prevalence was reduced by 93.0%, from 12.0% to 0.8%, after just two rounds of MDA in 
Vanuatu (Fraser et al. 2005). In Northern Uganda, a reduction of MF prevalence from 3.7% to 
0.4% (an 89.2% decrease) was reported after 3 MDAs (Ashton et al. 2011). Therefore, it is not 
surprising that three effective rounds of MDA would reduce the MF prevalence to below 1% in 
11 out of 12 districts in the current LF elimination programme, given the relatively low MF 
prevalence at baseline. 
 
The successful implementation of the LF programme benefited from the existing 
onchocerciasis control programme by using the CDTI as the platform (Hodges et al. 2011). 
Health workers had already been trained and were available to provide technical support in 
additional training, supervision and surveys. Treatment has been given between September 
and December each year, as this is the period that was found to be convenient for the 
communities (i.e. harvest and post-harvest period). All the lessons learnt from CDTI during the 
years of the onchocerciasis control programme were used to improve the LF elimination 
programme. 
   
There is reason for optimism with the results of this survey because some research suggests 
that residual infections of filariasis disappear when prevalence is below 1.0% (Mitja et al. 
2011). However, it is prudent to consider experiences and lessons learnt from other countries. 
In Tanzania, it was demonstrated that MDA using ivermectin and albendazole reduced MF 
prevalence by 21.2% and 40.4% after the first and second MDA respectively, but in subsequent 
MDAs, the effect levelled off and transmission, albeit low-level, was still noted after the third 
MDA (Simonsen et al. 2010).  In Leogane, Haiti, there was a significant reduction in MF rates 
after several rounds of MDA for LF, but transmission was not interrupted (Grady et al. 2007). 
MF prevalence detected after three MDAs does not demonstrate a change in filariasis 
transmission (Weil et al. 2008; Ashton et al. 2011). The drug combination destroys the 
microfilaria over the four-six year it takes for the adult worm to die a natural death (Weil et al. 
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2008; Ashton et al. 2011; Ottesen 2000). Therefore, MDA must continue each year for four-six 
years, which is equivalent to the lifespan of the adult worm. It is noted that two health districts 
in the Western Area have not reached three effective rounds of MDA, and Bombali still had MF 
prevalence of 1.58%. Therefore, the NTDP needs to continue with MDA in all health districts, 
even though MF prevalence is already <1.0% in 11 out of 12 districts. 
 
 
CONCLUSION 
There was a significant reduction in MF prevalence and density across the 12 rural districts in 
Sierra Leone after three annual MDAs. This was coupled with good MDA adherence and 
relatively low baseline endemicity. The results show that the LF elimination programme in 
Sierra Leone is on course to reach the objective of eliminating LF by the year 2020. However, 
experiences and lessons must be learnt from other countries, and MDA should continue in all 
health districts to reach the recommended number of rounds.  
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Figure 13 Reduction of MF prevalence after three annual MDAs for LF in 12 districts of Sierra 
Leone 2008–2010 
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Figure 14. Reduction of entire-population mf density after three annual LF MDAs in 12 
districts of Sierra Leone 2008–2010 
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Figure 15. Reduction of positive-only mf density after three annual LF MDAs in 12 districts of 
Sierra Leone 2008–2010 
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Figure 16. Survey sites and spatially smoothed contour maps of predicted LF MF prevalence in Sierra Leone*. A. Predicted MF 
prevalence at baseline; B. Predicted MF prevalence after three rounds of MDA.  
 
*The same legend scale was used for the contour map of both A and B for easy comparison. Triangles and labels show the survey 
locations and the observed MF prevalence in each location.
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Table 8: Crude microfilaraemia prevalence and mf density by district, sex and age group in Sierra Leone after three rounds of MDA 
  Baseline survey  Mid-term assessment  Percentage reduction from 
baseline 
Significance test for 
reduction (p values) 
No of 
persons 
examined 
for MF 
MF 
prevalen
ce (%) 
Populatio
n MF 
density 
(mf/ml) 
Positive-
only MF 
density 
(mf/ml) 
 No of 
persons 
examine
d for MF 
Percentage 
MF 
prevalence 
(95% CI) 
Population 
MF density 
(mf/ml) 
(95% CI) 
Positive-only 
MF density 
(mf/ml) (95% 
CI) 
 MF 
prevale
nce 
Populati
on MF 
density 
Positive-
only mf 
density 
MF 
preval
ence 
Populati
on MF 
density 
Positive-
only MF 
density 
Overall 8233 2.4 1.19 50.3  6023 0.30 (0.19 – 
0.47) 
0.05  
(0.03 – 
0.08) 
17.59  
(15.64 – 
19.55) 
 87.5 95.5 65.0 0.000  0.000 0.001 
By district                 
Bo 1005 2.0 1.97 99.17  500 0 0  0  100 100 100 0.001 0.002-  - 
Bombali** 830 6.9 1.93 28.07  506 1.58 (0.80 – 
3.09) 
0.26  
(0.08 – 
0.45) 
16.67 (-)  77.1 86.3 40.6 0.000  0.000 0.068 
Bonthe 504 1.2 0.83 69.44  499 0.20 (0.04 – 
1.13) 
0.03 
 (0 – 0.10) 
16.67 (-)  83.3 96.0 76.0 0.060  0.059  0.295 
Kailahun** 624 2.6 2.08 81.25  499 0.20 (0.04 – 
1.13) 
0.03  
(0 – 0.10) 
16.67 (-)  92.3 98.4 79.5 0.001  0.001 0.472 
Kambia** 619 2.1 0.97 46.15  500 0.40 (0.11 – 
1.45) 
0.07 (0 – 
0.16) 
16.67 (-)  81.0 93.1 63.9 0.014  0.014  0.311 
Kenema 1016 0.6 0.34 58.33  500 0 0  0  100 100 100 0.085  0.085  - 
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Koinadugu** 636 5.7 1.99 35.19  498 0.80 (0.31 – 
2.05) 
0.17 (0 – 
0.34) 
20.83 (7.57 
– 34.09) 
 86.0 91.6 40.8 0.000 0.000 0.454 
Kono** 875 2.4 1.11 46.03  499 0 0  0  100 100 100 0.000 0.000 - 
Moyamba 500 1.0 0.67 66.67  500 0 0  0  100 100 100 0.025 0.025 - 
Port Loko 500 4.4 3.53 80.30  499 0.20 (0.04 – 
1.13) 
0.03 (0 -
0.10) 
16.67 (-)  95.5 99.1 79.2 0.000 0.000 0.219 
Pujehun** 624 0 - -  500 0 -  -  - - - - - - 
Tonkolili 500 2.4 0.63 26.39  523 0.19 (0.03 – 
1.08) 
0.03 (0 – 
0.10) 
16.67 (-)  92.1 94.9 36.8 0.002  0.002  0.442 
By sex                 
Male 3863 3.0 1.66 54.42  3170 0.35 (0.19 – 
0.62) 
0.06 (0.03 
- 0.10) 
18.18 (14.80 
- 21.56) 
 88.3 96.2 66.6 0.000  0.000 0.013 
Female 4370 1.8 0.78 44.13  2853 0.25 (0.12 – 
0.51) 
0.04 (0.01 
- 0.07) 
16.67 (-)  86.1 94.7 62.2 0.000  0.000 0.023 
By age 
groups 
                
5--14 - - - -  1947 0.21 (0.08 – 
0.53) 
0.04 (0 - 
0.09) 
20.83 (7.57 
– 34.09) 
 - - - - - - 
15-20 1614 1.8 0.78 44.44  858 0.12 (0.02 – 
0.66) 
0.02 (0 - 
0.06) 
16.67 (-)  93.3 97.6 62.5 0.000  0.000  0.341 
21-30 1750 2.6 1.77 68.59  858 0.58 (0.25 – 
1.36) 
0.10 (0.01 
- 0.18) 
16.67 (-)  77.7 94.5 75.7 0.000  0.000 0.042 
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31-40 1623 2.4 1.01 43.02  849 0.59 (0.25 – 
1.37) 
0.10 (0.01 
- 0.18) 
16.67 (-)  75.4 90.3 61.3 0.000  0.000 0.059 
41-50 1271 3.4 1.60 47.87  640 0.47 (0.16 – 
1.37) 
0.08 (0 - 
0.17) 
16.67 (-)  86.2 95.1 65.2 0.000  0.000 0.159 
>50 1975 2.1 0.89 42.96  871 0 0  0  100 100 100 0.000 0.000 - 
*The table shows crude MF prevalence and MF density by district, sex and age group, their percentage reductions and significance test 
for reductions in MF prevalence and density after three rounds of MDA in Sierra Leone. 
**Districts that piloted MDA in 2007. 
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Table 9: Summary results of annual MDA carried out for LF elimination in Sierra Leone 2008–2010 
Districts  
Villag
es/ 
Urban 
areas 
target
ed* 
Village
s/ 
Urban 
areas 
treated 
2008 2009 2010 
Total 
pop. of 
IUs 
Eligible 
pop. of 
IUs 
Total 
treated 
in IUs 
Epid
. 
Cov.
  by 
IUs 
 Pro
g. 
cov. 
by 
IUs 
Total 
pop. of 
IUs 
Eligible 
pop. of 
IUs 
Total 
treated 
in IUs 
Prog. 
Cov.  
by 
IUs 
 Drug 
cov. by 
IUs 
Total 
pop. of 
IUs 
Eligible 
pop. of 
IUs 
Total 
treated 
in IUs 
Prog. 
Cov.  
by 
IUs 
Drug 
cov 
by 
IUs 
 Bo 1367 1367 574053 487945 380676   78.0 595318 506020 420968 70.7 83.2 613178 521201 445996 72.7 85.6 
 Bombali** 1596 1596 440932 374792 316672 71.8 84.5 454604 386413 350278 77.1 90.6 498115 423398 363078 72.9 85.8 
Bonthe 550 550 166140 141219 98856 59.5 70.0 150718 128110 110834 73.5 86.5 154860 131631 117201 75.7 89.0 
Kailahun** 977 977 392819 333896 287536 73.2 86.1 401215 341033 313367 78.1 91.9 410509 348933 322206 78.5 92.3 
Kambia** 837 837 269673 229222 202999 75.3 88.6 289136 245766 211926 73.3 86.2 310705 264099 234910 75.6 88.9 
Kenema 1380 1380 551797 469027 391778 71.0 83.5 601661 511412 439136 73.0 85.9 583278 495786 449763 77.1 90.7 
Koinadugu** 1041 1041 207995 176796 151395 72.8 85.6 216472 184001 157339 72.7 85.5 222966 189521 162059 72.7 85.5 
Kono** 1360 1360 466223 396290 321833 69.0 81.2 442235 375900 323907 73.2 86.2 461562 392328 346719 75.1 88.4 
Moyamba 1539 1539 309436 263021 232327 75.1 88.3 304416 258754 232859 76.5 90.0 350779 298162 268876 76.7 90.2 
Port Loko 1769 1769 376212 319780 250457 66.6 78.3 547672 465521 386929 70.6 83.1 480920 408782 363026 75.5 88.8 
Pujehun** 813 813 261509 222283 188872 72.2 85.0 272436 231571 210954 77.4 91.1 250280 212738 193485 77.3 90.9 
Tonkolili 1024 1024 368678 313376 252785 68.6 80.7 418828 356004 318229 76.0 89.4 412404 350543 304195 73.8 86.8 
  14253 14253 4385467 3727647 3076186 70.1 82.5 4694711 3990504 3476726 74.1 87.1 4749556 4037123 3571514 75.2 88.5 
*Geographic coverage of villages and urban areas was 100% in all 12 districts over the three years (2008-2010). 
**Districts that piloted MDA in 2007. 
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CHAPTER 6: PRE-TRANSMISSION ASSESSMENT SURVEY FOR 
LYMPHATIC FILARIASIS AFTER FIVE EFFECTIVE ANNUAL ROUNDS 
OF MASS DRUG ADMINISTRATION IN SIERRA LEONE 
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ABSTRACT 
Background 
Previous studies on LF in Sierra Leone have shown a significant reduction in LF MF prevalence 
and MF density. A pre-TAS was conducted in the 12 districts that have completed five effective 
rounds of MDA in accordance with WHO guidelines and recommendations. 
Methodology 
The LF MF prevalence and intensity in the 12 districts were determined using the TBF method 
and results compared with baseline data from 2007–2008 and midterm data of 2011. 
Results 
The overall MF prevalence was 0.54% (95% CI: 0.36-0.81%); 0.7% (95% CI: 0.43-0.14%) for 
males and 0.36% (95% CI: 0.17-0.74%) for females. Males had higher MF prevalence although 
the prevalence for males and females was below 1% and the difference was not statistically 
significant (P=0.128970). Four districts are considered to have failed the pre-TAS: Koinadugu 
with 0.98% MF prevalence (close to 1%), Bombali with 2.67%; Kailahun with 1.56%, and 
Kenema district with 0% MF prevalence. Kenema is considered to have failed the pre-TAS even 
though the MF prevalence was 0% because the districts was paired with Kailahun district that 
failed the TAS to form a unit with a population of close to a million with Kailahun having the 
sentinel site and Kenema the spot check site. Both districts are considered to have failed due 
to the pairing. 
Conclusion 
There was a significant reduction in MF prevalence and density across the 12 provincial 
districts after five annual MDAs. Eight of 12 districts have passed the pre-TAS with <1% MF 
prevalence and now qualify for a TAS. The other four districts need to conduct two additional 
rounds of MDA and repeat the pre-TAS (re-pre-TAS). 
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BACKGROUND  
LF and onchocerciasis are two PC NTDs currently targeted for elimination (Molyneux et al. 
2003; Ottesen et al. 2008; WHO 2011a). Mapping and baseline studies conducted for LF and 
onchocerciasis in Sierra Leone have demonstrated that all 14 districts of Sierra Leone are 
endemic for LF while 12 are coendemic for onchocerciasis and LF (Hodges et al. 2011; Koroma 
et al. 2012; Koroma et al. 2013). Integrated LF/onchocerciasis treatment with albendazole and 
ivermectin was piloted in six of the 12 coendemic districts in 2007 and upscaled to all 12 
coendemic districts in 2008 (Koroma et al. 2013). MDA results reported by the NTDP between 
2008 and 2012 indicate good community adherence with treatment: epidemiological coverage 
was, in general, ≥65%, programme coverage was ≥80%, and geographic coverage was 
maintained at 100%. This success has partly been attributed to the use of CDTI as a platform 
for introducing LF treatment in the country (Koroma et al. 2013). The NOCP was transformed 
into the NTD program in 2007 and with the experience already acquired in the control of 
onchocerciasis the NTDP was able to reach all targeted communities in all 12 districts using the 
CDTI plus albendazole strategy: albendazole was added to ivermectin and CDDs were selected 
in all villages to conduct mass drug distribution in villages targeted for treatment with 
supervisory support from district health workers (Bockarie, Kelly-Hope, Haskew 2010).  
 
The CDTI plus albendazole strategy, which was based on CDDs volunteering and not being paid 
for their services, could not work in district headquarter towns as they were highly urbanised. 
People in headquarter towns also refused to accept medication from volunteers who had not 
been trained officially as health workers. Therefore, students in health and nursing institutions 
were trained to conduct treatment in headquarter towns and other urban areas within districts 
(Hodges et al. 2010).  By early 2013, all 12 provincial health districts had received at least five 
rounds of MDA. In accordance with WHO guidelines, a pre-TAS for LF was conducted in 
October/November 2013 after five rounds of MDA in sentinel and spot check sites of the 12 
rural health districts to assess progress towards LF elimination and identify districts that have 
reached the phase of conducting a TAS (WHO 2005, WHO 2011a). The aim of this study is to 
determine whether the criteria for initiating TAS has been met.  In this chapter, the impact of 
five rounds of MDA (2008-2012) on LF prevalence and MF density in the 12 districts is 
discussed to assess indicators for initiating TAS. 
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METHODS 
Ethics statement 
This study was conducted by the NTDP of the MOHS, Sierra Leone as part of the routine 
monitoring and evaluation activities of the NTDP. Ethical approval for the study was obtained 
from the MOHS Research and Ethics Committee. Informed oral consent was obtained from 
each participant before samples were collected and their acceptance was recorded on a form 
by the leader of the study team, as literacy rates are low in the country. All participants aged 
five years and above in each site were eligible for inclusion without discrimination on gender, 
social status, religion or ethnicity. Participants’ identities were protected by collecting, 
recording and analysing data such that participants remained anonymous.  
 
Mass drug administration 
Integrated onchocerciasis/LF annual MDA with ivermectin and albendazole continued in all 12 
onchocerciasis/LF coendemic districts between 2008 and 2013. Mass drug distribution is 
district-wide covering all villages, towns and district headquarter towns. The CDTI strategy 
used for onchocerciasis treatment was expanded to include albendazole and used to treat all 
12 districts for onchocerciasis and LF. Within rural communities, Ivermectin plus albendazole 
were distributed by CDDs who are literate members of different communities that are selected 
by their communities and trained by health workers to conduct MDAs and report all incidences 
of adverse events following treatment to district health workers. The CDDs are trained to use 
dose poles to determine the number of ivermectin tablets to be administered depending on 
the height of the person treated and between one and four tablets of 3mg ivermectin is 
administered to all those treated. Only one tablet of albendazole is administered to all those 
eligible for treatment (i.e. all those five years and above or with a height greater than 90cm, 
women who are not pregnant or not in the two first weeks after delivering a baby, and all 
those who are not seriously ill).  District health workers conducted training of CDDs and 
supported them to carry out the MDA within their communities. NTDP staff and members of 
the DHMTs also supported training and supervision for MDAs. MDA was performed once a year 
between September and December, which is the post-harvest period that communities have 
accepted for MDAs. The addition of albendazole to the already existing treatment with 
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ivermectin for onchocerciasis control did not create problems for the CDDs because only one 
tablet of albendazole is given to those treated. 
 
Community registers that were previously used for onchocerciasis treatment were modified to 
include treatment with albendazole and provided to all targeted villages. The register is 
designed to capture all members of each community targeted for treatment, including those 
eligible for treatment and those not eligible for treatment, and is, therefore, a good source of 
demographic information for the communities that use them.   Before each MDA in rural areas, 
CDDs conduct a pre-MDA census and update the community register to reflect those that leave 
the community, those that join the community and the newly born. MDA details are also 
captured in the registers. Simple tally sheets are used in urban areas by health and nursing 
students for recording treatment data. Each level has a summary form for ease of reporting: 
CDDs and health/nursing students summarize treatment data in a community summary form 
and submit to the PHU; PHUs complete PHU summary forms and submit to the DHMT; and 
DHMTs compile all data from the PHUs into a district summary form that is submitted to the 
NTDP at central level.     
  
Survey site selection 
Sampling was conducted in accordance with WHO guidelines in one sentinel site and one spot 
check site per population of one million people. The 12 rural districts had all carried out at least 
five rounds of MDA and so were involved in the pre-TAS. As the populations of districts in 
Sierra Leone are small, two districts had to be put together to have a population that is close to 
one million. The 12 districts were put in six groups of two districts depending on geographical 
proximity and epidemiological characteristics so that the total population for each group was 
about a million (WHO 2005, WHO 2011a). For the baseline study in 2007 and 2008, SSs were 
randomly selected for all 14 health districts according to WHO guidelines (WHO 2011a; Koroma 
et al. 2012). In each of the six groups, a SS was selected in one district for this study, and a SCS 
was chosen in the other district. While the SSs selected were those from the LF 
mapping/baseline study, SCSs have been selected in consultation with DHMTs. DHMTs 
suggested the selection of villages from areas where a high number of hydrocoele and 
lymphedema is reported. The groups included the following pairs of districts: Bonthe (SS) and 
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Moyamba (SCS); Koinadugu (SS) and Bombali (SCS); Bo (SS) and Pujehun (SCS); Port Loko (SS) 
and Kambia (SCS); Kailahun (SS) and Kenema (SCS); Kono (SS) and Tonkolili (SCS). Since Bombali 
was the only district with greater than 1% MF prevalence at mid-term, 2 SCs were selected in 
the district. Koinadugu had close to 1% MF prevalence but had to be paired with Bombali 
because of proximity and so the SS in Koinadugu was maintained. See table 10 below for more 
details on study sites. Survey teams had to move to neighbouring villages when the number of 
participants in an SS or SCS is less than the 300 minimum required by WHO (2011a). All data 
obtained in the ¨sentinel site¨ districts and the ¨spot check site” districts were compared with 
mid-term and baseline results obtained in the original sentinel sites of these districts.  
 
Table 10: Survey site selection for LF Pre-TAS carried out in 12 districts in 2013 
S. No.  District  Sentinel site  Spot-check site  
1 
 
Bonthe  Moboya  
Moyamba   Mosenesie & Wubangay) 
2 Koinadugu  Kumala & Yataya  
Bombali   Kagberay 
Makaprr, Mayoba& Matak 
3 Bo  Gelehun & Gborgborbu  
Pujehun  Moala & Njaluahun 
4 Port loko  Gbabai and Mamamah  
Kambia   Yebaya 
5 Kailahun Manowa, Bunumbu & Madina  
Kenema   Ngolahun 
6 Kono Tombodu & Penduma  
Tonkolili  Massagble 
 
Sampling and diagnosis 
The survey teams met with community leaders upon arrival in communities and explained the 
nature of their work, after which, meetings were held with the general community to explain 
the study and its significance and respond to questions from community members before the 
study was conducted. At least 300 participants of five years of age or above were recruited per 
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site according to WHO guidelines (WHO 2011a). In sites with less than 300 participants, more 
participants were recruited in neighbouring villages. To ensure standardisation of activities and 
data, two-day practical training was conducted for all technicians before the study started. 
Fingertip blood was collected between ten pm and two am.  A 60 µl blood sample was 
collected from each participant, smeared gently and uniformly in a circular shape and allowed 
to air dry at room temperature for 12–24 hours.  The next day, the dried smear was 
dehaemoglobinized through flooding with distilled water for three–five minutes, air dried 
again, fixed with methanol for 30–60 seconds, stained with GIEMSA for ten minutes, and 
examined for MF under a light microscope by experienced examiners.  Positive findings of MF 
were recorded, and individual MF density of infection was calculated and expressed as the 
number of MF per ml of blood (mf/ml).  A total of 4,230 “midnight” blood samples were 
collected and examined for MF as shown in tables 11 and 12, male 2,275 (53.8%) and female 
1,955 (46.2%). For quality control, all positive slides and 10% of the negative slides were 
preserved and examined by an experienced researcher. There were no false positives and no 
false negatives. The coordinates of each sample site were recorded using hand-held units of 
global positioning system.  
 
Statistical analysis 
Results were entered into MS Excel and analysed in SPSS (IBM, Version 23). Prevalence and 
density of MF were calculated for all 12 districts and compared with the midterm and baseline 
data. The 95% CIs for prevalence were calculated using the Wilson score method without 
continuity correction (Newcombe 1998). The arithmetic mean MF density of infection with 
95% CI was calculated using the total population examined and the positive samples only 
(WHO 2005; Koroma et al. 2012). Treatment coverage was calculated according to the WHO 
guidelines (WHO 2011a). Epidemiological coverage was the percentage of people ingesting the 
drugs among the total population in the endemic districts. Programme coverage was the 
proportion of people ingesting the drugs among the total population targeted (or eligible for 
treatment) in the endemic districts. The total population used in rural areas was the total 
number of people registered during the pre-MDA census, while the total population used in 
urban/non-rural areas was the figure projected from the 2004 national census (Koroma, Turay, 
Moihua 2006), with an annual growth rate of 2.5% . A spatially smoothed contour map 
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showing summary results of the pre-TAS conducted after five rounds of MDA was produced 
(Zoure et al. 2011; Koroma et al. 2012).   
 
 
RESULTS  
Table 11 and 12 show LF MF prevalence, MF density for positives-only and MF density for the 
entire population studied at baseline, midterm (after 3 MDA rounds) and during the pre-TAS 
(after 5 MDA rounds). 
 
MDA results 2011-2014 
Annual MDA results for treatment with ivermectin and albendazole has been reported for the 
period 2011-2014 with 100% geographic coverage, ≥65% epidemiological coverage and ≥80% 
programme coverage8. See table 13 for details of treatment coverage for each district between 
2011 and 2014. A total of 14,253 villages and urban areas were treated each year during the 
four years in the 12 districts. This represents 100% geographic coverage for endemic villages 
and urban areas in all 12 districts during each of these four rounds of MDA, as shown in Table 
13. Over four million people were targeted for treatment each year during the four years. 
Overall epidemiological coverage was 75.9%, 79.6%, 80.3% and 78.2% in 2011, 2012, 2013 and 
2014 respectively at the national level, and was ≥65.0% in each district in each round. The 
overall programme coverage was 94.9%, 93.6%, 94.5% and 91.8% in 2011, 2012, 2013 and 
2014, respectively, and was ≥80% in each district in each round. The programme coverage is a 
measure of how well MDA was conducted and is considered adequate when ≥80.0% (WHO 
2011a).   
 
Microfilaraemia prevalence 
In total 23 persons (0.54%, 95% CI: 0.36-0.81%) had a positive blood smear. Males had 0.7% 
(95% CI: 0.43-0.14%) MF prevalence and females had 0.36% (95% CI: 0.17-0.74%) MF 
prevalence. Males had higher MF prevalence although both were below 1% and the difference 
was not statistically significant (P=0.128970). Five districts (Bonthe, Kambia, Kenema, 
                                                          
8 MDA results for the period 2008-2010 is discussed in the previous chapter (Koroma et al. 2013). 
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Moyamba and Tonkolili) had 0.0% MF prevalence; four districts had <0.7% prevalence (Bo- 
0.29%; Kono- 0.63%; Port Loko -0.28%; and Pujehun- 0.33%). Koinadugu district had 0.98% MF 
prevalence (close to 1%), and two districts had >1% MF prevalence: Bombali- 2.67%; and 
Kailahun- 1.56%. Thus, Koinadugu, Bombali and Kailahun are considered to have failed the pre-
TAS because Bombali and Kailahun had MF prevalence ≥1% and Koinadugu had MF prevalence 
close to 1%. Two SCs were selected for Bombali district and one SCS had the 2.6% MF 
prevalence while the other had 0% MF prevalence. The district is considered to have failed 
when one site had more than 1% MF prevalence. Kenema district had 0% MF prevalence but 
was paired with Kailahun district with Kailahun having the SS and Kenema the SCS. Both 
districts are considered to have failed due to the pairing. Prevalence by age group, 5-14 years 
(N=1621), 15-20 years (N=515), 21-30 years (N=572), 31-40 years (N=547),41-50 years (N=414), 
and >50 years (N=561) was 0.19%, 0.1.75%, 1.22%, 0.18%, 0.48% and 0.18% respectively. The 
age groups 15-20 and 21-30 had the highest MF prevalence. The difference between the MF 
prevalence of the two age groups (15-20 and 21-30) and the MF prevalence of the other 
groups is statistically significant (P=<0.05).  
 
Compared to the mid-term survey results, the overall MF prevalence increased from 0.3% to 
0.54%. The MF prevalence among males increased from 0.35% to 0.70% (almost twice), while 
the MF prevalence among females increased from 0.25% to 0.36%. The three districts with MF 
prevalence close to or greater than 1% have recorded increase in MF prevalence: Bombali from 
1.58% to 2.67%; Koinadugu from 0.80% to 0.98%; and Kailahun from 0.20% to 1.56%.   
 
Compared with the baseline, overall MF prevalence decreased by 77.5%, from 2.40% to 0.54%, 
after five rounds of MDA. As shown in Tables 11 and 12, among the 11 districts with baseline 
MF prevalence ≥1%, five districts showed MF prevalence reduction of 100%; five showed MF 
prevalence reduction of >60% and only one district (Kailahun) had MF prevalence reduction of 
less than 50% (40%). There was 76.67% decrease in MF prevalence among males: 3.00% to 
0.70%; and an 80.0% decrease in MF prevalence among females: 1.80% to 0.36%. There was 
0.19% prevalence among the age group five-14 years, but this could not be compared, as the 
baseline study did not include participants <15 years. Decreases in MF prevalence among the 
age groups 31-40, 41-50 and >50 years ranged between 85.4% and 92.5%. However, the 
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reduction in prevalence among the age groups 15-20 and 21-30 were 2.78% and 53.08% 
respectively. Figure 17 shows predicted MF prevalence for each of the 12 districts after five 
annual rounds of MDA.  
 
MF density 
The overall arithmetic mean MF density was 0.15 mf/ml (95% CI: 0.08-0.21 mf/ml) in the total 
participants examined and 26.87 mf/ml (95% CI: 22.66-31.08 mf/ml) among MF-positive 
individuals. The mean MF density for all categories (district, sex and age groups) was well 
below one mf/ml for the population examined and below 42 mf/ml among those who were MF 
positive. There was no significant difference in MF density in males versus females (p>0.05). 
However, four districts had significantly higher density for the population studied: Bombali-
0.69 mf/ml, 95% CI: 0.22-1.17 mf/ml; Kailahun-0.35 mf/ml, 95% CI: 0.05-0.64 mf/ml; 
Koinadugu-0.27 mf/ml, 95% CI: -0.05-0.60 mf/ml; and Kono-0.26 mf/ml, 95% CI: -0.11-0.63. 
The arithmetic mean MF density for the entire population studied was significantly higher 
within the age groups 15-20 years (0.49 mf/ml, 95% CI: 0.16-0.82) and 21-30 years (0.38 mf/ml, 
95% CI: 0.08-0.68 mf/ml) compared to the other age groups.  
 
Compared to results of the mid-term survey (see table 11 for details), the mean arithmetic MF 
density has increased significantly. The overall mean arithmetic MF density for the entire 
population studied increased from 0.05 mf/ml to 0.15 mf/ml and the overall arithmetic mean 
MF density for positives-only increased from 17.59 mf/ml to 26.87 mf/ml. The arithmetic mean 
MF density for the entire population studied for Bombali, Kailahun, Koinadugu and Kono and 
the age groups 15-20 years and 21-30 years also increased. At mid-term, the arithmetic mean 
MF density for the entire population studied was 0.26 mf/ml for Bombali, 0.03 mf/ml for 
Kailahun, 0.17 mf/ml for Koinadugu, and 0 mf/ml for Kono; and was 0.02 mf/ml and 0.10 
mf/ml for the age groups 15-20 years and 21-30 years respectively.  
 
Compared to baseline (see table 11 and 12 for details), the overall arithmetic mean MF density 
for the entire population studied dropped by 87.39% from 1.19 mf/ml to 0.15 mf/ml; and the 
overall arithmetic mean MF density for positives-only decreased by 46.58% from 50.30 mf/ml 
to 26.87 mf/ml. Among districts, the reduction of the arithmetic mean MF density for the 
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entire population studied ranges from 64.25% to 97.46%; and for positives-only ranges from 
7.45% to 83.16%. Bombali district had the lowest drop in arithmetic mean MF density for the 
entire population studied (64.25%), and the lowest drop in arithmetic mean MF density for 
positives-only (7.45%). The reduction in arithmetic mean MF density for positives-only was also 
low for Kono district (9.30%) and Koinadugu district (20.92%). Reduction in arithmetic mean 
MF density for the entire population studied ranges from 37.18% for the age group 15-20 years 
to 96.63% for the age group >50 years. The reduction of the arithmetic mean MF density for 
positives-only ranges from 22.36% for the age group 31-40 years to 61.13% for the age group 
>50%. Thus, in general, the lowest reduction of MF density was in the age group 15-20 years 
and the highest was in the age group >50 years.     
 
 
DISCUSSION 
Our results show that the criteria for initiating TAS were achieved in eight districts after five 
effective rounds of MDA. This indicates that the NTDP has made remarkable progress towards 
LF elimination since integrated onchocerciasis/LF MDA using ivermectin and albendazole was 
piloted in 2007 (Koroma et al. 2013). Effective epidemiological (≥65%) and programme 
coverage (≥80%) and 100% geographic coverage were achieved for the 12 districts in 2008 
(Koroma et al. 2013). The treatment coverage was verified through independent monitoring 
activities, as described previously (Hodges et al. 2011; Hodges et al. 2012). The epidemiological 
and programme coverage has been maintained at ≥65% and ≥80% respectively after the last 
assessment in 2010.  
 
Prior to MDA, the endemicity of LF in Sierra Leone was one of the highest in Africa (Michael 
and Bundy 1997). Blacklock in 1922 examined 240 men in Mabang village and found 20% to be 
microfilaraemic, with the prevalence of elephantiasis and hydrocoele of 4.6% and 3.8%, 
respectively ((Blacklock 1926; Hawking 1957). Surveys in the early 1990s also showed an 
average MF prevalence of 34.8% in three villages in the Moyamba district (Gbakima, Pessima, 
Sahr 1996). In 2007-2008, the pre-treatment MF prevalence for the 12 districts outside the 
Western Area ranged from 0 – 6.9%, although prevalence was below 3% in the southeastern 
districts (Koroma et al. 2012). This significant reduction of MF prevalence from earlier high 
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levels prior to the start of the LF MDA coincides with the onchocerciasis treatment efforts of 
the 1950s, 1960s, 1980s, 1990s, and up to 2006 as described in previous chapters (Hodges et 
al. 2011). The significant impact of onchocerciasis treatment with ivermectin on LF infection 
has been reported in a number of countries (Kyelem et al. 2003; Kyelem et al. 2005). 
Therefore, it is likely that annual nationwide CDTI may have impacted significantly on LF 
infections in Sierra Leone, resulting in a relatively low level of MF prevalence at baseline. The 
successful implementation of the LF programme also benefited from the existing 
onchocerciasis control programme by using the CDTI as the platform (Bockarie, Kelly-Hope, 
Haskew 2010; Hodges et al. 2011). Health workers had already been trained and were available 
to provide technical support in additional training, supervision and surveys. Treatment was 
provided between September and December each year as this is the period that was found to 
be convenient for the communities (i.e. harvest and post-harvest period). All the lessons learnt 
from CDTI during the years of the NOCP were used to establish and improve the LF elimination 
programme within a short period (Bockarie, Kelly-Hope, Haskew 2010).   
 
Five districts had 0.0% MF prevalence while 4 districts had <0.7% prevalence. Three districts 
have MF prevalence close to or above 1%. Thus, Koinadugu, Bombali and Kailahun are 
considered to have failed the pre-TAS because Bombali and Kailahun had MF prevalence ≥1% 
and Koinadugu had MF prevalence close to 1% (WHO 2011a). Since Kenema was paired with 
Kailahun district, it is also considered to have failed the pre-TAS even though the MF 
prevalence was 0% in an SCS.  Compared to the mid-term survey results, there was an increase 
in overall MF prevalence and overall MF intensity. The three districts with MF prevalence close 
to or greater than 1% recorded an increase in MF prevalence after the mid-term evaluation. 
However, it is worth noting that MF prevalence detected after three MDAs does not 
demonstrate a change in filariasis transmission (Weil et al. 2008; Ashton et al. 2011). The drug 
combination destroys the microfilariae with each round of MDA, but treatment should be 
continued for up to the four-six year it takes for the adult worm to die a natural death (Ottesen 
2000; Weil et al. 2008; Ashton et al. 2011). Therefore, MDA must continue each year for four-
six years, which is equivalent to the lifespan of the adult worm.  
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The observation made with male/female MF prevalence during the pre-TAS could be explained 
by transmission dynamics as males may be more active and located outside during the biting 
periods of the mosquitos. It has been suggested that females may be more resistant to LF 
infection due to hormonal activity (Lammie et al. 1994). The age-related observation that has 
more active age groups (15-20 years and 21-30 years) being more infected could also be 
explained by the same transmission dynamics. As described previously, the MF prevalence and 
MF density increases with age, peaks between 15 and 25 years, and then declines gradually in 
higher age groups. It is also suggested that vector biting rates is higher in these age groups 
(Lammie et al. 1994). Four districts were considered to have failed the pre-TAS: two because 
MF prevalence was >1%; one because MF prevalence was close to 1%; and the fourth district 
because it was paired with one of the districts that had >1% MF prevalence. The controversy of 
the fourth district was discussed, and it has been decided that during the re-pre-TAS all four 
districts will each have one SS and one SCS so decisions can easily be made for each district. 
The NTDP had organised special social mobilisation and health education meetings in the four 
districts before MDAs were conducted in 2013, 2014 and 2015 that involved district council 
members, paramount chiefs, community leaders and community members. These were the 
same community meetings that were organised before MDAs between 2005 and 2008 to bring 
treatment coverage to what they are now after the poor performance of 2003 and 2004. The 
communities of the four districts that were considered to have failed the pre-TAS need to 
know the negative implication of the failure and the importance of better adherence although 
treatment coverage reported for the districts have been good.  
 
It has also been suggested that the number of MDA rounds needed to eliminate LF depends on 
baseline infection rates, vectoral capacity, the efficacy of the MDA regimen used, and 
community adherence with treatment. It is possible to eliminate LF in some IUs with low 
baseline infection rates using less than five rounds of MDA, while more than six MDA rounds 
may be needed for IUs with relatively high baseline LF prevalence (El-Setouhy et al. 2007; 
Grady et al. 2007; Huppatz et al. 2009). The high level of reduction in MF prevalence and 
intensity in most of the districts after five rounds of MDA in Sierra Leone may have been partly 
due to the relatively low baseline MF level (Koroma et al. 2012). The relatively high baseline 
and pre-TAS MF prevalence and density for Bombali and Kailahun may be explained by this 
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theory. Three additional MDA rounds have been conducted by the NTD program after the pre-
TAS in 2013, 2014 and 2015 that were preceded by good social mobilisation. The social 
mobilisation also involved district health workers so they are also aware that all villages should 
receive the same attention during MDAs because the selection of the SCS can lead to another 
failure that can create an “embarrassment” for the DHMT. Another suggestion made within 
the NTDP was that cross-border factors may be responsible for the persistent high MF 
prevalence and density in the four districts considered to have failed the pre-TAS because all 
four are located along the border (Bombali, Koinadugu and Kailahun with Guinea; and Kailahun 
and Kenema with Liberia). Both countries have not yet succeeded in establishing an LF 
programme that covers the entire country. High prevalence rates were recorded in 
neighbouring Liberia prior to the 1980s (Brinkmann 1977; Zielke and Chlebowsky 1979).  
 
Some authors believe that Anopheles mosquitos are less efficient as LF vectors than Culex and 
so the large decrease in prevalence that has occurred in most of the LF-endemic districts after 
just five rounds of MDA may be due to this phenomenon (Weil et al. 2008). Many similar 
studies have been conducted in different countries to determine the impact of MDA on the 
prevalence and intensity of LF. It was demonstrated in Kenya that MF prevalence of 8 villages 
dropped from 20.9% to 0.9% after eight years of treatment even though MDA with 
diethylcarbamazine and albendazole was conducted only for four of the eight-year period. It 
was suggested by the authors that this results could be due more to high use of insecticide 
treated nets within these villages (Njenga et al. 2011). The impact of MDA with 
diethylcarbamazine and albendazole was measured after five rounds of MDA in four sentinel 
sites in Egypt with adherence rate >80%. In Giza, microfilaraemia rate fell from 11.5% to 1.2%, 
while in Qalubyia microfilaraemia rate reduced from 3.1% to 0% (Ramzy et al. 2006). Studies 
on LF conducted in Egypt showed that while residual infection rates were highest in those who 
reported never taking treatment, two doses were better than one dose and as effective as five 
doses for clearing MF (El-Setouhy et al. 2007).  
 
Overall success of the NTDP in Sierra Leone has been due also to other factors such as the 
effect of LF treatment (ivermectin and albendazole) on soil transmitted helminthiasis (Ottesen 
et al. 2008; WHO 2015), effect on scabies and lice (Meinking et al. 1995; David, Flinders, De 
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Schweinitz 2004; Burkhart and Burkhart 2006; Moncayo et al. 2008), and the anecdotal so-
called effect on ‘male sexuality’ as it is reported that older men become more virile when they 
take ivermectin. People have come to know the ‘onchocerciasis’ and lately the ‘big fut’ (or 
enlarged foot in English) treatment through earlier intensified social mobilisation within 
communities such that even after the EVD outbreak treatment coverage was still high within all 
communities targeted. Initial social mobilisation and health education had included talks on 
possible side effects relating to ivermectin. It was explained that the side effects are due to 
deaths of the worms (onchocerciasis or LF) due to the treatment and side effects reduce as 
treatment continues and the worm load reduces. Therefore, due to initial treatment for 
onchocerciasis with ivermectin within these districts, the number of adverse events reported 
has been few, and no severe adverse event has been reported during treatment for LF 
(unpublished NOCP/NTDP Reports 2005-2015). 
 
This study has also shown the importance of having SCSs for monitoring the impact of MDAs 
for any control programme. The SCSs are randomly selected usually in consultation with 
DHMTs, and they are changed with each study. The SCSs to be chosen for the re-pre-TAS will 
be different from those selected before midterm and pre-TAS and the same SSs used at 
baseline will be chosen for districts where only SCSs have been selected at mid-term and pre-
TAS. The SCSs and the way they are selected ensure that district health authorities and PHU 
staff give the same attention to all sub-district areas to ensure that coverage is good in every 
village and that future assessments end up with a ‘pass’ for their district.  
 
There are several possible limitations of the study. Districts were paired to meet the WHO 
recommendation of having one SS and one SCS per one million populations such that one 
district had an SS while the other had an SCS. This appears to have created a problem in the 
interpretation of the pre-TAS results. Furthermore, the districts that were paired based on 
proximity and topographic features may not be so similar in relation to transmission dynamics 
as shown by the pre-TAS results of Kailahun and Kenema; Kailahun had >1% MF prevalence 
while MF prevalence was 0% for Kenema. The re-pre-TAS will be conducted with one SS and 
one SCS for each district to avoid a repeat of this situation. Having one SS and one SCS per 
district may also not be enough to ensure that all areas of a district are ‘free’ from the disease. 
192 
 
192 
 
The number of sites currently selected for pre-TAS as recommended by WHO may be too small 
to be sure that the entire district is ‘clean’ from the disease. To address this, the village 
selected as SCS for the re-pre-TAS will be different from those used as SCS in the midterm and 
pre-TAS and will be selected in consultation with the DHMTs based on rumours and 
registration of signs and symptoms of the disease in the registers of the PHUs within districts. 
The night blood method used to determine MFs may not be the ideal method at this stage 
when prevalence and density are so low in all communities. It has been suggested that other 
methods that identify LF antigenaemia and/or antibodies may be better at this stage (Braga et 
al. 2003; Weil and Ramzy 2007). WHO currently recommends the use of a new tool (the FTS) 
that has replaced ICT cards for pre-TAS (WHO 2016c). The FTS will be used for the pre-TAS and 
TAS. The key difference between MF detection and use of FTS in terms of interpreting results is 
that the threshold for FTS will be 2% and not the 1% used for NBS/TBF. Another possible 
limitation is that it is impossible to compare baseline data for the ages five-14 years because 
this age was not studied at baseline based on previous WHO guidelines (WHO 2005; WHO 
2011a). However, it is good to note that the ages five-9 years and 10-14 years had 0.14% and 
0.22% MF prevalence during the pre-TAS. The age group five-14 years had 0.21% and 0.19% 
MF prevalence at mid-term and pre-TAS, respectively. This indicates low infection among 
children and indirectly shows that LF transmission has significantly reduced in the country. 
 
 
CONCLUSION 
There was a significant reduction of LF MF prevalence and density across the 12 rural districts 
in Sierra Leone that are coendemic for LF and onchocerciasis after five annual MDAs. Eight of 
12 districts have passed the pre-TAS with <1% MF prevalence and now qualify for a TAS that 
has not yet been implemented due to the recent EVD outbreak. The other four districts need 
to conduct two additional rounds of MDA and repeat the pre-TAS (re-pre-TAS) (WHO 2011a). 
These relatively promising results were possible because of good MDA adherence and 
relatively low baseline endemicity. The results also show the importance of using SCSs for 
193 
 
193 
 
monitoring programme implementation and that the LF elimination programme in Sierra 
Leone is on course to reach the objective of eliminating9 LF by the year 2020.   
 
 
 
 
  
                                                          
9 Elimination here is considered to be availability of evidence through the TAS that justifies stopping 
MDA in the whole country. 
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Figure 17: Map showing predicted LF MF prevalence for each of the 12 districts of Sierra 
Leone after five annual rounds of MDA  
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 Table 11: Summary results for all LF studies in Sierra Leone from 2005 to 2013 in 12 districts 
 
Baseline survey Mid-term Pre-TAS 
 
No of 
pers
ons 
exam
ined 
for 
MF 
Percentage 
prevalence 
of MF 
positives 
(95% CI) 
Population MF 
density 
(mf/ml) (95% 
CI) 
Positive-only MF 
density (mf/ml) 
(95% CI) 
No of 
perso
ns 
exam
ined 
for 
MF 
Percentage 
prevalence of 
MF positives 
(95% CI) 
Population MF 
density 
(mf/ml) (95% 
CI) 
Positive-only 
MF density 
(mf/ml) (95% 
CI) 
No of 
perso
ns 
exam
ined 
for 
MF 
Percentage 
prevalence of 
MF positives 
(95% CI) 
Population MF 
density 
(mf/ml) (95% 
CI) 
Positive-only MF 
density (mf/ml) 
(95% CI) 
Overall 9288 2.4 (2.1 - 2.7) 1.19 (0.90 - 1.48) 50.3 (39.89 - 60.71) 6023 0.30 (0.19 – 0.47) 0.05 (0.03 – 0.08) 
17.59 (15.64 – 
19.55) 4230 0.54 (0.36-0.81) 0.15 (0.08-0.21) 26.87 (22.66-31.08) 
By district 
            
Bo 1005 2.0 (1.3 - 3.1) 1.97 (0.84 -3.11) 
99.17 (58.32 -
140.01) 500 0 0 0 350 0.29 (0.05-1.60) 0.05 (-0.05-0.14) 16.7 (-) 
Bombali1 830 6.9 (5.3 - 8.8) 1.93 (1.28 - 2.57) 28.07 (21.70 - 34.44) 506 1.58 (0.80 – 3.09) 0.26 (0.08 – 0.45) 16.67 (-) 337 2.67 (1.41-5.00) 0.69 (0.22-1.17) 25.98 (19.21-32.74) 
Bombali2 - - - - - - - - 303 0.00 (0.00-1.25) - - 
Bonthe 504 1.2 (0.6 - 2.6) 0.83 (0.02 - 1.63) 
69.44 (13.68 - 
125.21) 499 0.20 (0.04 – 1.13) 0.03 (0 – 0.10) 16.67 (-) 309 0.00 (0.00-1.23) - - 
Kailahun 624 2.6 (1.6 - 4.1) 2.08 (0.00 - 4.89) 81.25 (0.00 - 195.58) 499 0.20 (0.04 – 1.13) 0.03 (0 – 0.10) 16.67 (-) 385 1.56 (0.72-3.36) 0.35 (0.05-0.64) 22.27 (13.22-31.32) 
Kambia 619 2.1 (1.2 - 3.6) 0.97 (0.23 - 1.71) 46.15 (17.04 - 75.27) 500 0.40 (0.11 – 1.45) 0.07 (0 – 0.16) 16.67 (-) 300 0.00 (0.00-1.26) - - 
Kenema 1016 0.6 (0.3 - 1.3) 0.34 (0.00 - 0.70) 58.33 (4.42 - 112.24) 500 0 0 0 313 0.00 (0.00-1.21) - - 
Koinadugu 636 5.7 (4.1 - 7.7) 1.99 (0.95 - 3.04) 35.19 (19.83 - 50.54) 498 0.80 (0.31 – 2.05) 0.17 (0 – 0.34) 
20.83 (7.57 – 
34.09) 305 0.98 (0.34-2.85) 0.27 (-0.05-0.60) 27.83 (3.88-51.79) 
Kono 875 2.4 (1.6 - 3.6) 1.11 (0.37 - 1.84) 46.03 (20.09 - 71.97) 499 0 0 0 320 0.63 (0.17-2.25) 0.26 (-0.11-0.63) 
41.75 (-64.35-
147.85) 
Moyamba 500 1 (0.4 - 2.3) 0.67 (0.00 - 1.36) 66.67 (6.33 - 127.00) 500 0 0 0 330 0.00 (0.00-1.15) - - 
Port Loko 500 4.4 (2.9 - 6.6) 3.53 (1.48 - 5.59) 
80.30 (44.49 - 
116.12) 499 0.20 (0.04 – 1.13) 0.03 (0 -0.10) 16.67 (-) 357 0.28 (0.05-1.57) 0.09 (-0.09-0.28) 33.40 (-) 
Pujehun 624 0 (0 - 0.6) - - 500 0 -  - 305 0.33 (0.06-1.83) 0.11 (-0.11-0.33) 33.40 (-) 
Tonkolili 500 2.4 (1.4 - 4.2) 0.63 (0.24 - 1.03) 26.39 (17.99 - 34.79) 523 0.19 (0.03 – 1.08) 0.03 (0 – 0.10) 16.67 (-) 316 0.00 (0.00-1.20) - - 
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By sex 
            
Male 4335 3.0 (2.6 - 3.6) 1.66 (1.11 - 2.20) 54.42 (38.81 - 70.02) 3170 0.35 (0.19 – 0.62) 0.06 (0.03 - 0.10) 
18.18 (14.80 -
21.56) 2275 0.70 (0.43-1.14) 0.19 (0.09-0.29) 27.14 (21.63-32.65) 
Female 4953 1.8 (1.4 - 2.2) 0.78 (0.52 - 1.04)) 44.13 (32.50 - 55.76) 2853 0.25 (0.12 – 0.51) 0.04 (0.01 - 0.07) 16.67 (-) 1955 0.36 (0.17-0.74) 0.09 (0.02-0.17) 26.24 (17.99-34.50) 
By age 
groups 
            5--9 - - - - - - - - 716 0.14 (0.02-0.79) 0.02 (-0.02-0.07) 16.7 (-) 
10--14 - - - - - - - - 905 0.22 (0.06-0.80) 0.04 (-0.02-0.07) 16.7 (-) 
5--14 - - - - 1947 0.21 (0.08 – 0.53) 0.04 (0 - 0.09) 
20.83 (7.57 – 
34.09) 1621 0.19 (0.06-0.54) 0.03 (-0.00-0.07) 16.7 (-) 
15-20 1873 1.8 (1.3 - 2.5) 0.78 (0.38 - 1.19) 44.44 (26.37 -62.52) 858 0.12 (0.02 – 0.66) 0.02 (0 - 0.06) 16.67 (-) 515 1.75 (0.92-3.29) 0.49 (0.16.-0.82) 27.83 (21.42-34.25) 
21-30 2019 2.6 (2.0 - 3.4) 1.77 (0.73 - 2.80) 
68.59 (31.79 -
105.39) 858 0.58 (0.25 – 1.36) 0.10 (0.01 - 0.18) 16.67 (-) 572 1.22 (0.59-2.50) 0.38 (0.08-0.68) 31.01 (20.36-41.67) 
31-40 1830 2.4 (1.8 - 3.2) 1.01 (0.55 - 1.47) 43.02 (27.55 -58.50) 849 0.59 (0.25 – 1.37) 0.10 (0.01 - 0.18) 16.67 (-) 547 0.18 (0.03-1.03) 0.06 (-0.06-0.18) 33.40 (-) 
41-50 1404 3.4 (2.5 - 4.4) 1.60 (0.94 - 2.27) 47.87 (32.75 - 62.99) 640 0.47 (0.16 – 1.37) 0.08 (0 - 0.17) 16.67 (-) 414 0.48 (0.13-1.74) 0.12 (-0.06-0.30) 
25.05 (-81.05-
131.15) 
>50 2162 2.1 (1.6 - 2.8) 0.89 (0.49 - 1.30) 42.96 (27.40 - 58.53) 871 0 0 0 561 0.18 (0.03-1.00) 0.03 (-0.029-0.09) 16.7 (-) 
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Table 12: Comparison of results of baseline survey and Pre-TAS for LF in Sierra Leone 
 
Baseline survey Pre-TAS Percentage reduction from Baseline  
 
Percentage 
prevalence 
of MF 
positives 
(95% CI) 
Population 
MF density 
(mf/ml) (95% 
CI) 
Positive-only MF 
density (mf/ml) 
(95% CI) 
Percentage 
prevalence of 
MF positives 
(95% CI) 
Population MF 
density (mf/ml) 
(95% CI) 
Positive-only MF 
density (mf/ml) 
(95% CI) 
MF 
prevalence 
(%) 
Population 
MF density 
(%) 
Positive-
only MF 
density 
(%) 
Overall 2.4 (2.1 - 2.7) 1.19 (0.90 - 1.48) 50.3 (39.89 - 60.71) 0.54 (0.36-0.81) 0.15 (0.08-0.21) 26.87 (22.66-31.08) 77.50 87.39 46.58 
By district 
      
   
Bo 2.0 (1.3 - 3.1) 1.97 (0.84 -3.11) 99.17 (58.32 - 140.01) 0.29 (0.05-1.60) 0.05 (-0.05-0.14) 16.7 (-) 85.50 97.46 83.16 
Bombali1 6.9 (5.3 - 8.8) 1.93 (1.28 - 2.57) 28.07 (21.70 - 34.44) 2.67 (1.41-5.00) 0.69 (0.22-1.17) 25.98 (19.21-32.74) 61.30 64.25 7.45 
Bombali2 - - - 0.00 (0.00-1.25) - - - - - 
Bonthe 1.2 (0.6 - 2.6) 0.83 (0.02 - 1.63) 69.44 (13.68 - 125.21) 0.00 (0.00-1.23) - - 100.00 - - 
Kailahun 2.6 (1.6 - 4.1) 2.08 (0.00 - 4.89) 81.25 (0.00 - 195.58) 1.56 (0.72-3.36) 0.35 (0.05-0.64) 22.27 (13.22-31.32) 40.00 83.17 72.59 
Kambia 2.1 (1.2 - 3.6) 0.97 (0.23 - 1.71) 46.15 (17.04 - 75.27) 0.00 (0.00-1.26) - - 100.00 - - 
Kenema 0.6 (0.3 - 1.3) 0.34 (0.00 - 0.70) 58.33 (4.42 - 112.24) 0.00 (0.00-1.21) - - 100.00 - - 
Koinadugu 5.7 (4.1 - 7.7) 1.99 (0.95 - 3.04) 35.19 (19.83 - 50.54) 0.98 (0.34-2.85) 0.27 (-0.05-0.60) 27.83 (3.88-51.79) 82.81 86.43 20.92 
Kono 2.4 (1.6 - 3.6) 1.11 (0.37 - 1.84) 46.03 (20.09 - 71.97) 0.63 (0.17-2.25) 0.26 (-0.11-0.63) 41.75 (-64.35-147.85) 73.75 76.58 9.30 
Moyamba 1 (0.4 - 2.3) 0.67 (0.00 - 1.36) 66.67 (6.33 - 127.00) 0.00 (0.00-1.15) - - 100.00   
Port Loko 4.4 (2.9 - 6.6) 3.53 (1.48 - 5.59) 80.30 (44.49 - 116.12) 0.28 (0.05-1.57) 0.09 (-0.09-0.28) 33.40 (-) 93.64 97.45 58.41 
Pujehun 0 (0 - 0.6) - - 0.33 (0.06-1.83) 0.11 (-0.11-0.33) 33.40 (-) - - - 
Tonkolili 2.4 (1.4 - 4.2) 0.63 (0.24 - 1.03) 26.39 (17.99 - 34.79) 0.00 (0.00-1.20) - - 100.00 - - 
By sex 
      
   
Male 3.0 (2.6 - 3.6) 1.66 (1.11 - 2.20) 54.42 (38.81 - 70.02) 0.70 (0.43-1.14) 0.19 (0.09-0.29) 27.14 (21.63-32.65) 76.67 88.55 50.13 
Female 1.8 (1.4 - 2.2) 
0.78 (0.52 - 
1.04)) 44.13 (32.50 - 55.76) 0.36 (0.17-0.74) 0.09 (0.02-0.17) 26.24 (17.99-34.50) 
80.00 88.46 40.54 
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By age 
groups 
      
   
5--9 - - - 0.14 (0.02-0.79) 0.02 (-0.02-0.07) 16.7 (-) - - - 
10--14 - - - 0.22 (0.06-0.80) 0.04 (-0.02-0.07) 16.7 (-) - - - 
5--14 - - - 0.19 (0.06-0.54) 0.03 (-0.00-0.07) 16.7 (-) - - - 
15-20 1.8 (1.3 - 2.5) 0.78 (0.38 - 1.19) 44.44 (26.37 -62.52) 1.75 (0.92-3.29) 0.49 (0.16.-0.82) 27.83 (21.42-34.25) 2.78 37.18 37.38 
21-30 2.6 (2.0 - 3.4) 1.77 (0.73 - 2.80) 68.59 (31.79 -105.39) 1.22 (0.59-2.50) 0.38 (0.08-0.68) 31.01 (20.36-41.67) 53.08 78.53 54.79 
31-40 2.4 (1.8 - 3.2) 1.01 (0.55 - 1.47) 43.02 (27.55 -58.50) 0.18 (0.03-1.03) 0.06 (-0.06-0.18) 33.40 (-) 92.50 94.06 22.36 
41-50 3.4 (2.5 - 4.4) 1.60 (0.94 - 2.27) 47.87 (32.75 - 62.99) 0.48 (0.13-1.74) 0.12 (-0.06-0.30) 25.05 (-81.05-131.15) 85.88 92.50 47.67 
>50 2.1 (1.6 - 2.8) 0.89 (0.49 - 1.30) 42.96 (27.40 - 58.53) 0.18 (0.03-1.00) 0.03 (-0.029-0.09) 16.7 (-) 91.43 96.63 61.13 
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Table 13: Summary of coverage for LF treatment conducted in 12 districts of Sierra Leone 2011 – 2014 
  2011 2012 2013 2014 
 
Population Treatment Coverage Population Treatment Coverage  Population  Treatment coverage  Population  Treatment coverage 
 Districts Elig pop Total pop 
Total 
treated 
Epid 
cov 
Prog 
Cov Elig pop Total pop 
Total 
treated 
Epid 
cov 
Prog 
Cov Elig pop Total pop 
Total 
treated 
Epid 
cov 
Prog 
Cov Elig pop Total pop 
Total 
treated 
Epid 
cov 
Prog 
Cov 
Bo 444317 555397 427682 77.0 96.3 483417 568727 449508 79.0 93.0 494507 581774 459785 79.0 93.0 505875 595148 461300 77.5 91.2 
Bombali 390424 488030 366980 75.2 94.0 424781 499743 399794 80.0 94.1 434550 511236 419077 82.0 96.4 444542 522991 406188 77.7 91.4 
Bonthe 118597 148246 112424 75.8 94.8 128703 151416 120640 79.7 93.7 131676 154915 124719 80.5 94.7 134704 158476 126223 79.6 93.7 
Kailahun 343508 429386 335567 78.2 97.7 373737 439691 349889 79.6 93.6 382142 449580 364629 81.1 95.4 390925 459912 359677 78.2 92.0 
Kambia 258571 323214 244376 75.6 94.5 281326 330972 263822 79.7 93.8 287795 338583 270923 80.0 94.1 294409 346364 271964 78.5 92.4 
Kenema 488245 610307 463162 75.9 94.9 531550 625354 501280 80.2 94.3 543408 639305 512759 80.2 94.4 555904 654005 509953 78.0 91.7 
Koinadugu 300392 375491 282735 75.3 94.1 326826 384502 307878 80.1 94.2 334343 393346 318488 81.0 95.3 342027 402385 314522 78.2 92.0 
Kono 358286 447858 342241 76.4 95.5 389816 458608 364975 79.6 93.6 398730 469095 382121 81.5 95.8 407896 479878 378940 79.0 92.9 
Moyamba 261017 326272 238818 73.2 91.5 283987 334103 264863 79.3 93.3 290518 341787 270205 79.1 93.0 297197 349644 274331 78.5 92.3 
Port Loko 399995 499994 378976 75.8 94.7 434034 510629 403508 79.0 93.0 444016 522373 415108 79.5 93.5 454223 534380 411029 76.9 90.5 
Pujehun 188875 236094 176924 74.9 93.7 205496 241760 192140 79.5 93.5 210276 247385 198626 80.3 94.5 215110 237529 198516 83.6 92.3 
Tonkolili 341039 426299 325639 76.4 95.5 370702 436121 345643 79.3 93.2 379193 446111 355057 79.6 93.6 387911 456366 353296 77.4 91.1 
  3893266 4866588 3695524 75.9 94.9 4234375 4981626 3963940 79.6 93.6 4331154 5095490 4091497 80.3 94.5 4430723 5197078 4065939 78.2 91.8 
*Geographic coverage of villages/urban areas was 100% in all 12 districts over the four years (2011-2014) 
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CHAPTER 7: IMPACT OF THE EBOLA OUTBREAK ON THE NTD 
PROGRAM IN SIERRA LEONE 
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ABSTRACT 
Background 
A qualitative study was designed to determine the effect of the EVD outbreak on the treatment 
for NTDs in Sierra Leone as part of the effort to understand the effect of the outbreak on NTD 
control. The findings of the study were used to advise the NTDP on the way forward for NTD 
control in the country after the EVD outbreak ends. 
Methodology 
The study was conducted through interviews using a simple questionnaire with open-ended 
questions and focus group discussion (FGD). Interviews using open-ended questions were used 
when high-level officials were interviewed and focus group discussions were used for PHU staff 
and CDDs.   
Principal Findings 
The EVD outbreak in May 2014 led to many deaths including the death of many health 
workers. The outbreak was controlled and declared over in November 2015 after a lot of 
improvement in treatment and diagnosis of the diseases. Although there was a delay of about 
a year in implementing MDAs, the NTDP has successfully completed two rounds of MDA since 
the outbreak, one of the two conducted while the outbreak was still ongoing in May/June 
2015. However, all disease-specific assessments for LF and onchocerciasis were suspended till 
early 2017 for fear that the communities targeted will reject an intervention that involves 
blood and the skin. The importance of using CDDs, who are members of their communities, to 
treat their own people and intensified health education/social mobilisation for maintaining 
effective treatment coverage was highlighted.  
Conclusions/Significance 
Through the use of CDDs and intensified health education/social mobilisation the NTDP has 
conducted two MDAs with effective coverage including one that was conducted while the 
outbreak was ending. Intensive social mobilisation and health education must be continued for 
the MDAs and disease-specific assessments to maintain good community acceptance and 
adherence to the NTDP treatment and disease-specific assessments. 
202 
 
202 
 
 
INTRODUCTION 
Sierra Leone is a poor West African country that belongs to what MacKinnon and MacLaren 
(2012) describe as “fragile and conflict-affected states”. The country’s socio-economic and 
health indicators are among the worst in the world (UNDP 2015; African Health Observatory, 
WHO AFRO 2016). After going through a civil war between 1991 and 2002 that devastated the 
economy and almost brought the entire health care delivery system to a standstill, there has 
been significant progress since 2005 in controlling the PC NTDs in the country (LSTM 2014). 
Many partners of the MOHS, including partners of the NTDP such as the USAID NTDP, FHI 360, 
HKI, CNTD (now Known as FPSU) and Sightsavers, have been at the forefront of assisting Sierra 
Leone rebuild its health system since 2007 and significant achievements were being made in 
controlling the PC NTDs (LSTM 2014). Unfortunately, an EVD outbreak, which started in Guinea 
in December 2013 and had spread to neighbouring Liberia by March 2014 and Sierra Leone by 
May 2014, appeared to be a threat to all the achievements made in the fight against NTDs in 
the country (Bociaga-Jasik et al. 2014; Dixon et al. 2014; LSTM 2014; Greiner et al. 2015; Boisen 
et al. 2015; Hersey et al. 2015; Lu et al. 2015; Gleason et al. 2015; Lokuge et al. 2016).  
 
The outbreak appeared to be having negative impact on the human resources for health and 
the negative effect on the socio-economic situation in the country (Helleringer and Noymer 
2015; Brolin-Ribacke et al. 2016; Fitzgerald et al. 2016). The NTDP has had to address the weak 
human resources for health in the country by using the community directed treatment with 
Ivermectin plus albendazole strategy in its efforts to eliminate onchocerciasis and LF in the 
country (Bockarie, Kelly-Hope, Haskew 2010; MacKinnon and MacLaren 2012; Koroma et al. 
2013). It appeared at the height of the outbreak that health workers were more at risk of dying 
from the disease (Kilmarx et al. 2014). All NTD and other public health program activities were 
suspended in the country for about a year as the outbreak spread to all 14 districts. The 
situation improved significantly early in 2015, and the outbreak was declared over on 7th 
November 2015 albeit with warnings from WHO of possible flare-ups after the declaration 
(GoSL 2015).  
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The author made several visits to the country between May 2015 and November 2015 to 
support the NTDP in understanding the effect of the outbreak on the NTD program and 
determine the way forward for NTD control/elimination in the country including planning the 
restart of the programme. A qualitative study was designed to determine the effect of the EVD 
outbreak on the treatment for NTDs in Sierra Leone as part of the effort to understand the 
impact of the outbreak on NTD control. The findings of the study were used to advise the NTDP 
on the way forward for NTD control in the country. The visits were organised against the 
background that some authors were referring to the EVD as an NTD (Troncoso 2015) and there 
were also calls to simultaneously deal with EVD and NTDs within the affected countries (Hotez 
et al. 2015).  
 
Two visits were organised in early May 2015 and September 2015. The objectives of the 
interviews were:  
a. To determine when and how NTDP activities can be restarted in the country. 
b. To determine the effect of the EVD outbreak on the NTD capacity in terms of staff loss and 
staff morale towards the NTDP.  
c. To determine attitude changes towards the NTD program within affected communities in 
terms of adherence to treatment. 
d. To document positive changes that may have taken place within the health system while 
addressing the outbreak that can strengthen the health system in general and therefore 
the NTDP.  
 
 
METHODS 
Ethics statement 
The interviews were conducted by the author with administrative support from the NTDP at 
national and district levels. All meetings were pre-arranged through the NTDP at the different 
levels. Ethical approval for the study was obtained from the Ethics Committee of the MOHS. 
The information obtained was filtered and only information relevant to the NTDP is reported in 
this chapter. The author first explained the objectives of the study and obtained the consent of 
those interviewed and the participants of the FGDs before interviews/discussions were 
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conducted. All those interviewed were adults. The analysis of the information obtained is 
conducted such that no individual’s identity can be revealed upon publication of the results.  
 
Interviews and FGDs 
The study was conducted through qualitative research methods - interviews using a simple 
questionnaire with open-ended questions, and FGD. Interviews with open-ended questions 
were used for senior personnel of the GoSL (a representative of the Office of the President, a 
representative of the National Ebola Response Centre (NERC), senior officials of the MOHS, 
NTD partners- HKI, Sightsavers, WHO Country Office, and the DMOs. This first part was 
accomplished in early May 2015 over a year after the last MDA was completed in March 2014. 
The FGDs were conducted in September 2015 among PHU staff and CDDs. CDDs as members of 
their communities gave an insight into the community aspects of what was required in the 
study. All interviews and FGDs were recorded mostly in the vernacular (Krio) to allow people to 
express themselves freely.  
 
Interviews were conducted on six levels:  
(1) National level interviews with representatives from the Departments/agencies that were 
coordinating the Ebola response within the GoSL (the Office of the President and the NERC);  
(2) Interviews with representatives of NTD partner organisations- WHO Country Office in 
Freetown, Sightsavers and HKI Sierra Leone;   
(3) National level interviews within the MOHS- senior officials including the Director of PHC, 
the DPC Director that supervises the NTDP, and the NTD Program Manager;  
(4) Interviews with the DHMTs (DMOs and selected members of the DHMTs);  
(5) FGDs with PHU personnel who serve as coordinators of the NTD program within chiefdoms 
and villages); and  
(6) FGDs with CDDs. 
 
The first three interviews above were conducted in the capital Freetown while the district level 
interviews and FGDs were conducted in only four of the 12 LF/onchocerciasis coendemic 
districts: Port Loko and Bombali district in the north; Bo district in the south and Kenema 
district in the east. It was assumed that the districts selected will be representative of the other 
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districts within their regions. While the same set of questions were used in all interviews, the 
questions were adjusted depending on the person being interviewed: interviewing health 
workers was different from interviewing non-health workers, and so questions were modified 
accordingly. 
 
Analysis of information 
No specific method was used to analyse the results. The results discussed in this chapter are 
obtained after listening to the recording of the interviews and the FGDs. The interpretation of 
the results is based on what was recorded during the interviews and have been filtered to 
show general EVD-related issues and issues that directly or indirectly relate to NTDP in Sierra 
Leone. 
 
 
RESULTS 
May 2015-Interview with a representative of the Office of the President: the main 
objective of this interview was to know the position of the GoSL on allowing the restart of 
public health programmes while the outbreak was still ongoing albeit on a small scale. By May 
2015 only a few cases were still being detected in a district that borders with neighbouring 
Guinea (the Kambia district). The ban on travelling and curfew starting at nine pm daily was still 
being maintained, but the Government was aware of the non-Ebola morbidity and deaths 
occurring because of the restrictions and suspension of public health interventions. The 
Government had already started engaging the public health programmes, DHMTs and NGOs to 
see how interventions can be started without any negative impact on the achievements made 
to control the outbreak. The President himself had led the social mobilisation campaign and 
had visited all the districts multiple times to get the communities to adhere to the restrictions 
on movement imposed and also for people to collaborate with the Ebola Response Team. As 
Malaria is the leading cause of mortality in the country, the Malaria Control Programme was 
prioritised and allowed to conduct mass treatment in the entire country in March 2015 and the 
campaign appeared successful. The GoSL was prepared to allow other community-based 
programmes such as treatment for onchocerciasis and LF conducted by CDDs to be 
implemented since community members do most of the work. The second argument put 
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forward to the GoSL representative was that the tablets that will be given to the people would 
not pose any danger to them. 
 
May 2015-Interview with a Representative of the National Ebola Response Centre 
(NERC): This visit was with the same objective as above, and similar sentiments were 
expressed: the restrictions on movement and the 9 pm curfew had to be maintained because 
they were yielding the right results in controlling the outbreak, but after the successful malaria 
campaign, other community-based campaigns can be considered. It was suggested that the 
NTDP coordinate directly with the district Ebola response centres (DERCs) for successful 
implementation of the MDA campaign. 
 
Interviews with Representatives of NTD Partner Organizations- HKI, Sightsavers and 
the WHO Country Office: The most negative aspect of the outbreak was that the masses had 
lost all their trust in the health system. Health workers to some extent were seen as carriers of 
the disease. The need for intensive health education and social mobilisation was noted. HKI, as 
the subgrantee in Sierra Leone for the USAID-supported END in Africa project, had already put 
a team together to develop messages on NTDs that reminds people of the onchocerciasis/LF 
treatment and explain that NTD is not linked with EVD. It was decided that the first MDA to be 
conducted should be preceded by a month of social mobilisation and CDDs must be at the 
forefront of this campaign. Posters, banners, brochures and jingles had already been 
developed and ready for use. It was reported that all NTD Partners were involved in the Ebola 
response. HKI worked on educating commercial bike riders about the disease and how they can 
avoid being infected. Sightsavers supported activities in a few treatment centres. The Disease 
Prevention and Control Advisor of the WHO Country Office in Sierra Leone blames the delayed 
response by the MOHS and WHO on bureaucracy because the MOHS and WHO still wanted to 
adhere to financial rules and regulations during the outbreak. This was however addressed 
when the government declared a State-of-Emergency and WHO declared the outbreak a public 
health emergency of international concern. Access to funds and therefore logistics became 
better (Bociaga-Jasik et al. 2014; Dixon et al. 2014; Hersey et al. 2015; Bogoch et al. 2015). 
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Interviews with Senior Officials of the MOHS: “We were caught with our pants down” was 
the statement from a MOHS official. There was almost zero knowledge on the management of 
an EVD outbreak among health workers, and when messages on EVD were disseminated 
nationwide, the communities refused to accept what was passed on. This led to many 
‘conspiracy theories’ about the origin of the disease. Initially, the MOHS was accused of 
exaggerating the seriousness of the disease to get donor funds until the high death rate 
became the convincing factor for the communities. Community response and collaboration 
with the Ebola Response improved only when the death rate became high. The MOHS had set 
up an Emergency Operation Center (EOC) with a Task Force that was jointly chaired by the 
CMO and the WHO Representative in the country. The role of the Task Force and the EOC 
became minimal as the masses lost confidence in the health services. There were reports of 
health workers being chased out of villages. The situation had to be controlled through the 
forces, and the MOHS was relegated to playing the role of advisors. During the visit, it was 
noted that the MOHS had seconded two senior officers to the NERC: The Director of PHC and 
the National Surveillance Manager, in addition to other cadres. In May 2015, the outbreak was 
still ongoing in the capital Freetown and a few northern districts. The reason for that was that 
the outbreak had initially started in the eastern district of Kailahun and people in the other 
regions tended to think that the disease would stay in the east. Health education messages on 
how to avoid the infection were disseminated nationwide, but it appeared that the eastern and 
southern districts adhered better to them than people in the north. The figures on death 
among health workers was not available with the MOHS officials but the media reported EVD-
related death of an estimated 200 health care workers. However, the number of medical 
doctors that had died was given as 11 in May 2015.   
 
Interview with the NTDP manager: When the outbreak was declared in May 2015 all public 
health programme activities stopped, the personnel of the public health programmes were 
posted to Ebola treatment Centres (ETCs) and the NTDP manager was in charge of the of the 
ETC on the outskirts of Freetown (in Hastings). Other NTDP staff were also involved in the 
outbreak response. All MOHS personnel were posted and obligated to play a role in the 
outbreak response. Vehicles belonging to the NTDP were also ‘borrowed’ and use for outbreak 
response. It was reported that the vehicles became worn out and were not replaced by the 
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GoSL. This meant that vehicles had to be rented for implementation of future NTDP activities. 
The NTDP was prepared and ready to work with partners to restart NTD interventions. All 
NTDP vehicles were part of the outbreak response. In the districts, PHU staff and CDDs were 
either in ETCs or served as contact tracers and specimen collectors. The NTD partner 
organisations were all involved in the outbreak response by either supporting ETCs or working 
with specific social groups to improve knowledge on EVD.  
 
Interviews with 4 DMOs: The interviews with the DMOs was more to advocate for their 
support to have MDAs for NTDs restarted. All the four DMOs interviewed recognised that the 
suspension of other health interventions was leading to many unreported deaths within 
communities, possibly higher than that reported for the EVD. The DMOs readily accepted the 
need for restarting public health programmes such as the LF/onchocerciasis MDA and were 
ready to use the Ebola Response System within districts to conduct the MDA. The reason for 
this is that human resources for health are limited especially in the rural areas and in general 
the same staff are used for all health-related interventions including those for the EVD. CDDs 
are currently accepted as part of the district health workforce due to the CDTI strategy. For the 
Ebola response, CDDs were being used mostly as contact tracers while health workers 
managed EVD treatment centres or served as specimen collectors. 
 
FGDs with PHU Staff and CDD: During the discussion, the PHU staff showed good 
knowledge of the disease and indicated that they have been trained on the disease and were 
also well equipped with enough medication and logistics to prevent themselves and patients 
from the disease. Initially, most of the PHU staff had heard of the diseases but linked the 
disease with East Africa. So when the disease was announced, the announcement was met 
with scepticism until many people started dying. In the Kailahun district, many health workers 
died in the first three months of the outbreak, and most health workers abandoned their 
PHUs. They returned because NGOs partners came in with necessary logistics and financial 
incentives for health workers. Health workers served as specimen collectors from suspected 
cases, and some were responsible for EVD treatment units. Most of the PHUs were used as 
EVD treatment units. Contact tracers were selected from each community/village, and most of 
the people selected as contact tracers were CDDs. They had the responsibility of investigating 
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to find out all those who had contacted anyone who was suspected of the disease so they can 
be isolated and observed for 21 days. The most obvious negative effect was that NTDP 
interventions were suspended during the outbreak. They believed that there were no other 
negative effects because the use of CDDs for treatment served well to allay the fears of 
communities. They trusted their own more than the health workers so complied well with the 
last MDA in May-July 2015. 
 
At the onset of the outbreak there was also a complete breakdown of the health services for 
various reasons: the health system was unprepared for the outbreak (health facilities did not 
have PPEs, medications for treating cases, and a large part of the health service personnel did 
not know how to handle the infection, and so lost the respect of the general population. At 
some point, people who fall ill were kept away from the health workers because there was a 
fear they (the sick) were ‘being killed’ by health workers. Health workers themselves at some 
point realised that treating people could lead to contact with those infected and deserted the 
health facilities. Diagnosis of EVD was late in the initial part of the outbreak and those infected 
were kept together with those not infected in health facilities. Poor triaging meant that those 
who were not infected with the EVD were kept together with those infected with the disease 
and this led to the nosocomial spread of the disease. Consequently, many people with other 
diseases that had symptoms similar to the EVD symptoms lost their lives by seeking help in 
health facilities. At the peak of the infection, when there were many deaths, it appeared to 
people that all those taken from their houses ended up dying. Being picked up by the response 
team signalled death to many people during the peak of the outbreak. A few people believed 
that Ebola patients were being killed deliberately instead of being treated to stop the spread of 
the infection. It was also thought that health workers were trying to make the situation looked 
worse than it was to attract donor funding. There were other allegations of corruption within 
the MOHS. At the peak of the infection around September 2014, there was a complete 
mistrust of the health system and the government in general. The government had to use the 
forces to take control of the situation, and the Minister of Defence was appointed the head of 
the NERC to enforce all decisions. It was noted that tablets are seen as not so dangerous 
especially when given by CDDs who are members of communities. However, it was advised 
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that any intervention such as surveys for LF and onchocerciasis that involve blood and touching 
of the skin should be avoided.  
 
The current surveillance system for EVD is that community members mostly CDDs now called 
‘community health workers’ are trained to report any unusual occurrences within their 
communities to the DHMT who will immediately alert the surveillance programme within the 
MOHS and action is supposed to be taken within 48 hours. Action should include the visit of a 
team including surveillance officers from the national level and surveillance officers from the 
DHMT to the village and examination of the person with the unusual symptoms/signs. Action 
to be taken afterwards depends on the findings. The MOHS officially took over this 
responsibility from the NERC when the outbreak was declared over in November 2015.  
 
The positive aspect of the EVD in relation to NTDs is that there is significantly more laboratory 
in the country with more people trained on laboratory methods that can be invited to support 
NTD-related evaluations within districts. It was noted that the delay of one year in 
implementing the MDAs meant that communities were eager to receive the treatment. The 
use of CDDs who are members of their respective communities for drug distribution has a 
positive impact on adherence to treatment. It was believed that during the EVD outbreak 
transmission of onchocerciasis and LF had to be minimal because of the many years of MDA 
and because there was minimal movement between districts due to the ban on movement 
between districts and the curfew imposed. The belief is that the epidemiological situation 
should not have changed much since people were forced to remain within their immediate 
environs during the outbreak. This is different from the civil war when mass movement took 
place, and the two diseases were spread nationwide. 
 
Because of the initial findings in May 2015, a meeting was held with HKI, Sightsavers and the 
DPC Advisor for WHO and a date was set for the start of integrated MDA for LF and 
onchocerciasis. This visit was used to convince the donor USAID that it was possible and not a 
waste of money to conduct MDA at that moment. MDA was started at the end of May and was 
allowed to continue till mid-July 2015 so that coverage can be as high as possible. Even though 
it appeared as if MDA can be conducted within communities, the findings indicated that any 
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attempt to conduct diseases specific assessments that involve blood and skin (assessments for 
LF and onchocerciasis respectively) will be rejected and so all DSAs relating to LF and 
onchocerciasis were postponed for at least 12 months and intensive social mobilization will be 
needed to help improve acceptance and participation within communities. 
 
 
DISCUSSION 
It is interesting to note that EVD has been called an NTD (Troncoso 2015). The LSTM (2014) 
highlighted the possible negative effect that the outbreak could have on NTDs. Hotez (2015) 
advised simultaneous interventions to address the EVD and NTD problems. The first question 
that needed an answer for the NTDP in Sierra Leone was when and how to restart MDAs for 
the NTDs after such deadly outbreak that had forced a whole country to shut down? 
Discussions with different people at the highest level revealed that it was already known that 
people were also dying from other causes besides EVD and public health programmes had to 
be started (Helleringer and Noymer 2015). Through negotiations, the LF/onchocerciasis MDA 
became the second large-scale public health intervention in May 2015 after the Malaria 
campaign in March 2015. The treatment period was extended so that as many people as 
possible could be treated. The MDA results for the onchocerciasis/LF MDA was better than 
expected mainly because of the use of CDDs for community drug distribution as they are also 
members of their respective communities (Bockarie, Kelly-Hope, Haskew 2010; Hodges et al. 
2011; Koroma et al. 2012). Two effective rounds of MDA have since been conducted in 2015 
and 2016. However, it was decided that disease-specific assessment for onchocerciasis and LF 
will be conducted one whole year after the end of the outbreak. The TAS in 8 districts and pre-
TAS in 6 districts are now planned for early 2017 over a year after the outbreak was declared 
over. 
 
The media announced that an estimated 200 health workers died from EVD, but this could be 
an underestimation because the information of EVD among health care workers (Olu et al. 
2015) provides a completely different picture from what was previously reported. Kilmarx et al. 
(2014) reported that about 5.2% of EVD positive cases were health workers and in the Kenema 
district up to 12.9% of the positive EVD cases were health workers. The numbers reported by 
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the media on EVD-related deaths among health workers do not add up because the final 
figures from WHO are a total of 14,123 people infected and 3,956 deaths from EVD (WHO 
2016e). However, given the already poor human resource situation in the country, any number 
of deaths among health care workers creates an extra burden for the health services 
(Fitzgerald et al. 2016). The numbers announced did not report for CDDs that died, and to date, 
there is no detailed report on the number of CDDs that died. It was, however, easier to know 
that 11 doctors died because the death of doctors received more media coverage. The 
magnitude of the outbreak, especially in Sierra Leone, showed the fragility and weakness of 
the health system and the country succeeded in controlling the outbreak only through the help 
of NGDOs (Gursky 2015; Fitzgerald et al. 2016). With the death of over 200 health workers (this 
does not include CDDs), the already bad human resource for health situation has deteriorated 
further (Kilmarx et al. 2014, Fitzgerald et al. 2016). During the outbreak access to essential 
health services was almost zero (Brolin Ribacke et al. 2016). Therefore, the non-EVD related 
deaths could have been high although difficult to determine. Some experts have suggested 
that life expectancy in the country dropped due to the EVD outbreak and could be the same as 
the immediate post-war period (Helleringer and Noymer 2015). 
 
Boyles (2015) and Gleason et al. (2015) also reported that there was a delay in diagnosing EVD 
cases initially that had led to nosocomial transmission and many avoidable deaths. However, 
significant progress was made towards the end of the outbreak that led to the control of the 
outbreak that was declared over in November 2015 (Bogoch et al. 2015). 
 
The positive aspect of the EVD in relation to NTDs is that there are significantly more 
laboratories in the country with more laboratory trained personnel who can participate in NTD 
evaluation studies. It was reported that the delay of one year in implementing the MDAs made 
communities even ‘eager’ to receive the onchocerciasis/LF treatment probably because of the 
additional benefits communities get from the treatment such as deworming of children and 
adults (Ottesen et al. 2008; WHO 2015), and the effect on scabies and lice (Meinking et al. 
1995; Burkhart, Burkhart 2006). The CDDs who are members of their respective communities 
served as a bridge between the NTDP and communities and thus contributed to improving 
community adherence to treatment. The district health workers believed that transmission of 
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both LF and onchocerciasis was limited during the outbreak firstly because the situation was 
already good for both diseases (low prevalence and density) before the outbreak, and also 
because of the restriction of movement between districts, several ‘lock downs’, and curfew 
imposed during the outbreak. They expect results to be good because the NTDP would have 
conducted two rounds of MDAs before the next diseases specific assessment early in 2017.  
 
A similar review of the situation in Liberia concluded that there is a high degree of community 
trust in the MDAs conducted for NTDs, but concerns were expressed that the coverage may be 
relatively worse that before because there is fear within communities that EVD and MDAs for 
NTDs may be linked. These were the same fears expressed in Sierra Leone and are being 
addressed currently with the help of CCDs and intensified social mobilisation with positive 
results (Bogus et al. 2016). 
 
 
CONCLUSION 
The EVD outbreak that started in the country in May 2014 led to many deaths including the 
death of many health workers. The outbreak was controlled and declared over in November 
2015 after a lot of improvement in treatment and diagnosis of the diseases. The PHUs in the 
entire country are prepared for any resurgence of the EVD as they have received adequate 
training and logistics to manage and report EVD cases. There was an ongoing surveillance 
within communities lead by community health workers to detect any strange health-related 
occurrences within communities. Although there was a delay of about a year in implementing 
MDAs, the NTDP has successfully completed two rounds of MDA since the outbreak. However, 
disease-specific assessments were suspended till early 2017 for fear that the communities 
targeted will reject an intervention that involves blood and the skin. Intensive social 
mobilisation and health education must be continued for the MDAs and disease assessments 
to maintain good community acceptance of the NTDP and adherence to treatment and 
assessments. 
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QUESTIONNAIRE (Open ended questions used for the interviews and FGDs) 
1. What do you know about the Ebola Virus Disease (EVD)? 
2. Did you know anything about the disease when it was announced? 
3. Did you believe that it was real when announced? 
4. If no, why did you not believe it was real? 
5. What changed your perception of the disease? 
6. How did you learn about Ebola- cause, prevention, what to do and how not to get the 
disease? 
7. Were you affected by the disease? How? Please explain. 
8. What have you done to help combat the disease? Have you been involved in any Ebola 
response? 
9. What did you have to go through during this outbreak? What were the challenges 
encountered? How did you overcome them? 
10. How is the surveillance system set up to detect EVD currently? 
11. In what way is the EVD experience affecting the NTD program currently? 
12. We need to understand peoples’ beliefs to bring change. What were/are the fears 
within communities in relation to NTD treatment and research studies?  
13. Do you think communities are prepared to accept onchocerciasis/LF treatment? 
14. How can we get people to trust the health system again and the NTDP? 
15. Can you think of any positive change that has taken place within the MOHS? 
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CHAPTER 8: WAY FORWARD FOR ELIMINATION OF 
ONCHOCERCIASIS AND LF 
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INTRODUCTION 
While the NTDP has reached the ‘end game’ for LF, there is still some work needed for the 
elimination of onchocerciasis. In this chapter what has to be done between now and the WHO 
verification of elimination of both diseases in the country is discussed.  
 
It should be noted that both diseases (onchocerciasis and LF) have a lot in common. Diagnosis 
of both diseases is done at an individual level to define the population at risk and population 
eligible for MDA, and also to monitor the impact of MDA (Taylor, Hoerauf and Bockarie 2010). 
LF and onchocerciasis are parasitic diseases that constitute a serious public health problem in 
tropical regions of the world (including Sierra Leone), the filarial nematodes that cause these 
diseases are transmitted by blood-feeding insects, and both diseases produce chronic and 
long-term infection by suppressing the immunity of the host (Taylor, Hoerauf and Bockarie 
2010). The pathogenesis of both diseases is linked to inflammatory processes within the host 
that are triggered by the death of the parasites thus causing hydrocoele, lymphoedema, and 
elephantiasis for LF, and skin disease and eye disease (including total blindness) for 
onchocerciasis (Taylor, Hoerauf and Bockarie 2010). Among the eight filarial nematode species 
that have a human host, three produce disease-causing infections among which two are 
responsible for LF (W. bancrofti and B. malayi); and the third disease-causing species is O. 
volvulus. LF affects an estimated 120 million people globally while O. volvulus affects more 
than 37 million people globally in 34 countries and is most prevalent in Africa (Taylor, Hoerauf 
and Bockarie 2010).  
 
Policies for implementation of programs for the two diseases present challenges and 
opportunities as not all elements of mapping, monitoring and surveillance can be integrated 
during programme implementation. New opportunities for integration besides integrated 
MDAs for the two diseases are many although research is still needed to advance the 
integration of interventions for the two diseases (Baker et al. 2010). Programmes for control 
and elimination of both diseases have been developed and established in Sierra Leone to 
provide sustained delivery of drugs to affected communities for the interruption of 
transmission of the diseases and ultimately to eliminate their burden on public health. Drugs 
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for integrated filariasis treatment in Sierra Leone include ivermectin, and albendazole, which 
are used in combination to reduce microfilariae in blood for LF, and the skin for onchocerciasis 
(Taylor, Hoerauf and Bockarie 2010).  
 
 
WAY FORWARD FOR ELIMINATION OF ONCHOCERCIASIS IN SIERRA 
LEONE 
The WHO has set the goal of eliminating onchocerciasis in selected African countries by 2020 
(WHO 2016b). Six annual rounds of integrated onchocerciasis/LF treatment have been 
conducted since the last onchocerciasis evaluation in 2010 (2010-2015) with effective 
treatment coverage (100% geographic coverage, ≥65% epidemiological coverage and ≥80% 
programme coverage). An onchocerciasis evaluation is planned for early 2017 in the same 39 
sentinel sites that were evaluated in 2010 to determine the MF prevalence and MF density 
after 13 years of treatment (2003-2015). Effective treatment coverage has so far been 
reported for only nine of the 13 years: 2003 and 2004 treatments had poor coverage, 2005 
treatment could not reach the effective coverage for all districts, and 2015 treatment results 
are yet to be released by the NTDP. The study will be done 11 months after the last treatment 
for 2015 before the 2016 treatment is conducted in the first half of 2017 (Katabarwa et al. 
2008; Katabarwa et al. 2012; Katabarwa et al. 2013). These MDAs are usually conducted in 
October-December each year, but in the past three-four years, the NTDP has had to conduct 
MDAs later than planned in the first quarter of the following year. This delay was exacerbated 
by the EVD outbreak, and MDAs continue to be delayed and conducted in April-June of the 
following year. The NTDP is committed to pushing the MDA period backwards so they can be 
completed latest in the first quarter of the following year. The NTDP is contemplating using a 
newly developed tool (OV16 rapid diagnostic tests (RDTs)) for future onchocerciasis 
evaluations. Details of this tool are discussed below (Weil et al. 2000; Lipner et al. 2006; 
Golden et al. 2016). The sampling and registration of participants will be the same as described 
in chapters 3 unless new guidelines on monitoring the impact of MDA on onchocerciasis is 
developed and the survey methodology will be adjusted accordingly.  
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Assuming results of the 2015 treatment will be good, the results of the next onchocerciasis 
evaluation in 2017 will determine the impact of ten effective annual rounds of MDAs. It is 
recommended that one site per district be selected as spot check site in addition to the 39 
sentinel sites for future onchocerciasis evaluations to ensure that reductions in MF prevalence 
occur evenly in all areas treated. A decision on the way forward will be made based on the 
results of the evaluation. However, it is speculated and projected that at least another five 
years of effective MDA will be needed to bring the number of effective rounds of MDA to 15 
and reduce the onchocerciasis MF prevalence to 0% or close to 0% in all sentinel sites so that 
stop-MDA evaluations can be conducted (WHO 2016d). Current WHO guidelines indicate that 
15-17 years of treatment is needed for onchocerciasis to reduce the MF prevalence to 0% or 
close to 0%. The years of treatment considered here are those for which effective 
epidemiological and programme coverage was achieved and geographic coverage was 100% 
(2006-2013, 2015, 2016). It is assumed that 15 years of treatment will be enough for the NTDP 
in Sierra Leone to reach 0% or close to 0% for onchocerciasis based on the results of the study 
after five effective rounds and also because it is believed that treatment before 2006 will also 
have an impact even though coverage was not effective. The additional five MDAs after 2016 
will be carried out between 2017 and 2021 and during this treatment period surveys will be 
conducted to determine the impact of MDAs (WHO 2016d). However, the question that is still 
outstanding in relation to impact assessment for onchocerciasis is that the threshold for 
deciding when to move to stop-MDA evaluation has still not been determined for 
onchocerciasis as it is for LF (<1% MF prevalence or <2% antigenaemia prevalence) (WHO 
2011a). The threshold must be different for skin snip method that detects MFs and the OV16 
RDTs that detects antibodies to the onchocerciasis OV16 antigen (Weil et al. 2000, Lipner et al. 
2006). Assuming the right results are attained with these studies conducted, stop MDA 
onchocerciasis evaluation will be conducted as described below in 2022. The results of the 
stop-MDA evaluations will be reviewed by an onchocerciasis elimination committee (OEC) that 
will also advise the NTDP on whether to stop MDA or not based on the stop-MDA evaluation 
results. A post-MDA surveillance for onchocerciasis will be conducted after MDA is stopped 
nationwide and on the advice of the OEC a dossier will be prepared and submitted to WHO 
that will announce the elimination of transmission of OV in the country. The dossier will be 
reviewed by a committee that will be set up by WHO. The Committee will visit the country to 
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ascertain that all that has been reported in the dossier on the disease is correct. The 
committee then advises WHO to accept the claim of elimination or reject it based on the 
review of the dossier and the findings of the country visit. The WHO Director-General will 
provide a letter of acknowledgement of elimination based on the advice of the WHO 
committee. It is projected that verification of elimination of onchocerciasis in Sierra Leone by 
the WHO Director-General will take place between 2027 and 2030 if the situation continues to 
be stable and MDAs are not disrupted. Post-elimination surveillance must be conducted after 
the letter of acknowledgement is received from the WHO Director-General to monitor and 
ensure that there is no resurgence or reintroduction of the infection from neighbouring 
countries. For onchocerciasis, the same entomological and serological methodologies are used 
for stopping MDA, post-MDA surveillance and post-elimination surveillance (WHO 2016d). 
 
 
WAY FORWARD FOR ELIMINATION OF LF IN SIERRA LEONE 
The LF programme in Sierra Leone is currently in the ‘end-game’ and if not for the EVD 
outbreak should already have reached the phase of stopping MDA for LF in all districts by 2016. 
LF TAS was planned in 2014 for the eight districts that passed the pre-TAS in 2013. The four 
districts coendemic for LF and onchocerciasis that failed the pre-TAS in 2013 needed to 
conduct two additional rounds of MDA (2013 and 2014 MDAs) and then repeat the pre-TAS in 
2015 (WHO 2011a). The two districts in the Western Area started MDA two years later (in 
2010) but would also have qualified for pre-TAS in 2015. If successful, the last TAS would have 
been conducted in 2016 so MDA can be stopped in all 12 districts. The eight districts that 
passed the pre-TAS could not conduct the TAS due to the EVD outbreak, but at least three 
annual rounds of MDA have been conducted since the pre-TAS in these districts (in 2013, 2015 
and 2016). It hoped that these additional three rounds of MDA would ensure a pass in the TAS 
for these eight districts. The three additional rounds of MDA also conducted in the other 
districts means that the required number of additional treatment rounds for the four districts 
that failed the pre-TAS in 2013 were reached in 2014 (2013 and 2015 MDAs) and the two 
Western Area districts that completed five annual rounds of MDA in 2015 also now qualify for 
a pre-TAS. Therefore, currently, TAS will be conducted in eight districts and pre-TAS in six 
districts early in 2017. FTS will be used for the pre-TAS and the TAS as described previously 
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(WHO 2011a; Chu et al. 2013). Although the diagnostic tool to be used will be changed (from 
NBS/thick blood film to FTS, the sample size remains the same and selection of sites will be as 
already discussed (one SS and one SCS per district to avoid the confusion noted in the last pre-
TAS of 2013). For the pre-TAS, the threshold for a pass is 2% for antigenaemia detection (using 
FTS) instead of the 1% used with the night blood survey/thick blood film method that detects 
MF. All six districts will go on to conduct a TAS the following year (2018) if the LF antigenaemia 
is below 2% using FTS. It is projected that MDA can be stopped in all 14 districts of Sierra Leone 
by 2018 after which post-MDA or post-treatment surveillance will commence. Post-MDA 
surveillance currently involves two additional TAS conducted two-three and then five-six years 
after MDA is stopped. With a pass in both additional TAS (TAS2 and TAS3), the country is 
considered to have interrupted LF transmission and can move towards the preparation of a 
dossier based on the advice of an LF elimination committee. The process is repeated for LF as 
described for onchocerciasis above and ends with a letter of acknowledgement of LF 
elimination from the WHO Director General. If MDA is stopped in all districts by 2018, followed 
by five-six years of post-MDA surveillance, the letter of acknowledgement can be obtained by 
2026 (WHO 2011a; WHO 2016a). The methodology and sampling for the TAS before stopping 
MDA and after stopping MDA remains the same as described previously (WHO 2011a; Chu et 
al. 2013; WHO 2013). 
 
 
GLOBAL INNOVATIONS FOR NTD ELIMINATION 
There are currently over 40 ongoing studies to identify or develop new treatments for NTDs by 
different research institutions. Many gaps remain in developing new diagnostic tools that will 
improve the evaluation of NTDs. New tools are being developed for easy detection of NTDs 
including onchocerciasis and LF that have been demonstrated to be highly sensitive and 
specific (Uniting to Combat NTDs 2015). A public-private partnership between the Program for 
Appropriate Technology in Health (PATH), the National Institutes of Allergy and Infectious 
Diseases, part of the US National Institutes of Health, Standard Diagnostics Inc., and the global 
onchocerciasis community through funding from the BMGF  was able to develop several new 
tools for NTD surveillance that are cheap and easily affordable, easy to use, field friendly, and 
provide results within a short time in field conditions. They include the OV16 RDTs that detect 
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antibodies to the onchocerciasis OV16 antigen, the Biplex test or SD Bioline Onchocerciasis and 
LF IgG4 RDT that at the same time detects antibodies to the onchocerciasis OV16 antigen and 
the Wb123 LF antigen, and the Wb123 RDT or SD Bioline LF IgG4 RDT that detects antibodies to 
the Wb123 LF antigen alone (PATH 2012; PATH 2013; PATH 2014; PATH 2016). The WHO 
recently also announced the availability of FTS for use for LF impact assessment to replace the 
ICT cards used previously (WHO 2016c). Significant progress has also been made to replace the 
‘human capture” method with use of traps to collect black flies during entomology studies for 
onchocerciasis (Rodríguez-Pérez et al. 2013; Rodríguez-Pérez et al. 2014; Toe et al. 2014). 
 
Many studies have been conducted on the proposed tools to validate their use. Weil et al. 
(2000), Lipner et al. (2006) and Golden et al. (2015) reports results of studies conducted to 
validate the use of the OV16 RDTs; OV16 ELISA, and development of positive control for the 
serology test. The OV16 RDT and OV16 ELISA tests are proven to be good serology tests for 
detecting the presence of antibodies to the OV16 onchocerciasis antigen in human blood and 
therefore exposure to onchocerciasis infection. They detect latent infection in the absence of 
MF in the skin and thus indicate exposure to the onchocerciasis infection. This means that they 
become useful in the final phase of the onchocerciasis elimination programme and are 
recommended for use in the stop-MDA evaluations, post-MDA evaluation and post-elimination 
evaluation. Testing of children <ten years of a programme that lasts for over ten years means 
these children should be less exposed to the onchocerciasis infection and so should not test 
positive in high numbers. The OV16 RDTs are also being recommended for use to study the 
impact of MDAs on onchocerciasis as they detect the antibodies to the OV16 onchocerciasis 
antigen and therefore exposure to the onchocerciasis infection. They could be a good 
replacement for skin snip that is invasive (painful and scary to many children and adult). 
However, since the antibodies reduce more slowly in the body than onchocerciasis MFs, adults 
could remain positive even when the infection is already absent due to control measures. 
Therefore, the appropriate threshold needs to be defined when using this tool during surveys 
for assessing the impact of MDAs while MDAs are being conducted. Threshold also needs to be 
defined when using this tool to decide when to conduct stop-MDA evaluations. While the 
decision to use OV16 in place of skin snip methodology for assessments during treatment still 
remains unclear (as adults can test positive for the antibodies to the OV16 antigen even when 
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they do not have the disease), threshold also need to be determined for cases when 
programmes decide to use skin snip methodology to detect onchocerciasis MFs. The threshold 
should be established that will guide the decision by programmes while treatment is ongoing 
to conduct stop-MDA evaluations. It has been noted that antibodies to the OV16 antigen 
reduce more slowly than onchocerciasis MFs during control measures, and so the threshold for 
skin snip will be different from the threshold for OV16 (Weil et al. 2000; Lipner et al. 2006).  
 
Many authors have also reported studies conducted to compare the FTS and ICT cards and 
have validated its use for LF surveillance and also its replacement of the BinaxNOW Filariasis 
ICT cards (Weil et al. 2013; Rebollo and Bockarie 2013; Yahathugoda et al. 2015). The FTS 
detects antigen of W. bancrofti in human blood and was developed by Alere (Scarborough, ME, 
United States) the company that was producing the BinaxNOW Filariasis ICT cards. The 
development of this new tool was made possible through funding from the BMGF (WHO 
2016c). A similar study was also reported for the Biplex with positive results showing high 
specificity and sensitivity of the tool (Steel et al. 2015).  
 
 
POSSIBLE USE OF BIANNUAL TREATMENT TO REDUCE ADDITIONAL 
YEARS NEEDED FOR TREATMENT OF ONCHOCERCIASIS 
The author’s analysis has indicated that MDA cannot be stopped nationwide for onchocerciasis 
before 2020 and LF MDA can be stopped nationwide in 2018 provided all the districts pass the 
pre-TAS/TAS. The additional five rounds of MDA needed for onchocerciasis can be conducted 
in less than five years if the NTDP can change from annual MDAs to biannual MDAs (Cupp et al. 
2004; Cupp et al. 2005; Molyneux et al. 2014). This will demand more coordination at all levels, 
more health education and social mobilization within targeted communities, extra financial 
and logistics support. However, all these extra requirements will be balanced by a reduced 
number of years of treatment needed.  It is projected that with biannual treatment, only three 
additional years of treatment will be needed (2017, 2018 and 2019) and the NTDP can meet 
the 2020 target to stop MDA nationwide by 2020 (WHO 2011a). 
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The current LF situation appears straightforward- TAS in 8 districts and pre-TAS in 6 districts in 
2017, and then TAS in the 6 districts in 2018. It is expected that all the districts will pass the 
pre-TAS and the TAS. However, biannual treatment can be implemented during the two 
additional years of treatment that will be needed if any districts fails the pre-TAS or TAS (WHO 
2011a).  
 
 
POSSIBLE USE OF DOXYCYCLINE FOR LF AND ONCHOCERCIASIS 
ELIMINATION IN AREAS OF PERSISTENT HIGH INFECTION 
As discussed previously, most of the filarial species that infects humans co-exist in mutualistic 
symbiosis with Wolbachia bacteria that are essential for growth, development, and survival of 
their nematode hosts (Hoerauf 2008; Wanji et al. 2009; Tamarozzi et al. 2012; Molyneux et al. 
2014). These endosymbionts contribute to inflammatory disease pathogenesis and are a target 
for doxycycline therapy, which delivers macrofilaricidal activity, improves pathological 
outcomes, and is effective as monotherapy (Taylor, Hoerauf and Bockarie 2010; Molyneux et 
al. 2014). Use of doxycycline, therefore, is a possible solution for areas where there will be 
persistently high prevalence of the two diseases after many years of treatment. This is 
especially possible for countries like Sierra Leone where both diseases are coendemic in 12 of 
the 14 health districts. Treatment of some districts can be done using the proposed 
community-directed treatment with doxycycline although the treatment has to be conducted 
for six weeks with multiple daily doses to be administered (Hoerauf 2008; Wanji et al. 2009; 
Tamarozzi et al. 2012; Molyneux et al. 2014). 
 
 
CONCLUSION 
The path towards the elimination of the two diseases in Sierra Leone appears clear. However, 
it should be noted that many questions still exist especially for onchocerciasis surveillance that 
need to be addressed by the NTD community in collaboration with research institutions. 
Another fact that should be noted is that due to conflicts and most recently outbreaks of other 
more virulent infection (the EVD), Sierra Leone will not be among the countries meeting the 
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WHO 2020 targets for elimination of LF (WHO 2015; WHO 2016a) and will also not meet the 
onchocerciasis 2020 target (Uniting to Combat NTDs 2015). 
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CHAPTER 9: GENERAL DISCUSSIONS, SUMMARY AND 
CONCLUSIONS  
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GENERAL DISCUSSIONS 
Sierra Leone is highly endemic for the neglected tropical diseases that are amenable to 
preventive chemotherapy. Among these, LF and onchocerciasis have been targeted for 
elimination. The goal of this study was to determine the impact of preventive chemotherapy 
on the transmission intensity of LF and onchocerciasis measured through changes in the 
human infection status using standard epidemiological indicators as described in the WHO 
guidelines for monitoring national programmes.  This was achieved through the following 
specific objectives: i) evaluate the impact of vertical treatment of onchocerciasis (2005-2006) 
plus integrated onchocerciasis/LF treatment (2007-2009) on transmission of onchocerciasis in 
Sierra Leone; ii) determine the impact of vertical treatment of onchocerciasis in Sierra Leone 
(before 2007) on the LF transmission and endemicity; iii) evaluate the impact of integrated 
onchocerciasis/LF treatment in Sierra Leone at mid-term (i.e. after three effective MDA rounds) 
on the LF transmission intensity; iv) evaluate the impact of integrated onchocerciasis/LF 
treatment in Sierra Leone after five effective rounds of MDA on the LF transmission intensity; 
and v) determine the way forward to achieve elimination of both diseases as public health 
problems using the latest available WHO guidelines and diagnostic tools.    
 
The targeted outcomes for the quantitative research studies reported in this study are all WHO 
requirements for successful completion of the onchocerciasis and LF programs. The studies 
were designed and conducted strictly in line with WHO recommendations for the two diseases. 
Data collection and archiving in resource poor settings in Sierra Leone and through this project 
the studies conducted relating to onchocerciasis and LF elimination are documented. 
According to WHO recommendations and requirements, the NTDP will need to put together a 
dossier of survey and treatment data that will be used in the near future by the Elimination 
Committees that will be set up to verify elimination of onchocerciasis and LF in Sierra Leone. 
This study and its content will serve as a good collection of all data needed by the NTDP for 
verification of elimination of onchocerciasis and LF. Data reported and information available in 
this project will be used by the NTDP for decision making as the onchocerciasis and LF 
programmes continue to be implemented. The international scientific community, especially 
the NTD community, will benefit from the documented onchocerciasis/LF elimination 
227 
 
227 
 
experiences obtained from co-implementation of activities for the two diseases and 
integration of onchocerciasis and LF programme coordination within the MOHS service 
delivery system in Sierra Leone. It is also hoped that countries with similar challenges (post-
conflict background, co-endemicity of onchocerciasis and LF, and maintaining the NTDP during 
and after the outbreak of a far deadlier disease), especially in Africa, can learn from the 
experience in Sierra Leone.  
 
The NTDP, including the NOCP that existed alone before the establishment of an integrated 
programme for all NTDs, has had and continues to receive good support, either technical or 
financial, direct or indirect, from many international and national NTD partners: the WHO HQ, 
AFRO, APOC, USAID, HKI, CNTD Liverpool (now known as FPSU), Johnson & Johnson, the World 
Food Program, the World Bank, TOMS Shoes, the school and adolescent health programme of 
the Ministry of Health (Baker et al. 2010). Mebendazole/albendazole for soil transmitted 
helminthiasis treatment has been donated from the Saint Andrews Clinic for Children in Sierra 
Leone, De-worm the World, Feed the Children, and World Vision Sierra Leone. One of the 
important aspects of the NTDP globally is the donation of the drugs needed for treatment. In 
1987 Merck and Co. Inc. offered to donate ivermectin free of cost for treatment of 
onchocerciasis, and in 1998 also for treatment of LF, for as long as it is needed. This support 
has been coordinated through the MDP (Alleman, Twum-Danso, Thylefors 2006; Boatin 2008; 
Colatrella 2008; Thylefors, Alleman, Twum-Danso 2008; Thylefors 2008; Yameogo 2008; Baker 
et al. 2010; Hopkins and Boatin 2011; Hodges et al. 2011; Meredith, Cross, Amazigo 2012). 
Similarly, GlaxoSmithKline also donates albendazole for LF control globally (Hodges et al. 2011). 
This contribution by the drug companies comes down to billions of US Dollars, without which 
the global LF and onchocerciasis elimination programmes cannot continue (Alleman, Twum-
Danso and Thylefors 2006; Boatin 2008; Colatrella 2008; Thylefors, Alleman, Twum-Danso 
2008; Thylefors 2008; Yameogo 2008; Baker et al. 2010; Hopkins and Boatin 2011; Hodges et 
al. 2011; Meredith, Cross, Amazigo 2012). The contribution of the BMGF in supporting research 
for the development of new tools and drugs for NTD control and the contribution by research 
institutions such as PATH, the TASK for Global Health and CDC has to be acknowledged 
because they shape the strategies used for NTD control and they help the development of 
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better tools for disease assessment (PATH 2012; PATH 2013; PATH 2014; PATH 2016; Uniting to 
Combat NTDs 2015; WHO 2016c). 
 
However, the NTDP has been and is still being implemented under challenging circumstances. 
Sierra Leone is a poor West African country with a weak and fragile economy with poor socio-
economic and health indicators (MacKinnon and MacLaren 2012; Fitzgerald et al. 2016). Many 
health reports present different health indicators for Sierra Leone, but there is a consensus 
that the country is among the poorest in the world with one of the lowest life expectancy. The 
socio-economic and health situation in Sierra Leone is critical compared even to other sub-
Saharan African countries. About 70% of Sierra Leoneans lived below the poverty level in 2007 
(i.e. earn less than one US$ per day). (GoSL, MOHS 2009; UNDP 2014a,b; UNDP 2015; African 
Health Observatory WHO AFRO 2016; Focus 1000 2016). The country is currently ranked 181 
out of 188 in terms of human development index (UNDP 2015; Focus 1000 2016). A greater 
part of the country’s population is involved in agriculture, mostly subsistence farming. Yet a 
high proportion (about 70%) of total health expenditure is out-of-pocket spending because of 
the low government expenditure on health (GoSL, MOHS 2009; UNDP 2009).  
 
Within the MOHS the NTDP to a large extent remains ‘neglected’ because of the other 
competing priorities that the MOHS has to deal with including one of the highest infant and 
maternal mortality rates in the world, and other killer diseases such as Malaria, TB, HIV/AIDS, 
nutritional deficiencies, pneumonia, anemia, respiratory tract infection and diarrhoeal 
diseases. Maternal mortality and infant mortality rates still remain among the highest in the 
world. High infant mortality is linked to high prevalence of malaria, diarrhoea, and pneumonia. 
High maternal mortality is due to obstructed labour, haemorrhage, anaemia, and toxaemia in 
pregnancy (GoSL, MOHS 2010; WHO Sierra Leone 2009; GoSL, MOHS 2012a).  
 
The ‘neglect’ of NTDs is compounded by a weak HRH situation (MacKinnon and MacLaren 
2012; Fitzgerald et al. 2016). In 2008, the country had a sixth of the minimum number of health 
personnel recommended by WHO. Accessibility to health care services (and in this case to 
health personnel) is poor especially in rural areas due to an acute shortage of trained health 
professionals, the significant dichotomy of staff between rural and urban health facilities, 
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unequal distribution of health cadres, and poor access to good quality health care. The scarcity 
of physicians and registered nurses is even more pronounced in rural areas where two-thirds 
of the population live. The total health workforce was estimated at 6,000, and there were 95 
physicians practising in the country in 2008 (MacKinnon and MacLaren 2012; Fitzgerald et al. 
2016). More recent data on human resources for health report that the overall health 
workforce in the country is slightly above 8000 personnel. However, about half of all health 
personnel are in the Western Area alone. The limited human resource for health is a concern 
of the GoSL (GoSL, MOHS 2012a; Fitzgerald et al. 2016).  
 
The NTDP has used the health services provided at the different levels well. District hospitals 
manage serious adverse events cases following treatment that are referred to them and also 
are responsible for a large part of the morbidity management for LF (hydrocoele surgery and 
lymphoedema/elephantiasis management) and onchocerciasis (eye care). The NTDP is 
coordinated within districts by DHMTs in collaboration with central level NTDP staff, and each 
of the 14 districts has a district NTD focal point. The health system personnel that work within 
the PHUs (CHCs, CHPs and MCHPs) provide direct support to the community volunteers or 
CDDs that implement MDAs within their respective communities and report treatment results. 
Since accessibility to health care services is poor especially in rural areas due to an acute 
shortage of trained health professionals, the NTDP implements activities within communities 
using community volunteers or CDDs who are supervised, trained and monitored by PHU staff. 
These CDDs have gradually become the backbone of all the NTDP activities in the rural setting. 
While in the rural setting CDDs serve as volunteers within the NTDP, in the district headquarter 
towns and the Western Urban district and Western Rural district there are no volunteer CDDs 
and NTD drugs are distributed by paid health workers for a fixed number of days (Hodges et al. 
2011; MacKinnon and MacLaren 2012; Fitzgerald et al. 2016). 
 
The EVD outbreak that started in Guinea in late 2013 and spread to Sierra Leone is believed to 
have caused almost the same devastating socio-economic effect as the civil war of 1991-2002 
and appeared to have derailed the NTDP (Boisen et al. 2015; Hersey et al. 2015). 
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The study has used baseline data for onchocerciasis obtained using the skin snip method for 
the period 1988 – 2005; baseline data for LF including mapping results obtained using ICT cards 
in 2005 and baseline survey results obtained using the NBS/TBF method in 2007/2008; results 
of onchocerciasis evaluation conducted in 2010; results of mid-term evaluation conducted for 
LF in 2011 after three years (2008-2010); results of pre-TAS conducted in 2013 for LF after five 
years of treatment (2008-2012) in sentinel and spot-check sites; results of MDA for 
onchocerciasis (2005-2015) and LF (2008-2015); annual Implementation plans for the period 
2005-2015; annual NTDP Reports for the period 2005-2015 and publications on NTDs focusing 
on onchocerciasis and LF. All treatment results for the period 2005-2015 (for onchocerciasis 
and LF), and all research studies conducted at baseline (1988-2008) and during universal 
treatment (2008-2013) for monitoring the impact of treatment were reviewed. Apart from 
NTDP data and information, an extensive literature search was conducted using the 
appropriate search words and information obtained was used to review the data obtained 
from treatment and research studies. Some of the data obtained from the research studies 
have been published already in international peer-reviewed journals (please see attached in 
the appendices). This study and all the data it contains will also be made available to the MOHS 
for use in the future as part of the dossier to be prepared for verification of elimination of 
onchocerciasis and LF in Sierra Leone.  
 
The fight to combat NTDs reached an unprecedented peak for public health programmes with 
the formation of a coalition of partners including donors, international health-oriented NGDOs, 
and pharmaceutical companies that are prepared to support endemic countries globally with 
their efforts to eliminate NTDs. This big development started in 2012 with the London 
Declaration on NTDs during which key donors pledged their support for this development and 
committed to continue either donating drugs or providing the funds needed for the 
interventions. The highest level of financial and other support was attained around the London 
Declaration in 2012. This coalition offers countries like Sierra Leone the opportunity to improve 
the socio-economic status of its people by reducing the prevalence and density of the two 
diseases that are known to be poverty-promoting parasitic diseases (Uniting to combat NTDs 
2015). The two diseases also result in often stigmatising conditions such as total blindness, 
hydrocoele, lymphoedema and elephantiasis (Taylor, Hoerauf and Bockarie 2010). Apart from 
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affecting mainly the poor and exacerbating their poverty, there is strong evidence that when 
infected with NTDs one becomes increasingly susceptible to or there is worsening of the 
progression of morbidity from HIV/AIDS, TB, and Malaria. Therefore, NTD control/elimination 
is an indirect effective, low-cost means of reducing morbidity and mortality associated with 
these three global health problems (Gloeckner et al. 2010). Ocular diseases, total blindness and 
skin diseases relating to onchocerciasis, and hydrocoele, lymphoedema and elephantiasis due 
to LF can all be reduced within the population and prevented from affecting future generations 
(Taylor, Hoerauf and Bockarie 2010).  
 
Onchocerciasis is caused by the filarial worm O. volvulus and transmitted in Sierra Leone by the 
black fly Simulium damnosum (Gbakima and Sahr 1996). Sierra Leone has always been known 
to be endemic for onchocerciasis since 1926 when Blacklock first described the disease 
transmission in the Kono district (Blacklock 1926). There have been efforts to control 
onchocerciasis in the country albeit haphazard between the 1950s and the establishment of 
the NOCP in 1988-1989. Many studies were conducted on onchocerciasis by the NOCP and 
other researchers to determine areas of the country that should be treated for onchocerciasis. 
Thus, it was determined that only the 12 provincial districts of Sierra Leone are endemic for 
onchocerciasis. Each of the 12 onchocerciasis-endemic districts has hyper-endemic, meso-
endemic and hypo-endemic areas and so onchocerciasis treatment was not conducted in 
entire districts. Treatment was conducted between 1989 and 1996 only in some areas of the 
country mainly due to insecurity related to a civil conflict between 1991 and 2002 and the then 
onchocerciasis policy of treating only meso-endemic and hyper-endemic areas. Before the 
introduction of CDTI in 1997-1998, treatment for onchocerciasis control was done in meso-
endemic and hyper-endemic communities using mobile teams. Treatment was completely 
stopped in 1997 and restarted in 2003 under the SIZ that was coordinated by APOC. Therefore, 
the CDTI strategy could only be established in Sierra Leone in 2003. Challenges with restarting 
the onchocerciasis programme after a five-year absence of interventions resulted in relatively 
poor treatment coverage for onchocerciasis in 2003 and 2004 (Hodges et al. 2010; Hodges et 
al. 2011).  
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There has been a paradigm shift from onchocerciasis control to elimination after it was 
demonstrated in many south American countries and some countries in Africa that elimination 
of onchocerciasis is possible after 15-17 years of treatment (Diawara et al. 2009; APOC 2010; 
Tekle et al. 2012; Crump et al. 2012; Traore et al. 2012; Uniting to Combat NTDs 2015). The 
NTDP is also towing this line and has targeted onchocerciasis elimination in Sierra Leone. 
Results of the onchocerciasis evaluation conducted in 2010 demonstrated that there has been 
a significant reduction in MF prevalence and density. It should be noted that the situation will 
be even better now after additional six annual rounds of treatment conducted between 2010 
and 2016. The remarkable observation made is that women and children who usually bear the 
brunt of diseases in the country are reaping the best benefits from this programme. The results 
of 2010 show that women are less affected by onchocerciasis and children are also less likely to 
be infected with onchocerciasis than adults. This means that onchocerciasis transmission is 
generally low in the country as those born after initiation of programme activities are less 
exposed to the disease. The vegetation ranges from mangrove along the coasts to forest 
covered hills and savannah as one moves further inland and this has created regional variations 
of onchocerciasis distribution (McMahon et al. 1988c; Gbakima and Sahr 1996). Baseline 
onchocerciasis results show that northern districts had relatively higher prevalence, followed 
by southern and then eastern having the lowest relative prevalence. This variation appears to 
have changed slightly in 2010, as by then the southern districts had relatively the highest 
average prevalence, followed by the average prevalence of eastern districts, and northern 
districts have relatively the lowest average MF prevalence.  
 
LF is endemic in all 14 districts of Sierra Leone, transmitted by Anopheles mosquitoes, and all 
districts qualified for MDA intervention in 2005 in accordance with WHO guidelines because 
they had baseline LF antigenaemia prevalence by ICT cards ≥1.0%. Baseline studies were also 
conducted in 2007/2008 using the night blood survey/thick blood film method to obtain data 
that can be used to monitor decline in LF MF prevalence and density in the country. The NTDP 
has made remarkable progress towards LF elimination since integrated onchocerciasis/LF MDA 
using ivermectin and albendazole was piloted in 2007. The results of the mid-term assessment 
and pre-TAS show significant reductions in MF prevalence and MF density. Pre-TAS results 
show that eight of the 12 districts coendemic for onchocerciasis and LF passed the pre-TAS and 
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will conduct TAS in 2017. The four that failed the pre-TAS in 2013 have since conducted three 
additional rounds of treatment as required by WHO (in 2013, 2015 and 2016). The two 
Western Area districts that had not qualified for the pre-TAS in 2013, now also qualify for pre-
TAS after completing five effective rounds of MDA and all six districts will conduct pre-TAS in 
2017 (re-pre-TAS for the four that failed in 2013). Another remarkable observation with LF is 
that transmission has reduced significantly because fewer children are now being infected with 
the disease. Women are also less infected that men. This means that the same pattern is noted 
for women and children for the two diseases. 
 
The study suggests that LF prevalence may have reduced significantly at baseline because of 
the effect of onchocerciasis treatment on LF before LF treatment proper was started in 2007 
(Kyelem et al. 2003; Kyelem et al. 2005). The study shows that the rapid reduction of MF LF 
prevalence and density could also be due to many factors including low baseline MF 
prevalence (Ottesen 2000), the LF vector (the Anopheles mosquitos) being less efficient as LF 
vectors than Culex (Weil et al. 2008), and high community adherence to treatment because 
communities appreciate the effect of LF/onchocerciasis treatment on soil transmitted 
helminthiasis, scabies and lice (Meinking et al. 1995; Burkhart, Burkhart 2006; Ottesen et al. 
2008; WHO 2015). The study also shows the importance of having SCS in addition to SS for 
monitoring the impact of MDAs for LF that are randomly selected usually in consultation with 
DHMTs and changed with each study (WHO 2011a). This same policy can be applied to 
assessments conducted for onchocerciasis.  
 
The EVD outbreak that started in Sierra Leone in 2014 was first detected in the eastern 
Kailahun district but had spread to the entire country before it was controlled (Gleason et al. 
2015; Lokuge et al. 2016). Initially, the response to the outbreak was uncoordinated and was 
compounded by the weak health system in the country. With the support of international 
organisations, the MOHS succeeded in stopping the outbreak by November 2015 (MOHS 2015; 
Fitzgerald et al. 2016). All public health interventions including NTD interventions were 
suspended nationwide so the entire health service can be used to control the EVD outbreak. 
After successful implementation of a nation-wide Malaria treatment campaign in March 2015, 
the NTDP became the second public health programme post-EVD to conduct an MDA for 
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onchocerciasis and LF in June 2015. Although there have been challenges in restarting 
onchocerciasis/LF MDAs, they were overcome through concerted efforts and the support of 
CDDs who served as a bridge between the NTDP and communities. There was a delay of about 
a year in implementing MDAs, but the NTDP has successfully completed two rounds of MDA 
since the outbreak. Based on findings of the qualitative study in 2015, a decision was made to 
suspend disease-specific assessments for onchocerciasis and LF till early 2017 for fear that the 
communities targeted will reject an intervention that involves blood and the skin. Intensive 
social mobilisation and health education had to be conducted to maintain the usual effective 
treatment coverage and should be continued before and during MDAs to maintain good 
community acceptance and adherence to treatment. The disease-specific assessments should 
be preceded by the same intensive social mobilisation and health education to have good 
community participation in the assessments.  
 
Cross-border transmission of infectious diseases including NTDs is cited as a major problem for 
many infectious disease and NTD control efforts (Kaferstein, Motarjemi, Bettcher 1997; 
Bhumiratana et al. 2005; Asian Development Bank 2010; Bhumiratana et al. 2010; HKI 2010; 
International Coalition for Trachoma Control 2011; NNN 2011; Centers for Disease Control and 
Prevention 2011; The Carter Center and MOH Uganda 2011; Bhumiratana et al. 2012; Hodges 
et al. 2012a; Hodges et al. 2012b; WHO 2012; Gustavsen, Sodahlon, Bush 2016). Resurgence or 
importation of the NTDs targeted presently for elimination in Africa from neighbouring 
endemic countries remains a concern due to possible cross-border disease transmission, which 
must be addressed to sustain achievements in these countries because neighbouring countries 
may not have achieved similar results (Gustavsen, Sodahlon, Bush 2016). The NTDs that are 
currently targeted for elimination in Sierra Leone (onchocerciasis and LF) can be reintroduced 
into the country from neighbours Liberia and Guinea that have not achieved similar results in 
controlling the two diseases. The threat of cross-border transmission of NTDs has been 
expressed by the NTDP in Sierra Leone and other NTDPs in countries that the author has 
worked with. It is the opinion of the author that the cross-border issue must be addressed and 
talk should be translated into action at this stage of the global NTDP when endemic countries 
are making remarkable achievements in controlling NTDs, and many countries are reaching the 
‘end game’.  
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The cross-border problem for NTDs can be addressed if countries can provide technical support 
and services to each other, share experiences and knowledge through cross-border meetings, 
establish common surveillance and reporting systems, and use similar indicators and forms for 
reporting NTDs. Experiences from successful cross-border initiatives established for other 
diseases such as malaria and HIV/AIDS in Africa and elsewhere can be used to inform decisions 
on addressing possible cross-border issues in West Africa. It has been reported that countries 
make recommendations for addressing cross-border issues during cross-border meetings but 
appear to have many challenges in implementing the recommendations they make. There has 
recently been positive progress in this direction as a few organisations are implementing 
interventions that will improve country collaboration for addressing cross-border problems. 
The END in Africa project is introducing aspects of cross-border collaboration in agreements 
with countries supported to encourage synchronisation of treatments along borders, and the 
World Bank has introduced a project in Niger, Burkina Faso and Mali to help address cross-
border issues (World Bank 2015; FHI360 2016). 
 
While the NTDP has reached the ‘end game’ for LF, there is still some work needed for the 
elimination of onchocerciasis. After reviewing the necessary interventions and procedures 
needed for eliminating the two diseases in the country, it is projected that both LF and 
onchocerciasis can only be eliminated in the country between 2025 and 2030, later than the 
2020 targets set by international NTD community. This is mainly because of the many 
challenges highlighted above. Although policies for implementing NTDPs present challenges 
and opportunities as not all elements of mapping, monitoring and surveillance can be 
integrated for onchocerciasis and LF during programme implementation, it is demonstrated in 
this study that the NTDP in Sierra Leone has been successful in integrating the treatment of the 
two diseases.  
 
There are currently many ongoing studies by different research institutions with the support of 
many donors to identify or develop new treatments for NTDs, to address the many gaps in 
knowledge for NTDs, and also to develop better tools for disease assessment. The availability 
of the options of conducting biannual treatment (Cupp et al. 2004; Cupp et al. 2005) and using 
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doxycycline to treat for both diseases in the country has been noted although this will require 
long-duration treatment (up to 6-weeks) (Hoerauf 2008; Wanji et al. 2009; Tamarozzi et al. 
2012; Molyneux et al. 2014). These strategies will require more coordination, intensive health 
education and social mobilization with targeted communities, more logistical and financial 
support. This treatment option can be reserved for areas of persistent high onchocerciasis and 
LF prevalence to speed up the elimination process. The decision can be made based on results 
of the onchocerciasis and LF assessments that are planned for 2017. This way elimination of 
both diseases can be achieved earlier than the period projected above. Furthermore, new tools 
have been developed and put in the market for the assessment of onchocerciasis and LF that 
can be used by the NTDP in Sierra Leone for future diseases assessments (PATH 2012; PATH 
2013; PATH 2014; PATH 2016; WHO 2016c).   
 
Although many gaps remain in developing new diagnostic tools that will improve the 
evaluation of NTDs, several new tools have been developed for easy detection of 
onchocerciasis and LF through public-private partnerships that have been demonstrated to be 
highly sensitive and specific (Uniting to Combat NTDs 2015). For onchocerciasis, there is the 
OV16 rapid diagnostic tests and OV16 ELISA, serology tests that detect antibodies to the 
onchocerciasis OV16 antigen. For LF the ICT cards have been replaced by the FTS that were 
modified to be easier to use in the field in terms of the temperature at which they can be 
stored (refrigeration is not needed when they are used in areas with temperature up to a 30 
degree centigrade) and also the Wb123 RDT or SD Bioline LF IgG4 RDT that detects antibodies 
to the Wb123 LF antigen alone is now available for use by programmes. The Biplex test or SD 
Bioline Onchocerciasis and LF IgG4 RDT that at the same time detects antibodies to the 
onchocerciasis OV16 antigen and the Wb123 LF antigen is also available for use by 
programmes (PATH 2012; PATH 2013; PATH 2014; PATH 2016; WHO 2016c).  
 
Many studies have been conducted on some of the proposed tools to validate their use. 
Available evidence shows that programmes can use the OV16 RDTs and FTS for monitoring the 
impact of MDA on onchocerciasis and LF respectively (Weil et al. 2000; Lipner et al. 2006; 
Rebollo and Bockarie 2013; Weil et al. 2013; Golden et al. 2015; Yahathugoda et al. 2015). The 
OV16 RDT and OV16 ELISA tests are proven to be good serology tests for detecting the 
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presence of antibodies to the OV16 onchocerciasis antigen in human blood and therefore 
exposure to onchocerciasis infection. They detect latent infection in the absence of MF in the 
skin and thus indicate exposure to the onchocerciasis infection. This means that they become 
useful in the final phase of the onchocerciasis elimination programme and are recommended 
for use in the stop-MDA evaluations, post-MDA evaluation and post-elimination evaluation. 
Testing of children <ten years of a programme that lasts for over ten years means these 
children should be less exposed to the onchocerciasis infection and so should not test positive 
in high numbers. These tests (especially the OV16 RDTs) are also being recommended for 
studying the impact of MDAs on onchocerciasis as they detect the antibodies to the OV16 
onchocerciasis antigen and therefore exposure to the onchocerciasis infection and could be a 
good replacement for skin snip that is considered invasive (painful and scary to many children 
and adult). However, since the antibodies reduce more slowly in the body than onchocerciasis 
MFs, adults could remain positive even when the infection is already absent due to control 
measures. Therefore, the appropriate threshold needs to be defined when using this tool 
during surveys for monitoring impact of MDAs. Threshold also needs to be defined when using 
this tool to decide when to conduct stop-MDA evaluations. Furthermore, while the decision to 
use OV16 in place of skin snip methodology for assessments during treatment still remains 
unclear (there is still no WHO guideline on this), the threshold also need to be determined for 
cases when programmes decide to continue using the skin snip methodology that detects 
onchocerciasis MFs to monitor the impact of MDAs. Threshold also should be defined for 
making the decision to move to stop-MDA evaluations for onchocerciasis when using the skin 
snip methodology to measure the impact of MDAs. It has been noted that antibodies to the 
OV16 antigen reduce more slowly than onchocerciasis MFs during control measures, and so 
the threshold for skin snip will be different from the threshold for OV16 (Weil et al. 2000; 
Lipner et al. 2006). The NTDP in Sierra Leone is considering using the OV16 RDTs for the next 
surveys to monitor the impact of MDAs on onchocerciasis. However, it is important that an 
appropriate threshold is defined for this tool to guide programmes in making programme 
decisions based on survey results. 
 
Available evidence also shows that the FTS is better than the ICT cards for field use, has better 
sensitivity and specificity and can be used by programmes for monitoring impact of MDA and 
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endgame evaluations (stop-MDA evaluation, post-MDA surveillance and post-elimination 
surveillance) (Weil et al. 2013; Rebollo and Bockarie 2013; Yahathugoda et al. 2015). Studies 
have also been conducted to demonstrate the high specificity and sensitivity of the Biplex 
(Steel et al. 2015) but more studies are needed to demonstrate their suitability for field use. 
Further research is also needed to demonstrate field use of the Wb123 RDT or SD Bioline LF 
IgG4 RDT that detects antibodies to the Wb123 LF antigen alone.  
 
The disadvantages of using the night blood method for monitoring MDA have been highlighted 
by many authors. MF testing (through microscopy of thick blood films) is determined to be 
insensitive for active infections and misses people with low MF density and people with 
amicrofilaraemic LF infection that can lead to irreversible major lymphatic damages in these 
patients and they (the patients) can still contribute to transmission in the future within their 
communities. Thus, MF testing can lead to underdiagnosis and exclusion of areas with active LF 
transmission (Braga et al. 2003; Weil and Ramzy 2007). Other challenges of MF testing are the 
unsociable hours that the tests are conducted (before and after midnight) with high refusal 
and the extensive microscopy needed that requires extensive training (Bockarie et al. 2013). 
The recommendation to use antigenaemia detection with ICT cards and now FTS for 
monitoring the impact of MDAs on LF instead of the night blood method is considered here a 
good development for the LF programme in Sierra Leone. FTS are therefore recommended for 
use in the next pre-TAS to be conducted in 2017 instead of the NBS/TBF method.   
 
This project has demonstrated how onchocerciasis control activities can be co-implemented 
with LF control activities in areas where both diseases exist and the effectiveness of co-
implementation for control of both diseases. The project also shows how the onchocerciasis 
and LF control programmes can be integrated into a country’s health care delivery system. 
Similar countries with weak health systems can learn how an integrated control program can 
be conducted in a post-conflict country with a weak health system and weak human resources 
for health. 
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SUMMARY OF KEY FINDINGS 
The findings are summarised as follows: 
LF and onchocerciasis are highly endemic in Sierra Leone. Using WHO guidelines for monitoring 
national programmes where both infections are co-endemic, this study aimed to determine 
the impact of preventive chemotherapy on transmission intensity by measuring changes in 
human infection status using standard epidemiological indicators.  
 
Separate longitudinal studies designed to deliver WHO outcomes for programmes targeting 
the elimination of both diseases were conducted. 
1. Studies to map onchocerciasis using skin snip method in 1988-2005 across Sierra Leone 
showed that 12 of the 14 health districts were onchocerciasis-endemic. The baseline 
average MF prevalence was 53.1%, and MF densities in positive-only or entire populations 
were 28.87 and 15.33 mf/snip, respectively. MF prevalence and density increased with age 
and was higher in males than females.  
2. Mapping and baseline prevalence and intensity surveys showed that LF was endemic in all 
14 districts (Wuchereria bancrofti antigenaemia prevalence > 1%) and MDA was necessary 
nationwide for elimination to be achieved. LF prevalence by ICT cards was 21% (males 28%; 
females 15%) with higher prevalence in the northeast (Bombali 52%; Koinadugu 46%; 
Tonkolili 37%; Kono 30%) and lower in the south-west (Bonthe 3%; Pujehun 4%). MF 
prevalence by night blood method was 2.4% (males 3.0%; females 1.8%). MF prevalence 
was also relatively higher in the northeast (Bombali 6.7%; Koinadugu 5.7%; Port Loko 4.4%; 
Kono 2.4%) and higher in the over 20 years’ age-group (2.5%) than younger (1.7%). 
Arithmetic mean MF density was 50.30 mf/ml among MF-positive individuals and 1.19 
mf/ml in the population examined.  
3. Relatively better treatment coverage for onchocerciasis was achieved between 2005 and 
2009 after the end of an 11-year civil conflict in the country in 2002 using the CDTI strategy 
although treatment coverage was effective nationwide only in four of the five districts.  
Assessments conducted in 2010 showed that five rounds of MDA had significantly reduced 
the MF prevalence and intensity. MF prevalence was reduced by 60.22% from 53.09% at 
baseline to 21.12%. Overall MF intensity reduced by 71.29% among MF-positive individuals 
from 28.87 mf/snip at baseline to 8.29 mf/snip, and 88.58% among the entire population 
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from 15.33 mf/snip at baseline to 1.75 mf/snip. MF prevalence and density were higher in 
males, lowest in the 1-9 and highest in the 40-49 year age groups.  MF prevalence was 
reduced by >50% in 10/12 districts, and reduction in skin MF density ≥50% among 
positives-only in 11 out of 12 districts. 
4. After MDAs with effective treatment coverage in 2008-2010, LF MF prevalence decreased 
to less than 1% in 11 of the 12 provincial districts. MF prevalence fell by 88.5% from 2.4% 
at baseline to 0.3%, with decreases of 70-95% in seven districts and 100% (0 prevalence) in 
four districts, respectively. Overall arithmetic mean MF density after three MDAs was 
17.59 mf/ml among MF positive individuals and 0.05 mf/ml for the entire population 
examined. 
5. Previous studies on LF in Sierra Leone have shown a significant reduction in LF MF 
prevalence and MF density. A pre-TAS was conducted in the 12 districts that have 
completed five effective rounds of MDA in accordance with WHO guidelines and 
recommendations. After five MDAs, eight of the 12 districts had <1% MF prevalence and so 
passed the pre-TAS and therefore qualified for a TAS to determine whether MDA could be 
stopped. The overall MF prevalence was 0.54% and was higher in males (0.7%) than 
females (0.36%). Four districts failed the pre-TAS: Koinadugu with 0.98% MF prevalence 
(close to 1%), Bombali with 2.67%; Kailahun with 1.56%, and Kenema district with 0% MF 
prevalence. In accordance with WHO recommendations of selecting one sentinel site and 
one spot check site per million population, Kenema district was paired with Kailahun 
district to form a unit with a total population close to one million. Kailahun had the 
sentinel site and Kenema the spot check site. Kenema is considered to have failed the pre-
TAS even though the MF prevalence is 0% because Kailahun district failed. 
6. A qualitative study designed to determine the effect of the EVD outbreak on the treatment 
for NTDs in Sierra Leone was conducted to inform post EVD disease prevention strategies.  
The EVD outbreak in May 2014 led to many deaths including the death of many health 
workers. The outbreak was controlled and declared over in November 2015 after a lot of 
improvement in treatment and diagnosis of the diseases. Although there was a delay of 
about a year in implementing MDAs, the NTDP has successfully completed two rounds of 
MDA, one of them while the outbreak was still ongoing in May/June 2015. However, 
disease-specific assessments were suspended till early 2017 for fear that the communities 
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targeted will reject interventions that involve blood and the skin surveys. Intensive social 
mobilisation and health education should be continued for the MDAs and disease 
assessments to maintain good community acceptance of the NTDP and adherence to 
treatment and assessments. 
 
In conclusion, while the NTDP has reached the ‘end game’ for LF, there is still some work 
needed for the elimination of onchocerciasis. The path towards the elimination of the two 
diseases in Sierra Leone appears clear. However, it should be noted that many questions still 
exist, especially for onchocerciasis surveillance, that should be addressed by the NTD 
community in collaboration with research institutions. Another fact that should be noted is 
that challenges for effective MDA implementation in the country during the EVD outbreak will 
affect progress towards achieving the 2020 target for the elimination of LF and control of 
onchocerciasis.  
 
 
RELEVANCE OF WHO GUIDELINES TO CONCLUSIONS OF STUDY 
Countries generally look up to WHO for guidelines on how to control or eliminate PC NTDs 
including interventions that should be conducted such as MDAs, the assessment/evaluations of 
the impact of MDAs, strategies including methodologies for MDA campaigns and evaluations, 
the tools to be used and guidance on ‘who, what, where, when, how and why’ for these 
interventions. In Sierra Leone WHO guidelines were used to conduct mapping, MDAs, and 
assessment of the impact of MDAs on the two diseases.  
 
The study shows that while the NTDP has reached the ‘end game’ for LF, there is still some 
work needed for the elimination of onchocerciasis. Although the path towards the elimination 
of the two diseases in Sierra Leone appears clear, WHO guidelines are still needed on the way 
forward for the country to achieve elimination of onchocerciasis and LF in addition to those 
guidelines already available and mentioned above. Many questions still exist, especially for 
onchocerciasis surveillance, that should be addressed by WHO in collaboration with the NTD 
community and research institutions.  
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Gaps still exist on the tools and types of surveys that should be conducted for monitoring the 
impact of MDAs on onchocerciasis. Should spot check or control sites be used in addition to 
sentinel sites as is done for LF so that reductions in MF prevalence and density can be 
monitored better in endemic districts? How should spot check or control sites be selected for 
surveys to monitor the impact of treatment? 
 
Recent WHO guidelines on stop MDA evaluations and verification of onchocerciasis elimination 
(WHO 2016d) have addressed many questions that countries have on the endgame for 
onchocerciasis. However, there are questions that should be answered such as the level at 
which stop MDA evaluations should be conducted. Countries want to use the district level for 
stop MDA evaluations (author’s personal experience dealing with some onchocerciasis-
endemic countries in West Africa) while the guidelines recommend the use of transmission 
zones. The concept of transmission zones remains unclear to countries and WHO guidelines are 
needed on the subject so that countries can easily make decisions for stop MDA evaluations.   
Cross-border transmission of NTDs could become a major challenge for achieving elimination 
of onchocerciasis and LF in endemic countries with the possibility of resurgence or importation 
from neighbouring endemic countries (The Carter Center and MOH Uganda 2011; Bhumiratana 
et al. 2012; Hodges et al. 2012a; Hodges et al. 2012b; WHO 2012; Gustavsen, Sodahlon, Bush 
2016). WHO should be involved in the efforts being made by some NTD partners to address 
this challenge especially so when the implementation of recommendations made during cross-
border meetings are hardly implemented by countries (Gustavsen, Sodahlon, Bush 2016). 
 
New tools are being developed and put in the market for the assessment of onchocerciasis and 
LF that can be used by the NTDP in Sierra Leone for future diseases assessments (PATH 2012; 
PATH 2013; PATH 2014; PATH 2016; WHO 2016c).   
Should serology (OV16 RDTs or OV16 ELISA) be used to monitor the impact of MDAs for 
onchocerciasis before stop-MDA evaluations are conducted? What should be the threshold for 
the OV16 RDTs or OV16 ELISA when they are used for monitoring the impact of MDAs on 
onchocerciasis for deciding to conduct stop-MDA evaluations? If OV16 RDTs are not useful for 
monitoring impact of MDAs on onchocerciasis given that the antibodies they detect reduce 
more slowly in the body than onchocerciasis MFs, and adults could remain positive even when 
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the infection is already absent due to control measures, can countries continue with the skin 
snip method? What should be the threshold for deciding to conduct the stop MDA evaluations 
when the skin snip method is used? Some countries want to use microfilaredermia prevalence 
of 5% while others go for 1% copying from the LF programme. 
For LF there is the Wb123 RDT or SD Bioline LF IgG4 RDT that is now available for use by 
programmes that detects antibodies to the Wb123 LF antigen alone. There is also the Biplex 
test or SD Bioline Onchocerciasis and LF IgG4 RDT that at the same time detects antibodies to 
the onchocerciasis OV16 antigen and the Wb123 LF antigen available for use by programmes 
(PATH 2012; PATH 2013; PATH 2014; PATH 2016; WHO 2016c). These tools could make 
integrated assessments for onchocerciasis and LF possible but WHO should develop guidelines 
on how national programmes can use these new tools. 
 
 
LIMITATIONS OF THE STUDY 
The main limitation of this study is the absence of entomological investigations and morbidity 
surveys to establish the role of MMDP in relating to both diseases. The relevance of both issues 
in Sierra Leone was, however, discussed in the in the literature review.  While there is no WHO 
MMDP requirement for elimination of onchocerciasis (WHO 2016d), the WHO MMDP 
requirement for LF is data supporting availability and provision of the basic recommended 
package of care for LF patients (WHO 2016a). While stop-MDA evaluation for onchocerciasis 
prioritises entomology and entomology results are needed for verification of onchocerciasis 
elimination (WHO 2016b,d), there is no entomology requirement for verification of LF 
elimination (WHO 2016a).  
 
 
RECOMMENDATIONS 
While the study has highlighted the progress and achievements made in addressing 
onchocerciasis and LF in the country, the following recommendations are made for effective 
and efficient elimination of both diseases:  
1. Surveys for monitoring the impact of MDAs on onchocerciasis should be conducted in spot 
check or control sites as well as sentinel sites as is done for LF so that reductions in MF 
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prevalence and density can be monitored better in endemic districts. The sites selected as 
control sites should be changed with each study. 
2. The threshold should be defined for the OV16 RDTs when they are used for monitoring the 
impact of MDAs on onchocerciasis. 
3. Guidelines should be developed to guide national programmes on deciding whether to use 
serology method (OV16 RDTs) or skin snip method for monitoring the impact of MDAs on 
onchocerciasis. 
4. The threshold should, in general, be defined for making the decision to move towards 
stop-MDA evaluations for onchocerciasis. 
5. Intensive social mobilisation and health education should be continued before and during 
MDAs and disease-specific assessments to maintain good community acceptance of the 
NTDP and maintain high adherence to treatment and assessments. The social mobilisation 
should involve district health workers as well as communities so that district health 
workers are also aware that all villages should receive the same attention during MDAs 
because the selection of the SCS can lead to another failure that can create an 
“embarrassment” for the DHMT. 
6. NTD partners should continue to support cross-border meetings to encourage 
collaboration between NTD endemic countries. Countries should be encouraged to 
participate more in cross-border initiatives, and NTD partners and donors should consider 
supporting initiatives for addressing possible cross-border transmission that go beyond the 
usual cross-border meetings. 
7. More research is needed to investigate the suitability for field use of some of the new tools 
developed for assessment of NTDs such as the Biplex. 
8. Experts should conduct a review of the proposed inclusion of cross-border component in 
agreements between NTD partners and programmes in countries and the recently 
established World Bank Sahel project to inform future decisions on cross-border 
collaboration.  
9. The NTDP in Sierra Leone should consider biannual MDA or the use of community-directed 
distribution of doxycycline after 2016 for areas that will still require MDA for 
onchocerciasis and LF based on results of onchocerciasis and LF assessments that will be 
conducted early in 2017. The NTDP and NTD partners supporting the NTDP in Sierra Leone 
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will need to advocate for the additional logistics and financial resources that will be 
needed for these new treatment strategies. The NTD partners will need to work together 
with the NTDP in coordinating biannual MDAs and/or community-directed treatment with 
doxycycline to ensure successful implementation. 
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Abstract
Background: National mapping of lymphatic filariasis (LF) was conducted using Immunochromatographic tests
(ICT) in 2005 to determine endemicity and geographic spread of the disease. A baseline microfilaria survey was
then conducted to determine LF prevalence and microfilaria intensity.
Methods: In 2005 1,982 persons of 15 years and over from 14 health districts were selected and fingertip blood
samples were tested with ICT cards. In 2007-8 blood samples were taken between 10 p.m. and 2 a.m. and
examined for microfilaria (mf) from 9,288 persons from 16 sentinel sites representing each district and 2 additional
sites for districts with populations over 500,000 (Bo and Kenema).
Results: The overall LF prevalence by ICT cards was 21% (males 28%, females 15%). All districts had a prevalence
of Wuchereria bancrofti antigen > 1%. Distribution of LF prevalence showed a strong spatial correlation pattern
with high prevalence in a large area in the northeast gradually decreasing to a relatively low prevalence in the
southwest coast. High prevalence was found in the northeast, Bombali (52%), Koinadugu (46%), Tonkolili (37%) and
Kono (30%). Low prevalence was found in the southwest, Bonthe (3%) and Pujehun (4%). The mf prevalence was
higher in the northeast: Bombali, 6.7%, Koinadugu 5.7%, Port Loko 4.4% and Kono 2.4%. Overall there was a
significant difference in mf prevalence by gender: males 2.9%, females 1.8% (p = 0.0002) and within districts in
Kailahun, Kono, Port Loko, Moyamba and Koinadugu (all p < 0.05). The mf prevalence was higher in people > 20
years (2.5%) than in people ≤ 20 years (1.7%) (p = 0.043). The overall arithmetic mean mf density was 50.30 mf/ml
among mf-positive individuals and 1.19 mf/ml in the population examined which varied significantly between
districts.
Conclusions: The ICT results showed that LF was endemic nationwide and that preventive chemotherapy (PCT)
was justified across the country. Both the ICT and microfilaraemia surveys found that prevalence was greater in
males than females. The increase in microfilaraemia prevalence by age was evident when grouped as ≤ 20 versus
> 20 years demonstrating early exposure. Baseline LF microfilaria load will be used to monitor PCT program
progress.
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Background
Lymphatic filariasis (LF) is a chronic, debilitating disease
that affects people in tropical and subtropical areas of
Asia, Africa, the Western Pacific and some areas of the
Americas caused by the parasites Wuchereria bancrofti
or Brugia malayi and B. timori, transmitted by Culex,
Anopheles and other mosquitoes [1-4]. An estimated
90% of all LF cases worldwide and all cases in Africa are
infections with the parasite W. bancrofti. The main vec-
tors in West Africa are the Anopheles mosquitoes [5].
Over 120 million people in over 80 countries worldwide
in the tropics and subtropics and over 40 million people
in Africa are infected with the parasite [6,7]. Bancroftian
filariasis, which is prevalent in Africa, is endemic in
rural as well as urban communities thriving within poor
communities [5,8,9].
LF has a wide range of clinical manifestation from
acute attacks of filarial fever, chronic conditions such as
hydroceles, lymphoedema, elephantiasis of limbs, and
enlarged breasts, to kidney damage, thus causing great
morbidity and disability for those affected [10]. Filariasis
is one of the most common causes of permanent dis-
ability worldwide creating the highest disease burden in
terms of DALYs among tropical diseases [7]. Those
affected also suffer psychosocial stigmatization and eco-
nomic suffering as it can lead to job loss or inability to
work. The disease is therefore a major cause of poverty
as it creates economic burden for those affected, their
dependants, their communities and the country as a
whole [8,9,11-13]. In 1993 the International Task Force
on Disease Eradication identified LF as one of six dis-
eases that could be eradicated, which led the World
Health Assembly in 1997 to pass resolution WHA 50.29
calling for the elimination of LF as a public health pro-
blem in the world by 2020. In 1998, the Global Alliance
to Eliminate LF was formed to support LF elimination
programmes in endemic countries and World Health
Organization (WHO) launched a Global Programme for
the Elimination of LF as a result [2,3,13-15].
Circulating microfilariae (mf) are responsible for
transmission, therefore transmission can be broken/
interrupted by reducing the number of people with
microfilaraemia within affected communities through
annual mass drug administration (MDA) for 4-6 years
to ≥ 80% of the entire at-risk population which can
reduce mf to zero or close to zero [16,17]. Before MDA
is started in a country, implementation units to be tar-
geted should be determined through a rapid assessment
study and also baseline data on LF mf level should be
obtained to monitor effectiveness of MDA. There are
already countries that have succeeded in eliminating the
disease (Cape Verde, China, Costa Rica, Solomon
Islands, South Korea, Suriname, and Trinidad and
Tobago) using a combination of strategies that include
vector control and single annual doses of 2-drug treat-
ments (albendazole together with ivermectin or diethyl-
carbamazine) [16,17]. The current preferred strategy for
LF elimination recommended by WHO is the preventive
chemotherapy using the available drugs [18,19]. The glo-
bal LF elimination programme has been strengthened by
donation of albendazole by GlaxoSmithKline and con-
tinued donation of ivermectin by Merck & Co [20].
In Sierra Leone, reports from health facilities indicated
endemicity of LF in all districts, and in 1996, a study in
Moyamba district using the thick blood film method
showed mf prevalence: 10.2% with 36.5% clinical mani-
festation (26.6% hydroceles and 9.4% lymphoedema/ele-
phantiasis of the lower extremities) [21]. In 2004, a
country profile of communicable diseases in Sierra
Leone developed by WHO, quoting an anonymous 1999
study in 55 sites including the capital Freetown, showed
that 14.5% of people tested for circulating filarial antigen
of W. bancrofti were positive [22]. The Northern Pro-
vince had the highest prevalence (19.6%), followed by
Western Area (12.8%), Eastern Province (12.7%) and
Southern Province (10.9%) [22]. Infection was noted in
children, and this indicated ongoing transmission and
infections acquired early in life.
In preparation for the national LF elimination pro-
gramme, national mapping was conducted in 2005 using
immunochromatographic test (ICT) cards. The national
LF elimination programme started when the Ministry of
Health and Sanitation (MoHS), Sierra Leone in consul-
tation with WHO decided to conduct the integrated
management of onchocerciasis, LF, schistosomiasis, soil-
transmitted helminthes and trachoma, and the existing
National Onchocerciasis Control Programme became
National Neglected Tropical Disease Control Pro-
gramme (NTDCP) in 2006 [23]. Based on the mapping
results, the implementation units (districts) for LF MDA
were determined and national baseline data on mf level
were collected pre-MDA. The current paper presents
the distribution and the level of infection of LF in Sierra
Leone which formed the base for the national LF elimi-
nation programme.
Methods
Ethics statement
The studies were conducted by the National NTDCP of
the MoHS, Sierra Leone. Ethical approval for data col-
lection was obtained from the Ethics Committee of the
MoHS and upon arrival at the randomly selected com-
munities the investigating team met with the commu-
nity leaders and explained the nature of their work. All
participants aged 15 years or above in each site were eli-
gible for inclusion without discrimination on gender,
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social status, religion or ethnicity. People participated in
the studies after informed consent was verbally obtained
and recorded by the team leader, as literacy rates are
low in Sierra Leone. Data collection was conducted such
that participants remained anonymous during data entry
and analysis. No individual identity can be revealed
upon publication.
National mapping of LF with ICT cards in 2005
Although previous studies and clinical records indicated
that LF was prevalent particularly in the north, detailed
data on distribution and level of risk throughout the
country was not available, and all districts including the
Rural Western Area both Rural (RWA) and Urban Wes-
tern Area (UWA) were included in the mapping. Thirty-
four (34) communities were randomly selected from all
districts in consultation with WHO/AFRO with each
district having at least one community selected. Partici-
pants who were 15 years of age or above were selected
for the antigenaemia study using ICT cards [24]. During
the survey ICT cards were kept overnight at 8°C in dis-
trict cold rooms for the expanded programme on immu-
nization and during the day the cards were transported
in cold boxes and vaccine carriers with ice packs. The
left index finger was pricked with a sterile lancet after
cleaning with cotton wool soaked with spirit and 100 μl
blood collected and applied straight to the ICT cards.
The survey teams were trained to read the results of the
ICT cards at exactly 10 minutes after application,
according to the manufacturer’s instructions. No late
reading of ICT cards was reported by the survey teams.
Due to limited resources and the high sensitivity and
specificity of the ICT [25,26], fifty (50) persons were
sampled in each randomly selected community and if a
positive case was identified the sampling was complete
and the teams moved on to the next site. If in the first
50 samples there was no positive case found, a further
50 persons were sampled bringing the total to 100 per
site [26]. Training of technicians in the use of the ICT
cards to detect W. bancrofti antigen and data recording
took place in Makeni and York Village, RWA. Three
teams of three technicians (2 for specimen collection
and 1 for reading and recording of results) worked with
a village volunteer (usually a school teacher) who served
as registrar. Data included name, sex, village, chiefdom
and district. A total of 1,982 people were tested; males
904 (45.6%) and females 1,078 (54.4%).
Baseline microfilaraemia data collection before MDA
Sampling was conducted in accordance with WHO
guidelines [26] of two sentinel sites per implementation
unit (district for Sierra Leone) with a population of one
million people. Ten of the fourteen health districts of
Sierra Leone have a population below 500,000 and one
sentinel site per district was selected representing a
population ≤ 500,000. One sentinel site each was
selected for RWA (232,294) and UWA (901,953). Bo
district (Bo Town: Bo District, 222,561: 347,610) and
Kenema district (Kenema Town: Kenema District,
188,869: 377,067) had population above 500,000 and
two sentinel sites were selected in these two districts,
making a total of 16 sites. Communities/villages that
showed the highest ICT prevalence in each district in
2005 were selected as mf sentinel sites [26]. The survey
was performed in two phases according to funding avail-
ability: Bombali, Koinadugu, Kambia, Kono, Kailahun
and Pujehun in 2007 and Tonkolili, Port Loko, Kenema,
Bonthe, Moyamba, Bo, RWA and UWA in 2008. Pre-
sensitization was carried out before the survey in each
site. Five hundred participants of 15 years of age or
above were recruited per site. In sites with less than 500
people selected, extra participants were recruited in
neighbouring villages. To ensure the standardization of
activities and data, two day practical training was per-
formed before the study started for all technicians. Fin-
gertip blood was collected between 10 p.m. and 2 a.m.
from each volunteer. A 60 μl blood sample was col-
lected, smeared gently and uniformly in a circular shape
and allowed to air dry at room temperature for 12-24
hours. The following day the dried smear was dehaemo-
globinized by flooding with distilled water for 3-5 min-
utes, air dried again, fixed with methanol for 30-60
seconds, stained with Giemsa for 10 minutes then exam-
ined for mf under a light microscope by experienced
examiners. Positive findings of mf were recorded and
individual mf density of infection was calculated and
expressed as the number of mf per ml of blood (mf/ml)
[26-29]. A total of 9,288 night blood samples were
examined. The mean age (± standard deviation) of the
subjects examined was 37.7 ± 17.04 years (males: 37.27
± 17.6, females: 38.12 ± 16.5). For quality control, all
positive slides and 10% of the negative slides were pre-
served and examined by an experienced researcher.
Statistical analysis
Results were entered into Epi-Info version 3.5.2 and
analyzed in SPSS (IBM, Version 19). Prevalence of posi-
tive circulating LF antigen or microfilaraemia was calcu-
lated. The 95% confidence intervals (CIs) for prevalence
were calculated using the Wilson score method without
continuity correction [30]. The arithmetic mean mf den-
sity of infection with 95% CIs was calculated using the
total population examined and the positive samples only
[26]. Chi-square test was used to compare the differ-
ences in prevalence and Kruskal-Wallis test was used to
compare the differences in mf density. Correlation ana-
lysis was conducted for the two sets of data (ICT and
microfilaraemia prevalences) and the significance of the
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correlation tested [31]. The coordinates of each sample
site were recorded using hand-held units of global posi-
tioning system (site coordinates available upon request).
Spatial analysis of the LF antigenaemia prevalence (ICT
card data) was conducted using the kriging method in
the Geostatistical Analyst Extension of ArcGIS version
10 (ESRI, Redlands, USA). Spatially smoothed contour
maps of the interpolated prevalence of antigenaemia and
the predictive probability for the ICT prevalence of
greater than 1% were produced [32].
Results
Distribution of lymphatic filariasis in Sierra Leone
Table 1 summarizes the results of the survey using ICT
cards for each district. All the districts of Sierra Leone
were found to be endemic for LF with a prevalence of
ICT positive tests ≥ 1%. Point prevalence for each sur-
vey site was shown in Figure 1. Among 34 sites sur-
veyed, only one site in Bonthe district was shown to be
negative. The median prevalence across the 34 sites was
20% ranging from 0% to 68% (inter-quantile range: 11.7-
31%). Overall ICT positive prevalence was 20.8%. High
Table 1 Crude LF prevalence with antigen detection and microfilaraemia tests by district, sex and age group in Sierra
Leone
No of persons
tested by ICT
cards
Percentage prevalence
of antigen positives
(95% CI)
No of persons
examined for
Mf
Percentage prevalence
of Mf positives (95%
CI)
Population Mf
density (mf/ml)
(95% CI)
Positive-only Mf
density (mf/ml)
(95% CI)
Overall 1982 20.8 (19.1 - 22.7) 9288 2.4 (2.1 - 2.7) 1.19 (0.90 - 1.48) 50.3 (39.89 - 60.71)
By district
Bo 173 15.0 (10.5 - 21.1) 1005 2.0 (1.3 - 3.1) 1.97 (0.84 - 3.11) 99.17 (58.32 - 140.01)
Bombali 150 52 (44.1 - 59.8) 830 6.9 (5.3 - 8.8) 1.93 (1.28 - 2.57) 28.07 (21.70 - 34.44)
Bonthe 160 3.1 (1.3 - 7.1) 504 1.2 (0.6 - 2.6) 0.83 (0.02 - 1.63) 69.44 (13.68 - 125.21)
Kailahun 110 19.1 (12.8 - 27.4) 624 2.6 (1.6 - 4.1) 2.08 (0.00 - 4.89) 81.25 (0.00 - 195.58)
Kambia 110 15.5 (9.9 - 23.4) 619 2.1 (1.2 - 3.6) 0.97 (0.23 - 1.71) 46.15 (17.04 - 75.27)
Kenema 180 13.3 (9.1 - 19.1) 1016 0.6 (0.3 - 1.3) 0.34 (0.00 - 0.70) 58.33 (4.42 - 112.24)
Koinadugu 200 46 (39.2 - 52.9) 636 5.7 (4.1 - 7.7) 1.99 (0.95 - 3.04) 35.19 (19.83 - 50.54)
Kono 100 30 (21.9 - 39.6) 875 2.4 (1.6 - 3.6) 1.11 (0.37 - 1.84) 46.03 (20.09 - 71.97)
Moyamba 200 10.5 (7.0 - 15.5) 500 1 (0.4 - 2.3) 0.67 (0.00 - 1.36) 66.67 (6.33 - 127.00)
Port Loko 210 20.5 (15.6 - 26.4) 500 4.4 (2.9 - 6.6) 3.53 (1.48 - 5.59) 80.30 (44.49 - 116.12)
Pujehun 160 4.4 (2.1 - 8.8) 624 0 (0 - 0.6) - -
Tonkolili 100 37 (28.2 - 46.8) 500 2.4 (1.4 - 4.2) 0.63 (0.24 - 1.03) 26.39 (17.99 - 34.79)
WA Rural 69 7.3 (3.1 - 15.9) 500 1.2 (0.6 - 2.6) 0.33 (0.01 - 0.65) 27.78 (6.60 - 48.96)
WA Urban 60 11.7 (5.8 - 22.2) 555 0 (0 - 0.7) - -
By sex
Male 904 27.5 (24.7 - 30.6) 4335 3.0 (2.6 - 3.6) 1.66 (1.11 - 2.20) 54.42 (38.81 - 70.02)
Female 1078 15.2 (13.2 - 17.5) 4953 1.8 (1.4 - 2.2) 0.78 (0.52 - 1.04)) 44.13 (32.50 - 55.76)
By age
group
(yrs)
15-20 - - 1873 1.8 (1.3 - 2.5) 0.78 (0.38 - 1.19) 44.44 (26.37 - 62.52)
21-30 - - 2019 2.6 (2.0 - 3.4) 1.77 (0.73 - 2.80) 68.59 (31.79 - 105.39)
31-40 - - 1830 2.4 (1.8 - 3.2) 1.01 (0.55 - 1.47) 43.02 (27.55 - 58.50)
41-50 - - 1404 3.4 (2.5 - 4.4) 1.60 (0.94 - 2.27) 47.87 (32.75 - 62.99)
> 50 - - 2162 2.1 (1.6 - 2.8) 0.89 (0.49 - 1.30) 42.96 (27.40 - 58.53)
Figure 1 Geographical distribution of lymphatic filariasis point
prevalence by circulating antigen detection with ICT cards
according to survey locations in Sierra Leone.
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prevalence was found in the northeast part of the coun-
try (Bombali 52%, Koinadugu 46%, Tonkolili 37% and
Kono 30%). Relatively low prevalence was found in the
southwest coastal districts (Bonthe 3.1% and Pujehun
4.4%).
There were significantly more positive ICT tests in
males (27.54%, 95% confidence interval (CI): 24.7-30.6%)
than in females (15.2%, 95% CI: 13.2-17.5%) (p <
0.00001). Detailed analysis of prevalence among different
age groups was not carried out as detailed age informa-
tion was not recorded for the ICT card survey.
Microfilaraemia prevalence and density
Overall 9,288 night blood samples, male 4,335 (46.7%)
and female 4,953 (53.3%), were examined for mf as
shown in Table 1. There were less than 5% false posi-
tives and no false negative slides. All positive slides were
reexamined and 3 were redefined as artifacts. No mf of
Mansonella perstans was detected.
In total, 220 persons (2.4%, 95% CI: 2.1-2.7%) had a
positive blood smear and there was significantly higher
mf prevalence in males 3.0% (95% CI: 2.6-3.6%) versus
females 1.8% (95% CI: 1.4-2.2%) (p = 0.0002). Age distri-
bution of the mf prevalence is also shown in Table 1.
There was a significant difference in mf prevalence
among age groups with higher prevalence in persons of
41-50 years (p = 0.041).
The point prevalence of microfilaraemia for each site
is shown in Figure 2. There was a significant correlation
between the mf prevalence and the ICT card prevalence
(r = 0.86, p < 0.05). In line with the ICT results, the mf
prevalence (95% CI) was higher in the northeast part of
the country: Bombali, 6.9% (5.3-8.8%), Koinadugu 5.7%
(4.1-7.7%), Port Loko 4.4% (2.9-6.6%), Kailahun 2.6%
(1.6-4.1%) and Kono 2.4% (1.6-3.6%). No mf was found
in persons examined in the UWA and Pujehun.
The overall arithmetic mean mf density was 50.30 mf/
ml (95% CI: 39.89-60.71 mf/ml) among mf-positive indi-
viduals, and 1.19 mf/ml (95% CI: 0.90-1.48 mf/ml) in
the population examined (Table 1). There was signifi-
cantly higher mf density in the male population than in
the female population (p < 0.0001). There was also a
significant difference in mf density among age groups in
the total population examined (p = 0.041). There was
no significant difference in mf density by sex or age
groups of infected persons (p > 0.1).
Spatial prediction of LF distribution
The spatial analysis of the ICT card data showed a
strong spatial correlation pattern as the semi-variance in
prevalence data in relation to the distance between sur-
vey sites (Figure not shown). The predicted spatial dis-
tribution of LF by kriging is shown in Figure 3. This
shows a widespread distribution of LF prevalence with a
clear geographical distribution pattern in Sierra Leone:
high (> 40%) in a large area spanning the northeast of
the country with two clusters of predicted prevalence of
over 50%, gradually decreasing towards the southwest,
and ending low (< 5%) in the coastal part of Bonthe and
Pujehun districts. Figure 4 shows the predicted probabil-
ity of the LF prevalence being over 1%, which shows
Figure 2 Geographical distribution of lymphatic filariasis point
prevalence by mf detection and point mf density according to
survey locations in Sierra Leone.
Figure 3 Spatially smoothed contour map of predicted LF
prevalence by ICT cards in Sierra Leone.
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high probability throughout the country with only two
small clusters of relatively low probability (< 50%) in
Bonthe and Moyamba.
Discussion
All districts in Sierra Leone were endemic with LF and
qualified for MDA. Distribution of LF prevalence
showed a strong spatial correlation pattern with high
prevalence in a large area in the northeast gradually
decreasing to relatively low prevalence in the southwest
coast. ICT results showed two distinct patterns: males
were more infected than females and districts in the
northeast part of the country had a higher prevalence
than other districts. The ICT results obtained in this
study were higher than in 2004 but the same pattern of
a higher prevalence for circulating filarial antigen in the
north than all other regions was repeated [22]. Three
distinct patterns were also noted in the microfilaraemia
survey: microfilaraemia was higher in males (3.0%) ver-
sus females (1.8%), increased with age in the population
peaking at 41-50 years, and showed higher prevalence in
the northeast than in other parts of the country. In two
districts (UWA and Pujehun), microfilaraemia was not
identified among the subjects examined, even though
ICT prevalence was 11.7% and 4.4% respectively.
The mf prevalence was lower than that reported in
1996 but that study was conducted in an area with
clearly visible signs of the disease to highlight the ser-
iousness of the problem [21]. There were many such
areas in the districts where LF signs were clearly visible
among the population but in this study the sites were
randomly selected to avoid bias, therefore the results of
this study were more representative of the mf preva-
lence in the district population. The results acquired in
this study on mf prevalence and mf density/intensity
will form the basis for monitoring and evaluation of the
effectiveness of MDA in interrupting LF transmission in
each district.
Similar patterns are noted for both studies in geogra-
phical and sex distribution of the disease, which further
strengthens the notion that these results are representa-
tive of the actual national picture. The ICT positive pre-
valence was nine times greater than the mf prevalence.
Several authors have reported that ICT positive preva-
lence, which detects antigen released by adult W. ban-
crofti, can be 3-5 times higher than mf prevalence.
People can be infected with the disease and still be ami-
crofilaraemic, which may explain the zero mf prevalence
in UWA and Pujehun district in these studies [27,33,34].
Previous studies demonstrated the impact of long-
term treatment with ivermectin alone for onchocerciasis
control on LF prevalence and transmission, which
showed that in villages treated for many years with iver-
mectin, LF microfilaraemia prevalence and intensity
were significantly lower than in untreated villages
[35,36]. Antigenaemia rates were significantly higher
than microfilaraemia rates generally [35,36]. Onchocer-
ciasis was endemic in 12 out of the 14 health districts in
Sierra Leone [23]. Community based treatment with
ivermectin for the control of onchocerciasis in Sierra
Leone started in the late 1980s but did not reach full
geographical coverage due to insecurity at the beginning
of the civil war in 1991 and were subsequently sus-
pended in 1994. In 2003 community-directed treatment
with ivermectin (CDTI) was introduced but therapeutic
coverage was low in the post conflict setting. In 2005
the National Onchocerciasis Control Program (NOCP)
was reorganized and therapeutic coverage reached the
prerequisite ≥ 65% and has been maintained in all ende-
mic districts since [23]. The relatively low microfilarae-
mia rates in our study and the difference between
antigenaemia rates and microfilaraemia rates may have
been due to the ivermectin treatment for onchocerciasis
control in Sierra Leone before the surveys were
conducted.
The current results are in line with other studies that
males have higher prevalence than females for circulat-
ing filarial antigen as well as for microfilaraemia
[12,37,38]. The most probable reason for this is that
males spend more time exposed to the bites of mosqui-
toes. The distribution of mf prevalence increasing with
age shown in this study is in line with results of many
other studies [9,12,33,37,38]. This emphasizes the
Figure 4 Spatially smoothed contour map of the predicted
probability that the prevalence of LF antigenaemia exceeds
1%.
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socioeconomic impact of the disease as the age groups
affected most are the major workforce in the villages. In
Sierra Leone an estimated 70% of adults are farmers
[39], and disability from LF incapacitates those affected
and increases poverty, which is a cause for concern as
the country is among the poorest in the world and
demands appropriate attention for elimination of the
disease. It has been suggested that adults could be more
exposed to mosquito bites because of higher relative
heat, more carbon dioxide output or simply because
they have relatively greater surface area that can be bit-
ten by mosquitoes [38]. Similar studies on antigenaemia
and microfilaraemia for W. bancrofti have been con-
ducted in other countries that reflected similar gender
and age pattern as our studies [40-42].
There are certain limitations for the current studies.
Firstly, children below 15 years were not selected for
circulating filarial antigen and for microfilaria according
to the WHO guidelines [24]. The WHO profile for LF
in Sierra Leone in 2004 indicated that children were
infected and that the infection could be acquired early
in life [22]. It has been suggested that excluding children
below 15 years could bias the studies towards older peo-
ple and since it is common knowledge that filariasis
infection increases with age, the prevalence might have
been overestimated for the general population compared
to other studies that used population based sampling
methodology [33]. While this may have been true in this
study, considering the overall global objective is LF
elimination, such slight overestimation of LF prevalence
due to the age bias should not have made much differ-
ence in terms of MDA decision in Sierra Leone. Sec-
ondly, it is recommended that ICT cards be stored at or
around 8°C [13]. Although efforts were made to keep
the cards in cold box during the field work, the rela-
tively poor field conditions in the remote villages may
have made it difficult to keep the box cold at all time.
In such field conditions, reading every card within the
time limit may not have been guaranteed. This may in
part explain the higher ICT positive prevalence (nine
times greater than the mf prevalence) in the current stu-
dies than in other studies [27,33,34]. However, taking
both ICT and mf positive prevalence together, there is a
strong correlation between the results of the two surveys
for the 14 health districts as shown through correlation
analysis. Therefore, the results can be considered to be
representative of the true LF endemic situation in Sierra
Leone.
Based on the information provided by these studies,
the national NTDCP started LF MDA in 2007 [23].
Four rounds of MDA with albendazole and ivermectin
have been delivered in 6 districts, three rounds in 7
districts RWA and two rounds in the UWA [43]. The
mid-term impact assessment is now being conducted
at the sentinel sites plus several hot spots with local
knowledge of high occurrence of LF morbidity using
blood smears for mf detection. It is hoped that the
assessment results will provide tools to evaluate the
impact of the MDA and to adjust the course of MDA
if necessary.
Conclusion
LF mapping using ICT cards was successfully conducted
in 2005 in all districts of Sierra Leone which showed
that all districts were endemic for LF and qualified for
MDA. Baseline data collection with night blood smear
was conducted in 2007-08 before MDA, which provided
baseline values for mf prevalence and mf density and
confirmed LF endemic status determined by ICT card
survey across the country. These surveys provided tools
for the NTDCP to design and implement MDA and
provided the basis for future monitoring and evaluation
of the national LF elimination programme.
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Abstract
Background: 1974–2005 studies across Sierra Leone showed onchocerciasis endemicity in 12 of 14 health districts (HDs) and
baseline studies 2005–2008 showed lymphatic filariasis (LF) endemicity in all 14 HDs. Three integrated annual mass drug
administration (MDA) were conducted in the 12 co-endemic districts 2008–2010 with good geographic, programme and
drug coverage. Midterm assessment was conducted 2011 to determine impact of these MDAs on LF in these districts.
Methodology/Principal Findings: The mf prevalence and intensity in the 12 districts were determined using the thick blood
film method and results compared with baseline data from 2007–2008. Overall mf prevalence fell from 2.6% (95% CI: 2.3%–
3.0%) to 0.3% (95% CI: 0.19%–0.47%), a decrease of 88.5% (p= 0.000); prevalence was 0.0% (100.0% decrease) in four
districts: Bo, Moyamba, Kenema and Kono (p = 0.001, 0.025, 0.085 and 0.000 respectively); and seven districts had reductions
in mf prevalence of between 70.0% and 95.0% (p = 0.000, 0.060, 0.001, 0.014, 0.000, 0.000 and 0.002 for Bombali, Bonthe,
Kailahun, Kambia, Koinadugu, Port Loko and Tonkolili districts respectively). Pujehun had baseline mf prevalence of 0.0%,
which was maintained. Only Bombali still had an mf prevalence$1.0% (1.58%, 95% CI: 0.80%–3.09%)), and this is the district
that had the highest baseline mf prevalence: 6.9% (95% CI: 5.3%–8.8%). Overall arithmetic mean mf density after three
MDAs was 17.59 mf/ml (95% CI: 15.64 mf/ml–19.55 mf/ml) among mf positive individuals (65.4% decrease from baseline of
50.9 mf/ml (95% CI: 40.25 mf/ml–61.62 mf/ml; p = 0.001) and 0.05 mf/ml (95% CI: 0.03 mf/ml–0.08 mf/ml) for the entire
population examined (96.2% decrease from baseline of 1.32 mf/ml (95% CI: 1.00 mf/ml–1.65 mf/ml; p = 0.000)).
Conclusions/Significance: The results show that mf prevalence decreased to ,1.0% in all but one of the 12 districts after
three MDAs. Overall mf density reduced by 65.0% among mf-positive individuals, and 95.8% for the entire population.
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Introduction
Lymphatic filariasis (LF) and onchocerciasis are two of the
major neglected tropical diseases (NTDs), presently targeted for
elimination using the World Health Organization (WHO)
recommended strategy of preventive chemotherapy and transmis-
sion control (PCT) [1,2,3]. LF is a disease caused by the lymphatic
filarial roundworms Wuchereria bancrofti, Brugia malayi and Brugia
timori, and transmitted by mosquitos. It is highly endemic in the
tropics and subtropics (Africa, Asia, South Pacific and some parts
of South America). The elimination strategy is through annual
mass drug administration (MDA) with albendazole and ivermec-
tin/diethylcarbamazine [1,2]. LF elimination is implemented
through the Global Programme to Eliminate Lymphatic Filariasis
(GPELF) which has expanded MDA coverage from three million
people treated in 12 countries in 2000, to more than 450 million in
53 countries in 2010 [4,5]. During that period, the disease was
eliminated in China and Korea. Nine countries no longer require
MDA because of a natural decline in transmission intensity in
areas of low disease endemicity. Globally, a total of 73 countries
(including the recently independent Republic of South Sudan) are
presently endemic for LF. Onchocerciasis, caused by Onchocerca
volvulus, is transmitted by blackflies belonging to the Simulium
damnosum complex. It is mainly endemic in Africa, Yemen and the
Americas [6]. Control of the disease in Africa is through the
African Programme for Onchocerciasis Control (APOC) using the
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annual community-directed treatment with ivermectin (CDTI)
strategy [7]. In 2008 alone, 56.7 million people received treatment
in 19 endemic African countries [7].
In Sierra Leone, both diseases are widely distributed across the
country and co-endemic in 12 of the 14 health districts. The early
distribution and clinical manifestations of both diseases in Sierra
Leone were described in previous publications [8,9,10,11,12].
When Sierra Leone was included as part of the Onchocerciasis
Control Programme (OCP) of WHO in 1989, treatment strategy
for onchocerciasis control included aerial larviciding using
helicopters and aircrafts targeting the breeding sites of the
blackflies and ivermectin treatment as Merck & Co. Inc. had
started donation of Mectizan (ivermectin) in 1987. National
Onchocerciasis Control Programme (NOCP) records show that by
1994 annual biting rates of the savannah blackfly population
dropped from the 1988 pre-treatment level of 60 bites/person/day
to 1 bite/person/day and the community microfilaria load
decreased by over 90%. However, by 1996 onchocerciasis control
activities were stopped in all areas of the country when the civil
conflict that started 1991 engulfed the entire country. The civil
conflict ended in 2002, the same year that OCP was closed.
NOCP activities recommenced in 2003 under the Special
Intervention Zones (SIZ) established by APOC for some ex-
OCP countries, including Sierra Leone. Surveys on onchocerciasis
conducted in Sierra Leone after 2002 (unpublished NOCP data)
showed that vector biting rates and community microfilaria load
had reverted to pre-treatment levels in many communities. Since
2003 annual MDAs have been conducted for onchocerciasis
control using the CDTI strategy with technical and financial
support from APOC. The CDTI strategy, which promotes
community participation as the key aspect of ivermectin distribu-
tion to improve access to ivermectin and ensure community
ownership of the process, was adopted by APOC in the mid-1990s
after a multi-country study. At first the local health workers and
NGDO representatives introduce CDTI to the community in a
participatory manner. Through a series of community meetings
they explain the roles and responsibilities of communities in the
CDTI process. The communities themselves then direct the
planning and implementation of the interventions. The commu-
nity collectively selects the community drug distributors (CDDs)
and then plan the distribution process by deciding the method
used (house to house or central location), the place where the
distribution is conducted if fixed location is accepted, when the
distribution is conducted, by whom activities will be implemented,
how all activities will be monitored, and the support, if any, that
CDDs will receive (financial or otherwise) from the community.
With CDTI communities manage ivermectin by collecting their
supply from a central point agreed upon with the health services
and storing it within the community until the distribution period.
The health workers and NGDO representatives train, supervise
and monitor the CDDs while the community directs the process. It
has been observed that when the community takes charge of
onchocerciasis control MDAs can be sustained for up to 20 years.
Furthermore, programme costs are reduced significantly because
the community plays the leading role in all aspects of programme
implementation [13,14]. Apart from training of communities to
assume leadership of the CDTI process, NGDOs have also made
significant contribution to the CDTI process through operational
research, provision of resources to complement national pro-
grammes by supporting health staff in remote communities, and
provision of technical and financial support. An NDGO Coalition
was created in 1991 for onchocerciasis control that meets regularly
to coordinate collaboration at international and national levels
[15]. Annual MDAs using the CDTI strategy has significantly
reduced parasite prevalence and intensity in many communities of
Sierra Leone since control operations resumed in 2003 [16].
Reports from health facilities had always indicated high endemic-
ity of LF in all districts. Pre-baseline prevalence of LF was very
high in south-eastern Sierra Leone. Blacklock (1922) examined
240 men in Mabang village and found 20% to be microfilaraemic,
with prevalence of elephantiasis and hydrocoele of 4.6% and
3.8%, respectively [17]. Surveys in the early 1990s showed an
average mf prevalence of 34.8% in three villages in the Moyamba
district [18]. Similarly high prevalence rates were recorded in
neighboring Liberia prior to the 1980s [19,20]. In 2007–2008, the
pre-treatment mf prevalence for the 12 districts outside the
Western Area ranged from 0–6.9%, although prevalence was
below 3% in the south-eastern districts [21] with Moyamba district
showing pre-treatment mf prevalence of 1% (95%CI 0.4%–2.3%)
[21]. This significant reduction of mf prevalence from earlier high
levels prior to the start of the LF MDAs coincides with the
commencement of mass administration of ivermectin for oncho-
cerciasis control in the 1980s [16]. After national mapping of LF in
2005 and baseline data collection on microfilaria (mf) prevalence
and density in 2007–2008 [21], CDTI was expanded to include
albendazole distribution to control LF in six co-endemic districts in
2007 [16]. With support from the United States Agency for
International Development (USAID) NTD Control Program,
managed at the time by RTI International, the NOCP was
transformed into the National Neglected Tropical Diseases
Control Programme (NTDCP) in 2008 to upscale treatment for
LF from 6 districts to all 14 endemic districts and integrate other
NTDs such as schistosomiasis and soil transmitted helminthiasis
into the control effort [16]. After the civil war in Sierra Leone,
during which almost all health programmes had stopped, the
Ministry of Health and Sanitation (MOHS) had decided to put the
control of all NTDs under the existing onchocerciasis control
programme with 1(one) programme manager responsible for all
NTDs and working in close collaboration with strong district
health management teams (DHMTs). It was decided that running
vertical programmes for NTDs will be inefficient given the post
war situation and the limited number of health workers and so the
national coordination for NTDs had to work in close collaboration
with the DHMTs and the existing district health structure.
Author Summary
Onchocerciasis studies across Sierra Leone between 1974
and 2005 showed that 12 of the 14 health districts (HDs)
are endemic for onchocerciasis. Baseline lymphatic filariasis
(LF) studies 2005–2008 showed that all 14 HDs of Sierra
Leone are LF endemic. Three annual rounds of integrated
mass drug administration (MDA) with ivermectin and
albendazole 2008–2010 were conducted in the 12 HDs
that are co-endemic for onchocerciasis and LF with good
geographic, epidemiological drug (or programme) and
drug coverage. A midterm evaluation study of mf
prevalence and density was conducted in the 12 HDs in
2011. The hypothesis proposed for this study is that areas
previously exposed to ivermectin treatment for onchocer-
ciasis control may require less rounds of annual MDA to
eliminate LF (i.e. reduce microfilaremia (mf) prevalence to
,1%). Results of the midterm evaluation study showed
very significant and rapid reduction of mf prevalence and
density with 11 out of the 12 districts having mf
prevalence ,1%. Relatively low LF baseline prevalence
and effective integrated MDA for onchocerciasis and LF
have led to rapid reduction in LF prevalence.
Impact of 3 MDAs on LF in Sierra Leone
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Annual MDA with ivermectin and albendazole has been
implemented since then. By early 2011, all 12 rural health
districts (except Urban Western Area and Rural Western Area)
had received at least three rounds of MDA. LF antigenemia
prevalence (ICT) in 2005 was 11.7% (95% CI: 5.8%–22.2%) and
7.3% (95% CI: 3.1%–15.9%) for Urban Western Area and Rural
Western Area respectively and baseline microfilaremia prevalence
in 2008 was 0% (95% CI: 0%–0.7%) and 1.2% (95% CI: 0.6%–
2.6%) for Urban Western Area and Rural Western Area
respectively. The study presented in this manuscript is the
midterm evaluation of the LF programme in Sierra Leone as part
of the national NTD Control Programme and was conducted
following guidelines provided by WHO, which recommends
midterm programme review before the 4th round of MDA. The
2 LF-only districts were not included in this study because effective
MDA in these 2 districts started in 2010, while effective MDA in
the other districts started in 2007/2008. These 2 districts have
been treated through MDAs since 2010 but post-MDA microfil-
aremia studies have not yet been done. According to WHO
guidelines [22], a mid-term survey was conducted in July/August
2011 in sentinel and spot check sites in the 12 rural health districts.
The hypothesis of the study is that areas previously exposed to
ivermectin treatment for onchocerciasis control may require fewer
rounds of MDA to interrupt transmission of LF. Study objectives
are to assess midterm progress towards LF elimination by
measuring the microfilaremia prevalence for LF in districts that
had conducted 3 good round of MDA and identify any
implementation units (districts) that may require additional effort
to reach the target of LF elimination. In this paper we describe the
impact of three rounds of MDA on LF prevalence and mf density
in areas of low LF endemicity which may be related to previous
treatment with ivermectin for onchocerciasis control.
Methods
Ethics Statement
This study was conducted by the National NTDCP of the
MOHS, Sierra Leone as part of the routine monitoring and
evaluation activities of the national control programme. Ethical
approval for the study was obtained from the MOHS Research
and Ethics Committee. Informed oral consent was obtained from
each participant before samples were collected. Parents and
guardians provided informed consent for child participants to
participate in the study before samples were collected. The
acceptance of all participants/parents and guardians (for children)
was recorded on a form by the team leader, as literacy rates are
low in the country. All participants aged 5 years and above in each
site were eligible for inclusion without discrimination on gender,
social status, religion or ethnicity. Participants’ identities were
protected by collecting, recording and analyzing data such that
participants remained anonymous.
Mass Drug Administration
Annual MDA with ivermectin and albendazole was piloted in
2007 in six rural districts located in border areas with neighboring
Guinea and Liberia: Bombali, Kailahun, Kambia, Koinadugu,
Kono, and Pujehun. This was scaled up to cover 12 rural districts
in 2008 with six additional districts added to the previous six: Bo,
Bonthe, Kenema, Moyamba, Port Loko and Tonkolili. Geo-
graphic coverage for the endemic districts targeted reached 100%
in 2010 when MDA was scaled up to cover the remaining two
health districts: Urban Western area and Rural Western area [23].
Within rural communities ivermectin and albendazole were
distributed by CDDs who are literate members of the respective
communities selected by their communities and trained by health
workers. CDDs are trained by district health workers to conduct
pre-MDA census, house-to-house visits in the village, treat all
eligible members of the community by observing them while they
take the doses, conduct follow up visits to treat absentees and
complete the relevant reporting tools used at community level. 1
CDD is trained to cover approximately 100 people and for Sierra
Leone where the average population per community is about 200,
each community has on average 2 CDDs. In urban areas the
programme tried but could not succeed in getting community
volunteers (CDDs) to distribute the ivermectin and albendazole
without getting any financial payment as in rural areas and so
students in medical and nursing institutions were trained and paid
to conduct MDAs. District health workers conduct trainings for
MDA and provide supervision during MDAs. NTDCP staff and
members of the DHMTs also supported training and supervision
for MDAs. MDA is conducted once a year between September
and December, which is the post-harvest period that communities
have accepted for MDAs.
Before each MDA, CDDs conduct a pre-MDA census. Details
on all community members are recorded in the community
registers and updated each year prior to subsequent MDA. MDA
details are also captured in the registers. After each MDA, details
are summarized in the reporting forms by drug distributors and
submitted to the supervising health workers. The supervising
health workers prepare summary reports for all villages/urban
areas targeted and submit the reporting forms to the DHMTs.
Each DHMT then submits the district MDA report to the
NTDCP, which collates MDA results from all districts. It should
be noted that all activities were co-implemented for both
onchocerciasis and LF control starting from trainings of district
health workers and CDDs, community sensitization and mobili-
zation, advocacy and mass distribution of ivermectin and
albendazole. The NTD control programme is also strongly
integrated in the national and district health system and has
benefitted from a well-structured health system at district level that
has a focal person responsible for NTD control within each
district, which ensures high treatment and geographic coverage.
MDA in the 6 districts that piloted MDA for LF in 2007 took
place in rural areas (villages) only as the main aim of this pilot
MDA was to see how the CDDs and the district health workers
can manage integrated MDA for onchocerciasis and LF (i.e.
distribution of both ivermectin and albendazole). The onchocer-
ciasis control programme is not implemented in urban areas with
large populations or populations greater than 2000 people.
Therefore, the integrated MDA in 2007 was done only in areas
previously treated for onchocerciasis. As the 6 districts that piloted
MDA for LF in 2007 did not cover the urban areas (i.e. district
headquarter towns and other large towns with population .2000
people) with relatively poor treatment coverage (well below 65%),
the 2007 MDA results were considered inadequate. It was only in
2008 that urban areas of the 12 districts were treated using health
workers as distributors. 2008 is therefore considered year 1 when
MDA results were ‘‘adequate’’ as treatment coverage was above
65% and geographic coverage was 100%. Please see tables 1 and 2
for districts that conducted pilot MDA in 2007.
Survey Site Selection
34 Villages were randomly selected by AFRO in Brazzaville
using the available database for villages in Sierra Leone in 2005
with at least 2 villages selected per district depending on the
population and sent to the programme. After the mapping in
2005, villages with relatively very high antigenemia prevalence
were selected for all 14 health districts as sentinel sites for the
Impact of 3 MDAs on LF in Sierra Leone
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baseline mf survey in 2007/2008. The number of sentinel sites
selected per district depended on the population of the district.
The then WHO guidelines recommended 1 sentinel site per
500,000 population and 1 sentinel site was selected for districts
with population less than 500,000 and 2 for districts with
population more than 500,000 [21,24].
Sampling for the midterm survey July/August 2011 was
conducted in accordance with new WHO guidelines in one
sentinel site and one spot check site per population of one million
people [22]. The 12 rural districts that had conducted at least
three rounds of MDA were involved in this study. As the
populations of the districts were small, the 12 districts were put in
six groups of two districts depending on geographical proximity
and epidemiological characteristics so that the total population for
each group was about a million [22]. In each of the six groups
(table 3), a sentinel site was selected in one district for this study,
and a spot check site was selected in the other district, in
consultation with the DHMTs. The groups included the following
pairs of districts: Bonthe (sentinel site (SS)- Moboya) and
Moyamba (spot check site (SCS)- Taninahun Kapuima); Koina-
dugu (SS-Kumala) and Bombali (SCS-Makoba Yelima); Bo (SS-
Gelehun) and Pujehun (SCS- Kundorwahun); Port Loko (SS-
Gbabai) and Kambia (SCS- Kamasasa); Kailahun (SS-Manowa)
and Kenema (SCS- Joru); Kono (SS- Tombodu) and Tonkolili
(SCS-Rosint). In the ‘‘sentinel site’’ districts data obtained in this
study were compared with baseline data, while among the ‘‘spot
check site’’ districts, the results of this survey were compared with
baseline results obtained in the original sentinel sites in these
districts.
The spot check sites were selected in consultation with DHMTs
because according to WHO guidelines of 2011 spot check sites are
to be selected according to the local knowledge where LF is most
likely to be found as the objective of LF control is elimination [22].
By consulting with DHMTs and selecting areas where LF
prevalence could be high the possibility of selecting spot check
sites that will have zero prevalence while there were areas with
high prevalence within the same districts might have been avoided
[22].
Recent WHO guidelines [22] recommend study of a minimum
of 300 participants per sentinel/spot check site but villages in
Sierra Leone generally have small populations (average of 250)
and so in most cases all those 5 years and above that volunteered
in the sentinel/spot check villages were simply selected while
others in neighboring villages were randomly selected to have a
number greater than 300 participants. WHO recommends
convenience sampling for any group selected for LF survey
because they are seen to be at high risk [22].
Sampling and Diagnosis
The survey teams met with community leaders upon arrival in
communities and explained the nature of their work, after which,
meetings were held with the general community to explain the
study and its significance and respond to questions from
community members before the study was conducted. Some
300–500 participants of 5 years of age or above were recruited per
site according to WHO guidelines [22]. In sites with less than 300
participants, more participants were recruited in neighboring
villages. To ensure standardization of activities and data, two-day
practical training was conducted for all technicians before the
study started. Fingertip blood was collected between 10 pm and 2
am. A 60 ml blood sample was collected from each participant,
smeared gently and uniformly in a circular shape and allowed to
air dry at room temperature for 12–24 hours. The next day, the
dried smear was dehaemoglobinized through flooding with
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distilled water for 3–5 minutes, air dried again, fixed with
methanol for 30–60 seconds, stained with GIEMSA for 10 min-
utes, and examined for mf under a light microscope by
experienced examiners. The640 objective was used to first locate
the mf by moving patiently from left to right or right to left starting
at the extreme top end of the thick blood film and moving through
all available fields; then moving slightly downwards and repeating
the same process of moving from left to right or right to left until
all areas of the thick blood film are covered. When mf is located
the filarial species was identified using 6100 objective [22]. A
minimum of 50 microscopic fields were examined before a
specimen was considered negative. The research team included
laboratory technicians from the national reference laboratory and
the University of Sierra Leone who have adequate experience in
diagnostic detection of filarial parasites. The team leader was also
supported in 2007 by WHO and the NTD Support Center in
Ghana to receive further training on detection of filarial parasites
at the Noguchi Memorial Institute for Medical Research in Accra,
Ghana. Positive findings of mf were recorded and individual mf
density of infection was calculated and expressed as the number of
mf per ml of blood (mf/ml). A total of 6,023 ‘‘midnight’’ blood
samples were collected and examined for mf as shown in table 1,
male 3,170 (52.6%) and female 2,853 (47.4%). The mean age (6
standard deviation) of the subjects examined was 28.91618.92
years (males: 27.65618.77, females: 30.32618.92). For quality
control, all positive slides and 10% of the negative slides were
preserved and examined by a researcher, who was invited during
the design of the study to help in designing the study and to
conduct the quality control because he has been involved in the
study and detection of filarial parasites since 1995–1996 [18].
There were only 18 positive slides and these were submitted for
quality control together with 600 randomly selected negative
slides. Results of the quality control showed that all 18 positive
slides were true positives while the negative slides were all true
negatives. The coordinates of each sample site were recorded using
hand-held units of global positioning system (site coordinates
available upon request).
Statistical Analysis
Results were entered into MS Excel and analyzed in SPSS
(IBM, Version 19). Prevalence and density of mf were calculated
for all 12 districts and compared with the baseline data. The 95%
confidence intervals (CIs) for prevalence were calculated using the
Wilson score method without continuity correction [25]. The
arithmetic mean mf density of infection with 95% CI was
calculated using the total population examined and the positive
samples only [21,24]. The Chi-squared test was used to compare
the differences in prevalence and the Kruskal-Wallis test was used
to compare the differences in mf density. Treatment coverage was
calculated according to the WHO guidelines [22]. Epidemiolog-
ical drug coverage (EDC), otherwise known as Programme
coverage, is the treatment coverage reported using total
population of IU as denominator and is calculated as the number
of people who were reported to have ingested the medicines for
LF divided by total population in IU multiplied by 100. The
epidemiological drug coverage calculated using the total popu-
lation of the IU is a reflection of what proportion of the at-risk
population is being covered by MDA. Drug coverage (DC) is the
treatment coverage reported using individuals targeted or eligible
for treatment in the IU as denominator and is calculated as the
number of people who were reported to have ingested the
medicines for LF divided by all individuals targeted or eligible for
treatment in the IU multiplied by 100. The drug coverage in the
targeted or eligible population is considered the best measure of
how well MDAs are implemented. An adequate level of EDC is
estimated to be 80% and the DC should be close to 100%. These
indicators enable IU authorities to assess the status of the
elimination programme. WHO recommends that programme
managers use the reported coverage to identify areas with low
coverage, investigate the causes and find solutions that will
improve programme implementation as the programme contin-
ues [22]. The total population for rural areas used as
denominator for analyzing MDA results was the total number
of people registered during the pre-MDA census, while the total
population used in urban/non-rural areas was the projected
figure according to the 2004 national census [26], with an annual
growth rate of 2.5%. Spatial analysis of the LF mf prevalence was
conducted using the kriging method in the Geostatistical Analyst
Extension of ArcGIS version 10 (ESRI, Redlands, USA).
Spatially smoothed contour maps of the interpolated prevalence
of mf at baseline and after three MDAs were produced as
described previously [21,27].
Results
Mass Drug Administration Results 2008–2010
A total of 14,253 villages and urban areas were treated for LF
each year during the 3 years in the 12 districts. As all the villages
and urban areas were treated in each of the 12 districts, this
represents 100% geographic coverage for endemic villages and
urban areas in all 12 districts during each of these 3 rounds of
MDA, as shown in table 2. Over 4 million people were targeted for
treatment each year during the 3 years. Overall EDC was 70.1%,
74.1% and 75.2% in 2008, 2009 and 2010 respectively at the
national level, and was $65.0% in each district in each round,
except in Bonthe, where it was 59.5% in 2008. EDC also
improved between 2008 and 2010. Five districts had ,70.0% in
2008 (Bo: 66.3%, Bonthe: 59.5%, Kono: 69.0%, Port Loko:
66.6% and Tonkolili: 68.6%); while in 2009 and 2010, all districts
had .70.0% EDC, as shown in table 2. The overall DC was
82.5%, 87.1% and 88.5% in 2008, 2009 and 2010, respectively.
The DC is a measure of how well MDA was conducted and is
considered adequate when $80.0% [22]. DC by district in each
round was $80.0%, except in Bo, Bonthe and Port Loko, which
had 78.0%, 70.0% and 78.3% respectively in 2008, as shown in
table 2.
Table 3. Survey site selection.
Groups of districts Districts Sentinel sites Spot check sites
1 Bonthe Moboya -
Moyamba - Taninahun Kapuima
2 Koinadugu Kumala -
Bombali - Makoba Yelima
3 Bo Gelehun -
Pujehun - Kundorwahun
4 Port Loko Gbabai -
Kambia - Kamasasa
5 Kailahun Manowa -
Kenema - Joru
6 Kono Tombodu -
Tonkolili - Rosint
doi:10.1371/journal.pntd.0002273.t003
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Microfilaraemia Prevalence
Five districts (Bo, Kenema, Kono, Moyamba and Pujehun) had
0.0% mf prevalence. One district (Pujehun) had baseline mf
prevalence of 0.0%, which was maintained. Another six districts
had mf prevalence between 0.0 and 1.0%: Bonthe (0.20%; 95%
CI: 0.04%–1.13%), Kailahun (0.20%; 95% CI: 04%–1.13%),
Kambia (0.40%; 95% CI: 0.11%–1.45%), Koinadugu (0.80%;
95% CI: 0.31%–2.05%), Port Loko (0.20%; 95% CI: 0.04%–
1.13%) and Tonkolili (0.19%; 95% CI: 0.03%–1.08%). Only one
district had mf prevalence of over 1%: Bombali (1.58%; 95% CI:
0.80%–3.09%). Overall mf prevalence among males was 0.35%
(95% CI: 0.19%–0.62%), and among females 0.25% (95% CI:
0.12%–0.51%). Prevalence by age group, 5–14 years (N= 1947),
15–20 years (N= 858), 21–30 years (N=858), 31–40 years
(N= 849) and 41–50 years (N=640), was 0.21% (95% CI:
0.08%–0.53%), 0.12% (95% CI: 0.02%–0.66%), 0.58% (95%
CI: 0.25%–1.36%), 0.59% (95% CI: 0.25%–1.37%) and 0.47%
(95% CI: 0.16%–1.37%) respectively, while prevalence in the age
group .50 years (N= 871) was 0.0%. In total, 18 persons (0.30%,
95% CI: 0.19–0.47%) had a positive blood smear, and there was
Figure 1. Survey sites and spatially smoothed contour maps of predicted LF mf prevalence in Sierra Leone. A. Predicted mf prevalence
at baseline; B. Predicted mf prevalence after three rounds of MDA. The same legend scale was used for the contour map of both A and B for easy
comparison. Triangles and labels show the survey locations and the observed mf prevalence in each location.
doi:10.1371/journal.pntd.0002273.g001
Figure 2. Reduction of MF prevalence after 3 annual MDAs for
LF in Sierra Leone 2008–2010.
doi:10.1371/journal.pntd.0002273.g002
Figure 3. Reduction of entire-population mf density after 3
annual LF MDAs in Sierra Leone 2008–2010.
doi:10.1371/journal.pntd.0002273.g003
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no significant difference in mf prevalence in males as compared to
females (p = 0.47). There were also no significant differences in
prevalence among age groups.
Compared with the baseline, overall mf prevalence decreased
by 88.5% (p= 0.000), from 2.6% (95% CI: 2.3%–3.0%) to 0.30%
(95% CI: 0.19%–0.47%), after 3 rounds of MDA. As shown in
table 1, among the 11 districts with baseline mf prevalence $1%,
seven districts showed mf prevalence reduction of over 90% after
three rounds of MDA, three districts by over 80%, and only one
district by below 80%. Spatial prediction suggested a sweeping
reduction in mf prevalence from the baseline level after three
MDAs across the country. There was an 89.4% decrease
(p = 0.000) in mf prevalence among males: 3.3% (95% CI:
2.8%–3.9%) to 0.35% (95% CI: 0.19%–0.62%); and an 87.5%
decrease (p = 0.000) in mf prevalence among females: 2.0% (95%
CI: 1.6%–2.4%) to 0.25% (95% CI: 0.12%–0.51%). There was
0.21% (95% CI: 0.08%–0.53%) prevalence among the age group
5–14 years, but this could not be compared, as the baseline study
did not include participants ,15 years. Decreases in mf
prevalence among the age groups 15–20, 21–30, 31–40, 41–50
and .50 years ranged between 77.3% and 100.0% (p= 0.000,
0.000, 0.000, 0.000 and 0.000 respectively). Figure 1 shows
predicted mf prevalence at baseline (A) and predicted mf
prevalence after three rounds of MDA (B). Figure 2 shows the
overall decrease in mf prevalence and the decrease for each
district. A statistical comparison between the 6 districts that piloted
MDA for LF in 2007 and the other 6 showed no statistical
difference between the decreases in microfilaremia prevalence of
the 2 groups of districts. 3 out of the 4 districts that had 100%
decreases in mf prevalence had conducted only 3 MDAs.
Microfilaraemia Density
The overall arithmetic mean mf density was 0.05 mf/ml (95%
CI: 0.03 mf/ml–0.08 mf/ml) in the total participants examined
and 17.59 mf/ml (95% CI: 15.64 mf/ml–19.55 mf/ml) among
mf-positive individuals. The mean mf density by district was well
below 1 mf/ml for the population examined and below 21 mf/ml
among those who were mf positive. There was no significant
difference in mf density in males versus females (p.0.05). There
was also no significant difference in mf density among age groups
in the total population examined (p.0.05). Overall mean mf
density among mf positive individuals decreased by 65.4%
(p= 0.001), from 50.9 mf/ml (95% CI: 40.25 mf/ml–61.62 mf/
ml) at baseline to 17.59 mf/ml (95% CI: 15.64 mf/ml–19.55 mf/
ml); and in the total population examined, there was a 96.2%
decrease (p = 0.000), from 1.32 mf/ml (95% CI: 1.00 mf/ml–
1.65 mf/ml) at baseline to 0.05 mf/ml (95% CI: 0.03 mf/ml–
0.08 mf/ml). In Bo, Kenema, Kono and Moyamba, there was
100.0% decrease in mf density among both mf positive
participants and the entire population. Six districts, Bonthe,
Kailahun, Kambia, Koinadugu, Port Loko and Tonkolili, had a
.90.0% decrease in mf density for the entire population
(p = 0.059, 0.001, 0.014, 0.000, 0.000 and 0.002 respectively),
and a .36.0% decrease in mf density among positive participants
(p = 0.295, 0.472, 0.311, 0.454, 0.219 and 0.442 respectively).
Bombali had the lowest decreases in mf density, 86.3% for the
entire population (p = 0.000) and 40.6% among positive individ-
uals (p = 0.068). Table 1 shows the reduction of mf density in the
12 districts after 3 MDAs. There was a 96.7% decrease in mf
density among all males (p = 0.000) and a 67.0% decrease in mf
density among males that are mf positive (p = 0.013); and there
was a 95.4% decrease in mf density among all females (p = 0.000)
and a 62.8% decrease in mf density among females that are mf
positive (p = 0.023). The age groups 15–20, 21–30, 31–40 and 41–
50 years had .90.0% decrease in mf density for the entire
population (p= 0.000, 0.000, 0.000 and 0.000 respectively) and
.60.0% decrease in mf density among mf positive individuals
(p = 0.341, 0.042, 0.059 and 0.159 respectively). The age group
.50 years had a 100.0% decrease in mf density for the entire
population and among mf positive individuals. For details of mf
prevalence and density at baseline and after 3 MDAs, reductions
in mf prevalence and density after 3 MDAs and p values for the
reductions in prevalence and density please see table 1. Figures 3
and 4 show overall and district decreases in mf density for the
entire population and for those who were mf positive respectively.
Discussion
LF is widely endemic across Sierra Leone, transmitted by
Anopheles mosquitoes. All 14 health districts qualified for MDA
intervention in accordance with WHO guidelines because they
had baseline LF prevalence by ICT cards $1.0% [21,24].
Although MDA was piloted in rural areas of 6 health districts in
2007, the 2007 MDA results were relatively poor and considered
‘‘inadequate’’ and so 2008 is considered year 1 for LF MDA when
treatment and geographic coverage was $65% and 100%
respectively. The results from the 12 rural districts showed that
over the three years (2008–2010), geographic coverage was 100%
in all 12 districts, EDC was $65.0% in all districts except for
Bonthe in 2008 (59.5%), and DC was $80.0% in all districts
except for Bo (78.0%), Bonthe (70.0%) and Port Loko (78.3%) in
2008. The treatment coverage was verified through independent
monitoring activities, as described previously [23]. The current
assessment showed that the average mf prevalence in the country
was only 0.30% and the average population mf density was only
0.05 mf/ml after three rounds of MDA, with no microfilaria
detected in six of the 12 districts, including all the districts in the
Southern Province and only one district showing mf prevalence of
.1% (Bombali, 1.58%). This represents an overall reduction of
87.5% in mf prevalence and 95.5% in population mf density. The
zero mf prevalence recorded for Pujehun district at baseline may
have been as a result of the randomness of the selection of the
sentinel sites. Consequently, a spot check site was selected in
Pujehun for the midterm study in consultation with the DHMT of
Pujehun district based on results of reported hydroceles and
Figure 4. Reduction of positive-only mf density after 3 annual
LF MDAs in Sierra Leone 2008–2010.
doi:10.1371/journal.pntd.0002273.g004
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lymphedema, which increased the chances of finding mf positive
cases. Since the mf prevalence is again zero it is recommended that
another spot check site be selected for the next survey in the
district (the pre-transmission assessment survey). The use of pre-
MDA census data as denominator in rural settings versus use of
projected census population as denominator in urban or non-rural
settings for the calculation of MDA results may have created bias
in terms of interpretation and comparability of MDA results.
However, it should be noted that the issue of what denominator to
use for MDAs in urban settings still has to be resolved by the
international NTD community as this poses a big challenge for
national control programmes. Pre-MDA census in urban settings
could be cumbersome, very expensive and results reported cannot
be easily validated. The NTDCP therefore decided to use
projected census figures as denominator in the analysis of MDA
results for non-rural or urban areas of the districts.
The number of MDA rounds needed to eliminate LF depends
on baseline infection rates, vectoral capacity, efficacy of the MDA
regimen used, and community compliance with treatment. It is
possible to eliminate LF in some implementation units (IUs) with
low baseline infection rates using less than five rounds of MDA,
while more than six MDA rounds may be needed for IUs with
relatively high baseline LF prevalence [28,29,30]. The high level
of reduction in mf prevalence and intensity after three rounds of
MDA in Sierra Leone may have been partly due to the relatively
low baseline mf level [21].
Several studies on LF conducted before the baseline studies in
2007/2008 in Sierra Leone and neighboring Liberia show mf
prevalence $20% but the LF prevalence at baseline (2007/2008)
ranged from 0%–6.9% for all districts with prevalence of the
southeastern districts that were studied previously,3% at baseline
[21]. Many studies have shown that there are 3 drugs that have
microfilaricidal effect on the lymphatic filarial roundworms and
are available for LF treatment: diethylcarbamazine (DEC),
ivermectin and albendazole. Treatment with DEC or ivermectin
alone significantly reduces blood mf levels (up to 90% mf clearance
is reported) but combination of both drugs is more effective than
using one drug. The marked filaricidal effect of these drugs makes
them suitable for annual treatment designed to control transmis-
sion immediately and in the long term to control morbidity [31].
In Burkina Faso and India it was demonstrated that 5–14 years of
ivermectin treatment (i.e. treating with ivermectin alone) reduced
mf prevalence and intensities of W. bancrofti but transmission was
not interrupted. The treatment rounds with ivermectin alone can
significantly reduce prevalence and intensity of W. bancrofti
microfilaremia, which provides an opportunity for synergy where
onchocerciasis and LF are coendemic [32,33,34]. It is reported
that there is a strong relationship between mf prevalence and
intensity in humans and mf intake and development in the
mosquito vector which means that lower intensity can lead to
reduced transmission [34,35]. The mass administration of
ivermectin for onchocerciasis control using the CDTI strategy,
which has been demonstrated to be very effective in reaching the
target communities and populations, could have been responsible
for the reduction in mf prevalence and density at baseline as
indicated in previous studies mentioned above. The reduction in
mf prevalence as a result of ivermectin treatment could have
resulted in reduced transmission among the populations of the 12
districts because mf intake and development within the vector
depends on the level of mf prevalence and density. Low mf
prevalence and density could have resulted in reduced mf intake
and development in the mosquito vector, reduced mf transmission
and therefore even further reduction of mf prevalence and density
in the populations with time.
By studying infection and infectivity prevalence in the vector
mosquitos it was demonstrated in Nigeria that 5 years of semi-
annual MDAs with ivermectin alone targeted at onchocerciasis
control reduced but did not interrupt transmission of W. bancrofti
[36,37]. Adding albendazole provided better mf clearance (up to
99%) and clearance of soil transmitted helminths in communities
treated [34,35]. Addition of albendazole to ivermectin significantly
reduced mf prevalence in mosquitos in the sentinel villages
studied, which was an entomological confirmation of the
importance of albendazole for LF control [36,37]. This observa-
tion is related to our proposed hypothesis for the study (‘‘areas
previously exposed to ivermectin treatment for onchocerciasis
control may require less rounds of annual MDA to eliminate LF’’).
Since the populations of the 12 districts had been exposed to
ivermectin treatment for onchocerciasis control, this could have
resulted in massive lowering of mf prevalence and density because
ivermectin can reduce mf prevalence by up to 90%. The mf
population was already under a selective pressure (based on the
massive use of ivermectin), and this selective pressure was
enhanced with the addition of a second drug (albendazole) to
the MDA that has been occurring for years.
The successful implementation of the LF programme benefited
from the existing onchocerciasis control programme by using
CDTI as the platform [16]. The Onchocerciasis control
programme was already well established using the CDTI strategy
which allows communities to be in charge of all programme
activities that are implemented within communities thus ensuring
good sense of ownership and good compliance within communi-
ties. Health workers had already been trained and were available
to provide technical support in additional training, supervision and
surveys. Treatment has been given between September and
December each year, as this is the period that was found to be
convenient for the communities (i.e. harvest and post-harvest
period). With integration of Onchocerciasis control and LF control
CDTI plus (CDTI+) was adopted with the same principles as
CDTI and Albendazole added to Ivermectin [16,24,35]. All the
lessons learnt from CDTI during the years of the onchocerciasis
control programme were used to improve the LF elimination
programme, such as the use of the good health infrastructure in
the districts that had focal persons for coordinating onchocerciasis
control within districts to ensure a high treatment and geographic
coverage by the national programme. These district onchocerciasis
coordinators became district NTD coordinators. After the civil
war in Sierra Leone in 2002, during which almost all health
programmes had stopped, the MOHS had decided that running
the onchocerciasis control programme as a vertical programmes
would have been inefficient given the post war situation and the
limited number of health workers and so the national coordination
had to work in close collaboration with the DHMTs and within
the existing district health structure. Furthermore, community
directed interventions were continued for control of onchocerciasis
and LF with which communities plan activities with health
workers, decide treatment periods and select volunteers who are
trained to distribute ivermectin and albendazole in their own
communities.
Three rounds of MDA with compliance $65.0% in Papua New
Guinea reduced mf prevalence from 18.6% to 1.3%, a 94.0%
reduction [38]. The authors believed that the large decrease in
prevalence occurred in part because the vector transmitting LF in
the study area was the Anopheles mosquito, which is less efficient
than Culex in the transmission of filariasis [38]. This may have also
been the case in Sierra Leone. Similar successes in reducing mf
prevalence after annual MDA rounds have been reported by many
authors. In Kenya, there were similar reductions in mf prevalence
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(from 20.9% to 0.9%, a 95.7% reduction of mf prevalence) even
when there were missed rounds of MDA [39]. Prevalence was
reduced by 93.0%, from 12.0% to 0.8%, after just 2 rounds of
MDA in Vanuatu [40]. In Northern Uganda, a reduction of mf
prevalence from 3.7% to 0.4% (a 89.2% decrease) was reported
after 3 MDAs [41]. Therefore, it is not surprising that three
effective rounds of MDA would reduce the mf prevalence to below
1% in 11 out of 12 districts in the current LF elimination
programme, given the relatively low mf prevalence at baseline.
The NTDCP in Sierra Leone has succeeded in building on an
existing and effective CDTI programme for integrated manage-
ment of onchocerciasis and LF and had the unique opportunity of
using the integrated approach of managing both onchocerciasis
and LF for LF elimination. As a result of the effectiveness of
ivermectin alone in reducing LF in endemic communities baseline
LF prevalence was relatively low. The NTDCP was able to use the
good health infrastructure in the districts that had focal persons for
coordinating NTD control within districts to ensure a high
treatment and geographic coverage. Other countries embarking
on LF elimination can learn the following lessons: in countries
where the onchocerciasis control programme already exists and is
successfully implemented, NTD control programmes can build on
the existing CDTI structure for elimination of LF; integrated
approach can be used for management of onchocerciasis and LF
in areas co-endemic for onchocerciasis and LF (all activities can be
co-implemented for the 2 diseases from training, community
sensitization and mobilization to the MDA itself); in areas where
CDTI has been implemented for many years programmes should
expect to have relatively low baseline prevalence; integration of
NTD control activities into strong existing national and district
health system can ensure good programme implementation and
improve programme sustainability especially for post MDA
surveillance. Most African countries have problems providing
adequate number of staff for public health programmes and
integrating NTD programme into the national and district health
system and co-implementation of activities for control of multiple
NTDs can improve programme effectiveness and sustainability. It
should be noted also that use of CDDs who do not get financial
payments for the services they render may not work for MDAs in
urban areas. The main difference noted in the NTDCP in Sierra
Leone is that after the civil war 1991–2002, during which almost
all health programmes had stopped, the MOHS had decided to
put the control of all NTDs under the existing onchocerciasis
control programme with 1(one) programme manager responsible
for all NTDs and working in close collaboration with strong
DHMTs. It was decided that running vertical programmes for
NTDs will be disastrous given the post war situation and the
limited number of health workers. This decision was easy to
implement because before 2005–2008 when studies were con-
ducted to map the other NTDs only the Onchocerciasis Control
Programme was existing in the country.
The use of different sites for comparison (sentinel sites in 6
districts versus spot check sites for the other 6 districts) might be a
limitation of the study considering the comparability of the impact
assessment done in the districts where the same site was used
relative to the districts where different sites were used. However,
this depends on how you look at the study. In terms of the
programme implementation it is not a limitation because recent
WHO guidelines (WHO 2011) recommend 1 sentinel site per 1
million people. Only 1 district in Sierra Leone (the Urban Western
Area, which is not in this group of 12 districts) has more than 1
million people and should have 1 sentinel site and 1 spot check site
(total of 2 sites). The rest have far less than 1 million people per
district and so have been grouped as recommended by WHO [22]
depending on geographical proximity and epidemiological char-
acteristics so that each pair has a total population of about 1
million people. Bonthe and Moyamba for example are geograph-
ically neighboring districts and have low baseline antigenemia and
microfilaremia prevalence. The pair should have 1 sentinel site
and 1 spot check site, so the sentinel site (selected and used for the
baseline microfilaremia study) was used as sentinel site for the pair
(in the case of Bonthe/Moyamba, Moboya in Bonthe was selected
as a sentinel site) and a spot check site was selected in the other
district as explained above (Taninahun Kapuima was recom-
mended by the district health management team as good spot
check site). The possible limitation for our paper is that we use the
results obtained in the spot check sites and compare with baseline
results in villages previously considered sentinel sites. Given the
overall relatively low baseline microfilaremia prevalence and the
pattern that emerges of a huge decrease noted in this mid-term
evaluation, we believe that the impact assessment done in the
districts where the same site was used relative to the districts where
different sites were used are comparable if only to assess impact of
MDA. In the case of Pujehun that had baseline mf prevalence of
zero with the possibility that due to random selection the endemic
areas (communities) might have been missed during the random
selection of the sentinel sites at baseline, we think it is prudent to
select and study another site/village that is indicated to be more
LF endemic. In the pre-6th MDA survey (pre-TAS), it will be
recommended that another spot check site be selected, which is
even more likely to be LF endemic in Pujehun to avoid risk of
overlooking villages that could possibly still be a source of LF
transmission within the district.
There is reason for optimism with the results of this survey
because some research suggests that residual infections of filariasis
disappear when prevalence is below 1.0% [42]. However, it is
prudent to consider experiences and lessons learnt from other
countries. In Tanzania, it was demonstrated that MDA using
ivermectin and albendazole reduced mf prevalence by 21.2% and
40.4% after the first and second MDA respectively, but in
subsequent MDAs, the effect leveled off and transmission, albeit
low-level, was still noted after the third MDA [43]. In Leogane,
Haiti, there was a significant reduction in mf rates after several
rounds of MDA for LF, but transmission was not interrupted [44].
Mf prevalence detected after 3 MDAs does not demonstrate a
change in filariasis transmission [38,41]. The drug combination
destroys the microfilaria over the 4–6 year it takes for the adult
worm to die a natural death [38,41,45]. Therefore, MDA has to
continue each year for 4–6 years, which is equivalent to the
lifespan of the adult worm.
In conclusion, there was significant reduction of mf prevalence
and density across the 12 rural districts in Sierra Leone after three
annual MDAs. This was coupled with good MDA compliance and
relatively low baseline endemicity. The results show that the
proposed hypothesis is highly probable and that the LF
elimination programme in Sierra Leone is on course to reach
the objective of eliminating LF by the year 2020. Eliminating
diseases such as LF has to follow models that use rigorous scientific
data as is being demonstrated in this case. The next logical steps
after the midterm evaluation include the following: continuation of
annual MDAs for another 3 years (4th, 5th and 6th MDA rounds); a
pre-transmission assessment survey (pre-TAS) before the 6th MDA
rounds; a TAS after the 6th MDA rounds if district mf prevalence
continue to be below 1%; and then 2 more TAS at intervals of 2–3
years before a request is made for certification of elimination.
Manifestations of LF such as lymphoedema and hydroceles have
to be included within the national surveillance system and
monitored closely by the NTDCP.
Impact of 3 MDAs on LF in Sierra Leone
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